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Abstract 
Histone deacetylases (HDACs) are a group of epigenetic modulators, which catalyze the removal of ε-N-
acetylated lysine residues. Histones are the most studied targets, however, the acetylated state of a variety 
of other proteins are also modified by HDACs. Aberrant epigenetic processes have been associated with 
various types of cancer and HDACs have therefore been a target in the development of anticancer drugs. So 
far, two HDAC inhibitors have been approved by the food and drug administration (FDA) and several 
compounds are in clinical trials. 
Macrocyclic HDAC inhibitors are interesting compounds, as they can interact with a variety of amino acids 
on the surface near the binding site; these interactions may be used to obtain selectivity for specific HDAC 
isozymes. The azumamides are potent HDAC inhibitors and since they possess a relatively weak zinc-binding 
group (ZBG), the activity must arise from interactions with the large cap group. The natural compounds have 
been used as an inspiration to synthesize new HDAC inhibitors. 
A small structure activity relationship (SAR) study was conducted in collaboration with Jesper S. Villadsen. 
Aromatic substituents in the cyclic peptide were explored, while the primary modifications were done to the 
β-amino acid. Removal of the methyl group in the 2-position and changes to the unsaturation in the side at 
the 3-position, afforded six compounds. These were tested against HDAC enzymes from class I, IIb, and IV. 
Minor changes in activity were observed among the azumamide analogs; however, removal of the methyl 
group had a significant impact relative to the natural products. To understand this effect, the NMR structure 
was solved with the assistance from Casper Hoeck and Charlotte H. Gotfredsen and docked conformations 
were obtained from Niels J. Christensen and Peter Fristrup. Compared to the natural compounds, the 3D-
structure of the scaffold in the azumamide analogs were similar. Although a conclusion was not found, the 
preliminary docking results indicated favorable lipophilic interaction with the methyl group in the 
azumamides.  
Largazole is another macrocylic natural product with HDAC inhibitory activity. The compound has a 
thioester functionality in the side chain, which is hydrolyzed before interaction with the enzymes. In the 
attempt to mimic the prodrug nature of largazole, compounds containing a thiol group were designed, as it 
was hypothesized that acylation with different lipids could generate compounds with improved cell 
penetrating properties. A desmethylated azumamide analog containing a thiol side chain was synthesized 
and tested against HDAC3. A low activity was observed, which was explained by the unfavorable linker length.  
In the work performed at CalTech, five 2-α-phenylpyrroloindolines were synthesized; utilizing an NCS 
mediated cyclization as the key step. Chris Marotta and Christina McCleary Daeffler tested their effect against 
a variety of ligand-gated ion-channels. Among these, one compound proved to be an agonist for the GABAA 
receptor.  
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Resumé 
Histone deacetylaser (HDACer) er en gruppe af enzymer, der regulerer epigenetiske ændringer ved at 
katalysere kløvning af acetylgrupper fra ε-N-acetylerede lysiner. Den mest undersøgte målgruppe er 
histonerne, men andre proteiner er dog også påvirket af HDACer. Der er fundet en sammenhæng mellem 
atypiske epigenetiske ændringer i forbindelse med forskellige typer af cancer. HDACerne har derfor været et 
mål i udviklingen af lægemidler til bekæmpelse af cancer. Indtil videre er to HDAC inhibitorer blevet godkendt 
af den amerikanske food and drug administration (FDA) og flere stoffer er i kliniske tests. 
Makrocykliske HDAC inhibitorer er interessante stoffer, da de kan interagere med en stor del af 
aminosyrerne på overfladen tæt ved bindingslommen. Disse interaktioner kan muligvis blive brugt til at opnå 
selektivitet for specifikke HDAC isoenzymer. Azumamiderne er potente HDAC inhibitorer og eftersom de 
besidder en relativ svag zink bindende gruppe (ZBG), må aktiviteten opstå ved interaktioner med den store 
’cap’ gruppe. Naturstofferne er blevet brugt til inspiration for syntesen af nye HDAC inhibitorer. 
Et mindre struktur-aktivitets studie (SAS) er blevet udført i samarbejde med Jesper S. Villadsen. 
Aromatiske substituenter i det cykliske peptid er blevet udforsket, dog er den primære modifikation udført 
på ε-aminosyren. Ved fjernelsen af methylgruppen fra 2-positionen og ændringer til den umættede del af 
sidekæden i 3-positionen, blev seks kemiske forbindelser dannet. Disse blev testet imod HDAC enzymer fra 
klasse I, IIb og IV. 
En ubetydelig ændring i aktiviteten blev observeret iblandt azumamid analogerne, mens fjernelsen af 
methyl gruppen havde en betydelig effekt i forhold til naturstofferne. For at forstå denne effekt blev NMR 
strukturen opklaret med assistance fra Casper Hoeck og Charlotte H. Gotfredsen og docking strukturer blev 
dannet af Niels J. Christensen og Peter Fristrup. Sammenlignet med naturstofferne var 3D-strukturen af 
ringen i azumamid analogerne ens. Selvom der ikke kunne drages en endelig konklusion, indikerede de 
indledende docking resultater, at en favorabel lipofil interaktion kunne dannes med methyl gruppen i 
azumamiderne. 
Largazol er et andet naturstof med HDAC inhibitorisk aktivitet. Strukturen har en thioester i sidekæden, 
der hydroliseres før interaktion med enzymet. I et forsøg på at efterligne dette naturlige ’prodrug’, blev der 
designet strukturer med en thiol gruppe. Hypotesen var at strukturer med bedre celle penetrerende 
egenskaber kunne syntetiseres ved at acylere med forskellige typer fedtkæder. En desmethyl azumamid 
analog, indeholdende en thiol sidekæde, blev syntetiseret og testet imod HDAC3. En lav aktivitet blev 
observeret, hvilket blev forklaret af den ugunstige længde af linkeren.   
 I arbejdet foretaget på CalTech, blev fem 2-α-phenylpyrroloindoliner syntetiseret ved brug af en NCS 
medieret cyklisering. Deres aktivitet blev testet af Chris Marotta and Christina M. Daeffler imod forskellige 
typer ligandstyrede ionkanaler. Iblandt disse viste en af stofferne sig at være en agonist på GABAA receptoren. 
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1 Introduction 
1.1 Epigenetics 
All genetic information of living organisms is stored in DNA. The same DNA is present in all cells; however, a 
variety of cell types exists, containing different gene expression profiles. These processes can be explained 
by epigenetic mechanisms, which is defined by changes in gene expression without altering the DNA 
sequence. DNA methylation and histone modifications are among the most studied epigenetic 
mechanisms.[1] 
Long linear stretches of DNA coil around eight histone proteins consisting of two copies of H2A, H2B, H3, 
and H4. Linker DNA that wraps around histone H1 connects these units, known as nucleosomes.[2] The 
repeating nucleosome units, comprises the chromosome, which allows the DNA to be condensed into the 
small volume of the nucleus (Figure 1.1).  
 
Figure 1.1 DNA wraps around histone proteins to form the nucleosome. These are compacted further into the chromosome, which 
can fit into the cell nucleus. Epigenetic alterations includes DNA methylation and modifications to the histone tails. Epigenetic 
modulators (writers) include histone acetyltransferases and histone methyltransferases. These alterations can be recognized by 
specific domains in proteins (readers), while other proteins including histone deacetylases and lysine demethylases, remove the 
modification (erasers). The figure was modified from ref [1]. 
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The nucleosome plays a crucial role in transcription, as the packing prevents access of DNA-binding proteins 
to various loci.[2] The histones in each nucleosome are well defined, but the N-terminal tails that protrudes 
from the nucleosome are highly flexible. The tails contain a high proportion of conserved basic amino acids 
that can facilitate binding within the same nucleosome to stabilize contact to the DNA, as well as inter-
nucleosomal interactions, which define the chromatin structure.[3] The strong stabilizing effects arise, in part, 
by interactions between the positive charge from the basic amino acids and the negatively charged 
phosphates in the backbone of DNA.  
The histone tails are targets for posttranslational modifications at specific amino acid positions;[4] these 
include acetylation,[5] methylation,[6] phosphorylation,[7] and ubiquitylation.[8] Acetylation of lysine residues 
neutralize the positive charge, which leads to a weaker histone-DNA interaction. The structure of the 
chromatin will be less compact and become more accessible to various transcription factors. A specific 
acetylation on H4, lysine 16 (H4K16) is a crucial factor in shaping the dynamic chromatin structure.[9] 
Ubiquitylation of the C-terminal helix in H2B is another key site for posttranslational modifications, which has 
been shown to control the higher order structure of chromatin.[10] The ubiquitylated interference of the 
chromatin compaction proved to function in a cooperative fashion with acetylation at H4K16. While 
acetylated H4K16 affected the folding transition, ubiquitylated H2B was reported to occur at a later stage of 
the packing (Figure 1.2).  
 
Figure 1.2 Acetylation and ubiquitylation interferes with the chromatin structure in a cooperative fashion. Lysine 16 on histone H4 
and ubiquitylation of the C-terminal helix in H2B are key sites for the modifications. acH4: acetylated histone 4; uH2B: ubiquitylated 
H2B. The figure was obtained from ref [10]. 
In contrast to acetylation, histone methylation does not change the charged state of the amino acid residues. 
Different states of methylation can occur on the basic amino acids; lysine residues can be mono-, di-, or tri-
methylated, while arginine residues can be mono- or di-methylated. Mono-methylated histidines have also 
been observed, but this rare alteration is not well characterized.[6] Kinases can phosphorylate serine, 
threonine, and tyrosine residues in the histone tails. In combination with the aforementioned alterations as 
well as other epigenetic modifications, a vast number of posttranslational combinations can be generated. 
 Even though the structural compaction gives a rational explanation of transcriptional control, the process 
is much more complex. The specific patterns of modified histone proteins establish a code that can be 
recognized by chromatin-associated proteins, to either initiate or suppress transcription. Furthermore, it has 
been proposed that the local concentration and combination of modified histones alter the chromatin 
structure, resulting in different epigenetic states, leading to silencing or activation of particular regions.[11]  
Most of the enzymes that ‘read’ the histone code contain domains that recognize the specific alterations 
of the histones (Figure 1.1). This concept is demonstrated by heterochromatin protein 1 (HP1) that contains 
a chromo-domain, which is highly selective for methylated Lys9 in H3,[12] and by p300/CBP-associated factor 
(PCAF) containing a bromo-domain that targets acetylated Lys8 in H4 and Lys14 in H3.[13] 
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1.2 Histone transferases and histone deacetylases 
The acetylated state of histone proteins is important for many cellular mechanisms. Acetylation of newly 
synthesized histone proteins is required for their assembly into the nucleosome[14] and modifications of lysine 
residues have a role in shaping the chromatin structure.[9] In agreement with the histone code model, 
deacetylation at certain sites are also key factors for regulating transcription.[15] 
Two functional opposing enzymes, the histone acetyl transferases (HATs) and the histone deacetylases 
(HDACs) control the acetylation state of histone proteins. HATs catalyze acetylation of ε-amino groups of 
lysine residues using acetyl-coenzyme A (CoA) as a cofactor, while HDACs catalyze the reverse reaction. 
The human HDACs are grouped into four classes based on their sequence similarity and domain 
organization (Figure 1.3). The “classical” mammalian HDACs, which can be divided into class I, IIa, IIb, and IV 
contain a zinc ion in the active site of the enzyme, while the sirtuins, belonging to class III HDACs, require 
NAD+ as a cofactor. The sirtuins are structurally unrelated to the classical HDACs and will not be discussed 
further. 
Acetyl removal from histone proteins are the most studied enzymatic function of HDACs. Certain HDACs 
can however catalyze deacetylation of cytoplasmic proteins and transcription factors. These epigenetic 
modifications may have many consequences. For example, acetylation and ubiquitinylation can occur on the 
same lysine residue in p53;[16] HDACs can therefore move the equilibrium towards ubiquitinylation, an 
alteration that may act as signal for degradation of the protein. Other processes that are regulated by 
acetylation/deacetylation are translocation and protein-protein interactions.[17] 
 
Figure 1.3. Phylogenetic tree of HDACs. The proteins on the branches are placed in accordance to their sequence similarity. The figure 
was modified from ref [1]. 
Class I HDACs 
Class I HDACs are localized predominantly in the nucleus.[18] HDAC1 and 2 are closely related (Figure 1.3) and 
have a high sequence similarity (∼82%).[5] They interact with each other in at least three multi-protein 
complexes; switch intensive 3- (Sin3), nucleosomes remodeling and decatylase- (NuRD), and the co-repressor 
of RE1-silencing transcription (Co-REST) complex, where they constitute the catalytic core (Figure 1.4).[19] The 
proteins in these complexes are necessary for deacetylase activity and for binding to DNA.[20] The function of 
HDAC1 and 2 is also regulated by kinases; hyperphosphorylation of the enzymes increase the deacetylase 
activity, but it also disrupts the complex formation. In parallel, hypophosphorylation decrease deacetylase 
4 
activity, while it promotes formation of the protein complex. These contradictory mechanisms are thought 
to maintain the HDACs activity at a certain optimal level.[21]  
 
Figure 1.4 Composition of HDAC complexes. The figure was obtained from ref [22]. 
HDAC3 can be found in complex with nuclear receptor co-repressor (N-CoR) and silencing mediator for 
retinoic acid and thyroid hormone receptors (SMRT)[23] (Figure 1.4). Both N-CoR and SMRT contain a domain 
that activates HDAC3 for deacetylation.[24] Analysis of the HDAC3 crystal structure have identified a bound D-
myo-inositol-(1,4,5,6)-tetrakisphosphate (Ins(1,4,5,6)P4). Beside from functioning as a stabilizing link to 
connect HDAC3 and SMRT, Ins(1,4,5,6)P4 was essential for HDAC activity. It has been proposed that the 
dynamics and conformation of HDAC3 change after binding to SMRT and Ins(1,4,5,6)P4, which leads to a 
higher activity. Binding to Arg265 which is present in one of the loops surrounding the rim of the active site, 
seems to be particularly important, as the dynamic loop could facilitate access to the active site.[25] Recently, 
Ins(1,4,5,6)P4 was also found to exert a regulatory role in HDAC1 with a  protein from the NuRD-complex.[26] 
 Three crystal structures of HDAC2 exist, all of them co-crystalized with an inhibitor (PDB: 3MAX, 4XLZ, 
4LY1). None of the crystal structures contain residues from the protein complex, but due to the high sequence 
similarity of the enzymes, in particular in the loop binding Ins(1,4,5,6)P4, it is likely that inositol phosphate 
also have a role in regulating HDAC2. 
In contrast to HDAC1−3, HDAC8 does not associate with any protein complexes.[19] By overlaying HDAC8 
and HDAC3, a crucial difference is observed in the opening towards the active site. The important loop that 
is believed to facilitate ligand access in HDAC1 and 3, is much smaller in HDAC8. This crucial change could 
explain why HDAC8 is active as an uncomplexed enzyme.[25] 
With regard to structure, HDAC8 is probably the most studied isozyme, with 21 published crystal 
structures to date, many of them co-crystalized with an inhibitor. Two sites for binding monovalent cations 
have been identified; one of which lies 7 Å from the divalent cation in the active site (site 1), while the second 
site is placed 21 Å away (site 2). It has been demonstrated that the occupation of one of the binding sites is 
crucial for HDAC activity, while occupation of both sites lowers activity of the enzyme.[27] It has therefore 
been suggested that intracellular monovalent cation concentration could be a regulating factor in HDAC8. 
The raised activity after binding one cation is thought to occur after occupying site 2, due to a stabilizing 
effect of the active conformation. Binding to site 1 is thought to lower the activity by decreasing pKa of the 
corresponding acid of His142 (Figure 1.5), which takes part in the deacetylation mechanism. 
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Figure 1.5 Effect on histidine protonation state by K+ in HDAC8. Left: a protonated histidine is favored in the absence of K+. Right: a 
deprotonated histidine is favored in the presence of K+. The figure was modified from ref [27]. 
The functions of HDAC isozymes have been investigated in mice, by removing the gene that code for the 
specific HDAC. HDAC1 knockout mice have shown that the isozyme is crucial for embryonic development, as 
the mice die before embryonic day 10.5 (mouse stage E10.5). It was also shown that embryonic stem cells 
lacking HDAC1 had reduced proliferation rates, in accordance with an up-regulation of cyclin-dependent-
kinase (CDK) inhibitor p21 and p27.[11] Deletion of HDAC1 or HDAC2 in cardiac tissue does not have any 
apparent effect on the development and function of the heart, but if both genes are knocked out 
simultaneously, newborn lethality is observed. This finding suggests that HDAC1 and 2 can uphold the same 
role in cardiac gene expression.[28] 
The vital role of HDAC3 in embryonic development, has also been established from knockout mice, which 
showed an embryonic lethality by day 9.5 (mouse stage E9.5).[29] Deletion of HDAC3 in liver tissue has 
revealed a role in hepatic metabolism by disrupting lipid and cholesterol homeostasis,[30] and heart specific 
deletion has further revealed a role in regulating cardiac energy metabolism.[29] Deletion of HDAC3 in primary 
cells affect the S phase progression and cause DNA damage.[31] 
Class IIa HDACs 
Opposed to HDAC enzymes in class I, expression of class IIa HDACs are restricted to a certain number of cell 
types. A high expression of HDAC5 and 9 is seen in muscle-, heart-, and brain tissue; HDAC4 is highly 
expressed in the brain and growth platelets of the skeleton; while HDAC7 is highly expressed in endothelial 
cells and thymocytes.[18] All members of class IIa contain a large N-terminal domain that regulates transport 
between the nucleus and cytoplasm by binding to the protein 14-3-3. This binding is mediated by 
phosphorylation of conserved serine residues in the HDAC enzymes.[32] 
Class IIa HDACs can be found in the SMRT-N-Cor-HDAC3 complex (Figure 1.4).[33] Association with this 
complex is crucial, as isolated class IIa enzymes do not show any HDAC activity. It has therefore been 
suggested that HDAC4, 5, and 7 might function as a link to recruit HDAC3 containing complexes.[33] Another 
proposed explanation is that class IIa enzymes is activated in the presence of HDAC3.[34] This suggestion is 
based on other possible HDAC-HDAC interactions, like HDAC1 and 2 that are found in the same complex. 
HDAC4, 5, and 7 can all interact with myocyte enhancer factor 2 (MEF2). MEF2 has a significant regulatory 
role as a DNA transcription factor in muscle differentiation. When one of the HDACs associates with MEF2, 
the function is inhibited and muscle differentiation is blocked. Ca2+/calmodulin dependent kinase (CaMK) can 
regain the activity by phosphorylating the HDACs, which leads to dissociation of the HDAC-MEF2 complex.[35] 
During muscle differentiation, HDAC4, 5 and 7 are shuttled between the nucleus and the cytoplasm. The 
different localization in the various stages, suggests a specific role of gene regulation of each HDAC isoform 
during the cell differentiation.[5] HDAC4 knockout mice, show premature bone tissue formation as well as an 
early onset of chondrocyte hypertrophy. The regulatory role of HDAC4 arises from inhibition of transcription 
factor, runt related transcription factor 2 (Runx2).[36] HDAC9 can also interact with MEF2, CaMK and 14-3-3. 
This suggest a potential role in muscle differentiation as the other class IIa enzymes.[5] 
6 
Class IIb HDACs 
HDAC6 is mainly localized in the cytoplasm, whereas HDAC10 resides in both cytoplasm and the nucleus.[37]  
HDAC6 possess two catalytic domains and a zinc finger – a structural motif that coordinates zinc ions.[38] Two 
catalytic domains are also found in HDAC10, but only the N-terminal catalytic domain is functional. HDAC10 
is found in the liver, spleen, and kidney[5] and have been shown to bind to HDAC3 and SMRT.[39]  
 Aside from catalyzing deacetylation of histones, HDAC6 can also deacetylate α-tubulin[40], which regulates 
microtubule-dependent cell motility, and  heat-shock protein (HSP) 90[41] which in the hyper-acetylated state 
loose chaperone activity.[41] Furthermore, the zinc finger domain is responsible for binding to ubiquitin. 
HDAC6 can thereby interfere with other biological mechanisms including aggresome function and 
degradation of misfolded proteins.[42] 
 HDAC6 knockout mice develop normally and even though the highest expression of the isozyme is found 
in the testis, normal function is retained as well. Hyperacetylated tubulin is observed, but without being vital 
for the mouse.[43] 
Class IV HDAC 
HDAC11 is the only isoform belonging to class IV. The enzyme is found in the brain, heart, muscle, kidney, 
and testes.[18] HDAC11 is not a part of any known complexes, so it might have a distinct function. The enzyme 
can repress expression of interleukin 10 (IL-10),[44] a cytokine which serve as a regulator of the immune 
response. The potential for HDAC11 as a therapeutic target was shown in rats after a liver transplantation, 
where silencing of HDAC11 genes proved superior relative to rats treated with an immunosuppressant.[45] 
1.3 The role of histone deacetylases and histone deacetylase inhibitors in cancer  
Each member of the HDAC family seems to have a specific function, as shown by the detrimental impact in 
HDAC knockout mice. Although histone modification is the most studied function of HDAC enzymes, a wide 
range of proteins are affected by the posttranslational modification. With the use of high-resolution mass 
spectrometry, 3600 lysine acetylation sites on 1750 proteins have been identified.[17] This vast amount of 
substrates that are affected, highlights the important role of HAT and HDACs as posttranslational modulators. 
In addition to genetic defects, the onset and progression of cancer have been associated with aberrant 
epigenetic alterations.[46] One of the challenges in cancer therapy is to target malignant cells without affecting 
normal cells. It is therefore important to identify which type of HDAC enzymes that display abnormal activity 
in a given tumor type. An overview of HDAC expression related to cancer is shown in Table 1.1.   
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Table 1.1 HDAC expression in various cancer types.a 
Class I HDACs  
1 Upregulated in gastric, colorectal, esophageal and pancreatic cancer. 
2 Upregulated during early colorectal cancer at the polyb stage. Upregulated in cervical 
dysplasia and invasive carcinoma. 
3 Upregulated in lung cancer, prostate and colon cancer. 
8 Upregulated in neuroblastoma. 
Class IIa HDACs  
4 Upregulated in breast cancer samples compared with renal, bladder and colorectal cancer. 
5 Upregulated in colorectal cancer in contrast to renal, bladder and breast cancer. 
7 Upregulated in colorectal cancer in contrast to bladder, renal and breast cancer. 
9 Overexpressed in medulloblastoma/astrocytoma. 
Class IIb HDACs  
6 High in oral squamous cell carcinoma. 
10 Overexpressed in hepatocellular carcinoma. 
Class IV HDACs  
11 Overexpressed in breast cancer. 
a The table was modified from ref [47]. 
HDAC inhibitors have shown a great potential in cancer therapy, by exhibiting a high selectivity towards 
tumor cells.[48] In recent years, HDACs have therefore been a target in the development of new anticancer 
drugs. The majority of HDAC inhibitors up-regulate p21, which in turn can affect cyclin D and cyclin dependent 
kinase (CDK) 4 leading to cell cycle arrest and differentiation. Furthermore, HDAC inhibitors can induce 
apoptosis and inhibit angiogenesis (Figure 1.6).[49] 
 
Figure 1.6 p21 is induced by the majority of HDAC inhibitors, leading to an inhibition of cyclin D and CDK4, which in turn promotes 
cell-cycle arrest and differentiation. HDAC inhibitors are also known to induce apoptosis and inhibit angiogenesis. The figure was 
obtained from ref [49]. 
HDAC inhibitors induces apoptosis 
HDAC inhibitors have shown anticancer activity by selectively inducing the death receptors, cluster of 
differentiation 95 (CD95) and  death receptor 5 (DR5), and their corresponding ligands, CD95L and TNF-
related apoptosis-inducing ligand (TRAIL) respectively, in tumor cells (Figure 1.7).[50] Binding of CD95L to the 
death receptor, triggers adaptor proteins to bind which in turn recruits membrane-proximal activator 
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caspases (e.g. caspase-8 or -10). The activator caspase can then induce effector caspases (e.g. caspase-3 or -
7), leading to apoptosis.[51]  
 
Figure 1.7 The death receptor pathway and the mitochondrial pathway. Activation of the death receptor induces a pathway involving 
caspases, which leads to apoptosis. In the mitochondrial pathway, an ion channel is formed in the mitochondria, which leads to 
release of cytochrome c along with proapoptotic proteins. The figure was obtained from ref [52]. 
Alternatively, the mitochondrial pathway can be activated by activator caspases, which cleave the 
proapoptotic protein, BH3 interacting-domain death agonist (BID). Truncated BID relocates and can induce 
formation of the mitochondrial apoptosis-induced channel (MAC), which is regulated by members of the B-
cell lymphoma-2 (Bcl-2) family; the proapoptotic Bcl-2 homologous antagonist/killer (BAK) and Bcl-2-
associated X protein (BAX) as well as the anti-apoptotic Bcl-2, Bcl-xL[53] (Figure 1.7). Formation of MAC triggers 
the release of cytochrome c along with other proapoptotic proteins, ultimately leading to apoptosis.  
Multidrug resistance (MDR) is a complication that can arise in cancer treatment. A characteristic feature 
is the expression of the ABC-transporter P-glycoprotein (P-gp) that actively transports chemotoxins out of 
the cell. In addition, P-gp is able to inhibit caspase-3 activated apoptosis pathways.[54] The anticancer 
properties of the HDAC inhibitor, suberoylanilide hydroxamic acid (SAHA), has been investigated in a study 
of P-gp expressing MDR cancer cells. Even though the SAHA-induced caspase-3 pathway was inhibited by P-
gp, SAHA proved effective against the cancer cells by inducing a caspase independent pathway, leading to 
cleavage of BID, which in turn lead to the release of cytochrome c and production of reactive oxygen 
species.[55]  
In the non-acetylated form of Ku70 (a DNA-damage-response protein), the protein exists in a complex 
with BAX, suppressing apoptosis. When the cell is stressed, Ku70 is acetylated; the complex dissociates and 
BAX relocates to the mitochondria where apoptosis is induced.[56] HDAC6 has a role in this pathway, as the 
isozyme can interact with the Ku70-BAX complex.[57] Knocking out HDAC6 or using the HDAC6-specific 
inhibitor, tubacin, increased Ku70 acetylation which in turn triggered BAX-induced cell death.  
Cell cycle arrest 
A normal eukaryotic cell undergoes different phases before initiating cell division. Checkpoints in the cell 
cycle (G1, G2, M) ensure that the cell is healthy before proceeding to the next stage. A number of genes have 
important roles in these regulations; these include p53, Rb, and BRCA1, which are known as tumor 
suppressing genes. They can induce expression of cyclin-dependent kinase (CDK) inhibitors, which negatively 
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control cell cycle progression. Mutation or loss of these genes are common in many types of cancer, leading 
to uncontrolled cell growth.[58] 
The critical role of HDAC1 and 2 in regulating the G1 checkpoint, has been demonstrated in fibroblasts.[59] 
Cells lacking both enzymes were retained in the G1 to S phase, due to an up-regulation of CDK inhibitors p21 
and p57. p21 has generally been linked with cell arrest in the G1 phase, however, HDAC inhibitor induced up-
regulation of the CDK inhibitor has also shown to cause cell cycle arrest at the G2-M checkpoint.[60]  
HDAC inhibitors have also been implicated in blocking progression in the M phase. While many anticancer 
agents affect the formation of microtubules,[61] HDAC inhibitors have been shown to interfere with the 
kinetochore in two human cancer cell lines.[62]  
Anti-angiogenesis 
The progressive growth and metastasis of solid tumors rely on angiogenesis for supply of oxygen and 
nutrients, and for removal of CO2 and waste products. One of the key elements for controlling angiogenesis 
is the hypoxia-inducible factor 1α (HIF-1α), which can stimulate the production of proangiogenic factors, such 
as the vascular endothelial growth factor (VEGF).[63] 
Treatment with the HDAC inhibitor Trichostatin A (TSA), has shown an effect in vitro and in vivo by 
upregulating von Hippel Lindau (VHL) expression (promoting ubiquitination and degradation) and p53, while 
down-regulating HIF-1α and VEGF.[64] Others report that treatment  with HDAC inhibitors induce degradation 
of HIF-1α, independent of VHL and p53.[65] An enhanced interaction between HIF-1α and HSP70 was observed 
and as the activity of HSP90 was known to be controlled by HDAC6,[41] the anti-angiogenic mechanism of 
HDAC inhibition was proposed to arise from an improper maturation of HIF-1α, leading to degradation. 
1.4 Histone deacetylase inhibitors 
As mentioned in the previous section, HDAC inhibitors have shown a potential in cancer treatment. Currently 
two HDAC inhibitors; SAHA (Figure 1.10) and romidepsin (Figure 1.29) have been approved by the food and 
drug administration (FDA) for treatment of cutaneous T-cell lymphoma,[66] and in 2011, romidepsin was also 
approved for treatment of peripheral T-cell lymphoma.[67] Several other HDAC inhibitors are at various stages 
in the drug development process.[68] SAHA and romidepsin are potent inhibitors, but they are not very 
selective for any particular HDAC isoform. The development of selective HDAC inhibitors could have a 
potential in drug development, as an activity for multiple targets usually accompanies a range of side effects. 
Selective HDAC inhibitors are also desired in a research perspective, as an increased knowledge of each HDAC 
isoform could be obtained. 
Acyclic inhibitors 
An enormous progress in understanding the binding of inhibitors to HDAC enzymes occurred when Pavletich 
and co-workers co-crystalized TSA and SAHA, separately bound to the histone deacetylase-like protein 
(HDLP). Even though the overall sequence similarity of the bacterial homologue to HDAC1 is only 35.2%, the 
active site of HDLP has a high resemblance.[69] The crystal structure highlighted important features of the 
active site; a surface binding domain, an ∼11 Å deep narrow pocket leading to the catalytic zinc binding site, 
and a 14 Å internal cavity adjacent to the active site. (Figure 1.8).[69] 
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Figure 1.8 TSA (magenta, space filling model) bound to histone deacetylase-like protein (PDB: 1C3R). Amino acids involved in the 
deacetylation are shown as sticks. 
The crystal structure also gave rise to a suggested deacetylation mechanism by the enzyme (Figure 1.9). A 
water molecule in the active site coordinates to Zn2+. The zinc atom also coordinates the carbonyl oxygen 
from the acetylated lysine substrate, which will polarize the carbonyl, making it more susceptible to a 
nucleophilic attack. His131 activates the water molecule, which will react with the carbonyl group. A 
tetrahedral intermediate is formed, which is stabilized by Tyr297 and the zinc ion. Subsequent release of the 
acetate anion is assisted by His132 and Asp173. 
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Figure 1.9 Deacetylation mechanism by HDACs, proposed by Pavletich and co-workers.[69] A water molecule reacts with the carbonyl 
group of an acetylated lysine residue, activated by Zn2+ and His131. The tetrahedral intermediate, stabilized by Zn2+ and Tyr297 
collapses with the release of an acetate ion. The figure was modified from ref [70]. 
Alternatives to the deacetylation mechanism shown above, have been proposed by Zhang and co-workers 
suggesting that both His131 and His132 hydrogen bonds to the water molecule before the nucleophilic 
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attack,[71] and by Geerlings and co-workers, who suggested that a zinc-coordinated hydroxide, stabilized by 
Tyr297 would react with the acetylated lysine.[72] 
Based on X-ray structures and the activity shown by various inhibitors, a pharmacophore has been 
generated for HDAC inhibitors (Figure 1.10, left). The model consists of a cap group that interacts with motifs 
on the surface of the protein, a linker region, and a zinc-binding group (ZBG) reaching into the active site.  
 In 1971, Breslow and co-workers observed that DMSO induced growth and differentiation in cancer cells. 
The  attempt to understand this effect, lead to the discovery of the potent HDAC inhibitor, SAHA (Figure 
1.10).[73] Another hydroxamic acid containing compound was discovered in 1975 when Koizumi and co-
workers isolated TSA from strains of Streptomyces hygroscopicus.[74] However, the effect on mammalian 
HDACs were first discovered in 1990 (Figure 1.10).[75] Both TSA and SAHA are potent inhibitors of HDAC1, 2, 
3, and 6.  
 
Figure 1.10 Hydroxamic acid containing HDAC inhibitors. a Data was obtained from ref [76]. 
The high potency of TSA and SAHA has been attributed their strong ZBG. Through the years, many compounds 
have emerged that have utilized the hydroxamic acid moiety; the compounds in Figure 1.11 are all at various 
stages in drug development.[1] Except for ACY-1215, the inhibitors are not selective towards a specific HDAC 
isozyme. This could be explained by the strong ZBG that might be too dominant a factor to convey selectivity. 
One could imagine that the hydroxamic acid interacts with other metalloproteins, which could lead to a range 
of side reactions. However, a recent investigation suggests that metalloenzyme inhibitors show minor off-
target interactions.[77] SAHA was tested among these compounds, although off-target inhibition was 
observed, the effect was limited. 
 
Figure 1.11 A selection of hydroxamic acid containing HDAC inhibitors that are in clinical trials.[1]  
Another group of non-cyclic HDAC inhibitors contains an ortho-aminoanilide ZBG. Many of these compounds 
are linked to a phenyl group, which together with the ZBG comprise the benzamides. The compounds in this 
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group mainly inhibits class I HDAC enzymes, although they show a low activity towards HDAC8 (Figure 1.12). 
This selectivity within class I, has been explained by the presence of a specific amino acid near the binding 
site. In HDAC1, 2, and 3 a leucine is located close to the zinc-binding domain of the enzyme, while a 
tryptophan accommodates this position in HDAC8. Because of the tryptophan residue, the ortho-
aminoanilide motif cannot chelate zinc with the optimal geometry and therefore becomes a weaker 
inhibitor.[78] While MS-275, MGCD-0103, and CI-994 are most potent towards HDAC1, an HDAC3 selective 
compound (MI-192) have been found by using a different cap group.[79]  
 
Figure 1.12 Benzamide containing HDAC inhibitors. a Data was obtained from ref [80]. b Data was obtained from ref [81]. c Data was 
obtained from ref [79]. 
The internal cavity present in HDLP (Figure 1.8), which has also been observed in other members of class I 
HDACs (HDAC1[26], 2,[82] 3,[25] and 8[83]) have been of interest in the design of new HDAC inhibitors. Both 
Moradei[84] and Witter[80] independently found an improved potency against HDAC1 and HDAC2, when a 
thienyl sustituent was added to the para-position of the aminoanilide motif in MS-275 (1.1, Figure 1.13). 
Interestingly, the new compound lost activity against HDAC3, while retaining potency for HDAC1 and 2. 
A new class of compounds, containing an amino acid derived ZBG was found in a high throughput 
screening. One of the compounds (1.2) was confirmed by X-ray crystalography (PDB: 3SFH) to bind in the 
internal cavity as well.[83] The compound displayed a high selectivity towards HDAC8, being 19-fold more 
potent relative to HDAC1 and 43-fold more potent relative to HDAC2. 
 
Figure 1.13 HDAC inhibitors, which utilizes binding to the internal cavity. a data was obtained from ref [80]. b data was obtained from 
ref [83]. 
Valproic acid (VPA), which has been prescribed for the treatment of bipolar disorder, major depression, and 
schizophrenia, is the only HDAC inhibitor that has been approved for neurological disorders.[85] VPA does not 
contain any cap group and possess a relative poor ZBG. These features might be the reason why VPA is not a 
potent inhibitor and does not show any particular selectivity, besides an even lower activity against HDAC6 
and 10[86] (Figure 1.14). The therapeutic effect of VPA could be explained by a changed gene expression due 
to HDAC inhibition; however, VPA has been reported to influence a variety of biological pathways, so the 
direct contribution arising from HDAC inhibition is still unknown.[87]  
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Even though the majority of HDAC inhibitors fits the pharmacophore model, potent compounds that lack 
a cap group do exist. Even though the active site in the different HDAC isoforms has a high similarity, 
compound 1.3 and 1.4, were shown to be selective inhibitors for HDAC8.[88] Remarkably, the small HDAC 
inhibitor BRD9757 have been shown to display selectivity towards HDAC6.[89] 
 
Figure 1.14 Small molecule HDAC inhibitors. a Data was obtained from ref [86]. b Data was obtained from ref [88]. c data was obtained 
from ref [89]. 
Isoform selective inhibitors have successfully been synthesized by changing the cap group, thereby exploiting 
the varying amino acid sequence on the surface in different isoforms. The high selectivity of tubacin for 
HDAC6 (Figure 1.15) has been explained by the narrow shape of the surface area, towards the active site in 
the enzyme. Docking experiments showed that the large surface binding domain of tubacin simultaneous 
made favorable lipophilic and polar interactions. A wider surface area towards the active site was observed 
in HDAC1 and HDAC8. Consequently, tubacin would only interact with one side of the surface areas and the 
binding affinity to these isoforms would therefore be lower. In comparison, the decreased selectivity of SAHA 
was explained by the deficiency to distinguish between any surface area in the different HDAC isozymes, due 
to the small cap group.[90] 
 
Figure 1.15 HDAC inhibitors utilizing cap group modifications. a Data was obtained from [91]. b Data was obtained from [92]. c Data 
was obtained from ref [93]. 
The varieties of inhibitors that have been co-crystalized with HDAC8 have assisted in elucidating unique 
features that have been used in the design of selective compounds. The crystal structures show a large 
difference in the binding site, depending on the inhibitor bound. In some cases, the ligand is bound through 
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a single narrow pocket to the active site (Figure 1.16, left), while a second pocket next to the binding site can 
be observed in others (Figure 1.16, middle). Access to the second pocket depends on the position of Phe152 
and Tyr306, which are located between the two cavities. The binding site can even be seen as a single wide 
cavity after the movement of Phe152 (Figure 1.16, right). The selectivity observed for some inhibitors 
towards HDAC8, have been explained by the malleability of the enzyme.[94] Based on X-ray structures and 
molecular dynamics simulations, it has been suggested that the unbound enzyme exists as a wide cavity that 
will accommodate the ligand after coordination with zinc.[94] 
   
Figure 1.16 Binding of various inhibitors in HDAC8 demonstrates the malleability of the binding pocket. Left: single narrow pocket 
after binding of MS-344 (PDB: 1T67), middle: two pockets after binding with TSA (PDB: 1T64), right: wide cavity after binding of 
CRA-19156 (PDB: 1VKG). 
Docking studies of PCI-34051 have shown that due to the short linker region, the inhibitor was able to trap 
the enzyme in the open cavity state, thereby taking advantage of the unique flexibility of the binding pocket 
in HDAC8. The low activity of SAHA was explained by loss of several hydrophobic interactions, as the cavity 
was changed to a single narrow pocket, when occupied by this ligand.[94] Several other HDAC8 selective 
inhibitors have used the distinctive secondary pocket found in HDAC8, by incorporating a meta-substituted 
pattern, which would direct the substituents to the minor cavity.[95] 
 Very few compounds show selectivity towards class IIa HDACs. However, in 2013 Nolan and co-workers 
reported a series of inhibitors containing a trifluoromethyloxadiazole ZBG (Figure 1.17).[96] The high selectivity 
of the compounds was explained by the bulky ZBG in combination with the U-shaped conformation that 
these inhibitors adapted after binding, which was unlikely to fit in other HDAC isozymes. 
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Figure 1.17 Class IIa selective HDAC inhibitors. a Data was obtained from ref [96]. 
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Macrocyclic inhibitors 
The macrocyclic inhibitors comprise both non-peptidic macrocycles as well as cyclic peptides and 
depsipeptides. The use of cyclic peptides in drug development could have improved features compared to 
their linear analogs. While linear peptides degrade readily in vivo, the cyclic peptides are stable towards 
exopeptidases. Endopeptidases usually require the peptide to adopt an extended conformation, small cyclic 
peptides will therefore also have a certain stability towards these enzymes.[97]  
 Macrocyclic inhibitors have been a key factor for understanding HDAC enzymes; a huge breakthrough 
occurred when Schreiber and co-workers used a modified cyclic peptide to isolate the first HDAC enzyme.[98] 
Macrocycles have also shown their potential in the pharmaceutical industry, with romidepsin on the market 
for treatment of cutaneous T-cell lymphoma and peripheral T-cell lymphoma.[66b, 67] 
Most of the macrocyclic HDAC inhibitors are natural products or analogs based on these. However, a few 
non-natural compounds have been synthesized, which also show HDAC inhibitory activity. The wide range of 
macrocyclic HDAC inhibitors have expanded the knowledge regarding binding mode and selectivity.  
α-Epoxy ketone containing cyclic peptides 
Cyclic peptides containing an α-epoxy ketone as the ZBG includes WF-3161,[99] chlamydocin,[100] HC-toxin,[101] 
trapoxin A, B[102], and Cyl-1, 2[103] (Figure 1.18). All the peptides contain a proline or pipecolic acid next to the 
zinc-binding side chain and at least one D-amino acid.  
 
Figure 1.18 Cyclic peptides containing an α-epoxy ketone motif. 
Trapoxin was isolated by Yoshida and co-workers in 1993 and tested in vitro on HDAC enzymes, partially 
purified from mice.[104] The natural compound was a potent inhibitor with an irreversible binding mode. Since 
very little was known about the HDAC enzymes, Schreiber and co-workers utilized the irreversible binding 
mode of trapoxin to investigate the enzymes. An affinity matrix was therefore constructed from an analog of 
trapoxin B (Scheme 1.1).[105]  
 The threitol-derived compound (1.8) was subjected to Swern oxidation, followed by a Wittig reaction to 
obtain 1.9. Evans (S)-oxazolidinone was then added and the protected alcohol converted to the tosylate. 
Diastereoselective azidation afforded the (S)-azido imide, which was hydrolyzed to the free acid. 
Simultaneous hydrogenation of the alkene and azide afforded the amino acid, which was protected with a 9-
fluorenylmethoxycarbonyl (Fmoc) group (1.11) and coupled to a tripeptide.  
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The cyclization was done by adding the peptide via syringe pump to a solution containing (benzotriazol-
1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP), 4-dimethylaminopyridine (DMAP) 
and N,N-dimethylformamide (DMF). The slow addition minimized formation of dimers, which had been the 
main product in their total synthesis of trapoxin B. A protected lysine residue was incorporated as a 
replacement for one of the phenylalanines present in trapoxin B, so the cyclic peptide could be coupled to a 
solid support at a later stage (1.13). The acetonide was removed with aqueous HCl and the epoxide formation 
was facilitated by 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine (DBU). In the final step, an oxidation 
afforded the handle for the affinity matrix (K-trap), before attachment to the solid support. The phenylalanine 
to lysine substitution had little effect on HDAC binding in vitro, so by the use of [3H]-trapoxin in combination 
with the affinity matrix, Schreiber and co-workers managed to isolate the first HDAC enzyme, which is now 
classified as HDAC1.[98, 105]  
 
Scheme 1.1 (a) (COCl)2, DMSO, Et3N, CH2Cl2. (b) LiO2C(CH2)4CH=PPh3, THF. (c) Evans (S)-oxazolidinone, (CH3)3CCOCl, Et3N. (d) HF, 
pyridine, THF. (e) TsCl, iPr2NEt, DMAP. (f) KN(SiMe3)2, THF, –78 °C, trisylazide, AcOH, 35 °C. (g) LiOH, THF, H2O. (h) H2, 10% Pd/C. (i) 
Fmoc-OSu, 2,6-lutidine, THF. (j) tripeptide, EDC, HOBt, NMM. (k) LiOH, THF, MeOH, H2O. (l) BOP, DMAP, DMF. (m) 5% HCl, THF. (n) 
DBU, MeOH, 0 °C. (o) EDC, DMSO, Cl2CHCO2H.[105] 
Chlamydocin, Cyl-2 and trapoxin A, B have been evaluated against a selection of HDACs (Table 1.2). All HDAC 
inhibitors showed selectivity towards HDAC1 compared to HDAC6, Table 1.2.[106] Cyl-2 proved to be particular 
selective with a 57,000 fold preference for HDAC1. In correlation with previous studies, an irreversible 
binding of trapoxin B was confirmed in the case of HDAC1, but for HDAC6 the inhibition proved to be 
reversible.  
Table 1.2 HDAC inhibitory activity against HDAC1 and 6.  
IC50 (nM) 
Compound HDAC1 HDAC6 HDAC6/HDAC1 
Trapoxin A 0.82 ±0.29      524 ±240             640 
Trapoxin B 0.11 ±0.01      360 ±160          3,300 
Chlamydocin 0.15 ±0.03   1,100 ±430          7,300 
Cyl-2 0.7  ±0.45 40,000 ±11,000        57,000 
The data was obtained from ref [106].  
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A range of analogs, based on the scaffold of the natural compounds, was synthesized by substituting the α-
epoxy ketone moiety with a hydroxamic acid (Figure 1.18, Table 1.3). These cyclic hydroxamic-acid containing 
peptides (CHAPs) showed increased activity for HDAC6. Although the selectivity was severely reduced, the 
analogs maintained a higher activity for HDAC1. This suggests that the large cap group of the natural 
compounds, at least to some degree, confer selectivity. Moreover, replacing the epoxy ketone of trapoxin B 
to the hydroxamic acid, converted the inhibitor to a reversible binder.  
Table 1.3 HDAC inhibitory activity against HDAC1 and 6. 
IC50 (nM) 
Compound  HDAC1 HDAC6 HDAC6/HDAC1 
CHAP (trapoxin A)   6.1 ±1.4 (7) 150 ±84 (4) 25 
CHAP (trapoxin B)   1.9 ±0.5 (17)   19 ±3 (19) 10 
CHAP (Cyl-2)   1.2 ±0.7 (2)   36 ±17 (>1000) 30 
CHAP (Cyl-1)   4.4 ±1.8 110 ±84 25 
CHAP (WF3161) 0.94 ±0.33   22 ±10 23 
CHAP (chlamydocin) 0.44 ±0.23 (3)   38 ±12 (29) 86 
CHAP (HC-toxin)   2.9 ±2.1   61 ±14 21 
Potency relative to the natural compound is shown in parenthesis. Red: fold decrease, 
green: fold increase. The data was obtained from ref [106]. 
Even though the α-epoxy ketone containing compounds are potent inhibitors in vitro, only weak activity has 
been observed in animal models. This effect is thought to arise because of instability of the α-epoxy ketone 
moiety in the blood.[107] Whereas chlamydocin has a half-life of ∼2.5 min in blood, CHAP based on Cyl-1 is 
more stable, with a half-life of ∼50 min. This suggests that the therapeutic potential can be improved by 
changing the ZBG of the cyclic peptides. 
CHAPs based on chlamydocin have been explored further by modifying the phenylalanine and the 
aminoisobutyric acid. An acetylated thiol was also explored as a ZBG in some of the analogs (Figure 1.19).[108] 
The biological data shows that modifications to the core structure are well tolerated at the indicated 
positions, whereas compound 1.19–1.21 are less potent inhibitors, especially against HDAC6 (Table 1.4).  
 
Figure 1.19 CHAP analogs based on chlamydocin. 
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Table 1.4 HDAC inhibitory activity against HDAC1, 4, and 6. 
IC50 (nM) 
Compound HDAC1 HDAC4 HDAC6  Compound HDAC1 HDAC4 HDAC6 
TSA 23 34 65  1.18   10 (2)    15 (2)  96 (2) 
1.14   10 (2)       6 (6)     130 (2)  1.19   27 (2) nd >1000 (>15) 
1.15   15 (ep)     14(2)     160 (3)  1.20   28 (2) nd      380 (6) 
1.16   11 (2)     12(3)     170 (3)  1.21   38 (2) nd >1000 (>15) 
1.17   14 (ep)     19(2)     110 (2)      
Potency relative to CHAP (chlamydocin) is shown in parantheses. Red: fold decrease, ep: equipotent, green: fold 
increase. Data was obtained from ref [108]. 
Apicidin 
The fungal metabolites, apicidin and apicidin A (Table 1.5), were isolated in 1996 in a natural products screen 
against a broad range of parasites (apicomplexa). The anti-parasitic potency of apicidin is likely a 
consequence of its ability to inhibit apicomplexan HDACs with an IC50 of 1–2 nM.[109] The closely related 
analogs, apicidin B, C, D1, D2, and D3 (Table 1.5), were isolated in 2002,[110] and in 2010 variants E and F were 
discovered.[111] 
Table 1.5 Known apicidin compounds.  
 
Name R1 R2 R3 R4 R5 HeLa NEa 
Apicidin a OMe Et Me CH2CH2 1 
Apicidin A a H Et Me CH2CH2 2 
Apicidin B a OMe Et Me CH2 − 
Apicidin C a OMe Me Me CH2CH2 − 
Apicidin D1 b OMe Et Me CH2CH2 0.3 
Apicidin D2 c OMe Et Me CH2CH2 400 
Apicidin D3 b OMe Et Me CH2CH2 − 
Apicidin E d OMe Et Me CH2CH2 − 
Apicidin F e OMe Ph H CH2CH2 − 
 a Data was obtained from ref [110]. 
The first total synthesis of apicidin A was reported by Mou and Singh in 2001.[112] The side chain of apicidin 
was synthesized from L-glutamic acid to give the iodoamino ester 1.24, and the key step in the strategy was 
a radical coupling of ethyl vinyl ketone to form the protected (S)-2-amino-8-oxodecanoic acid (1.25) (Scheme 
1.2). The linear peptide was synthesized and activated as a pentafluorophenyl ester (1.27). Slow deprotection 
of the Cbz group afforded the cyclic peptide in 54% over 6 steps after deprotection of the indole. 
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Scheme 1.2 The first total synthesis of apicidin A by Mou and Singh.[112] Reagents and conditions: (a) HCHO, cat. p-TSA. (b) NaOMe, 
MeOH. (c) EtOCOCl. (d) NaBH4. (e) PPh3, I2, imidazole. (f) pent-1-en-3-one, n-Bu3SnH, hv, Et2O. (g) peptide synthesis. (h) Boc2O, DMAP. 
(I) NaOH. (j) C6F5OH, EDAC/DMAP. (k) H2/Pd, C6H12, dioxane. 
Cyclization of tetrapeptides is known to be difficult because of the strained conformation that the linear 
peptides have to adopt; dimerization is a byproduct that is often observed.[113] In other total syntheses of 
apicidin and similar cyclic tetrapeptides, the site of cyclization between the C-terminal of proline and the N-
terminal Aoda residue have been used.[105, 112, 114] 
An extensive SAR study on the side chain of apicidin has been conducted;[115] a selection of these are 
presented in Table 1.6. The importance of the carbonyl functionality was evident, as activity was lost after 
reduction (entry 2, 3). The retained activity of the aldehyde (entry 18), support this fact. The space in the 
active site was explored by incorporating large substituents; n-propyl was well tolerated, while activity was 
lost when incorporating an isopropyl and a phenyl substituent. Exchanging the ketone for other known ZBGs 
(entry 15, 17) gave highly active compounds; in the case of the α-epoxy ketone moiety, substitution on C9 
was better tolerated than on C7 (entry 15, 16). The optimal length of the side chain was found, in analogy to 
the length of an acetylated lysine, by having the carbonyl group at C8 (entry 8, 11). Interestingly, the 
acetylated thiols, which are hydrolyzed in vitro, showed the highest potency with the thiol at C7.  
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Table 1.6 Activity of apicidin analogs.  
 
IC50 (nM) 
Entry R HeLa Entry R HeLa Entry R HeLa 
1 
 
1 7 
 
74 13a 
 
110 
2 
 
1450 8 
 
0.4 14a 
 
3 
3  61 9  
7 15 
 
<0.1 
4 
 
1 10 
 
282 16 
 
5 
5 
 
235 11 
 
15 17 
 
0.2 
6 
 
700 12 
 
848 18 
 
6 
 a thiol generated in situ. Data was obtained from ref [115]. 
While apicidin exists as the all trans conformation in [D5]pyridine and CD2Cl2[116] three conformations have 
been observed in DMSO-d6, in a ratio of approximately 80:15:5.[117] The major conformation was still the all 
trans (t-t-t-t), whereas a cis amide bond was observed between valine and pipecolic acid in the second most 
abundant structure. The cis-trans-trans-trans (c-t-t-t) conformation has also been observed in a crystal 
structure of apicidin,[116] but the biological active conformation of apicidin was still unknown. Ghadiri and co-
workers therefore synthesized apicidin analogs containing 1,4-disubstituted 1,2,3-triazoles and 1,5-
disubstituted 1,2,3-triazoles mimicking a trans amide- and a cis amide bond respectively (Figure 1.20).[117] 
Overlaying NMR structures of the t-t-t-t and c-t-t-t triazole analogs with their corresponding apicidin NMR 
structures showed a close similarity, confirming the use of the analogs as representatives in the biological 
testing. Similar to 1.28 and 1.29, compound 1.30 displayed a single conformation (c-t-c-t) in NMR and was 
therefore evaluated in the HDAC assays as well.  
1.30 showed decreased HDAC inhibitory activity against all isozymes compared to the other apicidin 
analogs. For 1.28 and 1.29 no significant change of activity was seen against HDAC3, however, for HDAC1 the 
all trans compound (1.28) lost ∼8 fold potency, while 1.29 only displayed a minor change in IC50 value. 
Interestingly, 1.29 was more potent than apicidin for HDAC6 and especially against HDAC8 (Table 1.7). 
 
Figure 1.20 Conformational constrained apicidin analogs. 
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Table 1.7 HDAC inhibitory activity against HDAC1, 3, 6, and 8. 
 IC50 (nM) 
Compound HDAC1 HDAC3 HDAC6 HDAC8 
Apicidin 3 11 >10,000 750 
1.28 (t-t-t-t) 25 (8) 16 (2) >10,000 nda 
1.29 (c-t-t-t) 7 (2) 9 (ep) 6100 105 (7) 
1.30 (c-t-c-t) 75 (25) 119 (11) >10,000 nda 
Potency relative to apicidin is shown in parantheses. Red: fold 
decrease, ep: equipotent, green: fold increase. nd: not determined. 
Data was obtained from ref [117]. 
Even though minor structural changes occur in the analogs, the altered HDAC activity was explained by the 
conformational change in the cyclic core. Apicidin exist primarily as the t-t-t-t conformation in most 
solvents,[109] however, the data suggests that apicidin interact with HDAC enzymes in the c-t-t-t conformation.   
A significant change occurs in the backbone structure when the geometry of the peptide bond is altered, 
in particular the distance between Ile/Leu and Ala, but also the distance between Trp and the Aoda residue 
(Figure 1.21). The vector from Cα to Cβ in the Aoda, Trp, and Ile/Leu side chains seems to lie in the plane of 
the ring structure in 1.30, while it is projected above, in the biological active compounds 1.28 and 1.29. 
  
Figure 1.21 Changing the geometry of the amide bond alters the cyclic structure significantly. Left: 1.28: (t-t-t-t), 1.29: (c-t-t-t), 1.30: 
(c-t-c-t). Right: The vector from Cα to Cβ is projected above the plane in the biological active compounds. 1.28: magenta, 1.29: green 
and cyan, 1.30: yellow. The figure was modified from ref [117]. 
Ghadiri and co-workers designed a range of analogs based on the scaffold of apicidin. By incorporating β-
amino acids in the peptide backbone, a series of α3β and α2β2 cyclic peptides were constructed (Figure 
1.22).[118]  
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Figure 1.22 α3β and α2β2 cyclic peptides/peptoids based on apicidin.[118-119] 
From HeLa cell nuclear extracts it was clear that compounds with a β-amino acid in the position of tryptophan 
or alanine (1.41, 1.42, 1.43) were less potent. No significant change was observed for compound 1.31 and 
1.44, so the analogs were further modified by altering the ZBG (1.32−1.34, 1.45−1.46). Incorporating a 
hydroxamic acid increased the potency, while substituting for a carboxylic acid or an amide had a negative 
impact. The stereochemical requirements of the side chains were investigated by changing the chirality of 
individual residues (1.35-1.37). The tryptophan- and Aoda epimers showed a severe decrease in activity, 
while the change was modest when the alanine residue was modified. Analogs containing backbone 
methylated amides showed the same trend (1.38−1.40); while a modest decrease was observed for the 
alanine residue, changes to valine or tryptophan resulted in a significant loss of activity. The backbone 
scaffold was further investigated by incorporating an additional β-amino acid (α2β2). Changing tryptophan 
and valine to β-amino acids resulted in more than 700-fold loss in potency (not shown), while the activity 
loss was lower when alanine and valine were changed to β-amino acids (1.47).  
Recently, the 1.39 scaffold has been further investigated by substituting residues with peptoid units.[119] 
Although potency was decreased relative to apicidin (Table 1.8), compound 1.48 and 1.49 were potent 
inhibitors against HDAC1−3, with IC50 values ranging from 100−320 nM. 
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Table 1.8 HDAC inhibitory activity against HeLa NE. 
    IC50 (nM)    
Compound HeLa NE  Compound HeLa NE  Compound HDAC1 
1.31      19 (2)  1.40 > 1000 (>99)  1.48 180 (16) 
1.32      <1 (>9)  1.41 480 (53)  1.49 200 (18) 
1.33    300 (33)  1.42 200 (22)  Compound HDAC2 
1.34  2700 (>99)  1.43 >1000 (>99)  1.48 300 (9) 
1.35 >1000 (>99)  1.44 9 (ep)  1.49 370 (5) 
1.36     440 (49)  1.45 <1 (>9)  Compound HDAC3 
1.37 >1000 (>99)  1.46 250 (28)  1.48         100 (8) 
1.38   2000 (>99)  1.47 250 (28)  1.49         320 (25) 
1.39        40 (4)       
Potency relative to apicidin is shown in parenthesis. Red: fold decrease, ep: equipotent, green: fold increase. 
Data was obtain from ref [118-119]. NE: Nuclear extract. 
Largazole 
Largazole is a marine cyanobacterial secondary metabolite, isolated by Luesch and co-workers, from 
Symploca sp.[120] The natural compound consists of a long thioester side chain (the first known example 
produced by a cyanobacterium) and an unusual cyclic core containing a distinctive 4-methylthiazoline, linked 
to a thiazole (Figure 1.23). 
 
 Figure 1.23 Largazole is a natural prodrug, which is hydrolized to its biological active form in vivo. 
Largazole has attracted interest from a number of groups, demonstrated by at least 11 total syntheses. The 
first total synthesis was pulished by Luesch, Hong, and co-workers (Scheme 1.3).[121] Subunit 1.51 was made 
by condensation of 1.50 with H-(L)-Cys-CO2Me. After TFA deprotection, the building block was coupled to 
1.52, which had been synthesized by a stereoselective syn-aldol reaction, using a chiral thiazolidinethione 
auxiliary.[122] The last amino acid was then attached and the depsipeptide was cyclized between valine and 4-
methylthiazoline. The final compound was obtained by a cross metathesis with the thioester side chain using 
Grubbs 2nd generation catalyst. A high loading of the catalyst was needed (50 mol%), since the thioester 
coordinates to the ruthenium catalyst.  
Both Cramer and co-workers[123] as well as Phillips and co-workers,[124] chose to attach the side chain in 
the final step via a cross metathesis, but instead of using a chiral auxiliary for synthesis of the β-hydroxyacyl 
subunit, the chirality was obtained by enzymatic resolution of a racemic β-hydroxyl ester. 
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Scheme 1.3 Total synthesis of largazole by Luesch, Hong, and co-workers.[121] Reagents and conditions: (a) H-(L)-Cys-CO2Me, Et3N, 
EtOH, 50 °C, 72h. (b) TFA, CH2Cl2, 25 °C. (c) 1.52, DMAP, CH2Cl2, 25 °C, 1h. (d) 2,4,6-trichlorobenzyl chloride, Et3N, THF, 0 °C, then 
BocNH-(L)-Val-OH, DMAP, 25 °C, 10h. (e) 0.5 N LiOH, THF, H2O, 0 °C, 3h. (f) TFA, CH2Cl2, 25 °C, 2h. (g) HATU, HOAt, iPr2NEt, CH2Cl2, 25 
°C, 24h. (h) n-C7H15COSCH2CH2CH=CH2.  
The groups of Williams,[125] Ganesan,[126] and Xie[127] all chose to use a thiol protected β-hydroxy acid, in their 
total syntheses of largazole; Ganesans synthesis is shown in Scheme 1.4. Aldehyde 1.56 was obtained in two 
steps from acrolein and by using the same chiral auxiliary as in Luesch and Hong’s total synthesis, the thiol 
protected β-hydroxy acid (1.58) was synthesized in good yield. Cyclization followed by trityl deprotection and 
acylation yielded the target compound.  
 
Scheme 1.4 Total synthesis of largazole by Ganesan and co-workers.[126] Reagents and conditions: (a) TrtSH, Et3N, CH2Cl2. (b) 
Ph3P=CHCHO, benzene, reflux. (c) 1.57, TiCl4, i-Pr2NEt, CH2Cl2. (d) LiOH, aq. THF. (e) TMSEOH, DCC, CH2Cl2. (f) Fmoc-Val-OH, DCC,  
CH2Cl2. (g) 1.60, PyBOP, i-Pr2NEt, CH2Cl2, overnight. (h) TFA, MeCN, overnight. (i) HATU, HOBt, i-Pr2NEt, MeCN/CH2Cl2, overnight. (j) 
TFA, Et3SiH, CH2Cl2, 0 °C to rt, 2h. (k) n-C7H15COCl, Et3N, CH2Cl2, 0 °C to rt, 3h.  
Jiang and co-workers published another interesting example, shown in Scheme 1.5. The stereochemistry of 
the tert-butyl-silyl (TBS) protected diol 1.65 was already set, as the commercially available (−)-malic acid was 
used as starting material. The methyl ester was saponified and protected with 2-(trimethylsilyl)ethanol, 
where after a selective deprotection of the primary alcohol afforded compound 1.67. Swern oxidation to the 
aldehyde and Julia-Kocienski olefination afforded 1.69 favoring the E isomer (E/Z: 8/1). Selective removal of 
the primary alcohol, allowed insertion of a thioester using the Mitsunobu reaction and the final β-hydroxyacyl 
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building block was obtained by deprotecting the secondary alcohol. After connecting the subunits and 
cyclizing from the β-hydroxy acid to the thiazole subunit, the natural compound was obtained. Ghosh and 
co-workers chose to cyclize at the same position, but the β-hydroxy ester was obtained by enzymatic 
resolution followed by cross metathesis on the subunit.[128] 
 
Scheme 1.5 Total synthesis of largazole by Jiang and co-workers.[129] Reagents and conditions: (a) SOCl2, MeOH (b) BH3, Me2S, NaBH4. 
(c) TBSCl, imidazole, DMF. (d) KOH, THF/H2O. (e) DCC, TMS(CH2)2OH. (f) CSA, CHCl3/MeOH. (4:1) (g) (COCl)2, DMSO, Et3N. (h) 1.68, 
NaHMDS, THF. (i) CSA, CHCl3/MeOH (9:1). (j) octanethioic acid, DEAD, Ph3P, THF. (k) CSA, CHCl3/MeOH (2:1). (l) Fmoc-(L)-Val-OH, 
EDCl, HOAt, DIPEA, CH2Cl2, rt. (m) piperidine, DMF, 20 min, rt. (n) 1.60, EDC, HOAt, DIPEA, CH2Cl2, rt. (o) TFA, TES, CH2Cl2, 2h. (p) 
HATU, HOAt, DIPEA, CH2Cl2, 2 days, rt.  
Most total syntheses of largazole have made disconnections as seen in Scheme 1.6. Various strategies have 
been used for incorporating the side chain; these include acylation after cyclizing the scaffold, or attachment 
via a cross metathesis. Cyclization with the thioester side chain has also been performed. In all the strategies, 
the core structure from three building blocks have been assembled from a β-hydroxy acid, valine and the 4-
methylthiazoline linked thiazole. The stereochemistry for the β-hydroxy acid building block has primarily 
been obtained from an asymmetric aldol reaction or an enzymatic resolution. 
 
Scheme 1.6 Cyclization I: Luesch/Hong, Doi, Xie; Cyclization II: Williamms, Cramer, Phillips, Ghosh, Ye, Forsyth, Jiang, Ganesan; Thiol 
deprotection/acylation: Williams, Ye, Doi, Xie, Ganesan; Cross metathesis: Luesch/Hong, Cramer, Philips, Ghosh; Julia-Kocienski 
olefination: Jiang; Asymmetric aldol reaction: Luesch/Hong, Williams, Ye, Doi, Xie; Enzymatic resolution: Cramer, Philips, Ghosh. The 
figure was modified from ref [130]. 
Williams and co-workers demonstrated that largazole act as a prodrug and that the activity instead arises 
from its corresponding thiol.[125] This mode of action was discovered by testing largazole and its 
corresponding thiol against a number of HDAC isoforms. The data clearly showed the superior potency of 
largazole thiol, which was more than 250-fold more potent against HDAC1−3. When the inhibitory effect was 
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tested in a panel of melanoma cell lines, largazole was more potent (IC50 = 45−315 nM) compared to largazole 
thiol (IC50 = 360-2600 nM) emphasizing the prodrug nature. Largazole thiol has since been tested against the 
whole panel of HDAC enzymes (Table 1.9), showing high potency for HDAC1, 2, 3, 10, and 11, a decreased 
activity for HDAC6 and 8, while no inhibition is seen against class IIa. 
Table 1.9 HDAC inhibitory activity against all HDACs. 
    IC50 (nM)       
  Class I  Class IIa   Class IIb  Class IV  
HDAC  1 2 3 8  4 5 7 9  6 10  11  
Largazole thiol  0.4 0.9 0.7 102  IAa IA IA IA  42 0.5  3  
a IA: inactive below 1000 nM. The table was modified from ref [130]. 
In 2011, the binding mode of largazole as a thiol was further validated when the crystal structure of a 
HDAC8−largazole thiol complex was published.[131] When the crystal structure of largazole (uncomplexed) is 
compared with the binding mode in HDAC8,[123] minimal conformational changes are observed. In the HDAC8-
largazole thiol complex, the rigid backbone is located on the surface of the protein. The thiol, which is most 
likely ionized, reaches the zinc ion through a narrow tunnel and obtains an ideal metal coordination 
geometry. The enzyme needs to modify its conformation to accommodate the ligand. Especially the 
orientation of Tyr100 and Asp101 in the L2 loop (Leu98-Phe109) is altered (highlighted in magenta, Figure 
1.24).  
 
Figure 1.24. HDAC8−largazole thiol complex. Prominent conformational changes are colored magenta. Left: The large cap group of 
largazole-thiol interacts with amino acids on the surface of HDAC8. Right: The thiol side chain of hydrolyzed largazole reaches the 
zinc ion through a narrow binding pocket (PDB: 3RQD).[131] 
Although differences exist between the HDAC isozymes, the crystal structure of HDAC8-largazole thiol 
provides a basis for understanding the biological results of other macrocycles that have been synthesized. In 
some cases, analogs of the thioester have been tested against the unhydrolyzed largazole.[132] Even though 
the active form of largazole is the free thiol, activity is still observed when the thioester is used on isolated 
HDAC enzymes in vitro (although with a much lower activity).  
No improvement has been made when side chain modified analogs have been synthesized (Figure 1.25). 
The loss of activity, which is observed when altering the length of the linker (1.77−1.79), is in agreement with 
the crystal structure. If the length of the linker is too long, an unfavorable geometry in the zinc coordination 
is obtained, while removing a methylene results in the sulfur atom being unable to reach the zinc ion. The 
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low activity of 1.80 is not surprising, as the cap group of largazole would need to change its orientation 
dramatically in order for the side chain to reach the active site. The low potency of analogs with changed ZBG 
(1.72−1.76) is somewhat unexpected. However, activity might be regained if the length of the side chain was 
optimized further.  
 
Figure 1.25 Largazole analogs containing a modified side chain.
Table 1.10 HDAC inhibitory activity against HDAC1, 2, 3, and 6. 
IC50 (μM) 
Analogs HDAC1 HDAC2 HDAC3 HDAC6 
1.72a >30 (>99) >30 (>99) >30 (>99) >30 (>99) 
1.73a 0.27 (>99) 4.1 (>99) 4.1 (>99) >30 (>99) 
1.74a 23 (>99) 29 (>99) 14 (>99) >30 (>99) 
1.75a 0.67 (>99) 1.6 (>99) 0.96 (>99) 0.7 (>99) 
1.76a 1 (>99) 1.9 (>99) 1.5 (>99) 0.24 (6) 
a Potency relative to largazole thiol is shown in parenthesis. Red: fold 
decrease. Data was obtained from ref [133]. 
 
Table 1.11 HDAC inhibitory activity against HDAC1 and 6. 
IC50 (μM) 
Analogs HeLa NE HDAC1 HDAC6 
1.77a >20(>99) – – 
1.78a 7.6 (>99) 0.69(91) >10 (>5.5) 
1.79a 4.1 (>99) 1.9(>99) >10 (>5.5) 
1.80a >20(>99) – – 
a Potency relative to largazole thiol is shown in 
parenthesis. Red: fold decrease. Data was obtained 
from ref [132a]. 
 
Modifications to the macrocycle in largazole seem to be better tolerated, although only a few analogs with 
an increased activity have been synthesized. Inconsistent results have been published regarding the activity 
of compound 1.81. Nan and co-workers reported a 146-fold decrease in potency,[132b] while de Lera and co-
workers described a 3-fold increased activity (Table 1.12).[132c] By evaluating the reduced potency of the 
similar compound 1.92, (Table 1.12), a reduced activity seems to be most consistent. The thiazoline−thiazole 
subunit of largazole is pointed towards the solvent (Figure 1.26, right), the methyl group therefore does not 
seem to have any particular interaction. However, changing the subunit to a di-thiazole, will change the 
backbone structure, which could explain the lower potency. This explanation is in agreement with the equal 
activity of compound 1.84. Since the thiazoline−thiazole subunit points toward the solvent, adding a 
hydrophobic ethyl group (1.85) would lead to unfavorable interactions, which also agrees with the observed 
activity. Adding a benzyl in the same position (1.86), surprisingly, increase the activity. This might be 
explained by pi-pi interactions between the benzyl group and either Phe100 or Tyr152, which are located in 
the vicinity (Figure 1.26). 
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Figure 1.26 Largazole in HDAC8 (PDB:3RQD). Left: Phe100 and Tyr152 is located in the rim of the binding site and might interact with 
largazole analogs. Right: Surface view of largazole in HDAC8. The valine residue is exposed to the solvent. 
The lower activity observed by substituting the lactone to a lactam (1.95), could be explained by an 
unfavorable change to the scaffold, resulting in a linker that is too short to reach the active site. When the 
thiol side chain has been incorporated in cyclic peptides, an extra methylene is usually needed to obtain the 
optimal length.[115, 134] It would therefore be interesting to see if the activity of 1.95 could be optimized by 
increasing the length of the linker as well. 
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Figure 1.27 Largazole analogs with changes to the core structure. 
Table 1.12 HDAC activity compared to largazole 
IC50 (μM) 
Analogs HDAC1 HDAC2 HDAC3 HDAC4 HDAC6 
  1.81a,b 2 (146)a/0.0047 (3)b 18.5 (97)a 16.8 (69)a 3 (ep)b 14.7 (ep)a 
1.82a NA NA NA  NA 
1.83a NA 51.8 (>99) 22.6 (92)  NA 
1.84b         0.0137 (ep)   7.5 (3)  
1.85b         0.161 (14)   4.9 (2)  
1.86b         0.0045 (3)   3 (ep)  
1.87c         0.044 (6)    3.3 (2) 
Potency relative to the largazole is shown in parenthesis. Red: fold decrease, ep: equipotent green: 
fold increase. NA: Not active. a Data was obtained from ref [132b]. b Data was obtained from ref 
[132c]. c Data was obtained from ref [132a]. 
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Figure 1.28 Largazole thiol analogs with changes to the core structure. 
Table 1.13 HDAC activity against HDAC1, 2, 3, 6, and HeLa NE. 
IC50 (nM) 
Analogs HDAC1 HDAC2 HDAC3 HDAC6  Analogs HeLa NE 
1.88a 0.11 (92) 0.8 (>99) 0.58 (>99) 13 (>99)  1.96c 17.2 (>99) 
1.89a 1.2 (>99) 3.1 (>99) 1.9(>99) 2.2 (45)  1.97c 0.17 (4) 
1.90a 0.03 (25) 0.082 (23) 0.084 (25) 0.68 (14)  1.98c 3.15 (73) 
1.91a 0.002 (2) 0.005 (2) 0.004(ep) 0.13 (3)  1.99c 0.99 (23) 
1.92a 0.077 (64) 0.12 (34) 0.085 (25) >30 (>99)    
1.93a 0.0007 (2) 0.0017 (2) 0.0011 (2) 0.03 (ep)    
1.94a 0.0032 (4) 0.0008 (4) 0.0015 (3) 0.03 (ep)    
1.95b 0.0009 (9) 0.0004 (5) 0.0004 (4) 1.5 (38)    
Potency relative to the largazole thiol is shown in parenthesis. Red: fold decrease, green: fold increase, 
ep: equipotent.a Data was obtained from ref [133]. b Data was obtained from ref [135]. c Data was obtained 
from ref [126a]. NE: Nuclear extract. 
Overall, it seems like changes to the backbone conformation of the cap group are not well tolerated. An 
alternative strategy for synthesizing new potent compounds involve changes to other features, such as the 
valine, which is exposed to the solvent (Figure 1.26). It might be possible to gain some activity by substituting 
with a hydrophilic residue. Even though HDAC8 belongs to class I, together with HDAC1−3, and the biological 
data in general can be explained from the co-crystalized structure of largazole thiol in HDAC8, the isozyme 
differs especially around the rim towards the active site. Thus, the rationale for constructing potent inhibitors 
for HDAC8 might therefore not be valid for all enzymes in class I.  
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Romidepsin and related compounds 
The natural compound romidepsin was isolated from the Gram-negative bacterium C. violaceum in 1994, by 
Okuhara and co-workers in the search for compounds with antimicrobial and antitumor activities.[136] No 
significant effect was observed against microbes, but the natural compound showed potent activity against 
a variety of human carcinoma cell lines. Romidepsin is a 16-membered depsipeptide bridged by a disulfide. 
The compound is stable in serum and can readily penetrate the cell membrane. Once inside, the disulfide is 
reduced by glutathione reductase and the active structure is formed (Figure 1.29).[137] The free thiol most 
likely coordinates to the zinc ion in the active site, in a similar fashion as largazole (Figure 1.24). A docking 
structure of romidepsin in HDAC8 confirms a high similarity to the binding mode of largazole.[131] 
  
Figure 1.29 Romidepsin is a natural prodrug, which is reduced to its active form in vivo. 
The first total synthesis was achieved by Simon and co-workers (Scheme 1.7).[138] Starting from methyl 2,4-
pentadienoate a conjugate addition of triphenylmethanethiol (TrtSH) , followed by diisobutylaluminum 
hydride (DIBAL-H) reduction and Swern oxidation to the aldehyde afforded compound 1.56. The thiol-
containing β-hydroxy acid was then obtained, using Carreiras catalytic asymmetric aldol reaction. The 
enantiomer of 1.100 was originally synthesized in an effort to cyclize with an activated ester, but 
unacceptable low yields prompted a revised synthesis strategy. 1.101 was coupled to the tetrapeptide and 
cyclization was achieved using a Mitsunobu reaction to give the correct stereochemistry. A final oxidation 
with iodine in dilute MeOH afforded the natural product.  
 
Scheme 1.7 Total synthesis of romidepsin by Simon and co-workers.[138] Reagents and conditions: (a) TrtSH, Cs2CO3. (b) DIBAL-H. (c) 
(COCl)2, DMSO, Et3N. (d) ((1-(benzyloxy)vinyl)oxy)trimethylsilane , Ti(IV) cat. (e) LiOH, MeOH. (f) 1.102, BOP, i-Pr2Et3. (g) LiOH. (h) 
DIAD, PPh3. (i) I2.  
The total synthesis of romidepsin has also been reported by Ganesan[126b] and Williams.[139] Due to difficulties 
in reproducing the enantioselectivity in Carreiras asymmetric aldol reaction, utilized by Simon and co-
workers, both groups chose a different route for synthesizing the β-hydroxy acid. 
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 Williams and co-workers initiated their synthesis from methyl 3,3-dimethoxypropionate to afford the 
propargylic ketone (1.107) in two steps via the Weinreb amide (1.106, Scheme 1.8). Noyori’s asymmetric 
hydrogen transfer was then used to afford the R-propargylic alcohol in an enantiomeric excess (ee) of 98%, 
and the trans isomer (1.108) was obtained selectively using sodium bis(2-methoxyethoxy)aluminumhydride 
(Red-Al). Following selective tosylation of the primary alcohol, the dimethyl acetate was hydrolyzed with 
LiBF4 and then oxidized to the carboxylic acid. The trityl-protected thiol was introduced at the last step, by 
replacing the tosylate. The final steps for obtaining romidepsin were done in analogy to Simon and co-
workers, Scheme 1.7. 
 
Scheme 1.8 Synthesis of the key intermediate by Williams and co-workers.[139] Reagents and conditions: (a) iPrMgCl, HN(OMe)Me, 
THF, 0 °C, 1.5h. (b) (but-3-yn-1-yloxy)(tert-butyl)diphenylsilane, n-BuLi, THF, –78 °C to 0 °C, 14h. (c) (R,R)-cat. (10mol%), iPrOH, 4d. (d) 
Red-Al, Et2O, 0 °C to rt, 1h. (e) TBAF, THF, rt, 3.5h. (f) TsCl DMAP, CH2Cl2, rt, 2h. (g) LiBF4, MeCN, H2O, rt, 10d. (h) NaClO2, NaH2PO4, 2-
methyl-2-butene. (i) HSCPh3, t-BuOK, THF, 0 °C, 3h. 
Ganesan and co-workers already had a route for synthesis of the key intermediate (1.58), from their total 
synthesis of largazole, Scheme 1.4. Instead of a macrolactonization utilized by Simon and Williams, Ganesan 
chose a HATU mediated lactamization with D-Val on the N-terminal.[126b] 
Romidepsin is one of the most potent HDAC inhibitor known, with IC50 values ∼1 nM for HDAC1, 2, 3, 10, 
and 11 (Table 1.14). A cysteine residue near the active site is important for inhibition by romidepsin, as shown 
by an 8-fold decrease in potency after mutation of cysteine to serine. The cysteine residue (Cys151 in HDAC1) 
is conserved at least for HDAC1, 2, 3 and 8. The lower activity for HDAC8, must therefore be explained by 
other factors. At present, romidepsin is the only macrocyclic HDAC inhibitor that has been approved by the 
FDA.[66b] 
Table 1.14 HDAC inhibitory activity against all HDACs. 
 
 a reduced romidepsin, b IA: inactive below 1000 nM. The table was modified from ref [130]. 
The spiruchostatis and thailandepsin A-F possess a very similar scaffold as romidepsin (Table 1.15). However, 
a γ-amino acid in these natural compounds exchanges the two α-amino acids next to the ester in romidepsin. 
The cyclic depsipeptides therefore consist of a 15-membered rings structure, relative to the 16-membered 
ring in romidepsin. All members of thailandepsin and spiruchostatins is thought to be natural prodrugs like 
romidepsin and largazole, as they show severely reduced activity when tested as the disulfide.[140] 
  IC50 values (nM) 
 Class I  Class IIa   Class IIb  Class IV  
HDAC 1 2 3 8  4 5 7 9  6 10  11  
Romidepsina 0.8 1 1.3 IAb  647 IA IA IA  226 0.9  0.3  
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Table 1.15 Related romidepsin compounds 
    
   IC50 (μM) 
Compound R1 R2 HDAC1 HDAC4 HDAC6 
Thailandepsin Aa b f 0.00028 (ep)   37.22 (4)   0.83 (ep) 
Thailandepsin Ba c f 0.0012 (4)   57.44 (7)   1.19 (2) 
Thailandepsin Ca b e 0.0002 (ep)   38.04 (4)   0.78 (ep) 
Thailandepsin Da c e 0.00048 (ep)   46.97 (5)   0.93 (ep) 
Thailandepsin Ea b g 0.00098 (3)   58.88 (7)   1.68 (3) 
Thailandepsin Fa c g 0.0026 (9) 132.5 (15)   1.92 (3) 
Spiruchostatin Ab d e 0.0033 (ep) 
−   1.6 (4) 
Spiruchostatin Bb d f 0.0022 (ep) 
− 
1.4 (4) 
Spiruchostatin C a f 
− − − 
Potency relative to romidepsin is shown in parenthesis. Red: fold decrease, ep: 
equipotent. IC50 values are shown for the reduced form of the natural compound. a Data 
was obtained from ref [140a]. b Data was obtained from ref [140b]. 
Azumamide A−E 
In the search for antitumor lead compounds, five cyclic tetrapeptides, azumamide A-E, were isolated from 
the marine sponge Mycale izuensis in 2006.[141] The Azumamides possess three D-amino acids and an unusual 
β-amino acid; [(Z)-(2S,3R)-3-amino-2-methyl-5-nonene-dioic acid, 9-amide] (Amnaa) in azumamide A, B, and 
D, while a [(Z)-(2S,3R)-3-amino-2-methyl-5-nonenedioic acid] (Amnda) is incorporated in azumamides C and 
E (Table 1.16). Compared to other cyclic HDAC inhibitors (e.g. trapoxin and apicidin) the azumamides display 
an inverse direction of the amide bonds and contain a β-amino acid in the cyclic scaffold.  
Table 1.16 Azumamide A-E 
Name R1 R2 R3 
 
Azumamide A NH2 H Me 
Azumamide B NH2 OH Me 
Azumamide C OH OH Me 
Azumamide D NH2 H H 
Azumamide E OH H Me 
    
Since the discovery of the azumamides, different approaches to the total synthesis have been applied. 
Brown’s crotylboration reaction[142] was utilized by De Riccardis and co-workers[143] in the synthesis of 
azumamide A and E, Scheme 1.9.  
After oxidizing 3-benzyloxypropanol to aldehyde 1.112, the key step provided a high diastereo- and 
enantioselective (d.r.> 99%; 98 % ee) transformation to intermediate 1.113. Reductive ozonolysis followed 
by hydrolysis gave diol 1.114, which was converted to the tert-butyl carbamate (Boc) protected amine 1.116. 
Wittig reaction on aldehyde 1.117, followed by oxidation of the unprotected alcohol gave the final building 
block 1.119.  
In the synthesis of azumamide A, macrolactamization did not work when the amide functionality was 
present. Different coupling reagents were explored (Pentafluorophenyl diphenylphosphinate (FDPP), 
diphenylphosphorylazide (DPPA), and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) 
33 
with hydroxybenzotriazole (HOBt), but no trace of the product was observed. The β-amino acid was instead 
kept as the ethyl ester (1.119), coupled to a tripeptide and cyclized with phenylalanine on the C-terminal. 
FDPP mediated lactamization provided the cyclized peptide in 37% yield.  
 
Scheme 1.9 Synthesis of the β-amino acid by De Riccardis and coworkers.[143] Reagents and conditions: (a) (COCl)2, DMSO, Et3N, 
CH2Cl2. (b) (i) (+)-Ipc2BOMe, (E)-2-butene, t-BuOK, n-BuLi, BF3⋅Et2O, THF, –78 °C; (ii) Ac2O, py, CH2Cl2. (c) O3; CH2Cl2, PPh3, NaBH4, 
EtOH. (d) K2CO3, MeOH. (e) TPSCl, DMAP, py, CH2Cl2. (f) MsCl, Et3N, THF. (g) NaN3, DMF, 60 °C. (h) H2, Pt2O, EtOAc. (i) Boc2O, Et3N, 
CH2Cl2. (j) H2, Pd/C, EtOH. (k) oxalyl chloride, DMSO, Et3N, CH2Cl2. (l) KHMDS, THF, BrPPh3(CH2)3CO2Et, –78 °C to rt. (m) HF/Py, py. (n) 
TEMPO, phosphate buffer, NaClO2, NaClO, MeCN. 
Ganesan and co-workers used a different strategy in their synthesis of azumamide A and E,[144] where Ellman’s 
tert-butylsulfinyl auxiliary was used in the diastereoselective Mannich reaction, Scheme 1.10.[145] Introducing 
a trichloroethyl ester (Tce) (1.121) was nessesary, since alkaline hydrolysis of a benzyl ester protecting group 
was slow and caused epimerization of the β-amino acid. Dihydroxylation followed by hydrogenation and 
oxidative cleavage gave the β, γ-cis unsaturated aldehyde 1.122. Using Ellman’s chiral auxiliary in the Mannich 
reaction as the key step, the protected building block was obtained with high diasteroselectivity and a fair 
yield. Deprotection of the carboxylic acid gave 1.125, with the auxiliary conveniently used as a protecting 
group in the peptide elongation. A phenylalanine to alanine cyclization was performed using HATU as 
coupling reagent, which provided the tetrapeptide in yields ranging from 55-85% in individual experiments.  
 
Scheme 1.10 Synthesis of the β-amino acid by Ganesan and co-workers.[144] Reagents and conditions: (a) 2,22-trichloroethanol, DIC, 
DMA, CH2Cl2. (b) allyl bromide, K2CO3, CuCl, DMF. (c) OsO4, NMO, THF, H2O (d) H2, Lindlar cat., EtOAc. (e) NaIO4, CH2Cl2. (f) tBuSONH2, 
CuSO4, CH2Cl2. (g) CH3CH2CO2PMB, LDA, TiCl(O-iPr)3, THF. (h) TFA, anisole. 
Chandrasekhar and co-workers initiated their synthesis by coupling a protected 4-pentyne-1-ol with 
chlorobutyne-1-ol to obtain 1.127.[146] After selectively reducing one alkyne with LiAlH4, the (2S, 3R) 
stereochemistry of the Amnda residue was introduced by a Katsuki-Sharpless asymmetric epoxidation 
followed by epoxide opening with methyl cuprate (Scheme 1.11, 1.129, 1.131). An EDCI/HOBt mediated 
cyclization between the β-amino acid and valine gave the cyclized peptide in 79% yield (Figure 1.31). 
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Scheme 1.11 Synthesis of the β-amino acid by Chandrasekhar and co-workers.[146] Reagents and conditions: (a) PMBCl, NaH, THF,(n-
Bu)4NI, 25 °C. (b) Chlorobutyne-1-ol, CuI, NaI, K2CO3. (c) LiAlH4, Et2O. (d) (+)-diethyl tartrate, Ti(O-iPr)4 TBHP, CH2Cl2. (e) IBX (f) NaClO2, 
NaH2PO4, 2-methyl-2-butene. (g) CH2N2. (h) (CH2)2CuLi, Et2O. (i) H2, Pd/CuCO3, quinoline, benzene. (j) PPh3, DIAD, DPPA, THF. (k) PPh3, 
THF, H2O. * Used without further purification. 
Since no total synthesis of azumamides B-D existed and biological profiling had only been performed on 
azumamide E in HDAC1-9[147] Jesper S. Villadsen in our research group set out to synthesize all five 
azumamides.[148] The key step for synthesis of the Amnda and Amnaa side chains was an Ellman-type Mannich 
reaction (Scheme 1.12). The synthetic route also enabled synthesis of two analogs with an altered 
stereochemistry in the β 2- or β 3-position (1.145, 1.146, Figure 1.31). 
 
Scheme 1.12 Synthesis of the β-amino acid by Olsen and co-workers.[148] Reagents and conditions: (a) (COCl)2, DMSO, Et3N, CH2Cl2. 
(b) CuSO4, (S)-(–)-2-methyl-2-propanesulfinamide, CH2Cl2. (c) HMPA, LDA, THF, –78 °C. (d) AcOH, Bu4NF, THF 0 °C to rt, 1.5h. (e) 
NaHCO3, DMP, CH2Cl2, 0 °C to rt, 1.5h. (f) Ph3PBr(CH2)3COOEt, THF, –78 °C to rt, 18h. (g) TFA, CH2Cl2, 0 °C to rt 3h. (h) HCl, dioxane, 
3h. (i) Fmoc-OSu, dioxane, H2O, 0 °C to rt 2h. 
Cyclization at three different positions in the total synthesis of azumamide E had been published and in each 
case, a different coupling reagent was used (Figure 1.30). Cyclization at different points in the scaffold, were 
therefore attempted. 
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Figure 1.30 Left: Lactamization of azumamide E; a by Chandrasekhar and co-workers[146], b by Ganesan and co-workers[144], c by De 
Riccardis and co-workers.[143] Right: Lactamization of azumamide A-E; d by Olsen and co-workers[148] 
Azumamide A-E as well as the β 2- and β 3 epimers, were profiled against the full panel of HDAC members, 
Table 1.17, Table 1.19. The data revealed that azumamide C and E were most active. This is consistent with 
the carboxylic acid being a better ZBG relative to the amide in azumamide A, B, and D. Additionally, in contrast 
to previous profiling on HeLa cell extracts,[147] azumamide C proved to be ∼2-fold more active than 
azumamide C against most of the HDACs. Regarding the analogs, the potency of the azumamides was 
severely reduced when the stereochemistry in the β -amino acid was modified. 
Table 1.17 HDAC inhibitory activity against all HDACs. 
  Ki values (nM)  
  Class I  Class IIa  Class IIb  Class IV  
HDAC  1 2 3 8  4 5 7 9  6 10  11  
AzuA  >5000 >5000 3200 >5000  52%a IAb IA IA  IA IA  >5000  
AzuB  5000 3000 3000 IA  IA IA IA IA  IA IA  >5000  
AzuC  32±1 40±20 14±1 >5000  IA IA IA IA  2000 10±4  35±3  
AzuD  >5000 >5000 3700 IA  IA IA IA IA  IA IA  >5000  
AzuE  67±7 50±30 25±5 4400  IA IA IA IA  >5000 20±12  60±16  
a Percent inhibition at 50 μM inhibitor concentration. b IA = inactive (<50% inhibition at 50 μM). Data was obtained from ref [148]. 
From the limited number of azumamide analogs that have been synthesized (Figure 1.31), two analogs have 
shown an increased activity. 48% inhibition in HeLa NE was observed when 
10 μM of the sugar amino acid-containing analog (1.147) was applied, 
compared to 19% inhibition when the same amount of azumamide E was 
added (Table 1.18).[146] Changing the ZBG  to a hydroxamic acid (1.144), 
showed a more dramatic effect (Table 1.19).[144] ∼16-fold increase in 
potency was observed relative to azumamide E and more than 800-fold 
increase relative to azumamide A. These results show that the ZBG has an 
additive effect, which relates to the ability of the ZBG to coordinate zinc. 
Modifications to the cyclic peptide core has resulted in a negative effect on binding to the HDAC 
enzymes.[147] In analog 1.143 the Amnda residue had been changed to a (2R, 3S) configuration, thereby 
changing the vector of the side chain, while all stereocenters are inverted in analog 1.142. Since the 
azumamides display a reverse direction of the amide bonds, the enantiomer of azumamide E has a higher 
resemblance to other related cyclic peptides (e.g. trapoxin). 
Table 1.18 % HDAC inhibition. 
Compound HeLa 
Azumamide E (20 μM)  71 
Azumamide E (10 μM) 19 
1.147 (20 μM) 96 
1.147 (10 μM) 48 
Data was obtained from ref [146]. 
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Figure 1.31 Azumamide analogs.  
Table 1.19 HDAC inhibitory activity against HeLa and HDAC1-11. 
 
 
Potency relative to romidepsin is shown in parenthesis. Red: 
fold decrease, ep: equipotent, green fold increase. NE: 
nuclear extract, a NA: no activity (<50% inhibition at 50 μM), 
b Data was obtained from ref [147]. c Data was obtained from 
ref [144]. d Data was obtained from ref [148]. 
 
The binding conformation of azumamide E has been investigated by docking studies in the crystal structure 
of histone deacetylase-like protein (HDLP).[69] Favorable hydrophobic interactions were observed between 
the Amnda side chain and the tunnel of HDLP leading to the active site, and the carboxylic acid formed 
favorable hydrogen bonds with two histidines and a tyrosine, besides from chelation with the zinc ion. The 
cyclic core of the peptide was placed in a shallow groove on the outside of the protein with the valine residue 
pointing towards the solvent and the phenylalanine positioned in a deep pocket of HDLP (Figure 1.32, left).  
  
Figure 1.32 Left: Docking of Azumamide E in HDLP, Right: Docking of Azumamide E (yellow) and the enantiomer 1.142, (blue).[147] 
The lower activity of 1.142 and 1.143 was also examined in the docking study. Three binding modes were 
generated for 1.143; none of these were found to be optimal, due to ineffective zinc coordination or loss of 
favorable interactions by valine and phenylalanine. Compound 1.143 retained HDAC activity, but compared 
to azumamide E it was reduced ∼200-fold. Docking studies of this compound, showed interactions similar to 
azumamide E, but with the cyclic core inverted 180°, having L-Val of 1.143 occupying the space of D-Phe in 
IC50 (μM) 
Compounds HeLa NE Compounds HDAC1-11 
1.142b 26 (>99) 1.145 (2R,3R)d NAa 
1.143 (2R,3S)b NA 1.146 (2S,3S)d NAa 
1.144c  7 (16)   
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the natural compound (Figure 1.32, right). The loss of activity from analog 1.143 and 1.146 highlights the 
importance of the side chain positioning, while the amide bond direction seem to have a minor influence.  
Compound 1.145 and 1.146 showed a low potency against all HDAC enzymes (Table 1.19). The lower 
activity of compound 1.146 is not surprising, as it would be unlikely that the Amnda residue and the cap 
group would maintain favorable interactions. However, the lower activity of analog 1.145 is unexpected. A 
possible explanation for this result could be a steric clash with residues in the binding pocket.  
Miscellaneous cyclic inhibitors 
The large cap group of macrocyclic inhibitors has the possibility of forming multiple interactions with residues 
in the rim of the active site in HDAC enzymes. The rigidity of the scaffold could also be favorable from an 
entropic perspective. Hanessian and co-workers synthesized a range of compounds based on 1.148, which 
had shown to be a potent HDAC inhibitor.[149] The macrocycles that were generated utilized the rigid scaffold 
to probe the active conformation of the cap group, by simulating constrained analogs of the acyclic inhibitor 
(1.148).  
 
Figure 1.33 Macrocycles generated from lead compound 1.148. 
Cyclic compounds with only one aromatic substituent (not shown) lost activity relative to 1.148, whereas the 
presence of a double bond (1.150) did not affect the overall HDAC inhibition (Table 1.20). Compounds 
containing the S-stereochemistry were in general (slightly) more potent. 
 Compound 1.151 with a nitrogen at the α-position of the suberoyl chain, and 1.153 containing an 
acetamido group on the anilide ring, were potent HDAC inhibitors with an improved activity towards HDAC8. 
The diamide based compounds (1.149, 1.154a, and 1.154b) showed an overall decreased activity, however, 
a high selectivity was observed towards HDAC6. 
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Table 1.20 HDAC inhibitory activity against all HDACs. 
 IC50 (nM)  
   Class I  Class IIa   Class IIb  Class IV  
HDAC 1 2 3 8  4 5 7 9  6 10  11  
1.148 53.4 254 131 331  648 134 432 247  20.1 179  197  
1.149 245 584 331 297  1690 496 2230 602  4.4 627  379  
1.150 30.7 207 39.6 119  159 55.4 72.6 99.6  1.97 70.7  57.7  
1.150a 31.7 158 55.7 198  79.4 62.2 27.8 60.6  0.84 62.5  22.9  
1.150b 78.1 382 89 206  284 155 180 302  10.2 152  97.1  
1.151 27.7 171 15.8 39.3  52.1 24.7 15.9 22.6  0.75 46.5  34.8  
1.152 204 793 246 444  447 341 279 336  8.44 320  226  
1.152a 72.2 268 93.6 136  118 109 61.2 123  3.43 190  103  
1.152b 102 425 94.5 90.7  454 150 271 322  3.92 200  174  
1.153 41.3 128 63.1 45.4  64.8 65.2 43.3 47.7  0.4 65.1  45.9  
1.154a 864 3280 1114 534  5333 1660 4300 2020  59 2290  948  
1.154b 1340 2530 885 682  3480 1340 2070 1140  75 1880  1110  
Data was obtained from ref [149]. 
With the inspiration from macrolides that had been reported to function as peptide scaffold mimics,[150] 
Oyelere and coworkers incorporated the macrolide skeleton of TE-082 to mimic the prototypical peptidic 
macrocyclic cap group.[151] 
 Selectivity was observed for HeLa nuclear extract (consisting primarily of HDAC1 and 2),[151] relative to 
HDAC6 and 8. A linker dependence was also observed, with the optimal length of six methylenes (1.155b) 
between the triazole moiety and the ZBG. 
      Table 1.21 a measured from SAM-DI Mass spectrometry.[151] 
 IC50 (nM)  Ki (nM)a  
Compound HeLa NE HDAC8 HDAC6  HDAC8 
 
1.155a 7.77 796.2 1180.1  1100 
1.155b 1.03 544.6 728.7  210 
1.155c 104.2 1909.3 1709.8  580 
1.155d 163.6 2859.9 1916.9  620 
1.155e 208.2 4557.8 3203.1  825 
Etzkorn and co-workers have synthesized a macrocyclic inhibitor (1.156, Table 1.22), by combining the widely 
used hydroxamic acid head group with their previously synthesized peptide mimic.[152] 1.156 showed potent 
inhibition and ∼4 fold selectivity towards HDAC1 relative to HDAC8. The advantage of using a rigid scaffold 
as cap group was shown by testing the corresponding linear compound (1.157), which lost ∼3-fold activity. 
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Table 1.22 HDAC inhibitory activity against HeLa NE, HDAC1 and 8. 
 IC50 (nM)  
 
Compound HeLa NE HDAC1 HDAC8  
1.156 46±8 57±10 231±30  
1.157 167±20 174±28 –  
NE: Nuclear extract. 
Marcaurelle and co-workers discovered potent HDAC inhibitors in a diversity-oriented synthesis strategy.[153] 
Medium to large macrocycles (8−14 membered rings) containing a variety of stereocenters were generated 
and screened in a high throughput coupled biochemical assay. 22,506 library compounds were tested as a 
single dose against HDAC2, and 32 of these were investigated in a dose−response assay. One compound was 
further studied in a stereo/structure activity relationship (Figure 1.34). BRD-4805 (Table 1.23) was discovered 
as the most potent compound, and BRD-8172 was found by modifying the side chain of BRD-4805. It is worth 
noticing that these inhibitors do not possess any ZBG, the potency must therefore arise from interactions in 
the opening of the HDAC binding site. 
 
Figure 1.34 stereo/structure activity relationship study on selected compounds from a high throughput assay. The figure was modified 
from ref [153]. 
Table 1.23 HDAC inhibitory activity against HDAC1, 2, and 3. 
 IC50 (μM)   
Compound HDAC1 HDAC2 HDAC3  
BRD-4805 2.7±0.3 6.6±0.4 2.7±0.2  
BRD-8172 1.5±0.7 2.8±0.9 4.4±2.0  
     
Ghadiri and co-workers, who recently published their work on cyclic α3β-tetrapeptides, also investigated 
compounds lacking a ZBG (Chart 1).[154] A SAR study was performed by altering the side chains of the α-amino 
acids in the scaffold. A propyl side chain at the position, which usually contained the ZBG, afforded the most 
potent inhibitor in the series; interestingly, incorporation of shorter or longer alkanes lowered the activity 
significantly. The R3 side chain was sensitive to changes, but a potent compound was found by incorporating 
a substituted indole. 
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Chart 1 Structure activity relationship on cyclic peptides without a ZBG. 
 
  
 
Table 1.24 HDAC inhibitory activity against HDAC1, 2, 3, and 6. 
 IC50 (μM) 
Compound HDAC1 HDAC2 HDAC3 HDAC6 
1.159 0.98 1.5 1.4 >20a 
1.160 0.68 1.4 0.8 >20b 
a 37% inhibition at 20 μM. b 46% inhibition at 20 μM. Data was 
obtained from ref [154]. 
1.5 Summary 
Epigenetic mechanisms play a crucial role in a variety of cellular processes. Two functional opposing 
epigenetic modulators, HATs and HDACs, control the acetylation state of the histone proteins. These 
modifications can lead to a change in the chromatin structure, which regulates access for DNA-binding 
proteins. In combination with other posttranslational modifiers, the HATs/HDACs generate patterns that 
forms a ‘histone code’. These specific alterations that are recognized by proteins, forms the basis of a 
complex control of gene expression.  
 An aberrant HDAC expression have been associated with various types of cancer, HDAC inhibitors have 
therefore been a promising strategy in drug development. Two HDAC inhibitors (SAHA and romidepsin) have 
been approved by the FDA and several compounds are in clinical trials. SAHA and romidepsin are unselective 
HDAC inhibitors, whether or not this property is beneficial for anti-cancer treatment is still unknown. A lot of 
effort has been focused on synthesizing selective HDAC inhibitors, these compounds could be used as a tool 
for investigating the effect of each HDAC isozyme.  
 A pharmacophore, consisting of a ZBG, a linker, and a cap group, describes the majority of HDAC inhibitors. 
Among these are the macrocyclic HDAC inhibitor, which possess the most complex cap group. Due to their 
potential for interacting with less conserved amino acids on the rim towards the active site, a higher potential 
for HDAC inhibitory selectivity has been suggested.  
 A large number of macrocyclic natural products have exhibited inhibitory effects against HDACs. A range 
of these compounds has been utilized as lead structures in the search for higher activity or selectivity. These 
analogs have all aided in understanding the requirements for a potent inhibitor.  
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2 Desmethyl Azumamide Analogs 
SAR studies of desmethylated azumamide compounds were conducted in collaboration with Jesper S. 
Villadsen. Jesper has synthesized desmethylated analogs, as well as dimethylated compounds, both 
containing a side chain in the 3-position with a cis double bond. Jesper and I have tested the compounds in 
HDAC assays, to obtain duplicate measurements. 
 Casper Hoeck and Charlotte H. Gotfredsen have been a great help for obtaining 800 MHz NMR data from 
the Carlsberg laboratory. They also performed most of the work regarding the 3D-structure elucidation. Niels 
J. Christensen and Peter Fristrup have been conducting the docking studies. 
2.1 Introduction 
The azumamides are interesting compounds as they retain high activity as HDAC inhibitors, even though they 
have relatively poor ZBGs. The potency of the macrocyclic HDAC inhibitors may therefore be ascribed to the 
multiple interactions between the cyclic peptide core and the opening towards the active site in the HDAC 
enzymes. Macrocycles have been proposed to possess a scaffold with a higher potential for HDAC inhibitory 
selectivity.[155] This suggestion has been based on less conserved amino acids in the rim of the active site, 
across the HDAC isozymes.[156] The combination of a large cap group and a poor ZBG, could be an advantage 
for obtaining selective HDAC inhibitors, as a strong ZBG might be too dominant an interaction to confer high 
selectivity. 
 An overview of the amino acid variability of the solvent exposed area, was obtained by aligning class I 
HDACs using the program ‘Pymol’ (Figure 2.1). The greatest differences between the HDAC isozymes are 
observed in three areas on the surface near the binding pocket, these prominent residues are shown in Table 
2.1. HDAC1 and 2 are most similar, which is also evident from the sequence alignment. Glu98 and Asp99 are 
found near the opening in HDAC1; these amino acids are conserved in HDAC2, but in HDAC3 and 8, Glu98 (in 
HDAC1) has been changed to an aspartic acid and a tyrosine respectively. HDAC8 is less similar to the other 
HDAC isozymes, few amino acids are conserved in the sequence alignment and from Figure 2.1 the area near 
the pocket is wider, especially at the two locations that are circled in HDAC8. Areas near the binding site in 
HDAC1, 2 and 3 also seem to vary depending on the position of the carboxylic acid residues. However, it is 
important to emphasize that the crystal structures are only a representation of one conformation of a 
dynamic enzyme. In addition, each enzyme is crystalized differently. HDAC1 is co-crystalized with a protein 
domain from the NuRD-complex, HDAC2 and 8 are co-crystalized with an inhibitor, and HDAC3 is co-
crystalized with a co-repressor. The orientation of the amino acid residues might therefore be involved in 
other interactions in each circumstance.  
Table 2.1 Sequence comparison of amino acids from class I HDACs, near the opening towards the active site. 
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 20
1 
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 26
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0 
27
1 
HDAC1 G E D C P  Y G E - Y F - P  D R L 
HDAC2 G E D C P  Y G E - Y F - P  D R L 
HDAC3 G D D C P  Y G N - Y F F P  D R L 
HDAC8 G Y D C P  F S P G F F - P  D P M 
The numbering is based on the HDAC1 sequence 
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Overall, it seems plausible that interactions from a complex cap group could exploit differences further away 
from the binding site. However, introducing higher selectivity for either HDAC1 or 2 based on differences 
near the binding cavity would be a challenge. 
 
Figure 2.1 Comparison of the surface area on class I HDACs. Cyan: HDAC1 (PDB:4BKX), magenta: HDAC2 (PDB:4LY1), grey: HDAC3 
(PDB:4A69), green: HDAC8 (PDB: 3RQD). The structures were aligned in pymol. 
Jesper Villadsen in our research group completed the total synthesis of the azumamides.[148] The synthetic 
strategy enabled preparation of two azumamide analogs (1.145 and 1.146) with an altered stereochemistry 
in the β-amino acid residue; these compounds were also evaluated for HDAC inhibitory activity. The 
significant change in potency of the analog containing an inverted methyl group in the β 2-position, 
encouraged us to conduct a SAR study; hence dimethylated analogs as well as desmethyl compounds were 
designed. For the desmethylated compounds, the significance of the olefin in the side chain was also 
investigated. This was done by changing the olefin to a trans double bond at a position similar to largazole 
and romidepsin. An analog containing a saturated side chain (similar to apicidin) was also synthesized. 
Docking studies of azuamide E in HDLP, shows stabilizing hydrophobic interactions between phenylalanine 
and a pocket in the enzyme (Figure 1.32).[147] The presence of an aromatic amino acid residue in many other 
macrocyclic inhibitors (e.g. apicidin A and trapoxin) suggests that this residue is important for HDAC inhibitory 
activity. Beside from phenylalanine and tyrosine, which is present in the azumamides, a tryptophan residue 
was also incorporated in the analogs (Figure 2.2). 
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Figure 2.2 Left: trapoxin A, B, and apicidin possess an aromatic amino acid next to the side chain. Right: azumamide analogs for the 
SAR study. 
2.2 1st strategy 
Our first approach for synthesizing desmethylated azumamide analogs relied on the preparation of cyclic 
peptides containing a vinyl substituent. The side chain could thereafter be attached by cross metathesis; an 
approach previously reported by Bruno and co-workers, in their syntheses of FR235222 analogs,[157] and by 
Luesch, Hong, and co-workers in the total synthesis of largazole (Scheme 1.3).[121] From the vinyl cyclic 
tetrapeptides, a variety of compounds containing different ZBG’s could be accessed through cross 
metathesis. Since the methyl substituent had been removed from the β-amino acid, formation of the building 
block could be obtained from readily available L-aspartic acid (Scheme 2.1). 
  
Scheme 2.1 Retrosynthetic analysis of the azumamide analogs.  
Background; cross metathesis 
The metathesis reactions includes ring closing metathesis (RCM),[158] ring opening metathesis (ROM),[159] and 
cross metathesis (CM).[160] Some of the widely used catalysts for the olefin metathesis are shown in Figure 
2.3, developed by, Hoveyda, Grubbs, and Schrock.[161] 
 
Figure 2.3 widely used commercial available catalysts for olefin metatheses. 
Hérisson and Chauvin described the well-established mechanism for olefin metathesis in 1971,[162] illustrated 
in Scheme 2.2 for two terminal olefins, using Grubbs catalyst 1st generation. The catalytic activity arises when 
tricyclohexylphosphine (PCy3) dissociates, as a 14 electron species is generated. Although Grubbs catalyst 1st 
generation readily releases PCy3 (large k1) to form the reactive adduct, PCy3 quickly coordinates back to 
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ruthenium (K-1/K2>>1). In contrast, the dissociation of PCy3 from Grubbs 2nd generation catalyst is inefficient, 
but coordinates better with the olefin once PCy3 is lost (k-1/k2 ∼1).[163] A coordinates to the metal catalyst and 
makes a [2+2] cycloaddition, to form a metallocyclobutane intermediate B,[164] which rearranges to produce 
C. E can then coordinate to D, where after ethene is released. Coordination of I to H, will generate the desired 
cross metathesis product and a new catalytic cycle begins from D. 
 
Scheme 2.2 Mechanism of the cross metathesis.[162, 164] Grubbs catalyst 1st generation is activated after PCy3 dissociates. The catalytic 
cycle begins with a coordination of E to D, which ultimately forms the desired product K. The scheme was modified from ref [165] 
and [166]. 
The optimal pathway for the cross metathesis is shown in Scheme 2.2; however, each olefin can also form 
homodimers. This lack of selectivity have been addressed by Grubbs and co-workers, who created a model 
based on olefin reactivity to aid the prediction of selective and non-selective cross metathesis reactions.[167] 
The olefins were categorized in four classes, based on their ability to homodimerize and the ability to re-
enter the catalytic cycle after dimerization, (Table 2.2). 
Table 2.2 Categorization of olefins of type I–IV.  
Type I Rapid homodimerization, homodimers consumable 
Type II Slow homodimerization, homodimers sparingly consumable 
Type III No homodimerization 
Type IV Olefins inert to CM, but do not deactivate the catalyst 
The table was modified from ref [167]. 
The reactivity are highest in type I compounds, consisting of electron rich olefins and decreases to the least 
active olefins for type IV compounds, comprising sterically hindered or electron poor olefins. The most 
reactive type I olefins undergo rapid homodimerization; however, the dimer is still able to undergo a 
secondary metathesis by re-entering the catalytic cycle. To avoid a statistical mixture of homodimers and 
cross metathesis product, 10 equivalents of one of the olefins are necessary to obtain >90% selectivity of the 
desired compound. Olefins belonging to type II does not undergo homodimerization as fast as type I, but do 
not react as readily after formation of the homodimer either. Similar to type I compounds, combining two 
olefins from type II will result in a statistical mixture, but with lower yields as the olefins are less reactive. 
Type III compounds do not undergo homodimerization but can still react with olefins from type I or II. Type 
IV olefins do not undergo cross metathesis at all, but also do not inactivate the catalyst.  
Combining olefins of different types can effectively generate selective CM products. If a type I olefin is 
reacted to a type II or III, homodimers of type I olefins will initially form. However, as the homodimers readily 
undergo secondary metathesis, reaction to type II or III olefins will also occur. As ethylene is released from 
the system (Scheme 2.2), the product distribution is driven towards the CM product. 
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Building block synthesis 
The building block was prepared using a similar procedure from Bradner, Williams, and co-workers,[135] by 
reducing BocNH-L-Asp-(OtBu)-OH to the corresponding alcohol via an isobutyl anhydride intermediate 
(Scheme 2.3). A two-step procedure; oxidation immediately followed by a Wittig reaction, was crucial as the 
aldehyde was prone to epimerization. The vinyl building block was obtained, but the yield was unacceptable 
due to incomplete oxidation of the alcohol in the Swern reaction (entry 1, Table 2.3).  
Table 2.3 Optimization of the oxidation. 
 
Entry Reaction conditions Yield (%)  
1  DMSO, oxalylchloride, iPr2EtN.  37 
2  DMP (1.3 + 0.6 equiv), CH2Cl2. nda 
3 DMSO, oxalylchloride, Et3N. 85 
a nd: not determined, incomplete oxidation. DMP: Dess-Martin periodinane. 
Since Dess-Martin oxidation did not give a complete reaction either (entry 2), the conditions in the Swern 
oxidation were reevaluated. Hünig’s base, which was used in Bradners procedure,[135] has been used when 
compounds were prone to epimerize. However, since repeating attempts using Hünigs base did not give a 
complete reaction, the base was changed to triethylamine. This modification gave consistent results and 
afforded the alkene in 85% yield over two steps. The desired building block was obtained after removing the 
tert-butyl group with LiOH in quantitative yield (Scheme 2.3). 
 
Scheme 2.3 Reagents and conditions: (a) NMM, iBuOCOCl, NaBH4, MeOH, THF, –30 °C to rt, 3h. (b) (COCl)2, DMSO, Et3N, CH2Cl2, –78 
°C to –40 °C to rt, 2h. (c) PPh3CH3Br, KHMDS (0.5 M in toluene), THF, –78 °C to rt, 4 h. (d) LiOH, MeOH, THF. 
Solid-phase peptide synthesis and cyclization 
The linear peptide was prepared by solid-phase peptide synthesis (SPPS), using a 2-chlorotrityl resin. A 
sequence consisting of coupling and deprotecting Fmoc-amino acids was performed, until the desired 
peptide length was obtained (Scheme 2.4). 2.8 was added as the final amino acid, where after the peptide 
was cleaved from the solid support, at the same time removing the Boc group on the building block. 
Impurities were removed by triturating in Et2O, and the crude peptide was then cyclized under highly diluted 
reaction conditions, to avoid dimerization. Cross metathesis was attempted on the cyclized peptide; 
however, the compound was insoluble in solvents normally used in cross metatheses. Incorporation of a Boc 
protected tryptophan in the cyclic peptide overcame the solubility issue. However, no product was observed 
after refluxing in dichloromethane and attempts using microwave did not produce better results. 
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Scheme 2.4 Reagents and conditions: (a) Fmoc-D-Trp-OH, iPr2EtN; CH2Cl2. (b) 20% piperidine in DMF, DBU:piperidine:DMF (2:2:96). 
(c) HATU, 2,6-lutidine, Aa (Fmoc-D-Ala-OH, Fmoc-D-Val-OH, 2.8), DMF. (d) 20% piperidine in DMF, DBU:piperidine:DMF (2:2:96), 50% 
TFA in CH2Cl2. (e) HATU, iPr2EtN, DMF. (f) i. 5-hexenoic acid methyl ester, Hoveyda–Grubbs 2nd gen. cat., CH2Cl2, reflux. ii. 5-hexenoic 
acid methyl ester, Hoveyda–Grubbs 2nd gen. cat., CH2Cl2, μW. 
2.3 2nd Strategy 
Optimizing the Cross Metathesis 
To overcome complications with the vinyl containing cyclic peptide, another route was designed using 
building block 2.7 for the cross metathesis instead. The reaction was optimized by screening different 
catalysts. Besides the well-known Grubbs and Hoveyda-Grubbs catalysts (Figure 2.3), two catalysts containing 
an electron withdrawing group on the isopropoxybenzylidene ligand were also examined (Figure 2.4).  
 
Figure 2.4 Catalysts containing an electron-withdrawing group. 
The electron-withdrawing group have been shown to increase the activity of the catalyst, as the ether-
ruthenium bond is weakened.[168] Zhan catalyst-1B was commercially available, while 2.11 was synthesized 
using procedures from Grela and co-workers.[168b] Starting from commercially available 2-hydroxy-5-
nitrobenzaldehyde catalyst (2.11) was synthesized in three steps (Scheme 2.5). Purification of the final 
product was achieved by column chromatography, as the catalyst has an improved stability relative to the 
Grubbs catalysts (2.11 can be stored in air at 4 °C for more than 4 weeks without decomposition or loss of 
activity).[168b] 
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Scheme 2.5. Reagents and conditions: (a) 2-iodopropane, K2CO3, Cs2CO3, DMF. (b) Ph3PCH3Br, KHMDS (0.5m M in toluene), THF. (c) 
Grubbs cat. 2nd gen., CuCl, CH2Cl2. 
Both Grubbs and Hoveyda-Grubbs 1st generation catalysts (entry 1, 4; Table 2.4) gave poor yields in the 
reaction. Even though a significant improvement was observed for Zhan catalyst-1B and 2.11 (entry 6, 7), the 
activity was not improved relative to Grubbs and Hoveyda-Grubbs 2nd generation catalysts (entry 3, 5). The 
best conditions were found using 10% Hoveyda-Grubbs catalyst 2nd generation to give a 67% yield (entry 5).  
Table 2.4. Catalyst screening for the cross metathesis. 
 
entry catalyst yield (%)a 
1 Grubbs cat. 1st gen., 0.1 equiv 11 
2 Grubbs cat. 2nd gen., 0.05 equiv 54 
3 Grubbs cat. 2nd gen., 0.1 equiv 62 
4 Hoveyda-Grubbs cat. 1st gen., 0.1 equiv 12 
5 Hoveyda-Grubbs cat. 2nd gen., 0.1 equiv 67 
6 Zhan catalyst 1B, 0.1 equiv 62 
7 2.11, 0.1 equiv 52 
a isolated trans isomer. 
The free carboxylic acid, needed for the peptide synthesis was obtained in two steps by deprotecting with 
TFA, followed by re-protecting the amine functionality with Boc2O. The masked carboxylic acid in the side 
chain would hereby remain unaffected. The second building block, containing the saturated linker, could 
easily be obtained by reducing the double bond of 2.13, Scheme 2.6. 
 
Scheme 2.6. Reagents and conditions: (a) TFA, CH2Cl2, 2h. (b) Boc2O, iPr2EtN, CH2Cl2, 19h. (c) H2, Pd/C (10 wt %), 17h.  
Synthesis of desmethyl azumamide analogs 
The two building blocks were coupled to tripeptides on solid support containing D-Phe, D-Tyr or D-Trp at the 
C-terminal. After cleavage from the resin, the linear peptides were triturated and cyclized. The crude 
compounds were saponified with LiOH and then purified by preparative HPLC (Scheme 2.7).  
All the synthesized azumamide analogs were obtained in poor yields. The Trp analogs proved particular 
challenging; the synthesis of 2.2c was unsuccessful and only 3% yield was obtained for 2.1c. The low yields 
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could in part be explained by the low solubility of the products, as it was suspected that the cyclic peptides 
were precipitating on the column in the preparative HPLC runs. Purifying the compounds by column 
chromatography gave better yields; however, it was not possible to isolate the products in the desired purity.  
The difficulties observed with the Trp containing analogs, might be due to unwanted side reactions from 
the indole. This problem could easily be evaded by using a Boc-protected indole in the solid phase peptide 
synthesis (SPPS). Since trityl resins are highly labile to acids, the peptide can be cleaved in mild conditions 
without affecting the Boc group. 
 
Scheme 2.7. Reagents and conditions: Synthesis of desmethylated azumamide analogs. Reagents and conditions: (a) HATU, 2,6-
lutidine, DMF, 18h. (b) 50% TFA in CH2Cl2, 2x 30 min. (c) HATU, iPr2EtN, 17h–65h. (d) LiOH, THF, H2O. 
The position of the peptide cyclization could also have an effect on the yield. In total syntheses of the 
azumamides, researchers have utilized varying synthetic routes and chosen to cyclize at different positions, 
with yields ranging from 11% to 85% (Figure 1.30). Since a direct comparison of the yields is difficult due to 
the different coupling reagents used, a cyclization study was initialized. 
Cyclization Experiments 
Cyclization experiments were conducted on four linear simplified tetra peptide sequences, consisting of a 
vinyl β-amino acid, (D)-Val, (D)-Ala and (D)-Trp, each with a different amino acid on the C-terminal, Table 2.5. 
As standard reaction conditions, 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid 
hexafluorophosphate (HATU) was used as coupling reagent with addition of Hünig’s base and the linear 
peptide was diluted to 0.5 mM in DMF, to lower the risk of dimerization.  
Cyclizing at position A and C afforded the product with minimal degrees of byproducts (entry 1 and 4), 
while an N-terminal guanidinylated compound was observed when cyclization was attempted between D-Val 
and D-Ala (entry 2). To overcome this side reaction, a non-guanidino based coupling reagent, (benzotriazol-
1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP)), was examined. However, dimerization 
and epimerization of both the linear and cyclic peptide was observed (entry 3). Exchanging Hünigs base for 
2,6-lutidine gave a very slow reaction and an epimerized product was observed (entry 5). Even though all 
cyclization experiments were highly diluted, a large amount of dimerization was observed when cyclizing 
between D-Trp and the β-amino acid (entry 6). Since this was the same position that was used to synthesize 
compound 2.1a–c, 2.2a–c, we were confident that the yields could be optimized by changing the point of 
cyclization.  
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Table 2.5 Cyclization experiments on a simplified peptide. 
 
entry position conditions side reactions isolated yielda 
1 A HATU, DIEA, DMF,  1.5 h. Minimal degree of side reaction. 42% 
2 B HATU, DIEA, DMF, 26 h. N-terminal guanidinylation. 22% 
3 B PyBOP, DIEA, DMF, 3 h. Racemization, dimerization, 
incomplete cyclization. 
18% 
4 C HATU, DIEA, DMF, 26 h. Minimal degree of side reaction. 39% 
5 C HATU, 2,6-lutidine, DMF, 69 h. Racemization. 16% 
6 D HATU, DIEA, DMF, 26 h. Dimerization. 15% 
aIsolated yield from HPLC 
 
 
Synthesis of compound 2.2c 
Two positions were found from the cyclization experiments, which gave equally high yielding reactions. The 
position with the β-amino acid as C-terminal residue was chosen, since any unreacted starting material could 
be easily isolated after loading to the resin.  
 The N-terminal Boc protecting group of 2.14 was changed to the base labile Fmoc group, so the building 
block was compatible with the trityl resin. To avoid possible side reactions in the cyclization, a Boc-protected 
Trp was used in the peptide elongation. The protecting group was kept on the Trp, by changing the cleavage 
procedure, using 2,2,2-trifluoroethanol and acetic acid instead of TFA. After cyclizing the peptide and cleaving 
the protecting groups, compound 2.2c was obtained in a 48% yield over 12 steps, Scheme 2.8. 
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Scheme 2.8. Reagents and conditions: (a) 20% TFA in CH2Cl2, 4.5h. (b) FmocOSu, K2CO3, H2O, dioxane, 0 °C to rt, 2.5h. (c) Aa (Fmoc-D-
Trp-OH, Fmoc-D-Ala-OH, Fmoc-D-Val-OH), HATU, 2,6-lutidine, DMF; 20% piperidine in DMF, DBU:piperidine:DMF (2:2:96). (d) 
CF3CH2OH, AcOH, CH2Cl2. (e) HATU, iPr2EtN, DMF. (f) LiOH, THF, H2O. (g) 50% TFA in H2O. 
2.4 Biochemical testing 
Background; HDAC assays 
A biochemical assay for evaluating the potency of HDAC inhibitors has been developed by Bradner and co-
workers.[125, 169] Compound 2.21 (Figure 2.5) was used as substrate to evaluate the activity of HDAC1, 2, 3, 
and 6, but since a low catalytic turnover was observed for HDAC8 and class IIa HDACs, the acetyl group was 
replaced by the more labile trifluoroacetyl group (2.22).  
 
Figure 2.5 Left: Substrate 2.21 is used for analyzing HDAC1, 2, 3, and 6. Substrate 2.22 is used for analyzing HDAC 4, 7, 8, and 9. Right: 
Enzyme activity on substrate 2.21 and 2.22 using different HDAC isozymes. The figure was modified from ref [169].  
The substrate is a tripeptide with an acetylated/trifluoroacetylated lysine residue and a fluorophore (7-
amino-4-methylcoumarin) on the C-terminus. The HDAC inhibitory activity of a compound is based on 
fluorescence, as this property is correlated with the substrate turnover.  
After addition of an HDAC enzyme, the positively charged lysine residue on the peptide substrate is 
exposed. Trypsin, which is added subsequently, recognizes the positively charged lysine and cleaves the 
amide bond connecting the fluorophore. When 7-amino-4-methylcoumarin is amidated, the fluorescent 
properties are quenched, but after cleavage by trypsin, the coumarin compound becomes highly flouresent. 
If an inhibitor is added along with the HDAC enzyme, an amount of substrate will not be deacylated. Trypsin 
will not be able to recognize the substrate and a low fluorescence is observed (Scheme 2.9).  
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Scheme 2.9 Principles of the HDAC assays. If the HDAC enzyme is inhibited, trypsin will not cleave the amide bond connecting lysine 
and the fluorophore. Without inhibitor, HDAC enzymes will deacylate the lysine residue. The positively charged amine is recognized 
by trypsin that will release the fluorophore.  
Biochemical profiling 
The six cyclic peptides (2.1a–c and 2.2a–c) were tested in HDAC assays, along with desmethyl and dimethyl 
analogs containing a cis olefin (2.27a–c and 2.28a–c). An initial screen against HDAC4 and 7 indicated that 
the analogs were poor inhibitors of class IIa. The compounds were therefore only evaluated in class I, class 
IIb, and class IV (Table 2.6). IC50 values were converted to Ki values, using Cheng-Prusoff’s equation [Ki = 
IC50/(1 + [S]/Km][170] assuming a fast-on−fast-off mechanism. 
 
Figure 2.6 Compounds that were evaluated in the HDAC assay. a Compounds that were synthesized by Jesper S. Villadsen. 
Table 2.6 HDAC inhibitory activity against HDACs from class I, IIb, and IV. 
 Ki (μM) 
 Class I  Class IIb  Class IV 
Compound HDAC1 HDAC2 HDAC3 HDAC8  HDAC6 HDAC10  HDAC11 
2.1a 1.41±0.37 1.86±0.04 1.62±0.31 8.57±3.61  IAa IA  3.60±0.61 
2.1b 0.83±0.26 0.66±0.28 0.55±0.26 IA  2.60±0.96 0.30±0.004  1.43±0.42 
2.1c 0.57±0.08 0.45±0.31 0.65±0.44 3.35±2.06  4.44±0.36 0.26±0.005  1.24±0.61 
2.2a 1.02±0.39 0.85±0.11 0.78±0.23 IA  IA 0.53±0.163  2.43±1.27 
2.2b 0.78±0.68 0.32±0.20 0.26±0.16 IA  3.96±2.24 0.15±0.074  0.98±0.82 
2.2cb 1.15±0.13 1.58±0.38 2.35±0.91 12.17±0.77  IA 0.38±0.068  3.20±1.80 
2.27a 0.65±0.26 0.98±0.14 0.91±0.16 IA  IA 0.27±0.034  1.72±0.26 
2.27b 0.34±0.23 0.21±0.07 0.37±0.29 IA  7.08±0.72 0.15±0.007  0.87±0.40 
2.27c 0.23±0.13 0.17±0.01 0.57±0.16 5.93±0.71  IA 0.13±0.036  0.95±0.71 
a IA: inactive (IC50 > 20 μM), b The data will be reevaluated in the near future. 
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When the Ki values were analyzed, it became apparent that the results from 2.2c were outliers compared to 
the general trend. An analysis of the DMSO stock used in the enzyme assays showed a minor impurity, but it 
could not be determined if the impurity had also been present in the enzyme assays. A reevaluation of 
compound 2.2c will be performed in the near future. 
 The azumamide analogs showed the highest activity against HDAC10, followed by HDAC1-3. Activity was 
also found against HDAC11, while poor inhibition was observed against HDAC6 and 8. All desmethylated 
compounds were more potent against the isozymes relative to azumamide A, B, and D. The higher activity of 
the analogs is most likely due to the carboxylic acid moiety, which coordinates zinc better than the amide 
functionality.  
Table 2.7 gives an overview of the tyrosine containing compounds, compared with azumamide C while 
the phenylalanine containing analogs are compared with azumamide E in (Table 2.8). The only difference 
between compound 2.27a and azumamide E, as well as 2.27b and azumamide C, is the methyl group in the 
β 2-position; the direct influence of removing the methyl group can therefore be evaluated from these 
compounds.  
Compared to HDAC6 and 8, removal of the methyl group seem to have a minor effect. However, 
azumamide C and E are relatively weak inhibitors of these isozymes, so the small difference is also an 
expression of the general poor activity against the enzymes. When the other HDAC isoforms are compared, 
it is evident that the methyl group has an important function, as 2.27a and 2.27b show a 5 to 36-fold decrease 
in potency.  
Table 2.7 Potency of the tyrosine containing azumamide analogs. 
  Ki (μM) 
  Class I  Class IIb  Class IV 
Compound  HDAC1 HDAC2 HDAC3 HDAC8  HDAC6 HDAC10  HDAC11 
2.1b  0.83 (26) 0.66 (17) 0.55 (39) IA  2.6 (ep) 0.3 (30)  1.43 (41) 
2.2b  0.78 (24) 0.32 (8) 0.26 (19) IA  3.69 (2) 0.15 (15)  0.98 (28) 
      2.27b  0.34 (11) 0.21 (5) 0.37 (26) IA  7.08 (4) 0.15 (15)  0.87 (25) 
Potency relative to azumamide C is shown in parenthesis. Red: decreased potency, ep: equipotent. 
Table 2.8 Potency of the phenyl containing azumamide analogs. 
  Ki (μM) 
  Class I  Class IIb  Class IV 
Compound  HDAC1 HDAC2 HDAC3 HDAC8  HDAC6 HDAC10  HDAC11 
2.1a  1.14 (17) 1.86 (37) 1.62 (64) 8.57 (2)  IA IA  3.6 (30) 
2.2a  1.02 (15) 0.85 (17) 0.78 (31) IA  IA 0.53 (27)  2.43 (41) 
      2.27a  0.65 (10) 0.98 (20) 0.91 (36) IA  IA 0.27 (14)  1.72 (29) 
Potency relative to azumamide E is shown in parenthesis. Red: decreased potency, ep: equipotent. 
Compounds with a trans olefin in the side chain shows the weakest inhibitory activity, while analogs 
containing a cis olefin and a saturated side chain are equally potent. Regarding the aromatic residue, 
phenylalanine-containing compounds are the weakest inhibitors, while differences between compounds 
containing a tyrosine relative to a tryptophane is insignificant. These data are in agreement with the activity 
of azumamide C, which is the most potent inhibitor for all HDAC enzymes. The negative effect of 
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incorporating a phenylalanine and a trans olefin is evident from compound 2.1a, which portray the weakest 
inhibition for HDAC1−3, 10 and 11. 
Table 2.9 HDAC inhibitory activity against HDACs from class I, IIb, and IV. 
  % Enzyme inhibtion 
 Class I  Class IIb  Class IV 
Compound HDAC1 HDAC2 HDAC3 HDAC8  HDAC6 HDAC10  HDAC11 
2.28a (20μM) 16±9 8±4 8±8 IAa  IA IA  IA 
2.28a (10μM) 10±8 4±2 5±1 IA  IA IA  IA 
2.28b (20μM)   15±16  11±3 8±1 IA  IA IA  IA 
2.28b (10μM) 11±6 8±2 7±1 IA  IA IA  IA 
2.28c (20μM)   65±16  68±9  62±7 14±6  40±33 7±7  26±9 
2.28c (10μM) 54±8 53±25 47±21     6±1  17±23 IA     22±20 
a IA: inactive (IC50 > 20 μM) 
A low activity was observed for the dimethylated compounds in preliminary tests, the analogs were therefore 
only tested at two doses. 2.28a and 2.28b showed minor activity against the HDAC enzymes, with a maximum 
inhibition of ∼16% against HDAC1 at 20 μM. 2.28c displayed a higher activity with IC50 values ∼10 μM against 
HDAC1−3. 
2.5 Conformational analysis 
We were interested in solving the three dimensional structure of the desmethylated azumamide analogs, as 
the decreased activity might be explained by a conformational change in the core structure of the cyclic 
peptide. Casper Hoeck and Charlotte Held Gotfredsen did the primary work in elucidating the NMR structure. 
 All amide bonds in azumamide A-E exhibit trans conformations,[147] we therefore analyzed the NMR 
spectra of the azumamide analogs, to see if any cis amides were present. NOESY/ROESY interactions between 
Hα on adjacent amino acids would indicate a cis amide, but no correlations were found. The 1H-NMR of the 
desmethyl analogs indicated a second conformation, illustrated by peaks with intensities <10% of the major 
structure. A cis peptide bond was observed in this conformation, between the aromatic amino acid 
substituent and alanine. However, the 1H-NMR of azumamide A−E, also show a second conformation in 
similar proportions, so it seems unlikely that the loss of activity could be explained from this structure. 
 Even though the major conformation of the desmethylated analogs does not contain cis peptide bonds, 
an altered three-dimensional structure would still be a possible explanation for the lower activity. The 
identity of the side chains in small ring sized peptides have in particular been shown to alter the overall 
structure.[171] We therefore set out to solve the conformation of the desmethyl azumamide analogs in 
solution, with the use of NMR and modelling. Using a known distance as reference, the integrals of the ROESY 
correlations can be used to measure intramolecular distances. It is essential that the distance between the 
protons remain fixed on the NMR time scale and the number of ROESY signals that could be used, were 
further limited by scalar couplings. The challenges were partly overcome when the samples were recorded 
on an 800 MHz NMR machine from the Carlsberg laboratory. 
We hoped to solve the solution structure in water, as this conformation would resemble the assay 
conditions best. Unfortunately, the azumamide analogs were insoluble, up to 15% H2O in DMSO-d6 was 
54 
added, but an insufficient amount of compound was dissolved to obtain a useful NMR spectrum. All samples 
were therefore analyzed in DMSO- d6. 
Two computational methods were utilized for solving the three-dimensional structure. In the first method, 
the program ‘Maestro’ was used to simulate the lowest energy conformation in water. 200 structures from 
the ensample of generated conformations for 2.27b and azumamide A respectively (the functional group was 
removed in the calculations) were then correlated with the J-coupling and the NOESY/ROESY signals from the 
NMR data. A structure from each, which correlated best with the NMR data, were then overlaid for 
comparison (Figure 2.7). 
   
Figure 2.7 left: 50 conformations of 2.27b from the energy minimization in water. Middle: 50 conformations of azumamide A 
(functional group removed for the calculations) from the energy minimization in water. Right: an overlay of a representative structure 
from the energy minimization, which correlates best with the NMR data. Green: Azumamide E, Magenta: 2.27b. 
In the second method, NOESY/ROESY data were used to set constraints to the cyclic structure when the 
simulations were performed. This was done by adding a penalty to the system if the distance between two 
protons changed more than 20%, compared to the data from the NMR spectra. The 100 structures with the 
lowest energy is shown for 2.27b and azumamide A in Figure 2.8, (left, middle). A compound from each 
ensample is compared in Figure 2.8, right. 
   
Figure 2.8 Left: The 100 lowest energy conformations simulated with constraints for 2.27b. Middle: The 100 lowest energy 
conformations simulated with constraints for azumamide A. Right: overlay of a structure from each ensample. Green: azumamide E, 
magenta: 2.27b. 
The results from each method show that the difference in the core structure of the compounds do not vary 
significant. The greatest difference is seen in the second method, where an amide NH between the aromatic 
residue and alanine from the natural compound points to the middle of the structure. This conformation 
originates from the NOESY correlation between the NH and Hα-Ala. However, in this conformation, the 
distance between the NH and the methyl group in alanine does not correlate with the NMR data; so even 
though the cyclic peptide can be viewed as a rigid structure, the 3-D conformation is an ensample of closely 
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related structures with a certain flexibility. Overall, the structural difference in the backbone between the 
azumamides and the des-methylated compounds were small. Similar NOESY/ROESY correlations were found 
and the J-couplings were comparable.  
 Since the core structure of the desmethyl analogs did not change significantly relative to the azumamides, 
we speculated that the difference in HDAC inhibitory activity might arise from a preferred orientation of the 
side chain. The steric bulk from the methyl group in the azumamides might direct the side chain to a favorable 
position relative to the binding pocket. Since the azumamide analogs do not possess this group, a wider 
degree of freedom could be imagined, which would lead to a greater loss of entropy after binding. 
 Azumamide E and a desmethylated analog were simulated in water, using the same method as previously 
described for the energy minimization. 200 structures were obtained from the simulation, which each 
represented one conformation of the compounds after a given time period. The torsion angles between Cγ 
and Hα were then analyzed and plotted against the number of structures with the given angle (Figure 2.9). A 
positive angle denotes a direction pointing away from the methyl group, while a negative angle indicates a 
direction towards the methyl group. 
 
Figure 2.9 The number of generated structures from the energy minimization are shown as a function of the torsion angle between 
Cγ and Hα.  
The desmethyl analog are found in clusters around -60°, 60°, and 180° in accordance to lowest energy of a 
staggered conformation (Figure 2.7). Azumamide E primarily possess an angle at 60°, some around -60°, and 
very few close to 180°. These data shows that the natural compounds may have a favorable predefined 
conformation of the side chain, which could be an important factor in the enzyme interaction. 
2.6 Docking studies 
The increased potency of the natural compounds could arise from favorable hydrophobic interactions 
between the binding pocket and the methyl group. Docking investigations could give us insight into this 
aspect.  
 The docking simulations on 2.1a–c, 2.2a–c were performed in HDAC3 (PDB: 4A69)[25] by Niels J. 
Christensen and Peter Fristrup. The enzyme is crystalized as a dimer with SMRT and inositol phosphate; these 
co-factors were kept in the docking simulations (Figure 2.10, left). Although chain A and B are very similar, 
initial dockings showed slightly better results for chain B and this chain was chosen for further work. It should 
be noted that these preliminary docking results were performed on a rigid enzyme and thus neglects 
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potential induced fit effects. Optimized structures will be obtained by allowing the enzyme to minimize after 
the docking. 
    
Figure 2.10 Docking poses of 2.1b, 2.2b, and 2.27b in HDAC3. Left: Surface view of the docked structures in HDAC3. Right: Asp93 
coordinates to all amide nitrogens in the cyclic scaffold. Green: HDAC3, magenta: SMRT, orange: inositol phosphate, purple: 2.1b, 
yellow: 2.2b, cyan: 2.27b. 
Each analog bind in a similar fashion to HDAC3, compound 2.1b, 2.2b, and 2.27b is shown as representative 
examples in Figure 2.10. Asp93 has a particularly important interaction by coordinating with all the amide 
nitrogens in the cyclic core. Besides from coordination with the zinc atom, the carboxylic acid ZBG forms 
favorable interactions with His 134, His135, and 
Tyr298 (Figure 2.11). It is not clear from the docking 
results why the natural products possess a higher 
HDAC inhibitory activity relative to the analogs. 
However, favorable lipophilic interactions could occur 
between Phe200 and the methyl group in the 
azumamides.  
The phenylalanine containing compounds 
(including azumamide E), show a lower activity 
towards HDAC1−3. Since tyrosine and tryptophan can 
form hydrogen bonds, these interactions would be an 
obvious explanation for the higher activity. However, the phenylalanine containing compounds are only ∼2-
fold less potent. The change in activity might therefore be a combination of the negative effect from 
removing a water molecule from the binding site and the positive effect from obtaining favorable hydrogen 
bond interactions. No hydrophilic interactions can be seen from the docking results, but since a rigid enzyme 
has been used for the simulations, amino acids near the cavity might move to interact with the ligand. His22 
and Asp92 are located close to the aromatic substituent and might have a role in the binding. 
2.7 Summary 
The complex cap group, which is present in macrocyclic HDAC inhibitors, can interact with a range of residues 
in the rim towards the active site. Since the amino acids in this area are less conserved across the HDAC 
enzymes, there is a higher potential for macrocycles to selectively inhibit specific isoforms.  
Figure 2.11 Binding interactions of 2.2b docked in HDAC3.  
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 Even though the azumamides possess a relatively weak ZBG, they are potent HDAC inhibitors. The activity 
must therefore arise from interactions with the cyclic peptide. This cyclic scaffold was investigated by 
removing the methyl group from the β-amino acid. In addition, changes to the side chain were made, by 
incorporating a trans olefin- and a saturated side chain. A tryptophan residue was also integrated in these 
analogs. 
 The first strategy relied on synthesis of a cyclic peptide containing a vinyl substituent. A cross metathesis 
would then generate the target compound. Different reaction conditions were explored, but no product was 
observed. In the second strategy, the cross metathesis was performed on the amino acid building block 
instead. Incorporation in the linear peptide followed by a cyclization reaction afforded the desired 
compounds. The best yield was obtained by cyclizing between the β-amino acid residue and D-valine. 
 The desmethyl azumamide analogs were tested against HDAC enzymes in class I, IIb, and IV. The 
compounds had a decreased potency against all HDAC isozymes. However, the loss of activity towards HDAC1 
relative to azumamide E, and HDAC1 and 2 relative to azumamide C, was not significant. The compounds 
with a phenylalanine as the aromatic substituent and a trans olefin in the side chain were the weakest HDAC 
inhibitors. 
 Casper Hoeck and Charlotte Held Gotfredsen performed conformational studies of the azumamide 
analogs, to find that the cyclic core of the scaffold was similar to the natural compounds. Regarding the side 
chain of the azumamide analogs, a higher flexibility was observed relative to the natural compounds. 
 Docking studies performed in HDAC3 by Niels J. Christensen and Peter Fristrup, showed a binding mode 
similar to the natural products. An important interaction was seen between Asp93 and all the NH-amides in 
the scaffold. A lipophilic interaction between Phe200 and the methyl group in azumamide C/E, could be 
determining for an altered activity, but the predefined orientation of the side chain in the natural products 
could also be a factor. His22 is located close to the aromatic amino acid in the ligand. This might explain the 
higher activity for compounds containing a tyrosine or a tryptophan.  
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3 Desmethylated thioester compounds 
3.1 Introduction 
The masked thiol of largazole facilitates transport across the cell membrane. Once inside, the natural product 
is activated after hydrolysis of the side chain. The ability of the azumamides to cross cell membranes might 
be improved in a similar fashion. We hypothesized that the potency of our desmethylated compounds could 
be increased, by changing the weak carboxylic acid ZBG to the more potent thiol. With this compound in 
hand, we could explore different motifs that would facilitate cell permeation. Interestingly, macrocyclic 
analogs with an incorporated thiol linker have an optimal length that differs from largazole and romidepsin 
(Figure 3.1).[115, 134] 
 
Figure 3.1 Left: Cyclic peptides containing a thiol side chain. a The disulfide was reduced in the assay.[134] b The thiol was generated in 
situ.[115] Right: active structure of largazole and romidepsin. 
We suspected that a chain consisting of five methylenes would have the optimal length, as the desmethylated 
azumamide core bears a higher resemblance to Cyl-1 and apicidin, than for largazole or romidepsin. Niels J. 
Christensen performed docking studies of analogs containing 4, 5, and 6 methylenes as the linker length of 
the thiol side chain in HDAC8, to see if a length of four methylenes would be able to reach the zinc atom 
(Figure 3.2). Since largazole is co-crystalized in HDAC8, a direct comparison of the linker length could be made 
when this isozyme was used. 
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Figure 3.2 Left: Desmethyl azumamide analogs docked in HDAC3 (PDB: 3RQD). Right: comparison of largazole and an azumamide 
analog with 4 methylenes (3.1a). Green: 3.1a (4 methylenes), cyan: 3.1b (5 methylenes), magenta: 3.1c (6 methylenes), yellow: 
largazole (from the crystal structure).  
From the docking poses it seems likely that all the compounds are able to reach the zinc ion. In addition, the 
compound with a linker of 4 methylenes had a docking pose very similar to largazole (Figure 3.2, right).  
 Since the backbone of the desmethylated azumamides differs from Cyl-1 and apicidin, and the docking 
poses suggested that all compounds were able to reach the zinc atom, we planned to synthesize and test 
analogs containing a thiol linker with 4, 5, and 6 methylenes (Figure 3.3, left). 
Largazole is a natural pro-drug that penetrates the cell membrane, facilitated by the octanoyl side chain. 
Inside the cell, the thioester is hydrolyzed to generate the active compound.[125] We were curious to know if 
the membrane penetration could be enhanced in our analogs, by incorporating the octanoyl moiety from 
largazole. We were especially interested to know if the permeation could be optimized further by using a 
different type of thioester. Using lipoproteins as inspiration, the surface of which is covered by phospholipids, 
we envisioned the synthesis of 3.2a–3.2c (Figure 3.3).  
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Figure 3.3 Target compounds. Left: Thiol linker with different length. Right: Interesting thioesters for evaluation in cell membrane 
penetration studies. 
3.2 1st Strategy 
In the first strategy towards synthesis of thioester containing cyclic peptides, the focus was turned towards 
a side chain similar to the one found in largazole, Scheme 3.1. It was hypotesized that the thioester building 
block could be obtained by a cross metathesis, in a similar approach as in the syntheses of 2.1abc–2.2abc. 
Incorporation of the building block into a linear peptide followed by cyclization would give the azumamide-
largazole hybrid (3.2a), while 3.1a could be obtained by hydrolyzing the thioester. 
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Scheme 3.1 Retrosynthetic analysis of compound 3.1a. 
The thioester ligand for the cross metathesis was prepared by a three step procedure starting from octanoyl 
chloride. 3.4 was first generated via hydrolysis of a 1-(acylthio)ethaniminium chloride intermediate. The 
crude thioacid was then converted to the ligand by reaction with 4-bromo-1-butene, Scheme 3.2.[172]  
 
Scheme 3.2. Reagents and conditions: (a) ethanethioamide, 30 °C, 42h. (b) NaOH, 30 min. (c) 4-bromo-1-butene, K2CO3, 18h. 
The reaction conditions for the cross metathesis were optimized by changing the catalyst and evaluating 
different solvents (Table 3.1). Grubbs 2nd generation catalyst and the catalysts containing the electron 
withdrawing groups, gave the best results (entry 1, 4, 5). However, it was not possible to isolate a pure 
product. Even though the building block differed significantly from the starting material, both compounds 
had a similar retention time, making isolation difficult. The mixture of 2.7 and 3.5 (∼1:1) was therefore carried 
through to the next step in the synthesis.  
Table 3.1 Catalyst screening for the cross metathesis. 
 
entry Reaction conditions yield (%)a 
1  Grubbs cat. 2nd gen., 0.2 equiv, toluene, 60 °C. 38%, 60% BRSM 
2  Hoveyda-Grubbs cat. 2nd gen., toluene, 60 °C. 26%, 47% BRSM 
3 Hoveyda-Grubbs cat. 2nd gen., 0.2 equiv, DCM, 40°C 15%, 33% BRSM 
4  Zhan catalyst 1B, 0.2 equiv, toluene, 60 °C. 42% 
5  2.11, 0.2 equiv, toluene, 60 °C. 43%, 66% BRSM 
6  2.11, 0.1 equiv + 0.05 equiv, C2H4Cl2, 90°C. 11% 
a trans isomer calculated by NMR. 
The deprotected building block (3.6) was unstable during column chromatography; the mixture was 
therefore used directly in the peptide synthesis.*  
                                                          
* The synthesis was done before the optimized position in the peptide cyclization was evaluated. 
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The linear thioester tetrapeptide was isolated from the vinyl byproduct by preparative HPLC after cleavage 
from the resin (Scheme 3.2). Due to the small amount of linear peptide that was isolated, everything was 
used for the following cyclization reaction. Unfortunately no product was obtained from the reaction, this 
could be explained by an aminolysis. However, only one small peak appeared in the preparative HPLC run, 
which could not confirm the suggested byproduct.  
 
Scheme 3.3. Reagents and conditions: (a) TFA, CH2Cl2, 2h. (b) Boc2O, iPr2EtN, 24h. (c) H-D-Val-D-Ala-D-Tyr-(2-Cl-Trt-resin), HATU, 2,6-
lutidine, DMF, 15h. (d) 50% TFA in CH2Cl2, 2x 30 min. (e) HATU, iPr2EtN, 18h. ¤ ∼ 1:1 mixure with 2.7.  
3.3 2nd Strategy 
In Bradner and co-workers total synthesis of largazole, compound 3.8 was synthesized (Scheme 3.4).[135] The 
thiolprotected building block was obtained by cross metathesis of a free alcohol, followed by substitution 
with triphenylmethanethiol.  
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Scheme 3.4 Synthetic strategy utilized by Bradner and co-workers.[135] 
The reported procedure could conveniently be used in the synthesis of 3.2a. However, the reaction proved 
difficult to reproduce; less than 21% yield of an impure product was isolated from the cross metathesis (Table 
3.2, entry 1) and substituting the catalyst or changing the solvent, did not improve the yield (entry 2, 3). Since 
the unprotected hydroxyl group might coordinate too strongly with the catalyst, the alcohol was 
triisopropylsilane (TIPS) protected. Unfortunately, this modification did not improve the yield either (entry 
4). An attempt to obtain the protected thiol directly (entry 5) did not produce any product, only the 
thiolprotected homodimer was observed. 
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Table 3.2 Catalyst screening for the cross metathesis. 
 
Entry R reaction conditions Yield (%) 
1 OH Grubbs 2nd gen, CH2Cl2 ∼21, impure 
2 OH Hoveyda-Grubbs 2nd gen, CH2Cl2 LCMS: almost no product 
3 OH Grubbs 2nd gen, toluene LCMS: almost no product 
4 OTIPS Hoveyda-Grubbs 2nd gen, CH2Cl2 10%, impure 
5 STrt Hoveyda-Grubbs 2nd gen, CH2Cl2 No product (dimer byproduct) 
The ring closing metathesis (RCM) generally produce better yields, so it was envisioned that the building 
block could be set up for a RCM reaction, followed by hydrolytic ring opening to afford the product (Scheme 
3.5). 2.8 was reacted with 3-butene-1-yl bromide, to form the diene 3.11. The metathesis proceeded to form 
an impure product. Judged by NMR, a mixture of cis and trans isomers was obtained, with the cis isomer as 
the dominant compound (approximately 20% trans isomer). Because of the modest yield and the mixture of 
isomers, this strategy was abandonned. 
 
Scheme 3.5: Reagents and conditions: (a) 4-bromo-1-butene, K2CO3, DMF, 3h. (b) Grubbs 2nd gen. cat., CH2Cl2, 18h. 
3.4 3rd Strategy 
The new strategy involved oxidation of alcohol 2.6 to an aldehyde, which could be subjected to a Julia-
Kocienski olefination (Scheme 3.6). Substitution with triphenylmethanethiol would subsequently give the 
target building block. 
 
Scheme 3.6 Retrosynthetic analysis of the thiolprotected building block. 
Background; the Julia-Kocienski reaction 
The Julia-Kocienski reaction has been utilized in the total synthesis of many natural compounds,[173] among 
these are Jiang and co-workers total synthesis of Largazole.[129] The Julia-Kocienski reaction involves the 
reaction between an aldehyde and an α-metalated sulfone.[174] After addition of a strong base, an anti- (B) 
or a syn alkoxide (G) is formed, which subsequently undergoes a Smiles rearrangement[175] through a 
spirocyclic intermediate (Scheme 3.7). Due to steric interactions between R1 and R2, the intermediate of the 
anti-conformation is higher in energy (D). If the Smiles rearrangement is the rate determining step, it is most 
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likely that a cis alkene will form, as the anti-alkoxide will rearrange slower than the syn-alkoxide (k3 < k4). The 
olefin is obtained after another rotational change, to facilitate elimination of sulfur dioxide and the 
heterocycle.[174, 176] 
 
Scheme 3.7 Mechanism of the Julia-Kocienski reaction. The scheme was modified from ref [176b]. 
Kocienski optimized the one-pot procedure further, by introducing 1-phenyl-1H-tetrazol-5-yl sulfones (PT)[177] 
and 1-tert-butyl-1H-tetrazol-5-yl sulfones (TBT)[178] which are less prone to self-condensation, presumably 
because of the bulky substituent which shields a nucleophilic attack. The modified Julia reaction is therefore 
also known as the Julia-Kocienski reaction.  
Use of aliphatic PT sulfones have indicated an irreversible reaction with aldehydes.[176b] The relative 
reaction rate to form the alkoxides (k1, k2) will therefore dictate the selectivity of the reaction. Kocienski and 
co-workers demonstrated that PT sulfones provided a high ratio of trans alkenes in the absence of electronic 
and steric factors, in contrast to the Julia-Lythgoe reaction. The base counter ion increased trans selectivity 
in the series Li+ < Na+ < K+ and the stereoselectivity could be further improved by using a polar solvent such 
as THF and DME.[177] 
Synthesis 
The ligand for the Julia-Kocienski olefination was prepared from a mono protected 1,3-propanediol, which 
was subjected to a Mitsunobu reaction followed by oxidation to produce 3.15a/3.15b, Scheme 3.8.  
 
Scheme 3.8 Reagents and conditions: (a) PPh3, DIAD, THF, 1-phenyl-1H-tetrazole-5-thiol, 0 °C, 4h to rt, 1h. (b) NaHCO3, m-CPBA, 3h. 
KHMDS was chosen as base, because of the trans selectivity that has shown to increase with the size of the 
counter ion.[177] Less than 10% of impure product was isolated (Scheme 3.9), and substituting the TBDMS 
protecting group to the more stable TIPS, did not produce a better result.  
 
Scheme 3.9 Reagents and conditions: (a) (COCl)2, DMSO, Et3N, CH2Cl2, –78 °C to –40 °C to rt, 2h. (b) 3.15a, KHMDS (0.5 M in toluene), 
THF, –78 °C, 3h. 
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We speculated that the low yields might be a consequence of the α-metalated PT withdrawing a proton from 
the Boc-protected amine, instead of making the nucleophilic attack. To test this hypothesis, the olefination 
was attempted on a purified aldehyde. Adding one equivalent KHMDS, did not produce any compound, but 
when a second equivalent of KHMDS was added, the starting material was consumed and the product could 
be isolated in 29% yield (Scheme 3.10). Although the simple test was not conclusive, the higher yield in the 
reaction supported the hypothesis that the NH in the tert-butyl carbamate would release a proton.  
 
Scheme 3.10 Proposed explanation of the low yielding Julia-Kocienski reaction.  
Since aldehyde 3.16 is prone to racemization, adding more than one equivalent of base would not be a viable 
strategy. However, if the amino acid was di-Boc-protected, the Julia-Kocienski olefination would still be 
possible.  
The di-Boc-protected aspartic acid was synthesized in excellent yields over three steps from Boc-L-
Asp(tBu)-OH. However, reducing the carboxylic acid resulted in a low yield, and the Swern oxidation did not 
produce any desired product, Scheme 3.11. Instead of exploring different oxidation methods, we decided to 
try a different strategy, since both the Julia-Kocienski reaction as well as the reduction needed to be 
optimized. 
 
Scheme 3.11 (a) BnBr, K2CO3, DMF, 2h. (b) Boc2O, DMAP, MeCN, 20h. (c) H2, Pd/C (10%), MeOH, 24h. (d) NaBH4, NMM, iBuOCl, THF, 
–25 °C to –10 °C to rt, 2h. (e) oxalyl chloride, DMSO, Et3N, CH2Cl2, –78 °C to –40 °C to rt. 
3.5 4th Strategy 
The biological tests of the desmethyl azumamide analogs, showed that activity was decreased when a trans 
alkene was introduced. This activity could be regained to some extent by reducing the side chain (Table 2.6). 
We therefore decided to focus on the saturated thioester. This way, the side chain could be attached using a 
Wittig reaction, without considering cis-trans selectivity, as the double bond would be reduced in the 
following step, Scheme 3.12. 
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Scheme 3.12 Retrosynthetic analysis for thioester containing analogs. 
Background; the Wittig reaction 
The use of the Wittig reaction has been extensively reported in the literature and is one of the most effective 
ways of forming the carbon−carbon bond. Since Geissler and Wittig reported the reaction between 
methylenetriphenylphosphorane and benzophenone in 1953,[179] the Wittig reaction has evolved into 
variants including the Horner-Wadsworth-Emmons reaction,[180] and the Schlosser modification.[181] 
The Wittig reaction usually proceeds by generating a reactive phosphonium ylide, followed by addition of 
an aldehyde or ketone. Ylides can be categorized according to their relative stability, which depends on the 
substituent attached to the α-carbon (Scheme 3.13). Non-stabilized ylides will predominantly form cis 
alkenes, although a high trans selectivity can be obtained with certain phosphonium species.[182] For non-
stabilized- and semi-stabilized ylides, the highest cis selectivity occur for tertiary aldehydes, while reactions 
with primary aldehydes will favor trans selectivity.[183] Stabilized ylides generally show high trans selectivity 
in polar aprotic solvents.[184] 
 
Scheme 3.13 Classification of ylides. The figure was modified from ref [185]. 
Synthesis of thiol containing cyclic peptide 
A TIPS protected Wittig reagent was synthesized in two steps from 3-bromo-1-propanol in satisfying yields 
(3.26, Scheme 3.14). After addition of KHMDS, the ylide was reacted with aldehyde 3.16 to give the cis olefin, 
Scheme 3.14. 
 
Scheme 3.14 Reagents and conditions: (a) imidazole, 2-bromopropanol, TIPSCl, CH2Cl2. (b) PPh3, toluene, reflux, 4d. (c) (COCl)2, DMSO, 
Et3N, CH2Cl2, –78 °C to –40 °C to rt, 2h. (d) KHMDS (0.5 M in toluene), 3.16, THF, –78 °C to rt, 15h. 
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The alkene was reduced with H2 using Pd/C (10%) as catalyst. In addition to the desired compound, two 
byproducts had formed. The first byproduct had lost the TIPS protecting group (3.28), while the TIPSO had 
been cleaved in the other byproduct (3.29), Table 3.3. Since a free hydroxyl group was needed for the next 
steps, the TIPS removal was not an issue. However, to avoid byproduct 3.29, a small catalyst screen was 
performed, Table 3.3. 
Table 3.3 Catalyst screening for reduction of the olefin. 
 
entry catalysta Yield (%) 
  3.28 3.29 
1      10% Pd/C 48 16 
2      20% Pd(OH)2/C ndb ndb 
3      10% Pt/C 87 0 
aGeneral reaction conditions: (a) H2, catalyst, MeOH, 24h; (b) TBAF, AcOH, THF. b nd: no 
data, poor reaction judged by TLC. 
Changing the catalyst to Pd(OH)2/C gave multiple spots on TLC (entry 2), thus the catalyst was changed to 
Pt/C instead (entry 3). This change gave a quantitative yield of the reduced product, and 3.28 could be 
isolated in 87% yield over two steps. 
The protected thiol was introduced by tosylating the hydroxyl group followed by an SN2 reaction with 
triphenylmethanethiol. The cyclization experiments on the simplified peptide had shown that a higher yield 
was obtained with the β-amino acid on the C-terminal. The Boc protecting group was therefore exchanged 
to an Fmoc protecting group. After peptide elongation and cyclization, removal of protecting groups afforded 
the target compound (3.35), Scheme 3.15. 
 
Scheme 3.15 Reagents and conditions: (a) TsCl, DMAP, Et3N, 5h. (b) Ph3CSH, KOtBu, THF, 0 °C to rt, 4h. (c) TFA, CH2Cl2, 0 °C, 4h. (d) 
FmocOSu, K2CO3, H2O, DMF, 3h. (e) i. Cl-(2-Cl-Trt)-resin, iPr2EtN, CH2Cl2. ii. 20% piperidine in DMF, DBU:piperidine:DMF (2:2:96). iii. 
HATU, 2,6-lutidine, Aa (Fmoc-D-Tyr-OH, Fmoc-D-Ala-OH, Fmoc-D-Val-OH), DMF. iv. 20% piperidine in DMF, DBU:piperidine:DMF 
(2:2:96). v. 50% TFA in CH2Cl2. (f) HATU, iPr2EtN, DMF, 19h. (g) TFA, iPr3SiH, 0 °C to rt, 2h. 
67 
Synthesis of C5 and C6 thiol side chains 
After synthesizing the first thiol containing cyclic peptide (3.35), a modified route was chosen to circumvent 
the Boc to Fmoc manipulation. An orthogonal protecting group strategy was devised, involving a 2-
(trimethylsilyl)ethoxycarbonyl (Teoc) protected amine, which is stable to the alkaline conditions in the Wittig 
reaction and still compatible with the trityl resin in the SPPS. The alcohol was protected with a benzyl group 
that could be removed in the same step as the alkene reduction (Scheme 3.16).  
 
Scheme 3.16 Retrosynthetic analysis of protected thiol building block. 
The Teoc-protected alcohol was obtained in good yield starting from H-Asp(OtBu)-OH (Scheme 3.17). 
 
Scheme 3.17 (a) Teoc-ONp, Et3N, H2O, dioxane, 24h. (b) iBuOCOCl, NMM, 1,2-dimethoxyethane, NaBH4, H2O, 40 min. 
The Wittig reagent was prepared by monoprotecting a diol, followed by an Appel reaction to convert the 
unprotected alcohol to a bromide (3.42a, 3.42b, Scheme 3.18). Triphenylphosphine was added in the last 
step, and the reaction was refluxed in toluene for 3 days.  
 
Scheme 3.18 (a) NaH, BnBr, THF, reflux, 18h. (b) PPh3, CBr4, Et2O, reflux, 2h. (c) PPh3, toluene, reflux, 24h. 
The standard procedure of precipitating the Wittig reagent in an apolar solvent, proved difficult for 3.43b 
compared to 3.43a. The presence of an extra methylene in combination with the benzyl ether resulted in a 
lipophilic compound that formed an oil when trituration was attempted.  
Inconsistent results were observed in the synthesis of the phosphonium bromide (3.43a). In the first 
attempt, am impurity was observed in the 1H-NMR, while a clean product was isolated in the second attempt, 
albeit in a significant lower yield. By further examination, the byproduct from the first reaction was found to 
be benzyltriphenylphosphonium bromide. After searching the literature for similar side reactions, it was 
uncovered that Keller and co-workers had seen a similar byproduct when they synthesized the same Wittig 
reagent.[186] They were able to optimize the reaction by exchanging the bromide to an iodide, lowering the 
reaction temperature (80°C) and allowing longer reaction time (158h). Although complications arose in the 
syntheses towards 3.1b and 3.1c, a viable strategy was found. We expect to synthesize the final compounds 
in the near future. 
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3.6 Biochemical data 
 As a preliminary study, 3.1a was tested against HDAC3 using the same assay conditions as previously 
described (section 2.4). However, to avoid disulfide formation, 
tris(2-carboxyethyl)phosphine (TCEP) was added to the buffer 
solution.  
 Even though the carboxylic acid in the desmethyl azumamide 
scaffold was substituted for a potent ZBG, the analog exhibited 
poor inhibition against HDAC3, with an IC50 of ∼20 μM (Table 
3.4). These data suggest that the linker length is not optimal for 
HDAC inhibition. 
3.7 Summary 
The side chain of largazole is an octanoyl thioester, which upon entry to the cell is hydrolyzed to the thiol. 
This natural prodrug was used as inspiration in the design of cyclic peptides containing the desmethyl 
azumamide scaffold.  
 To obtain the optimal length for binding in the HDAC enzymes, thiol side chains consisting of four, five, or 
six methylenes were designed. Different approaches for synthesizing these thiol-containing azumamides 
have been investigated.  
 In the first strategy, synthesis of a thioester building block via cross metathesis was accomplished in 
moderate yields. Although difficulties arose in the purification, a linear peptide was obtained. However, 
attempts on cyclizing the peptide did not provide the target compound. In the second strategy, different 
ligands were investigated in a cross metathesis with a vinyl building block to obtain a trityl protected thiol. 
However, the reaction was unsuccessful and exploring a ring closing metathesis strategy, did not provide the 
product in the desired yields either. In the third strategy, the Julia-Kociensky reaction was explored. The Boc-
protected amine functionality proved to be insufficient for the reaction conditions and complications 
emerged in attempts to prepare a new building block. 
 The Wittig reaction was successfully applied in the synthesis of a cyclic peptide containing a thiol side 
chain with a length of four methylenes. The compound, which was tested against HDAC3 proved to be a poor 
inhibitor. Optimization of the protection group strategy gave complications in the preparation of Wittig 
reagents. However, new reaction conditions have been found and synthesis of the final compounds will be 
completed in the near future. 
 
Table 3.4 Potency of 3.1b  against HDAC3 
Compound concentration 
% Enzyme  
inhibition 
3.35 20 μM 52 
3.35   5 μM 20 
3.35     1.25 μM 0 
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4 Work performed at California Institute of Technology 
Part of the Ph.D. studies at the Technical University of Denmark involves an external stay. Sarah E. Reisman 
was kind to welcome me into her research group at California Institute of Technology. During the six month, 
I worked on two projects. Synthesis of pyrroloindolines with Dr. Lindsay Repka, and total synthesis of SCH 
64877. 
4.1 Synthesis of 2α-phenylpyrroloindolines for biological evaluation 
Dr. Lindsay Repka, a former graduate student in Sarah E. Reisman’s research group, initiated the project 
concerning synthesis of 2α-phenylpyrrolindolines. The biological evaluation was conducted by Chris Marotta 
and Christina McCleary Daeffler from Dennis Dougherty’s research group at California Institute of 
Technology.  
Introduction  
The pyrroloindoline scaffold is present in many natural products and a broad range of biological properties 
are associated with these compounds. For example, the epidithiodioxopiperazine compounds, bionectin A 
and B exhibit antibacterial activity,[187] asperazine has shown selective cytotoxicity against leukemia,[188] and 
physostigmine is a cholinesterase inhibitor[189] (Figure 4.1). 
  
Figure 4.1 Pyrroloindoline natural products. Bionection A and B exhibit antibacterial activity, asperazine show anticancer activity and 
physostigmine is a cholinesterase inhibitor. 
Methods for synthesizing enantioenriched pyrroloindolines, within the context of natural product synthesis, 
have been investigated in the Reisman research group. Lindsay M. Repka and Jane Ni have synthesized a 
range of pyrroloindolines, starting from C(3)-substituted indoles. The reaction proceeds by a [3+2] 
cycloaddition,  catalyzed by an (R)-BINOL·SnCl4 complex[190] (Scheme 4.1). 
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Scheme 4.1 Proposed mechanism for the [3+2] cycloaddition. Reagents and conditions: (a) (R)-BINOL, SnCl4, CH2Cl2, 23 °C. 
A stepwise mechanism was proposed; after a conjugate addition of the indole to the acrylate, a catalyst-
controlled protonation afforded 4.3, which was subsequently cyclized onto the iminium ion.[191] The enantio- 
and diastereoselectivity was found to be dependent on the type of acrylate that was used; the best results 
was obtained by using 4.5 as shown in Scheme 4.1. 
Preparation of 1st generation pyrroloindolines 
When the same conditions were applied for the synthesis of tryptophan derivatives using 2-phenylindole as 
starting material, a low yield and poor ee was obtained. However, the reactivity was significantly improved 
when a  methyl 2-acetamidoacrylate was used.[191]  
Lindsay Repka used these conditions to synthesize a carboxylic acid containing hydroxy pyrroloindoline 
(4.10, Scheme 4.2). After the Friedel−Crad conjugate addition to afford 4.8, the amide was methylated using 
NaH as base. Compound 4.9 was obtained in good yields, but with a substantially reduced ee. By in situ 
formation of HCl, the acetamide was hydrolyzed, although the reaction was slow and low yielding. 4.10 was 
cyclized using N-chlorosuccinimide (NCS), and the hydroxy pyrroloindoline was obtained after quenching 
with NH4OH and stirring in SiO2. The exo and the endo compounds were obtained in a dr of 64:36, and could 
be isolated by preparative HPLC, although in less than 90% purity. 
Saponification of the exo compound (4.11) using LiOH, gave the corresponding carboxylic acid, but only 
11% of the product was obtained. Crude NMR following saponification of the endo product, suggested 
formation of the corresponding carboxylic acid, but after preparative HPLC, the exo product (4.12) was 
obtained in 1% yield. The data suggested that decomposition and isomerization could be a factor.[192] 
 
Scheme 4.2 Synthesis of carboxylic acid containing 2-α-phenylpyrroloindoline, conducted by Lindsay Repka. Reagents and conditions: 
(a) 4.7, (R)-3,3’-dibromo-BINOL, CH2Cl2. (b) NaH, MeI, DMF, 0 °C. (c) AcCl (32 equiv), MeOH, 60 °C, 76h. (d) NCS, MeCN. (e) NH4OH, 
SiO2, MeCN, H2O. (f) LiOH >25 equiv, THF/H2O (1:1). 
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Electrophysiological experiments on compound 4.12 (41% ee) 
Ion channels can be activated by changes in the potential near the channels (voltage gated ion channels) or 
by interaction with specific chemicals (ligand gated ion channels). Voltage clamp techniques, make it possible 
to distinguish between these effects.[193] 
The two-electrode voltage clamp method is an electrophysiological technique that utilizes two intracellular 
electrodes to set the membrane potential at a fixed value. One 
electrode is used as a voltage sensor (ev), while the other 
electrode can inject current (ei) (Scheme 4.2). If ions cross the 
cell membrane, the potential is measured by ev, and ei injects a 
current equal to the change, thereby stabilizing the potential at 
a fixed value. Specific ion channels can be investigated by 
injecting RNA into frog oocytes, which will express the specific 
proteins on the membrane surface.[194] 
 The biological investigation of compound 4.12 was 
conducted on oocytes expressing a variety of different ligand-
gated ion channel receptors (Table 4.1). A minor selectivity 
was observed, with no significant inhibition of the GlyR, 
GluR2A, and 5HT3A receptors.  
Table 4.1 Preliminary results of compound 4.12 (41%ee), tested against I variety of ligand gated ion channels. 
Entry Receptor % current reduction 
1 (α1)2(β1-L9’A)δγ mouse muscle  21 ± 1 
2 (α4)2(β2)3 nAChR  20 ± 1 
3 α7-T6’S nAChR  67 ± 1 
4 5HT3AR    3 ± 1 
5 (α1)2(β2)2γ2 GABAAR   27 ± 4 
6 GlurR2     6 ± 1 
7 GlyR2    6 ± 1 
Ligands can inhibit the ion channels by binding at the primary binding site, at an allosteric binding site, or by 
functioning as a channel blocker. To get a better understanding of the binding mode, new target compounds 
were designed (Figure 4.3).  In contrast to the zwitterionic nature of 4.13 and 4.14 compound 4.15, 4.16, and 
4.17 are believed to be positively charged at physiological pH. It should be possible to determine if these 
compounds bind as channel blockers, by switching to a positively current in the two-electrode voltage clamp 
experiments. If they bind in the ion channel, the positive charged compounds should be released quickly.  
 
Figure 4.3 Target compounds for further biological investigations. 
Figure 4.2 Two-electrode voltage clamp method.
The electrode ei can inject current to stabilize the 
membrane potential, which is measured by ev. 
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When I joined the Reisman research group, I continued the project initiated by Lindsay Repka. Besides from 
synthesizing 4.15−4.17, a new strategy for the synthesis of compound 4.13 was going to be attempted, so 
the ee could be optimized (Figure 4.3) 
Synthesis of pyrroloindoline 4.16 
Synthesis of 4.22 was commenced from tryptamine, which was Cbz protected followed by methylation of the 
protected amine and the indole nitrogen. Arylation of the indole was conducted using procedures from 
Albericio, Lavilla and co-workers (Scheme 4.3).[195] 
 
Scheme 4.3 Reagents and conditions: (a) NaHCO3, Cbz-Cl, H2O, CH2Cl2, 40 min. (b) NaH, MeI, THF, 0 °C to rt, 2h. (c) 2-NO2Bz, AgBF4, 
Pd2(OAc)2, DMF, PhI, rt, 30 min, then μW 150 °C 4 min. (d) Et3SiH, Et3N, Pd2(dba)3⋅CHCl3, CH2Cl2, 16h. 
After deprotecting the amine functionality, the oxidative cyclization proved to be a challenge. Previous 
cyclization attempts by Lindsay Repka had indicated an optimal reaction time of 90 min as the product 
decomposed over time.  
 In contrast to the former observation, the product did not decompose, when I reproduced the reaction 
conditions. The starting material had been consumed after 4h, without decomposition of the product (entry 
1, Table 4.2). Unfortunately, the reaction could not be reproduced, so different reaction conditions were 
investigated. 
NCS is unstable in light, so it was crucial that the reaction was kept in the dark. Adding an additional 
equivalent of NCS caused the product to decompose (entry 3, 4). Furthermore, if NCS and 4.22 were mixed 
before adding the solvent, the reaction would usually not succeed (entry 5). The most consistent results were 
obtained when recrystallized NCS was dissolved in MeCN and added dropwise to 4.22 in MeCN. 4Å molsieves 
were added and the reaction was kept under argon, while keeping the reaction in the dark (entry 6, 7).  
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Table 4.2 Exploration of the NCS mediated oxidative cyclization. 
 
Entry Additive NCS method of  
addition (equiv) 
Scale (µmol); 
Conc. (mM) 
Time (h) Result a 
1 – solution (1.0) 50; 33 4 4.23 
2 4Å MS neatb (0.83) 20; 20 1 4.23 
3 4Å MS neatb (1.1) 20; nd 4 nrc 
4 – Solutionb (1.0 + 1.0)  50; 50 7 nr 
5 – neatb (1.0) 50; 33 6.5 nr 
6 4Å MS solutionb (1.0) 50; 50 2 4.23 
7 4Å MS solutionb (1.0) 140; 56 2 4.23 
a Reactions were conducted under an argon atmosphere in the dark. Conversion to 4.23 was 
monitored by LCMS. b NCS was recrystallized from toluene. nd: not determined. c nr: no reaction.  
In the procedure for synthesizing 4.12 (Scheme 4.2), Lindsay Repka reported the use of NH4OH for quenching 
the reaction, followed by stirring in SiO2. When the same conditions were used for the synthesis of 4.22, a 
peak could be detected on LCMS (M+H =280.2 g/mol), with one mass unit less than the target compound. 
The new product turned out to be 4.24 (Scheme 4.4) due to a substitution by NH3. 4.16 was instead obtained 
by quenching with aqueous Na2S2O4 followed by stirring in H2O/MeCN with SiO2. The unstable chloride 
intermediate would thereby be converted to a hydroxy containing pyrroloindoline. A lower yield was 
obtained for 4.16 compared to 4.24. The cyclization conditions were similar for both compounds, so the 
difference in yields might be explained by the stability of the compounds under the different workup 
conditions. 
 
Scheme 4.4 Reagents and conditions: (a) i. NCS, MeCN, 4Å molsieves. ii. NH4OH, 3h. (b) i.NCS, MeCN, 4Å molsieves, 1.5h. ii.SiO2, H2O, 
MeCN. 
Synthesis of pyrroloindoline 4.17 
The Cbz protected tryptamine could be selectively methylated on the indole nitrogen using MeI and KOH. 
The following arylation succeeded in satisfactory yield and the oxidative cyclization was also performed 
without any difficulties to get the N-protected pyrroloindoline intermediate. It was decided to include 4.27 
in the biological testing, as the large Cbz protecting group most likely had an impact on activity, which could 
aid in elucidating the binding mode of these types of compounds. Minor impurities were observed after 
column chromatography of 4.27, a small amount was therefore purified by HPLC to obtain the purity needed 
for the biological testing. Removal of the Cbz group was achieved using Et3SiH as the H2 donor, but besides 
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the desired product, a silyl carbamate had formed. This intermediate could easily be cleaved by stirring the 
compound in a solution of NaHCO3 in THF. 
 
Scheme 4.5 Reagents and conditions: (a) MeI, KOH, Acetone, 1h. (b) PhI, 2-NO2Bz, AgBF4, Pd2(OAc)2, DMF, rt, 30 min then μW 150 °C 
4 min (c) i. NCS, MeCN, 4Å molsieves, 6h. ii. MeCN, H2O, SiO2 (d) Pd2(dba)3⋅ CHCl3, Et3SiH, Et3N, THF, 19h. (e) NaHCO3, THF, H2O, 5h. 
Synthesis of pyrroloindoline 4.13 
The original procedure for preparation of 4.13 had some synthetic challenges. Racemization was observed 
under the methylation conditions and a poor yield was obtained when hydrolyzing the acetamide. 
Furthermore, a lot of compound was lost upon saponification of the methyl ester. We therefore sought a 
new route for synthesizing the carboxylic acid containing pyrroloindoline. 
Racemization of the compound could be avoided by starting with a carboxylic acid instead of the methyl 
ester from the original strategy. (L)-Trp was therefore Cbz protected followed by addition of MeI. Arylation 
of the indole gave compound 4.31 in fair yields. Gratifyingly, with minor loss of enantiomeric purity. 
 
Scheme 4.6 Reagents and conditions: (a) Cbz-succinimide, K2CO3, H2O, DMF, 0 °C to rt, 40 min. (b) MeI, NaH, THF, 0 °C to rt, 29h. (c) 
PhI, 2-NO2Bz, AgBF4, Pd2(OAc)2, DMF, rt 30 min, then μW 150 °C 4 min. (d) Pd2dba3 ⋅ CHCl3, Et3SiH, Et3N, CH2Cl2, 29h. (e) NCS, MeCN, 
SiO2. (f) NCS, MeCN, TFA additive, SiO2. 
Purification of 4.32 proved to be challenging due to the low solubility of the compound. By combining 
fractions from several reactions, it was possible to obtain pure material for the indole cyclization. Different 
solvents were attempted as well as multiple oxidation reagents, but no successful cyclization was observed. 
The carboxylic acid was therefore protected as the methyl ester, where after the Cbz protecting group was 
removed (Scheme 4.7). The unprotected compound once again proved troublesome to purify, which was 
reflected in the low yield. Cyclization of the pyrroloindoline protected methyl ester, afforded a mixture of 
two diastereomers (4.35, 4.36) that could not be separated by column chromatography. Both compounds 
were therefore carried through to the next step. Saponification of the methyl ester, using LiOH at room 
temperature, was monitored on LCMS. While the endo compound reacted slowly, the exo compound was 
saponified readily. Purification by column chromatography afforded 4.13 as a pure compound in 33% yield, 
while the endo product could not be isolated.  
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 The saponification was repeated, but with the temperature kept at 0 °C. When the exo-compound 4.36 
was consumed, the reaction was quenched and purified to afford 47% of 4.13 and a 50% recovery of 4.35.  
 
 
Scheme 4.7 Reagents and conditions: (a) SOCl2, MeOH, 40 °C, 5h. (b) Et3SiH, Et3N, Pd2(dba)3, CH2Cl2, 20h. (c) NCS, MeCN, 4Å molsieves, 
5.5h. (d) SiO2, MeCN, H2O, 30 min. (e) LiOH, THF, H2O, 0 °C, 2.5h. 
Synthesis of pyrroloindoline 4.15 
The hydroxy pyrroloindoline 4.15, could be elaborated from 4.31 by converting the carboxylic acid to the 
anhydride followed by NaBH4 mediated reduction. After removal of the Cbz protection group, the oxidative 
cyclization was attempted. Unfortunately, the reaction did not proceed while having a free hydroxy group 
present. 
 
Scheme 4.8 Reagents and conditions: (a) NMM, MeOCOCl, NaBH4, THF, –30 °C to –20 °C, 1.5h. (b) Pd2dba3 ⋅ CHCl3, Et3SiH, Et3N, CH2Cl2, 
18h. (c) NCS, MeCN. (d) Davis' oxaziridine, CH2Cl2. (e) DMDO, acetone, CH2Cl2. (f) NBS, MeCN. (g) 1,3-Dichloro-5,5-dimethylhydantoin, 
MeCN. 
4.38 was protected with TESCl, but due to time limitations, synthesis of compound 4.40 and 4.15 was not 
completed. 
 
Scheme 4.9 Reagents and conditions: (a) TESCl, Et3N, DMAP, THF, 0 °C to rt, 3h. 
Biochemical testing 
Chris Marotta and Christina McCleary Daeffler tested the five 2-α-phenyl pyrroloindolies (Figure 4.4) on 
oocytes expressing a variety of ion channels (Table 4.3). The effect of the compounds were tested along with 
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an agonist for the particular receptor, so the antagonistic effect could be measured. A fixed concentration of 
the pyrroloindolines were used in combination with the EC50 concentration of the agonist.  
 
Figure 4.4 
Enantioenriched 4.13 did not change the antagonistic activity compared to the previous data (Table 4.1). 
Compound 4.16, 4.17, 4.24, and 4.27 exhibited a similar low activity against GluR2A, GlyR, and 5HT3AR, while 
almost all compounds were antagonists to the nicotine acetylcholine receptors. The antagonistic effect from 
the structural diverse pyrroloindolines indicated that a specific binding interaction does not occur. The effects 
could instead arise from blocking the ion channel; however, a positive current was not used in the preliminary 
testing to verify the binding mode. 
   Interestingly, 4.16 potentiates the effect of GABA on the GABAA receptor by 52%. Furthermore, 4.16 is 
also able to activate the GABAA receptor without addition of GABA, generating ∼10% current relative to the 
isolated GABA induced signal (Figure 4.5). 40 μM of 4.16 and 11 μM GABA (=IC50) was used in both 
experiments.  
Table 4.3 Be sure that 20a is enantio enriched compound. 
 % Change in current 
Receptor 4.13 4.16b 4.24 4.17 4.27 
(α1)2(β1-L9’S)δγ mouse muscle  -21 ±1 - 53 ±3 - 81 ±6    - 7 ±3 - 29 ±3 
α7-T6’S nAChR  -67 ±1 - 92 ±4 - 96 ±3  - 57 ±10 - 68 ±7 
(α4-L9’A)2(β2)3 nAChR  -20 ±1 - 29 ±6 - 44 ±2 - 11 ±2 - 47 ±4 
(α1)2(β2)2γ2 GABAAR  -27 ±4    + 52 ±10 + 10 ±5   - 27 ±21   - 27 ±11 
 (α1)2(β2)2 GABAAR   nd +15 ±1 nd nd nd 
GluR2A -6 ±1     - 9 ±6 - 12 ±5 - 11 ±5 0 ±2 
GlyR -6 ±1     +3 ±7 - 16 ±6   + 18 ±10 - 9 ±9 
5HT3AR -3 ±1     - 3 ±5 - 11 ±8 + 3 ±12  -23 ±4 
20 µM concentration of the pyrroloindolines and EC50 concentrations of the agonists were used. 
Standard deviations are based on the average of three to four experiments. b Run with a 40 µM 
concentration of 4.16. nd: not determined. 
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Figure 4.5 Current trace: blue: 40 μM 4.16, 11 μM GABA (=IC50) 
4.2 Side chain preparation towards the epidithiodiketopiperazine SCH 64877 
Dr. Jay Codelli, a former graduate student in Sarah E. Reisman’s research group was working on total 
synthesis of the natural compound SCH 64877. When I joined the group, I assisted Jay in synthesizing the side 
chain of the compound. 
Introduction 
The epipolythiodioxopiperazines (ETP) are secondary metabolites from fungi, characterized by a bridged 
disulfide or polysulfide on a diketopiperazine. Compounds belonging to this group have shown a variety of 
biological activities, such as antitumor, antimicrobial, antiviral, immunosuppressive, and inhibitory activities 
on various enzymes. The biological activity has been assigned the disulfide/polysulfide moiety, as reduction 
of the functionality has typically led to complete loss of activity.[196] 
Three thiodiketopiperazine metabolites SCH 64874, SCH 64875, and SCH 64877 (Figure 4.6) was isolated 
in 1997 from an unidentified fungus.[197] The compounds showed antagonistic activity for the epidermal 
growth factor (EGF) receptor, with IC50 values of 1.0, 1.0, 1.25 μg/mL respectively. Compounds with a similar 
scaffold have been isolated from the fungi Arachniotus aureus (aranotin, acetylaranotin),[198] Aspergillus 
terreus (acetylaranotin),[199] and Emericella heterothallica (emathallicin C) (Figure 4.6).[200] 
 
Figure 4.6 SCH 64877 and related compounds.  
Towards the total synthesis of SCH 64877 
The total synthesis of acetylaranotin was completed in the Reisman research group in 2011.[201] The strategy 
opened up the possibility for accessing additional members of the ETP family. The natural compound SCH 
64877, containing four sulfur atoms bridging a diketopipeazine (Figure 4.6), could be obtained directly by 
elaborating on an intermediate from the total synthesis. The stereochemistry of the two β-hydroxyester side 
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chains are unknown; however, the exact structure of SCH 64877 could be elucidated if the total synthesis 
succeeded. 
Nelson and co-workers have showed that cis β-lactones can be synthesized with high enantio- and 
diastereoselection, using trimethyl silane (TMS) protected quinine (TMSq) or quinidine (TMSQ) as catalyst 
(Scheme 4.10).[202]  
 
Scheme 4.10 Cis-β−lactones can be generated by a ketene-aldehyde cycloaddition using TMS protected quinine (TMSq) or TMS 
protected quinidine (TMSQ) as catalyst.[202] 
Using these reaction procedures, Jay Codelli initiated synthesis of the side chains. Starting from propanoyl 
chloride and 2-methylbutyraldehyde he achieved to synthesize the side chain with the (2R, 3S, 4S) 
stereochemistry (Scheme 4.11). However, comparing the spectral data with the published spectra for SCH 
64877, the synthesized compound did not turn out to be the natural compound.  
 
Scheme 4.11 Incorporation of a side chain with the (2R, 3S, 4S) stereochemistry, was not the natural product, SCH 64877. 
When I joined the project, the focus was set on synthesizing the (2S, 3R, 4R) diastereomer. Jay Codelli had 
used a procedure, where the cis-β-lactone 4.43, could be obtained by a [2+2] cycloaddition using TMSQ as 
catalyst. The trans isomer could be formed by exposing 4.43 to alkaline conditions (Scheme 4.12). The cis- 
and trans-β-lactones could easily be separated by column chromatography, while the diastereomeric benzyl 
esters was separated using an automated flash chromatography system. 
 
Scheme 4.12 Initial syntheses by Jay Codelli. The trans-β-lactone could be formed by addition of a base and the benzyl-protected 
diastereoisomers (4.46, 4.47, 4.49, and 4.50) could be isolated. 
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1st strategy 
The proposed mechanism of the [2+2] cycloaddition (Scheme 4.13) starts from the ketene, which is generated 
in situ from the acid chloride. TMS protected quinine or quinidine adds to form an enolate, stabilized by the 
Lewis acid. A six membered transition state forms, which collapses to the cis-β-lactone. 
 
Scheme 4.13 Postulated mechanism for the [2+2] cycloaddition. Redrawn from ref [202]. 
The optimal reaction procedure employed by Nelson and co-workers[202] included dissolution of the 
protected quinine/quinidine and LiClO4 in Et2O, followed by addition of CH2Cl2 (Et2O was necessary to dissolve 
LiClO4). For challenging substrates, the amount of Lewis acid could be raised to increase the yields. After 
cooling the reaction to –40 °C or –78 °C, iPr2NEt was added followed by addition of the aldehyde. Dropwise 
addition of the acid chloride in CH2Cl2 (4 M) over 1–4 h ensured a slow conversion of the ketene. The reaction 
was run between 7–16 h before the reaction was quenched.  
The reaction conditions used by Jay in the first attempts in the [2+2] cycloaddition, were based on the 
original procedure in the formation of an α-substituted aldehyde. The best yields were obtained by raising 
the amount of Lewis acid to 3.3 equiv, but the product was still obtained in less than 40% yield. I therefore 
attempted to optimize the reaction by changing different parameters, Table 4.4. 
Dimerization of the ketene is a known byproduct, so by using a higher concentration of the aldehyde, 
formation of the byproduct might be lowered. Unfortunately, the product was obtained in a very low yield. 
Exchanging the acid chloride for an acid bromide did not change the outcome of the reaction and substituting 
iPr2NEt, with an inorganic base did not provide any compound at all. A higher amount of the Lewis acid was 
added, but this attempt was also unsuccessful. Since a larger volume of Et2O was needed to dissolve the 
LiClO4, the solvent might destabilize the transition state, resulting in lower yield. All the reactions had been 
performed at –40 °C. With the known risk of obtaining a mixture of diastereomers, the temperature was 
raised to 0 °C. However, only 10% yield was obtained from this reaction. 
The best result was obtained by increasing the amount of acid chloride, indicating that this starting 
material was consumed before reacting with the aldehyde, probably by dimer formation. The acid chloride 
was therefore diluted to a larger volume of CH2Cl2 before addition to the reaction mixture, hoping that an 
even lower concentration of the acid chloride would eliminate dimerization. As the yield did not improve, it 
was hypothesized that the lower ratio of Et2O present in the reaction mixture might be too low, leading to 
precipitation of the Lewis acid. The acid chloride was therefore dissolved in the same Et2O−CH2Cl2 ratio before 
addition. However, this change did not improve formation of the β-lactone.  
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Table 4.4  Exploration of different reaction conditions in the [2+2]-cycloaddition. 
 
Entry Changes to reaction conditions Yield 
1 Higher conc. of aldehyde 13% 
2 Diluted acid chloride  (DCM) 29% 
3 Diluted acid chloride  (Et2O/DCM 1:2) 31% 
4 Acid bromide 27% 
5 Temp.: 0⁰C 10% 
6 8 equiv. acid chloride 40% 
7 LiCO3 instead of iPr2NEt   0% 
8 10 equiv. LiClO4 nda 
a nd: not determined, low yield judged by crude NMR. 
The low yields in the reaction, can most likely be explained by the hindered aldehyde being too unreactive. 
A screen of different Lewis acids was planned, as activation of the aldehyde might afford the product in a 
better yield. Before a significant improvement to the reaction conditions was fund, it was uncovered that the 
reaction gave a low ee of 4.46, which was the target molecule. The synthetic strategy was therefore revised. 
2nd strategy 
For synthesis of the side chain, diastereoselectivity was a high priority. We envisioned that 4.53 and 4.57 
could be synthesized by a directed hydrogenation, while 4.54 and 4.58 could be obtained using Evans aldol 
reaction (Scheme 4.14). Beside the diastereomers shown, the enantiomers could be synthesized, starting 
from the R-oxazolidinone auxiliary. 
 
Scheme 4.14 Retrosynthetic analysis of side chains towards SCH-64877. 
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Synthesis of the side chain for SCH 46877 
Evans auxiliary was prepared from the methyl ester of phenylalanine. After Boc protecting the amine 
functionality, a Grignard reaction afforded compound 4.61. Cyclization after addition of tBuOK, provided the 
auxiliary in good yields over three steps (Scheme 4.15). 
 
Scheme 4.15 Reagents and conditions: (a) Boc2O, iPr2EtN, CH2Cl2, 12h. (b) MeMgBr, THF, Et2O, 0 °C, 12h. (c) tBuOK, THF, 0 °C, 30 min. 
Propionyl chloride was added to auxiliary 4.62 to afford 4.55 in good yield. Evans aldol reaction was 
thereafter applied, which provided 4.54 in a diastereomeric ratio (dr) of 94:6, calculated by NMR. 4.65 was 
obtained in a similar fashion, by using the R-auxiliary (4.63). 
 
Scheme 4.16 Reagents and conditions: (a) propionyl chloride, n-BuLi, THF, –78 °C to rt, 3h. (b) 2-ethyl acrolein, Bu2BOTf, DIPEA, CH2Cl2, 
0 °C to –78 °C to rt, 12h. *4.63 was obtained from the chemical storage room at CalTech.  
The final stereocenter was set by a directed hydrogenation, using [Rh(NBD)(DIPHOS-4)BF4] as catalyst. High 
pressure was necessary for obtaining high ee.[203] The reaction was therefore performed in an autoclave 
reactor, which was assembled in a glove box, since the catalyst was unstable in the presence of oxygen and 
H2O.  
  
Scheme 4.17 Reagents and conditions: (a) H2, [Rh(NBD)(DIPHOS-4)]BF4], CH2Cl2, 460 psi, 1h. 
The crude compound was filtrated and judged by NMR, a dr of 83:11:6 was calculated. Due to time 
limitations, the last steps in the syntheses were not performed.  
Summary 
2-α-phenyl pyrroloindolines were succefully synthesized to investigate the activity in ligand-gated ion 
channel receptors. An improved synthetic strategy afforded 4.13 in a high ee, and in the synthesis of 
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compound 4.16, a minor alterations in the workup conditions provided compound 4.24. The bulky Cbz 
protection group in 4.27 was included in the biological tests and 4.17 was obtained in one step from this 
compound. 
 From the electrophysiological experiments, compound 4.16 was found to potentiate the effect of GABA 
on the GABAA receptor. In addition, 4.16 was also able to activate the GABAA receptor without addition of an 
agonist. 
 Towards the synthesis of SCH 46877, different reaction conditions were investigated in a [2+2] 
cycloaddition reaction. However, the yields were not improved and a low ee was obtained. Evans aldol 
reaction was successfully applied and a directed hydrogenation provided 4.53, which after few modifications 
can be incorporated in the core structure of SCH 46877. 
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5 Conclusion and perspectives 
In recent years, there has been a huge progress in the field of HDACs and their epigenetic mechanisms. HDAC 
assays have been developed[169] and recombinant HDAC isozymes can be readily tested. A number of HDAC 
X-ray structures have been reported and many of these are co-crystalized with an inhibitor. These structures 
have in particular guided the design of new potent and selective compounds. 
  Six azumamide analogs have been synthesized, all with the methyl group removed from the 2-position of 
the β-amino acid. Different amino acids were investigated as well as modifications to the unsaturation in the 
side chain. The key step in the synthetic route was a cross metathesis on a vinyl amino acid building block, 
which could be obtained readily from commercially available L-aspartic acid. An optimized position for the 
cyclization was found, which lead to a significant improved yield. 
 The azumamide analogs were tested against HDACs from class I, IIb, and IV. The effect of removing the 
methyl group was clear as all the analogs had a substantial loss of activity. Compounds containing a 
phenylalanine and a trans olefin in the side chain, were slightly less potent. 
 The effect of removing the methyl group was further investigated by solving the NMR structure and 
analyzing the docking poses in the crystal structure of HDAC3. Although a minor conformational change in 
backbone of the desmethylated compounds was observed, the methyl group may have an effect by 
minimizing movement of the side chain. Docking poses of the analogs showed a similar binding mode as the 
natural compounds, but a lipophilic interaction with the methyl group in the azumamides might be an 
important factor.  
 With the knowledge from the biological activity as well as the NMR structure and docking conformations, 
it would be interesting to elaborate on azumamide modifications. Incorporation of a larger substituent in the 
β 2-position (an ethyl, isopropyl, or tert-butyl) could provide valuable information of a possible hydrophobic 
interaction with the enzymes. The direction of the side chain is known to be important for activity; another 
possible modification could therefore be to constrain the direction of the side chain. 
  In a related project, azumamide analogs containing a thioester side chain were designed with the focus 
on obtaining compounds with better cell penetrating capabilities. Using the Wittig reaction, a desmethylated 
azumamide analog containing a thiol side chain was synthesized and tested against HDAC3. The low HDAC 
inhibitory activity that was observed was most likely due to an unfavorable length of the side chain. With the 
establishment of a successful route, syntheses of compounds with an altered length will be readily accessible. 
Different thioesters can then be explored in relation to cell permeability.  
 
84 
6 Experimental 
Experimentals for Chapter 2 
General  
All chemicals and solvents were analytical grade and used without further purification. Vacuum liquid 
chromatography (VLC) was performed on silica gel 60 (particle size 0.015−0.040 µm). UPLC−MS analyses were 
performed on a Waters Acquity ultra high-performance liquid chromatography system. A gradient with 
eluent I (0.1% HCOOH in water) and eluent II (0.1% HCOOH in acetonitrile) rising linearly from 0% to 95% of 
II during t = 0.00–2.50 min was applied at a flow rate of 1 mL/min (gradient A) or during t = 0.00–5.20 min 
(gradient B). Analytical HPLC was performed on a [150 mm × 4.6 mm, C18 Phenomenex Luna column (3 µm)] 
using an Agilent 1100 LC system equipped with a UV detector. A gradient with eluent III (95:5:0.1, 
water−MeCN−TFA) and eluent IV (0.1% TFA in acetonitrile) rising linearly from 0% to 95% of IV during t = 
2−20 min was applied at a ﬂow rate of 1 mL/min (gradient C). Preparative reversed-phase HPLC was 
performed on a [250 mm × 20 mm, C18 Phenomenex Luna column (5 μm, 100 Å)] using an Agilent 1260 LC 
system equipped with a diode array UV detector and an evaporative light scattering detector (ELSD). A 
gradient C with eluent III and eluent IV rising linearly from 0% to 95% of IV during t = 5−45 min was applied 
at a flow rate of 20 mL/min. 1D and 2D NMR spectra were recorded on a Varian Mercury 300 instrument or 
a Varian INOVA 500 MHz instrument. All spectra were recorded at 298 K. Correlation spectroscopy (COSY) 
spectra were recorded with a relaxation delay of 1.5 sec before each scan, a spectral width of 6k × 6k, 
collecting 8 FIDs and 1k × 512 data points. Heteronuclear single quantum coherence (HSQC) spectra were 
recorded with a relaxation delay of 1.5 sec before each scan, a spectral width of 6k × 25k, collecting 16 FIDs 
and 1k × 128 datapoints. Heteronuclear 2-bond correlation (H2BC) spectra were recorded with a relaxation 
delay of 1.5 sec before each scan, a spectral width of 4k × 35k, collecting 16 FIDs at 295 K and 1k × 256 
datapoints. Heteronuclear multiple-bond correlation (HMBC) spectra were recorded with a relaxation delay 
of 1.5 sec before each scan, a spectral width of 6k × 35 k, collecting 32 FIDs and 1k × 256 datapoints. Chemical 
shifts are reported in ppm relative to deuterated solvent peaks as internal standards (δH, DMSO-d6 2.50 ppm; 
δC, DMSO-d6 39.52 ppm, δH, CD3OH 3.30 ppm, δH, CDCl3 7.26 ppm; δC, CDCl3 77.16 ppm). Coupling constants 
(J) are given in hertz (Hz). Multiplicities of 1H NMR signals are reported as follows: s, singlet; d, doublet; t, 
triplet; q, quartet; m, multiplet. 
(S)-tert-butyl 3-((tert-butoxycarbonyl)amino)-4-hydroxybutanoate (2.6).[135] 
To a solution of Boc-(L)-Asp(tBu)-OH (15.3 g, 53 mmol) in THF (260 mL) at –30 °C was added 
N-methylmorpholine (6 mL, 54 mmol) followed by dropwise addition of iBuOCOCl (7 mL, 54 
mmol). The reaction was warmed to –10 °C and stirred for 30 min, then cooled to –30°C 
where after NaBH4 (7.19 g, 190 mmol) was added in one portion, followed by dropwise 
addition of MeOH (53 mL). The reaction was stirred at room temperature for 2h, then quenched with sat. aq. 
NH4Cl (50 mL). The aqueous phase was extracted with Et2O (3 × 100 mL) and the combined organic phases 
were washed with 1M HCl (2 × 100 mL) and brine (2 × 100 mL), dried (Na2SO4), filtered, and concentrated. 
Purification by VLC (0–50% AcOEt in heptane) afforded the desired alcohol 2.6 (10.3 g, 71%) as white crystals. 
1H NMR (300 MHz, CDCl3) δ 5.23 (s, 1H), 4.05 – 3.83 (m, 1H), 3.65 (d, J = 4.8 Hz, 2H), 2.87 (brs, 1H), 2.53 (dd, 
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J = 15.3, 6.2 Hz, 1H), 2.47 (dd, J = 15.4, 6.2 Hz, 1H), 1.43 (s, 9H), 1.42 (s, 9H). 13C NMR (75 MHz, CDCl3) δ 171.3, 
156.0, 81.4, 79.8, 64.9, 49.7, 37.6; [α]25D = 6°; Mp = 39–42°C. 
 (S)-tert-butyl 3-((tert-butoxycarbonyl)amino)pent-4-enoate (2.7).[135] 
To a solution of oxalyl chloride (0.53 mL, 6.1 mmol) in anhydrous CH2Cl2 (25 mL) at –78°C was 
added DMSO (0.87 mL, 12.2 mmol) in anhydrous CH2Cl2 (4 mL) dropwise. After 20 min, 2.6 
(954 mg, 3.5 mmol) in anhydrous CH2Cl2 (4 mL) was added dropwise and the reaction mixture 
was stirred for another 20 min followed by dropwise addition of Et3N (2.6 mL) in anhydrous 
CH2Cl2 (9 mL). The reaction was then warmed to –40°C and stirred for 1 h. The solution was poured onto a 
mixture of Et2O/1 M KHSO4 (1:1, 120 mL) where after the organic phase was washed with KHSO4 (1 M, 60 
mL). The aqueous phases were then extracted with Et2O (75 mL) and the combined organic phases were 
washed with sat. NaHCO3 (2 × 100 mL) and brine (2 × 100 mL), dried (MgSO4, Na2SO4), filtered, and 
concentrated. The crude product was dried under high vacuum for 15 min and used without further 
purification. 1H NMR (300 MHz, CDCl3) δ 9.64 (s, 1 H), 5.6 (d, 1 H, J = 8.35 Hz), 4.32 (m, 1 H), 2.91 (dd, 1 H, J = 
4.84, 17.14 Hz), 2.73 (dd, 1 H, J = 4.98, 17.14 Hz), 1.46 (s, 9 H), 1.43 (s, 9 H). 
 KHMDS (0.5 M in toluene, 14.1 mL, 7.05 mmol) was added dropwise to a stirred solution of PPh3CH3Br 
(2.63 g, 7.36 mmol) in anhydrous THF (40 mL) at room temperature. After 1h the reaction was cooled to –78 
°C and crude the crude aldehyde in anhydrous THF (5 mL) was added dropwise. The reaction was warmed to 
room temperature over 1h, then stirred for an additional hour. The reaction was quenched with sat. aq. 
NH4Cl (25 mL) and extracted with Et2O (50 mL). The combined organic phases were washed with 1M HCl (2 × 
50 mL), sat NaHCO3 (2 × 50 mL), and brine (2 × 50 mL), dried (MgSO4), filtered, and concentrated. Purification 
by VLC (0–6% AcOEt in heptane) afforded the product (796 mg, 85% 2 steps) as white crystals. 1H NMR (300 
MHz, CDCl3) δ 5.81 (ddd, 1 H, J = 5.2, 10.4, 17.2 Hz), 5.19 (brs, 1 H),  5.18 (ddd, 1 H, J = 1.1, 1.7, 17.2 Hz), 5.11 
(ddd, 1 H, J = 1.1, 1.6, 10.4 Hz),  4.45 (brs, 1 H), 2.51 (dd, 1 H, J = 5.9, 15.3 Hz), 2.45(dd, 1 H, 6, 15.3 Hz), 1.42 
(s, 18 H) ); 13C NMR (75 MHz, CDCl3) δ 170.6, 155.2, 137.5, 115.2, 81.3, 79.5, 49.6, 40.5, 28.5, 28.2; [α]25D = 
21.5°; Mp = 37–39°C. 
(S)-3-((tert-butoxycarbonyl)amino)pent-4-enoic acid (2.8).[135] 
To 2.7 (432.9 mg, 1.6 mmol) in THF (10 mL) and MeOH (10 mL) was added 1 M LiOH (10 
mL). The reaction was stirred at 50°C for 7 h, and then quenched with 1M HCl (10 mL). The 
aqueous phase was extracted with Et2O (3 x 40 mL) and concentration to give the 
carboxylic acid (313 mg, 91%) as yellow crystals. 1H NMR (300 MHz, CDCl3) δ 5.86 (ddd, 1 
H, J = 5.4, 10.4, 17.2 Hz), 5.22 (ddd, 1 H, J = 0.9, 1.6, 17.2 Hz), 5.18 - 5.13 (m, 1 H), 5.16 (brs, 1 H), 4.51 (brs, 1 
H), 2.66 (d, 1 H, J = 4.7 Hz), 1. 45 (s, 9 H); 13C NMR (300 MHz, CDCl3) δ 176.3, 155.4, 137, 115.7, 80, 49.2, 39.1, 
28.4. ; [α]25D = +19°; Mp = 58–61°C. 
((R)-3-aminopent-4-enoyl)-D-valine-D-alanine-D-tryptophan (2.9). 
To a polystyrene 2-chlorotrityl resin in a fritted syringe, was added Fmoc-
D-Trp-OH (2 equiv) and iPr2EtN (4 equiv) in anhydrous CH2Cl2. The reaction 
was put on a tilting table for 1h, then washed with CH2Cl2 (x3). The resin 
was capped with a mixture of CH2Cl2:MeOH: iPr2EtN (4:1:0.5) for 20 min 
then was washed with DMF (x3), MeOH (x3), and CH2Cl2 (x3). The Fmoc 
group was removed with 20% piperidine in DMF (2x 30 min), then with DBU:piperidine:DMF (2:2:96) (15 
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min), and finally washed with DMF (x3), MeOH (x3), and CH2Cl2 (x3). Fmoc-D-Ala-OH (3 equiv) was 
preactivated with HATU (3 equiv) and 2,6-lutidine (6 equiv) in DMF for 5 min, then added to the resin. The 
reaction was put on a tilting table for 4h, then washed with DMF (x3), MeOH (x3), and CH2Cl2 (x3). The cycle 
was repeated with Fmoc-D-Val-OH, and 2.8. Cleavage of the tetrapeptide was done with 50% TFA in CH2Cl2 
(2x 30 min). The solvent was evaporated until a small volume was left, then triturated with Et2O. The peptide 
was used without further purification. 1H NMR (300 MHz, DMSO-D6) δ 10.86 (s, 1H), 8.34 – 7.94 (m, 6H), 7.52 
(d, J = 7.6 Hz, 1H), 7.33 (d, J = 8.0 Hz, 1H), 7.15 (d, J = 2.2 Hz, 1H), 7.06 (t, J = 8.0 Hz, 1H), 6.97 (t, J = 7.4 Hz, 
1H), 5.79 (ddd, J = 17.3, 10.6, 6.7 Hz, 1H), 5.31 (t, J = 14.5 Hz, 2H), 4.56 – 4.40 (m, 1H), 4.40 – 4.27 (m, 1H), 
4.27 – 4.14 (m, 1H), 3.99 (brs, 1H), 3.09 (ddd, J = 22.3, 14.7, 6.5 Hz, 2H), 2.76 – 2.53 (m, 2H), 1.93 (d, J = 6.6 
Hz, 1H), 1.20 (d, J = 7.0 Hz, 3H), 0.93 – 0.64 (m, 6H). 
(3R,6R,9R,13S)-3-((1H-indol-2-yl)methyl)-9-isopropyl-6-methyl-13-vinyl-1,4,7,10-tetraazacyclotridecane-
2,5,8,11-tetraone (2.10) 
To 2.9 (20.8 mg, 0.044 mmol) in DMF (87 mL) was added iPr2EtN (60.9 μL, 0.35 mmol) 
followed by HATU (33.5 mg, 0.088 mmol). The reaction was stirred at room temperature 
for 15h and the solvent was then evaporated. Purification by preparative HPLC gave the 
desired product as white needle crystals (2.9 mg, 15%). 1H NMR (500 MHz, DMSO) δ 10.88 
(s, 14H), 7.90 (d, 1H, J = 7.8 Hz), 7.84 (d, 16H, J = 6.5 Hz), 7.68 (d, J = 11.2 Hz, 1H), 7.60 – 
7.45 (m, 34H), 7.36 (dt, J = 28.4, 8.0 Hz, 50H), 7.24 (d, J = 9.8 Hz, 2H), 7.13 – 7.02 (m, 34H), 
7.02 – 6.92 (m, 18H), 5.93 (s, 1H), 5.84 (ddd, J = 17.2, 10.4, 4.6 Hz, 15H), 5.13 – 4.99 (m, 
34H), 4.40 (s, 32H), 4.32 (dq, J = 14.7, 7.3 Hz, 16H), 4.09 (d, J = 5.3 Hz, 9H), 3.97 – 3.93 (m, 1H), 3.82 (s, 16H), 
3.32 (s, 26H), 3.17 (d, J = 5.2 Hz, 32H), 3.06 (d, J = 2.5 Hz, 33H), 2.55 – 2.46 (m, 159H), 1.96 (d, J = 6.6 Hz, 16H), 
1.17 (d, J = 7.4 Hz, 46H), 0.92 (s, 89H), 0.81 (d, J = 6.8 Hz, 7H), 0.65 (d, J = 6.3 Hz, 3H). HRMS calc’d for 
C29H39N5O6H+ [M+H+] = 554.2973, found 554.2977. 
2-isopropoxy-5-nitrobenzaldehyde (2.13).[204] 
2-Iodopropane (0.59 mL, 5.91 mmol) was added to 2-hydroxy-5-nitro-benzaldehyde (494.2 mg, 
2.96 mmol), K2CO3 (1.64 g, 11.84 mmol), and Cs2CO3 (386 mg, 1.19 mmol) in DMF (10 mL). The 
reaction was heated to 60°C and stirred for 24 h. The reaction was diluted with AcOEt (10 mL), 
washed with 1M HCl (2 x 20 mL), NaHCO3 (2 x 20 mL) and brine (2 x 20 mL), dried (Na2SO4), 
filtered and concentrated. Purification by VLC (0–15% AcOEt in heptane) gave the product (520 
mg, 84%) as a white solid. 1H NMR (300 MHz, CDCl3): δ 10.46 (s, 1 H), 8.7 (d, 1 H, J = 2.9 Hz), 8.4 (dd, 1 H, J = 
2.9, 9.2 Hz), 7.09 (d, 1 H, J = 9.3 Hz), 4.84 (h, 1 H, J = 6.1 Hz), 1.48 (d, 6 H, J = 6.1 Hz); 13C NMR (300 MHz, CDCl3) 
δ 188, 164.5, 141.1, 130.6, 125.1, 124.7, 113.8, 72.8, 21.9. 
1-isopropoxy-4-nitro-2-vinylbenzene (2.14).[204] 
To Ph3PCH3Br (1.04 g, 2.9 mmol) in anhydrous THF (20 mL) was added 0.5 M KHMDS in toluene 
(5.5 mL, 2.74 mmol) dropwise. The reaction was cooled to -78°C and 2.13 in anhydrous THF 
(2.5 mL) was added dropwise. The reaction was warmed to room temperature over 30 min and 
quenched with NH4Cl (20 mL). The aqueous phase was extracted with Et2O (2 x 25 mL), washed 
with NaHCO3 (2 x 20 mL) and brine (2 x 20 mL), dried (Na2SO4), filtered and concentrated. 
Purification by VLC (0–15% AcOEt in heptane) gave the desired product (276 mg, 92%) as orange crystals. 1H 
NMR (300 MHz, CDCl3): δ 8.35 (d, 1 H, J = 2.8 Hz), 8.1 (dd, 1 H, J = 2.8, 9.1 Hz), 6.99 (dd, 1 H, 11.2, 17.8 Hz), 
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6.9 (d, 1 H, J = 9.2 Hz), 5.86 (dd, 1 H, 1.1, 17.7 Hz), 5.39 (dd, 1 H, 1.1, 11.2 Hz), 4.7 (h, 1 H, 6 Hz), 1.41 (d, 6 H, 
6.1 Hz); 13C NMR (300 MHz, CDCl3) δ 160.1, 141.1, 130.2, 128.2, 124.7, 122.5, 116.9, 112.3, 71.6, 22.0; Mp = 
31°C - 33°C. 
(1,3-dimesitylimidazolidin-2-yl)(2-isopropoxy-5-nitrobenzylidene)ruthenium(V) chloride (2.11).[204] 
Grubbs catalyst 2nd generation (148 mg, 0.17 mmol) and CuCl (18.4 mg, 0.17 mmol) in 
anhydrous CH2Cl2 (9 mL) were transfered to a schlenk tube and degassed with Ar. 2.14 
in anhydrous CH2Cl2 (4 mL) was added and the reaction stirred at 30°C for 24 h. 
Purification by VLC (0–25%) gave the desired product (48.5 mg, 42%) as a green solid. 1H 
NMR (300 MHz, CDCl3) δ 16.47 (s, 1H), 8.42 (dd, 1H, J = 9.1, 2.7 Hz), 7.82 (d, 1H, J = 2.7 
Hz), 7.1 (s, 4H), 6.89 (d, 1H, J = 9.0 Hz), 4.98 (sept, 1H, J = 6.21 Hz), 4.21 (s, 4H), 2.46 (s, 9H), 2.44 (s, 9H), 1.30 
(d, J = 6.1 Hz, 6H). 
 
(S,E)-1-tert-butyl 9-methyl 3-((tert-butoxycarbonyl)amino)non-4-enedioate (2.12) 
General methods for the cross methatesis. 
To 2.7 in degassed, anhydrous CH2Cl2 was added methyl 5-hexenoate (3 equiv), 
followed by a catalyst. The reaction was heated to reflux 17-20h, evaporated on silica 
and purified by VLC (0–40% AcOEt in heptane) to obtain the product (12-67%) as a 
brown oil.  
Entry 1 
The compound was synthesized according to the general procedure, using Grubbs catalyst 1st generation 
(0.1 equiv) as the catalyst. Yield: 18 mg, 11%. 
 
Entry 2 
The compound was synthesized according to the general procedure, using Grubbs catalyst 2nd generation 
(0.05 equiv) as the catalyst. Yield: 79 mg, 54%. 
Entry 3 
The compound was synthesized according to the general procedure, using Grubbs catalyst 2nd generation 
(0.1 equiv) as the catalyst. Yield: 89 mg, 62%. 
Entry 4 
The compound was synthesized according to the general procedure, using Hoveyda Grubbs catalyst 1st 
generation (0.1 equiv) as the catalyst. Yield: 17 mg, 12%. 
Entry 5 
The compound was synthesized according to the general procedure, using Hoveyda Grubbs catalyst 2nd 
generation (0.1 equiv) as the catalyst. Yield: 225 mg, 67%. 
Entry 6 
The compound was synthesized according to the general procedure, using Zhan catalyst 1B (0.1 equiv) as 
the catalyst. Yield: 92 mg, 62%. 
Entry 7 
The compound was synthesized according to the general procedure, using 2.11 (0.1 equiv) as the catalyst. 
Yield: 135 mg, 52%. 
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1H NMR (300 MHz, CDCl3) δ 5.58 (dtd, J = 13.6, 6.3, 0.8 Hz, 1H), 5.43 (dd, J = 15.5, 5.7 Hz, 1H), 5.14 (brs, 1H), 
4.41 (brs, 1H), 3.66 (s, 3H), 2.47 (d, J = 5.9 Hz, 2H), 2.29 (t, J = 7.5 Hz, 2H), 2.05 (q, J = 7.2 Hz, 2H), 1.69 (p, J = 
7.4 Hz, 2H), 1.43 (s, 18H). 13C NMR (300 MHz, CDCl3) δ 173.9, 170.5, 155, 130.4, 130.2, 81, 79.3, 51.5, 49.1, 
40.8, 33.2, 31.4, 28.4, 28, 24.2; HRMS calc’d for C19H33NO6H+ [M+H+] 372.2381, found 372.2379; [α]25D = –
1.1°. 
(S,E)-3-((tert-butoxycarbonyl)amino)-9-methoxy-9-oxonon-4-enoic acid (2.13). 
To 2.12 (212 mg, 0.57 mmol) in CH2Cl2 (20 mL) was added TFA (6 mL, 78.2 mmol). The 
reaction was stirred at room temperature for 2h and the solvent was then evaporated 
to give the crude product as an orange oil. 1H NMR (300 MHz, CDCl3) δ 7.87 (brs, 3H), 
6.85 (brs, 1H), 6.07 – 5.74 (m, 1H), 5.51 (dd, J = 15.3, 7.6 Hz, 1H), 4.06 (s, 1H), 3.65 (s, 
3H), 3.02 – 2.56 (m, 2H), 2.30 (t, J = 7.4 qHz, 2H), 2.19 – 1.94 (m, 2H), 1.85 – 1.60 (m, 2H). 
To the crude amino acid (176 mg, 0.53 mmol) and iPr2NEt (0.24 mL, 1.38 mmol) in CH2Cl2 (2 mL) was added 
di-tert-butyl dicarbonate (159 μL, 69 mmol) dropwise. The reaction was stirred at room temperature for 19 
h, then purified by VLC (0–40% AcOEt in heptane) to give the product (148 mg, 84% 2 steps) as a clear oil. 1H 
NMR (300 MHz, CDCl3) δ 5.60 (dt, J = 7.1, 6.5 Hz, 1H), 5.47 (dd, J = 15.5, 5.9 Hz, 1H), 5.15 (brs, 1H), 4.44 (brs, 
1H), 3.66 (s, 3H), 2.62 (d, J = 5.1 Hz, 2H), 2.30 (dd, J = 16.6, 9.2 Hz, 3H), 2.06 (q, J = 7 Hz, 2H), 1.69 (dq, J = 14.3, 
7.3 Hz, 2H), 1.44 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 176, 174.3, 131.2, 129.8, 51.7, 39.6, 33.3, 31.5, 28.5, 
24.3; HRMS calc’d for C15H25NO6H+ [M+H+] = 316.1755, found 316.1760; [α]25D = –4°. 
 
(R)-3-((tert-butoxycarbonyl)amino)-9-methoxy-9-oxononanoic acid (2.14). 
A solution of 2.13 (83 mg, 0.26 mmol) in THF (3 mL) was purged with argon. 10 wt. % 
Pd/C (10 mg, 10 wt. %) was then added and the mixture was purged with H2 for  5 
min then kept under H2 atmosphere and stirred for 17h. The mixture was filtered on 
celite and evaporated to obtain the product (98%, 81 mg) as a clear oil. 1H NMR (300 
MHz, CDCl3) δ 4.90 (brs, 1H), 3.88 (brs, 1H), 3.66 (s, 3H), 2.55 (brs, 2H), 2.30 (t, J = 7.4 Hz, 2H), 1.87 – 0.61 (m, 
8H), 1.44 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 176.7, 174.4, 155.6, 79.5, 51.6, 47.4, 39.2, 34.4, 34, 28.8, 28.4, 
25.9, 24.8; HRMS calc’d for C15H27NO6H+ [M+H+] = 318.1911, found 318.1912; [α]25D = +5.6°. 
(E)-6-((2R,5R,8R,11S)-8-benzyl-2-isopropyl-5-methyl-3,6,9,13-tetraoxo-1,4,7,10-tetraazacyclotridecan-11-
yl)hex-5-enoic acid (2.1a). 
2.13 (31.3 mg, 0.1 mmol), HATU (38.8 mg, 0.1 mmol) and 2,6-lutidine (23 μL, 
0.2 mmol) in DMF (1.5 mL) were preactivated for 5 min. and added to a 
tripeptide (Val-Ala-Phe) on solid support. After 18 h, the peptide was washed 
with DMF (x3), MeOH (x3) and CH2Cl2 (x3). The peptide was cleaved with 50% 
TFA in CH2Cl2 (2x 30 min) and evaporated. Precipitated in Et2O (8 mL) obtained 
a crude tetrapeptide (88 mg), which was dissolved in DMF (130 mL). iPr2NEt 
(140 μL, 0.8 mmol) was added followed by HATU (78 mg, 0.2 mmol). The reaction was stirred for 65h and 
then evaporated. LiOH (32 mg, 1.3 mmol) in THF:H2O (20 mL,1:1) was added to the crude compound and the 
mixture was stirred 7h. Preparative HPLC gave the desired product (3.8 mg, 7%, over 4 steps) as a white solid. 
1H NMR (500 MHz, DMSO) δ 12.03 (s, 1H), 7.87 (d, J = 6.8 Hz, 1H), 7.61 (d, J = 9.7 Hz, 1H), 7.40 (d, J = 7.5 Hz, 
2H), 7.33 – 7.11 (m, 5H), 5.46 – 5.41 (m, 2H), 4.41 – 4.31 (m, 1H), 4.31 – 4.24 (m, 2H), 3.82 (t, J = 6.6 Hz, 1H), 
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3.06 – 2.81 (m, 2H), 2.62 – 2.48 (m, 2H), 2.20 (t, J = 7.4 Hz, 2H), 2.07 – 1.97 (m, 2H), 1.97 – 1.87 (m, 1H), 1.66 
– 1.48 (m, 2H), 1.15 (d, J = 7.3 Hz, 3H), 0.92 (dd, J = 9.0, 7.0 Hz, 6H); HRMS calc’d for C26H36N4O6H+ [M+H+] = 
501.2708, found 501.2716; Analytical HPLC: (gradient A; retention time: 11.6 min, purity: >99%, 230 nm) 
(E)-6-((2R,5R,8R,11S)-8-(4-hydroxybenzyl)-2-isopropyl-5-methyl-3,6,9,13-tetraoxo-1,4,7,10-
tetraazacyclotridecan-11-yl)hex-5-enoic acid (2.1b). 
2.13 (31.3 mg, 0.1 mmol), HATU (38.8 mg, 0.1 mmol) and 2,6-lutidine (23 μL, 
0.2 mmol) in DMF (1.5 mL) were preactivated for 5 min. and added to a 
tripeptide (Val-Ala-Tyr) on solid support. After 18 h, the peptide was washed 
with DMF (x3), MeOH (x3) and CH2Cl2 (x3). The peptide was cleaved with 50% 
TFA in CH2Cl2 (2x 30 min.) and evaporated. Precipitated in Et2O (8 mL) 
obtained a crude tetrapeptide (89 mg), which was dissolved in DMF (130 mL). 
iPr2NEt (140 μL, 0.8 mmol) was added followed by HATU (78 mg, 0.2 mmol). 
The reaction was stirred for 65h and then evaporated. An unsuccessful purification gave 7 mg of impure 
compound. LiOH (1.3 mg, 0.054 mmol) in THF:H2O (20 mL,1:1) was added to the mixture and stirred 18h. An 
additional amount of LiOH (4 mg, 0.15 mmol) was added an the mixture was stirred 7h, then 63h  at 5°C. 
Preparative HPLC gave the desired product (4.2 mg, 8% over 4 steps) as a white solid. 1H NMR (500 MHz, 
DMSO) δ 9.23 (s, 1H), 7.85 (d, J = 6.7 Hz, 1H), 7.52 (d, J = 9.7 Hz, 1H), 7.38 (d, J = 9.9 Hz, 1H), 7.31 (d, J = 7.3 
Hz, 1H), 6.95 (d, J = 8.4 Hz, 2H), 6.66 (d, J = 8.4 Hz, 2H), 5.47 – 5.39 (m, 2H), 4.40 – 4.33 (m, 1H), 4.29 (dq, J = 
14.9, 7.6 Hz, 1H), 4.19 (td, J = 9.3, 6.0 Hz, 1H), 3.81 (t, J = 6.5 Hz, 1H), 2.84 (dd, J = 13.9, 5.8 Hz, 1H), 2.75 (dd, 
J = 13.8, 9.1 Hz, 1H), 2.58 – 2.40 (m, 2H), 2.20 (t, J = 7.4 Hz, 2H), 2.11 – 1.98 (m, 2H), 1.98 – 1.90 (m, 1H), 1.65 
– 1.48 (m, 2H), 1.16 (d, J = 7.4 Hz, 3H), 0.92 (dd, J = 8.3, 7.2 Hz, 6H); HRMS calc’d for C26H36N4O7H+ [M+H+] = 
517.2657, found 517.2660; Analytical HPLC: (gradient A; retention time: 10.3 min, purity: >99%, 230 nm). 
(E)-6-((2R,5R,8R,11S)-8-((1H-indol-2-yl)methyl)-2-isopropyl-5-methyl-3,6,9,13-tetraoxo-1,4,7,10-
tetraazacyclotridecan-11-yl)hex-5-enoic acid (2.1c) 
2.13 (31.3 mg, 0.1 mmol), HATU (38.8 mg, 0.1 mmol) and 2,6-lutidine (23 μL, 
0.2 mmol) in DMF (1.5 mL) were preactivated for 5 min. and added to a 
tripeptide (Val-Ala-Trp) on solid support. After 18 h, the peptide was washed 
with DMF (x3), MeOH (x3) and CH2Cl2 (x3). The peptide was cleaved with 50% 
TFA in CH2Cl2 (2 times 30 min.) and evaporated. Precipitated in Et2O (8 mL) 
obtained a crude tetrapeptide, which was dissolved in DMF (130 mL). iPr2NEt 
(140 μL, 0.8 mmol) was added followed by HATU (78 mg, 0.2 mmol). The 
reaction was stirred for 65h and then evaporated. An unsuccessful purification gave 3 mg of impure 
compound. LiOH (0.5 mg, 0.02 mmol) in THF:H2O (20 mL,1:1) was added and the mixture was stirred 18h. An 
additional amount of LiOH (1 mg, 0.04 mmol) was added and the mixture was stirred 5h. Preparative HPLC 
gave the desired product (1.4 mg, 3% over 4 steps) as a white solid. 1H NMR (500 MHz, DMSO) δ 7.82 (d, J = 
6.8 Hz, 1H), 7.55 (d, J = 9.7 Hz, 1H), 7.50 (d, J = 7.8 Hz, 1H), 7.45 (d, J = 9.8 Hz, 1H), 7.37 (d, J = 7.3 Hz, 1H), 
7.34 (d, J = 8.1 Hz, 1H), 7.16 – 7.04 (m, 2H), 6.98 (t, J = 7.5 Hz, 1H), 5.47 – 5.31 (m, 2H), 4.45 – 4.24 (m, 3H), 
3.82 (t, J = 6.5 Hz, 1H), 3.09 – 3.00 (m, 2H), 2.48 – 2.37 (m, 2H), 2.19 (t, J = 7.3 Hz, 2H), 2.06 – 1.87 (m, 4H), 
1.59 – 1.46 (m, 2H), 1.17 (d, J = 7.3 Hz, 3H), 0.92 (t, J = 6.4 Hz, 6H); HRMS calc’d for C28H37N5O6H+ [M+H+] = 
540.2817, found 540.2807; Analytical HPLC: (gradient A; retention time: 11.66 min, purity: >99%, 230 nm) 
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6-((2R,5R,8R,11R)-8-benzyl-2-isopropyl-5-methyl-3,6,9,13-tetraoxo-1,4,7,10-tetraazacyclotridecan-11-
yl)hexanoic acid (2.2a) 
2.14 (25.4 mg, 0.08 mmol), HATU (36.5 mg, 0.1 mmol) and 2,6-lutidine (18 μL, 
0.16 mmol) in DMF (1.5 mL) were preactivated for 5 min. and added to a 
tripeptide (Val-Ala-Phe) on solid support. After 18 h, the peptide was washed 
with DMF (x3), MeOH (x3) and CH2Cl2 (x3). The peptide was cleaved with 50% 
TFA in CH2Cl2 (2x 30 min.) and evaporated. Precipitated in Et2O (8 mL) 
obtained a crude tetrapeptide, which was dissolved in DMF (170 mL). iPr2NEt 
(140 μL, 0.8 mmol) was added followed by HATU (61 mg, 0.16 mmol). The reaction was stirred for 24h and 
then evaporated. LiOH (34 mg, 1.5 mmol) in THF:H2O (15 mL, 1:2) was added to the crude compound and 
stirred 4h, an additional amount of LiOH (19 mg, 0.8 mmol) was added and the reaction was stirred 5h. As 
the reaction had not finished, LiOH (35 mg, 0.8 mmol) was added and the reaction was stirred 17h. 
Preparative HPLC gave the desired product (4.2 mg, 10% over 4 steps) as a white solid. 1H NMR (500 MHz, 
DMSO) δ 11.97 (s, 1H), 7.78 (d, J = 6.6 Hz, 1H), 7.55 (d, J = 8.7 Hz, 1H), 7.41 (d, J = 8.4 Hz, 1H), 7.34 – 7.10 (m, 
6H), 4.31 – 4.20 (m, 2H), 3.81 (t, J = 7.0 Hz, 2H), 2.93 (dd, J = 13.7, 6.7 Hz, 1H), 2.84 (dd, J = 13.7, 8.5 Hz, 1H), 
2.59 – 2.45 (m, 1H), 2.41 – 2.27 (m, 1H), 2.19 (t, J = 7.4 Hz, 2H), 1.94 (dq, J = 13.4, 6.7 Hz, 1H), 1.58 – 1.21 (m, 
8H), 1.17 (d, J = 7.3 Hz, 3H), 0.92 (dd, J = 9.1, 7.0 Hz, 6H); HRMS calc’d for C26H38N4O6H+ [M+H+] = 503.2864, 
found 503.2870, Analytical HPLC: (gradient B; retention time: 18.3 min, purity: >99%, 230 nm)  
6-((2R,5R,8R,11R)-8-(4-hydroxybenzyl)-2-isopropyl-5-methyl-3,6,9,13-tetraoxo-1,4,7,10-tetraazacyclotridecan-
11-yl)hexanoic acid (2.2b) 
2.14 (25.4 mg, 0.08 mmol), HATU (36.5 mg, 0.1 mmol) and 2,6-lutidine (18 μL, 
0.16 mmol) in DMF (1.5 mL) were preactivated for 5 min. and added to a 
tripeptide (Val-Ala-Tyr) on solid support. After 18 h, the peptide was washed 
with DMF (x3), MeOH (x3) and CH2Cl2 (x3). The peptide was cleaved with 50% 
TFA in CH2Cl2 (2x 30 min.) and evaporated. Precipitated in Et2O (8 mL) 
obtained a crude tetrapeptide, which was dissolved in DMF (170 mL). iPr2NEt 
(140 μL, 0.8 mmol) was added followed by HATU (61 mg, 0.16 mmol). The 
reaction was stirred for 24h and then evaporated. LiOH (95 mg, 1.5 mmol) in THF:H2O (15 mL, 1:2) was added 
to the crude compound and stirred 24h, an additional amount of LiOH (37 mg, 1.5 mmol) was added and the 
reaction was stirred 24h. Preparative HPLC gave the desired product (3.1 mg, 7% over 4 steps) as a white 
solid. 1H NMR (500 MHz, DMSO) δ 9.21 (s, 1H), 7.77 (d, J = 7.0 Hz, 1H), 7.44 (d, J = 9.5 Hz, 1H), 7.37 (d, J = 9.8 
Hz, 1H), 7.17 (d, J = 7.4 Hz, 1H), 6.94 (d, J = 8.4 Hz, 2H), 6.65 (d, J = 8.4 Hz, 2H), 4.26 (dq, J = 14.8, 7.3 Hz, 1H), 
4.19 – 4.14 (m, 1H), 4.00 – 3.74 (m, 2H), 2.80 (dd, J = 13.8, 6.6 Hz, 1H), 2.72 (dd, J = 13.8, 8.4 Hz, 1H), 2.49 
(dd, J = 8.5, 6.8 Hz, 1H), 2.32 (dd, J = 14.5, 3.2 Hz, 1H), 2.20 (t, J = 7.3 Hz, 2H), 1.99 – 1.90 (m, 1H), 1.67 – 1.21 
(m, 8H), 1.18 (d, J = 7.4 Hz, 3H), 0.92 (dd, J = 8.5, 7.1 Hz, 6H); HRMS calc’d for C26H38N4O7H+ [M+H+] = 
519.2813, found 519.2813; Analytical HPLC: (gradient A; retention time: 10.4 min, purity: >99%, 230 nm) 
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(R)-3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-9-methoxy-9-oxononanoic acid (2.19) 
To 2.14 (171 mg, 0.54 mmol) in CH2Cl2 (20 mL) was added TFA (5 mL). After stirring 
at room temperature for 4.5h the compound was concentrated and used without 
further purification.  
     The crude compound was dissolved in H2O (5 mL) at 0°C followed by addition of 
K2CO3 (127 mg, 0.92 mmol). FmocOSu (202 mg, 0.59 mmol) in 1,4-dioxane (5 mL) was added and the reaction 
was allowed to warm to rt. After stirring for 2.5h the reaction was diluted with H2O (10 mL) and concentrated. 
The aqueous phase was washed with Et2O (2 x 30 mL), acidified with 1M HCl (10 mL), then extracted with 
Et2Cl2 (4 X 30 mL) and concentrated. Purification by VLC (0 – 30% AcOEt/heptanes + 0.2% AcOH) gave the 
desired product (57% in 2 steps, 127 mg) as a white solid. 1H NMR (300 MHz, cdcl3) δ 7.75 (d, J = 7.4 Hz, 2H), 
7.58 (d, J = 7.4 Hz, 2H), 7.38 (t, J = 7.4 Hz, 2H), 7.30 (t, J = 7.4 Hz, 2H), 5.22 (d, J = 9.1 Hz, 1H), 4.39 (d, J = 6.8 
Hz, 2H), 4.21 (t, J = 6.8 Hz, 1H), 3.96 (d, J = 5.5 Hz, 1H), 3.65 (s, 3H), 2.70 – 2.48 (m, 2H), 2.29 (s, 2H), 1.58 (s, 
4H), 1.33 (s, 4H); HRMS calc’d for C25H29NO6H+ [M+H+] = 440.2068, found 440.2080; [α]25D = +8.5°. 
 
6-((2R,5R,8R,11R)-8-((1H-indol-2-yl)methyl)-2-isopropyl-5-methyl-3,6,9,13-tetraoxo-1,4,7,10-
tetraazacyclotridecan-11-yl)hexanoic acid (2.2c). 
2.19 (95 mg, 0.22 mmol) was dissolved in anhydrous CH2Cl2 (5 mL) and iPr2NEt 
(75 μL, 0.43 mmol), then loaded to a trityl resin. The resin was washed with 
CH2Cl2 (x3), then capped with iPr2NEt:MeOH:CH2Cl2 (1:2:7). Loading of the 
resin was calculated to 0.7 mmol/g, corresponding to 96 μmol of 2.19. 
Standard conditions for SPPS was used to attach D-Trp(Boc), D-Ala, and D-Val. 
The peptide was cleaved with CH3CO2H:CF3CH2OH:CH2Cl2 (1:1:3) for 2.5h, and 
evaporated. Precipitation in Et2O (8 mL) obtained a crude tetrapeptide. Half 
of the crude compound was dissolved in DMF (170 mL) and iPr2NEt (100 μL, 0.6 mmol) was added followed 
by HATU (57 mg, 0.15 mmol). The reaction was stirred for 2h and then evaporated. LiOH (7 mg, 0.3 mmol) in 
THF:H2O (5 mL, 1:1) was added to the crude compound and stirred 5h, where after additional LiOH (48 mg, 2 
mmol) was added and the reaction was stirred 24h. The crude mixture was evaporated, then dissolved in 
CH2Cl2 (6 mL) followed by addition of TFA (6 mL). The reaction was stirred for 30 min, then evaporated. 
Preparative HPLC gave the desired product (12.4 mg, 48% over 12 steps) as a white solid. 1H NMR (500 MHz, 
DMSO) δ 11.97 (s, 1H), 10.81 (d, J = 56.2 Hz, 1H), 7.75 (d, J = 6.8 Hz, 1H), 7.57 – 7.41 (m, 3H), 7.33 (d, J = 8.0 
Hz, 1H), 7.22 (d, J = 7.2 Hz, 1H), 7.11 – 7.01 (m, 2H), 7.00 – 6.93 (m, 1H), 4.43 – 4.32 (m, 1H), 4.28 (dq, J = 
15.1, 7.4 Hz, 1H), 3.87 – 3.77 (m, 2H), 3.04 (dd, J = 14.7, 6.8 Hz, 1H), 2.99 (dd, J = 14.8, 7.6 Hz, 1H), 2.55 – 2.45 
(m, 1H), 2.31 (dd, J = 14.4, 3.3 Hz, 1H), 2.19 (t, J = 7.3 Hz, 2H), 2.03 – 1.85 (m, 1H), 1.54 – 1.10 (m, 8H), 1.18 
(d, J = 7.4 Hz, 3H), 0.91 (t, J = 6.5 Hz, 6H); HRMS calc’d for C28H39N5O6H+ [M+H+] = 542.2973, found 542.2978; 
Analytical HPLC: (gradient A; retention time: 11.98 min, purity: >99%, 230 nm) 
 
Biochemical profiling 
Assay Materials  
HDAC1 (Purity >45% by SDS-PAGE according to the supplier), HDAC4 (Purity >90% by SDS-PAGE according to 
the supplier), and HDAC 7 (Purity >90% by SDS-PAGE according to the supplier) were purchased from 
Millipore (Temecula, CA 92590). HDAC2 used for dose–response experiments (Full length, purity ≥94% by 
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SDS-PAGE according to the supplier) and HDAC 5 (Full length, purity ≥4% by SDS-PAGE according to the 
supplier) and HDAC8 used for dose-response experiments (Purity ≥90% by SDS-PAGE according to the 
supplier) were purchased from BPS Bioscience (San Diego, CA 92121). HDAC2 used for initial screening 
experiments (Full length, purity 50% by SDS-PAGE according to the supplier), HDAC3-NCoR1* complex (Purity 
90% by SDS-PAGE according to supplier), HDAC6 (Purity >90% by SDS-PAGE according to the supplier), HDAC8 
for initial screening experiments (Purity >50% by SDS-PAGE according to the supplier), HDAC10 (Purity >50% 
by SDS-PAGE according to the supplier), and HDAC11 (Purity >50% by SDS-PAGE according to the supplier) 
were purchased from Enzo Life Sciences (Postfach, Switzerland). HDAC9 (Full length, purity 12% by SDS-PAGE 
according to the supplier) was purchased from Abnova (Taipei, Taiwan). The HDAC assay buffer [50 mM 
tris/Cl, pH 8.0, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, and bovine serum albumin (0.5 mg/mL)]. Trypsin 
(10,000 units/mg, TPCK treated from bovine pancreas) was from Sigma Aldrich (Steinheim, Germany). All 
peptides were purified to homogeneity (>95% purity by HPLC230 nm using reversed-phase preparative HPLC), 
and the white fluffy materials obtained by lyophilization were kept at –20 °C. For assaying, peptide substrates 
were reconstituted in DMSO to give 5–10 mM stock solutions, the accurate concentrations of which were 
determined by co-injection on HPLC with a standard of known concentration. 
 
In Vitro Histone Deacetylase Inhibition Assays  
For inhibition of recombinant human HDACs the dose–response experiments with internal controls were 
performed in black low binding NUNC 96-well microtiter plates. Dilution series (3-fold dilution, 6 
concentrations) were prepared in HDAC assay buffer from 5–10 mM DMSO stock solutions. The appropriate 
dilution of inhibitor (5 µL of 5 × the desired final concentration) was added to each well followed by HDAC 
assay buffer (10 µL) containing substrate [Ac-Leu-Gly-Lys(Ac)-AMC (50 µM) for HDAC1, 2, and 3; (80 µM) for 
HDAC6 and (100 µM) for HDAC11; (500 µM) for HDAC8; and Ac-Arg-His-Lys(Ac)-Lys(Ac)-AMC (125 µM) for 
HDAC10]. Finally, a solution of the appropriate HDAC (10 µL) was added and the plate was incubated at 37 
°C for 30 min. Final HDAC concentrations: HDAC1: 6 ng/µL, HDAC2: 1 or 2 ng/µL, HDAC3: 0.2 ng/µL, HDAC6: 
2.4 or 3.6 ng/µL, HDAC8: 0.1 or 0.2 ng/µL, HDAC10: 10 or 14 ng/µL and HDAC11: 10 ng/µL. Then trypsin (25 
µL, 0.4 mg/mL) was added and the assay development was allowed to proceed for 15–30 min at room 
temperature, before the plate was read using a Perkin Elmer Enspire plate reader with excitation at 360 nm 
and detecting emission at 460 nm. Each assay was performed in duplicate. The data were analyzed as 
described in chapter 2. 
 
Cheng–Prusoff Ki Calculations 
Using the Cheng–Prusoff equation Ki = IC50/(1+[S]/Km) and assuming a standard fast-on–fast-off mechanism 
of inhibition, IC50 values were converted to Ki values using the substrate concentrations outlined above and 
the Km values determined by Bradner, mazitschek and co-workers[169] for HDACs 1–9 and by Chou and co-
workers[205] for HDAC11. For HDAC10, a Km value for the applied substrate (Ac-RHKacKac-AMC) was obtained 
as described in ref [206]. 
 
3D-structure elucidation 
NMR 
NMR spectra were acquired using standard pulse sequences on a Unity Inova 500 by Varian (499.9 MHz for 
1H, 125.7 MHz for 13C) or a Bruker Avance 800 MHz spectrometer (798.9 MHz for 1H and 200.9 MHz for 13C) 
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located at the Danish Instrument Centre for NMR Spectroscopy of Biological Macromolecules at Carlsberg 
Laboratory. 
The deuterated solvent used for all compounds was DMSO-d6. For homonuclear 2D experiments 4096 
data points were recorded in the direct dimension and 512 in the indirect dimension. Typical d1 times were 
from 2 to 4 seconds, which were found to give almost identical results compared to 8 seconds for 2.10 and 
2.27b. The T1 times were investigated for a model compound (2.10) and all nuclei were found to have T1’s 
up to approximately 1 second. All J-couplings were extracted from the 1D 1H and DQF-COSY spectra. 
Distances were obtained from 2D NOESY or ROESY experiments using the isolated spin pair approximation 
(ISPA).[207] ( The linear range was increased by the method suggested by Macur et al.[208] The used mixing time 
was 150 ms for all compounds. Prior different mixing times were used to construct buildup curves to ensure 
that only cross-peaks which fitted the ISPA were used. The J-couplings from angles were calculated by the 
Karplus equation for peptides.[209] 
 
Simulations 
Simulations were conducted using the program Maestro (Version 9.3.515, MMshare Version 2.1.515) from 
the Schrödinger suite. Conformational searches in implicit solvents (DMSO and H2O) were run by 
MacroModel (version 9.9, Schrödinger, LLC, New York, NY, 2012) using the force fields OPLS2005 and MMFFs. 
Monte Carlo torsional sampling was used to generate the structures and the minimization method was PRCG. 
The number of steps was 30,000 and only conformations within 20 kJ/mol of the found minimum were 
considered. The solvent DMSO was treated as a constant dielectric constant of 47.0.  The natural compound 
was altered to avoid very stable interactions with the ring amide functionalities, as this structure was not 
supported by the NMR data. The side chain amide (N-24) was thus exchanged with a methyl group. Both 
solvents and force fields gave similar results, and the distances and torsion angles were optimized by applying 
constraints on the side groups at C-6 and C-13 according to the observed J-couplings. The constraints were 
implemented by calculating the appropriate angles from J-couplings, using the structural knowledge 
obtained from NOE/ROEs. This angle was allowed to differ by 10 degrees and was governed by a force 
constant of 50 kJ/mol.  
The structures obtained as well as structures from non-restricted minimizations were placed in the center 
of a cubic box of 45x45x45 Å3, and explicit water was added using the program Desmond (Desmond 
Molecular Dynamics System, version 3.1, D. E. Shaw Research, New York, NY, 2012. Maestro-Desmond 
Interoperability Tools, version 3.1, Schrödinger, New York, NY, 2012) and the force field OPLS2005.[210] 
Berendsen coupling was used for temperature and pressure control.[211] The system was minimized by 
steepest decent to remove unwanted overlaps of atoms. The system was then heated from 30 K to 300 K in 
two steps; 30 to 100 K in 100 ps and 100 to 300 K in 200 ps. This was done with temperature coupling (tT=0.1 
ps). The resulting system was held at 300 K and 1 bar with temperature and pressure couplings (tT=0.1 ps, 
tP=0.5 ps) and simulations of 10 ns was conducted. Structures were recorded every 20 ps. Again very similar 
simulated structures were observed. 
 
Restricted simulations 
Restricted simulations in implicit DMSO were conducted in MacroModel using the force field MMFFs. The 
minimization method was PRCG, and 30,000 steps were used to find conformations within 30 kJ/mol of the 
found minimum. The solvent DMSO was treated as a constant dielectric constant of 47.0. The distances were 
referenced to a diastereotopic methylene proton pair with a distance set to 1.78 Å using ISPA. The calculated 
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distances were applied to the structure and allowed to differ 20 %, governed by a force constant of 100 kJ/Å2. 
Similar results to those of the unrestricted compounds were obtained. It should be noted that it was no 
longer needed to alter the side-chain of the natural compound, as the restrictions prevented the stable 
interactions with the ring amide functionalities.  
 
Table 5. Distances used for restricted simulations. The values were allowed to differ 20 %. 
2.27b Azumamide A 
Nucleus1 Nucleus2 Distance 
7 9a 2.94 
7 9b 2.27 
7 6 3.28 
7 11 2.68 
7 4 2.33 
1 11 2.05 
1 25a 2.94 
1 25b 3.75 
1 13 3.54 
11 9b 2.57 
11 25a 3.10 
11 25b 3.42 
11 10 3.12 
19 9b 3.67 
19 10 3.57 
13 25a 2.83 
13 25b 2.68 
9b 9a 1.78 
 
7 Nucleus1 8 Nucleus2 9 Distances 
10 1 11 25a 12 2.62 
13 1 14 25b 15 2.80 
16 1 17 11 18 2.23 
19 1 20 3 21 2.10 
22 4 23 3 24 2.66 
25 4 26 7 27 2.26 
28 7 29 9 30 2.82 
31 11 32 18a 33 3.14 
34 11 35 18b 36 2.90 
37 11 38 25a 39 2.52 
40 11 41 25b 42 2.42 
43 10 44 9 45 2.04 
46 9 47 18a 48 2.64 
49 18b 50 18a 51 1.78 
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Distances and J-couplings from unrestricted simulations 
Table 6. Distances of the conformation of 2.27b, which fitted the NMR data the best. Based on NOESY data 
at 150 ms from 800 MHz. a: used as reference, b: some scalar coupling observed and thus not used as 
reference. 
Nucleus1 Nucleus2 Meas Calc Lower bound Violation Upper bound Violation 
7 16/17 2.73 2.56 2.31  2.82  
7 15 2.53 2.70 2.43  2.97  
7 9a 3.41 2.86 2.57  3.14 0.27 
7 9b 2.16 2.16a 1.94  2.37  
7 6 2.98 3.08 2.77  3.39  
7 11 2.63 2.58 2.32  2.84  
7 4 2.25 2.29 2.06  2.52  
1 14 2.62 2.60 2.34  2.86  
1 25b 3.56 3.52 3.17  3.87  
1 25a 2.36 2.81 2.53 0.17 3.09  
1 13 2.98 3.29 2.96  3.62  
1 11 2.06 1.98 1.78  2.17  
4 14 2.49 2.65 2.39  2.92  
4 16/17 3.99 3.91 3.52  4.30  
4 15 2.29 3.25 2.92 0.63 3.57  
11 18a/18b 3.27 2.72 2.45  2.99 0.28 
11 9b 2.42 2.42 2.18  2.67  
11 25a 2.57 2.93 2.63 0.06 3.22  
11 10 2.93 2.84 2.55  3.12  
11 13 3.59 3.93 3.54  4.32  
27 14 2.92 3.76 3.39 0.47 4.14  
27 18a/18b 3.88 3.56 3.20  3.91  
27 25a 2.44 2.75 2.47 0.03 3.02  
27 25b 2.43 2.67 2.40  2.93  
27 13 2.99 3.15 2.84  3.47  
27 28 2.19 1.98b 1.78  2.17 0.02 
20 18a/18b 2.36 2.59 2.33  2.85  
19 18a/18b 2.39 2.29 2.06  2.52  
19 9b 2.46 3.34 3.00 0.54 3.67  
19 10 3.91 3.15 2.83  3.46 0.45 
3 14 2.33 2.26 2.03  2.49  
13 25a 2.74 2.58 2.33  2.84  
13 25b 3.06 2.41 2.17  2.65 0.41 
10 18a/18b/9a 2.06 1.94 1.74  2.13  
6 16/17 2.33 2.41 2.17  2.65  
6 15 3.08 2.59 2.33  2.85 0.23 
9b 9a 1.76 1.58b 1.43  1.74 0.02 
15 16/17 2.06 2.29 2.06  2.52  
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Table 7. J-couplings of the conformation of 2.27b, which fitted the NMR data the best.  
Nucleus1 Nucleus2 Meas Calc Diff 
1 13 9.7 9.5 0.2 
3 4 9.8 8.7 1.1 
6 7 6.9 9.1 2.2 
10 11 7 7.7 0.7 
25a 13 9.2 10.5 1.3 
15 6 6.8 12.9 6.1 
25b 13 5.8 1.8 4.0 
9b 10 12.6 12.6 0.0 
9a 10 4.4 2.3 2.1 
 
Table 8. Distances of the conformation of azumamide A, which fitted the NMR data the best. Based on ROESY 
data at 150 ms from 500 MHz. a: used as reference, b: some scalar coupling observed and thus not used as 
reference. 
Nucleus1 Nucleus2 Meas Calc Lower bound Violation Upper bound Violation 
1 14 2.73 2.62 2.36   2.88   
1 25a 2.41 2.61 2.35  2.87  
1 25b 3.25 2.86 2.57   3.15 0.11 
1 11 2.10 2.10a 1.89  2.31  
1 3 3.56 2.58 2.32   2.84 0.72 
4 16/17 3.12 2.59 2.33  2.85 0.27 
4 14 2.47 2.59 2.33   2.85   
4 15 2.17 2.42 2.18 0.01 2.67  
4 3 2.96 2.68 2.41   2.95 0.01 
4 7 2.30 2.35 2.12  2.59  
7 16/17 2.97 2.62 2.35   2.88 0.10 
7 31 2.23 2.20 1.98  2.42  
7 15 2.59 3.04 2.74 0.14 3.35   
7 9 3.58 3.21 2.89  3.53 0.05 
7 6 2.99 2.92 2.63   3.22   
27 25a 2.44 2.47 2.22  2.72  
27 25b 2.43 2.45 2.20   2.69   
27 13 3.01 2.62 2.36  2.89 0.13 
11 31 2.28 2.27 2.04   2.49   
11 18a 2.97 3.09 2.78  3.40  
11 18b 3.36 3.02 2.72   3.33 0.04 
11 25a 2.94 2.46 2.21  2.71 0.24 
11 25b 2.62 2.40 2.16   2.64   
11 10 2.93 2.59 2.33  2.85 0.08 
20 22 2.54 3.03 2.73 0.19 3.34   
20 9 3.83 3.00 2.70  3.30 0.53 
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19 10 2.97 2.75 2.47   3.02   
19 9 2.59 2.71 2.44  2.98  
3 14 2.34 2.29 2.06   2.52   
10 9 2.47 2.11 1.90  2.32 0.15 
6 15 3.08 2.95 2.65   3.24   
6 16/17 2.32 2.16 1.94  2.37  
9 31 2.28 2.13 1.92   2.35   
9 18a 3.18 2.73 2.46  3.00 0.18 
18b 31 3.81 2.89 2.61   3.18 0.63 
18b 18a 1.74 1.80 1.62  1.98  
18a 31 2.44 2.24 2.01   2.46   
 
 
 
 Table 9. J-couplings of the conformation of azumamide A which fitted the NMR data the best.  
Nucleus1 Nucleus2 Meas Calc Diff 
1 13 9.1 9.6 0.5 
4 3 8.7 8.3 0.4 
7 6 8.35 9.7 1.3 
11 10 8 7.7 0.3 
13 25a 9.4 5.1 4.3 
13 25b 6.7 5.3 1.4 
10 9 3.8 3.1 0.7 
6 15 10.1 12.9 2.8 
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Distances and J-couplings from restricted simulations 
Table 10. Distances of the conformation of 2.27b which fitted the NMR data the best. (NOESY data) at 150 
ms from 800 MHz. a: used as reference, b: some scalar coupling observed and thus not used as reference. 
Nucleus1 Nucleus2 Meas Calc Lower bound Violation Upper bound Violation 
7 17 2.920 2.851 2.566  3.136  
7 15 2.517 2.997 2.697 0.18 3.297  
7 9a 3.378 3.177 2.859  3.495  
7 9b 2.151 2.400 2.160 0.01 2.640  
7 6 2.974 3.421 3.079 0.105 3.763  
7 11 2.653 2.866 2.579  3.152  
7 4 2.228 2.551 2.296 0.07 2.806  
1 14 3.019 2.888 2.599  3.177  
1 25b 3.698 3.911 3.520  4.302  
1 25a 2.516 3.128 2.815 0.30 3.440  
1 13 2.989 3.655 3.290 0.30 4.021  
1 11 2.019 2.196 1.976  2.416  
4 14 2.882 2.952 2.656  3.247  
4 17 4.540 4.344 3.910  4.779  
4 15 2.350 3.609 3.248 0.90 3.969  
11 18a/18b 2.749 3.021 2.719  3.323  
11 9b 2.437 2.696 2.426  2.966  
11 25b 3.526 3.517 3.166  3.869  
11 25a 2.495 3.255 2.929 0.43 3.580  
11 10 2.932 3.155 2.839  3.470  
11 13 3.588 4.369 3.932 0.35 4.806  
27 14 3.607 4.182 3.764 0.16 4.600  
27 18a/18b 6.194 3.957 3.561  4.352 1.84 
27 25a 2.402 3.055 2.750 0.35 3.361  
27 25b 2.505 2.964 2.668 0.16 3.261  
27 13 2.770 3.507 3.156 0.39 3.857  
27 28 2.194 2.198 1.978  2.418  
20 18a/18b 3.512 2.884 2.595  3.172 0.34 
19 18a/18b 2.315 2.550 2.295  2.805  
19 9b 3.397 3.709 3.339  4.080  
19 10 3.451 3.500 3.150  3.850  
3 14 2.646 2.512 2.261  2.763  
13 25a 2.571 2.874 2.586 0.02 3.161  
13 25b 3.092 2.679 2.411  2.947 0.15 
10 18a/18b/9a 2.218 2.153 1.938  2.369  
6 16 2.411 2.674 2.407  2.942  
6 15 3.083 2.880 2.592  3.168  
9b 9a 1.760 1.760 1.584  1.936  
15 17 2.086 2.547 2.292 0.21 2.802  
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Table 11. J-couplings of the conformation of 2.27b which fitted the NMR data the best.  
Nucleus1 Nucleus2 Meas Calc Diff 
1 13 9.7 9.5 0.2 
3 4 9.8 8.7 1.1 
6 7 6.9 8.9 2.0 
10 11 7 7.8 0.8 
25a 13 9.2 12.8 3.6 
15 6 6.8 12.9 6.1 
25b 13 5.8 2.5 3.3 
9b 10 12.6 12.8 0.2 
9a 10 4.4 2.6 1.8 
 
Table 12. Distances of the conformation of azumamide A which fitted the NMR data the best. Based on ROESY 
data at 150 ms from 500 MHz. a: used as reference, b: some scalar coupling observed and thus not used as 
reference. 
Nucleus1 Nucleus2 Meas Calc Lower bound Violation Upper bound Violation 
1 14 3.909 2.646 2.381  2.910 1.00 
1 25a 3.153 2.885 0.268  2.597  
1 25b 3.278 2.637 0.641  2.373  
1 11 2.123 2.123 1.911  2.335  
4 16 2.978 2.610 2.349  2.871 0.11 
4 14 2.693 2.612 2.351  2.874  
4 15 2.104 2.445 2.201 0.10 2.690  
4 3 2.980 2.704 2.434  2.975 0.01 
4 7 2.586 2.373 2.136  2.610  
7 16 4.125 2.639 2.375  2.903 1.22 
7 31 2.211 2.218 1.997  2.440  
7 15 2.545 3.069 2.762 0.22 3.376  
7 9 3.544 3.237 2.914  3.561  
7 6 2.977 2.951 2.656  3.246  
27 25a 2.322 2.494 2.245  2.744  
27 25b 2.669 2.470 2.223  2.717  
27 13 3.022 2.647 2.382  2.911 0.11 
11 31 2.358 2.285 2.057  2.514  
11 18a 3.098 3.117 2.806  3.429  
11 18b 3.480 3.051 2.746  3.356 0.12 
11 25a 3.122 2.417 0.704  2.176  
11 25b 2.151 2.482 0.330  2.234 0.08 
11 10 2.900 2.615 2.353  2.876 0.02 
20 22 2.517 3.060 2.754 0.24 3.366  
20 18b 3.822 2.771 2.494  3.048 0.77 
20 9 3.656 3.027 2.725  3.330 0.33 
100 
20 10 3.871 3.116 2.804  3.428 0.44 
19 10 3.478 2.770 2.493  3.047 0.43 
19 9 2.566 2.738 2.464  3.012  
3 14 2.335 2.310 2.079  2.540  
10 9 2.423 2.129 1.917  2.342 0.08 
6 15 3.076 2.975 2.677  3.272  
6 16 2.321 2.175 1.957  2.392  
9 31 2.278 2.154 1.939  2.369  
9 18a 3.206 2.753 2.478  3.029 0.18 
18b 31 3.780 2.921 2.629  3.213 0.57 
18b 18a 1.740 1.818 1.636  2.000  
18a 31 2.415 2.256 2.030  2.482  
15 16 2.061 2.072 1.864  2.279  
7 11 2.211 3.103 2.792 0.58 3.413  
  
 
 Table 13. J-couplings of the conformation of azumamide A, which fitted the NMR data the best.  
Nucleus1 Nucleus2 Meas Calc Diff 
1 13 9.1 6.3 2.8 
4 3 8.7 9.6 0.9 
7 6 8.4 9.1 0.7 
11 10 8 6.6 1.4 
13 25a 6.7 2.0 4.7 
13 25b 9.4 10.3 0.9 
10 9 3.8 3.6 0.2 
6 15 10.1 12.9 2.8 
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Azumamide A 
 
52 # 
53 δH [ppm]/ 
54 J coupling constants [Hz] 
55  56 COSY 
57  
58 HMBC 
59  
60 1 61 7.71 62  63 13 64  
65 2 66 - 67  68 - 69  
70 3 71 4.13 72  73 4,14 74  
75 4 76 7.68 77  78 3 79  
80 5 81 - 82  83 - 84  
85 6 86 3.73 87  88 6,15 89  
90 7 91 7.41 92  93 6 94  
95 8 96 - 97  98 - 99  
100 9 101 2.53 102  103 10,31 104  
105 10 106 4.00 107  108 9,11,18a,18b 109  
110 11 111 7.10 112  113  114  
115 12 116 - 117  118 - 119  
120 13 121 4.14 122  123 1,25a,25b 124  
125 14 126 1.16 127  128 3 129  
130 15 131 2.11 132  133 6,16,17 134  
135 16 136 0.86 137  138 15 139  
140 17 141 0.88 142  143 15 144  
145 18a 146 2.21 147  148 19 149  
150 18b 151 2.40 152  153 19 154  
155 19 156 5.27 157  158 20,18a,18b 159  
160 20 161 5.40 162  163 19,21 164  
165 21 166 2.26 167  168 20 169  
170 22 171 2.09 172  173  174  
175 23 176 - 177  178  179  
180 24a 181 6.73 182  183  184  
185 24b 186 7.26 187  188  189  
190 25a 191 2.93 192  193 13,25b 194  
195 25b 196 3.01 197  198 13,25a 199  
200 26 201 - 202  203  204  
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205 27 206 7.25 207  208 28 209  
210 28 211 7.18 212  213 27 214  
215 29 216 - 217  218  219  
220 31 221 1.30 222  223 9 224  
 
2.27b 
 
225 # 
226 δH [ppm]/ 
227 J coupling constants [Hz] 
228 δC 
[ppm] 
229 COSY 
230  
231 HMBC 
232  
233 1 234 7.54 (9.7) 235  236 13 237  
238 2 239 - 240  241 - 242  
243 3 244 4.26 (9.7,7.4) 245  246 4,14 247  
248 4 249 7.41 (9.8) 250  251 3 252  
253 5 254 - 255  256 - 257  
258 6 259 3.79 (6.6,6.6) 260  261 6,15 262  
263 7 264 7.85 (6.7) 265  266 6 267  
268 8 269 - 270  271 - 272  
273 9a 274 2.28 (11.3,3.8) 275  276 10,9b 277  
278 9b 279 2.46 (14.0,12.4) 280  281 10,9a 282  
283 10 284 3.92 (m) 285  286 11,18,9a,9b 287  
288 11 289 7.24 (7.1) 290  291  292  
293 12 294 - 295  296 - 297  
298 13 299 4.15 (9.4,9.4,5.9) 300  301 1,25a,25b 302  
303 14 304 1.15 (7.3) 305  306 3 307  
308 15 309 1.93 (oct: 6.8) 310  311 6,16,17 312  
313 16 314 0.90 (6.8) 315  316 15 317  
318 17 319 0.92 (6.8) 320  321 15 322  
323 18a 324 2.25 - 325  326 19/20 327  
328 18b 329 2.25 - 330  331 19/20 332  
333 19 334 5.36 - 335  336 20 337  
338 20 339 5.47 - 340  341 19 342  
343 21 344 2.25 -  345  346 19/20 347  
348 22 349 2.25 - 350  351 19/20 352  
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353 23 354 - 355  356  357  
358 24 359 12.07 360  361  362  
363 25a 364 2.68 (13.9,9.3) 365  366 13,25b 367  
368 25b 369 2.81 (13.9,5.7) 370  371 13,25a 372  
373 26 374 - 375  376  377  
378 27 379 6.93 (8.4) 380  381 28 382  
383 28 384 6.63 (8.4) 385  386 27 387  
388 29 389 - 390  391  392  
393 30 394 9.22 s 395  396  397  
 
Experimentals for chapter 3 
S-(but-3-en-1-yl) octanethioate (3.3).[172] 
To thioacetamide (463 mg, 6.16 mmol) in anhydrous toluene (40 mL) was added octanoyl 
chloride (1.1 mL, 6.28 mmol) dropwise at 30°C. The reaction was stirred for 42h 
whereafter additional octanoyl chloride (0.84 mL, 4.93 mmol) was added. The reaction was stirred for 4h and 
the solvent evaporated. The crude product was hydrolyzed with 10% wt. NaOH (30 mL). The reaction was 
stirred for 30 min. and acidified with 1M HCl until pH = 2. The product was extracted with AcOEt (2 x 50 mL), 
dried (MgSO4) and concentrated. The crude product (3.4) was used without further purification. 
 The thioacid was diluted with acetone (25 mL) whereafter K2CO3 (766 mg, 5.54 mmol) was added followed 
by 4-bromo-1-butene (0.56 mL, 5.54 mmol). The reaction was stirred at room temperaturefor 18h, then 
filtered and evaporated. Purification by VLC (1 – 10% CH2Cl2/heptane) gave the desired product (667 mg, 51% 
2 steps) as a reddish oil. 1H NMR (300 MHz, CDCl3) δ 5.77 (ddt, 1H, J = 16.9, 10.2, 6.6 Hz), 5.11 – 4.99 (m, 2H), 
2.92 (t, 2H, J = 7.3 Hz), 2.52 (t, 2H, J =7.54 Hz), 2.35 – 2.26 (m, 2H), 1.64 (p, 2H, J = 7.4 Hz), 1.36 – 1.18 (m, 
8H), 0.96 – 0.81 (t, 3H, J = 6.9 Hz); 13C NMR (300 MHz, CDCl3) δ 199.6, 136.3, 116.5, 44.3, 33.8, 31.7, 29.03, 
29.01, 28.1, 25.8, 22.7, 14.2. 
(S,E)-tert-butyl 3-((tert-butoxycarbonyl)amino)-7-(octanoylthio)hept-4-enoate (3.5) 
General methods for the cross methatesis. 
To 2.7 in degassed, anhydrous solvent (c = ∼0.1 M) was added 3.3 (2 equiv), followed 
by a catalyst. The reaction was heated for 17-23h, evaporated on silica and purified 
by VLC (0–10% AcOEt in heptane) to obtain the product (11−43%) as a dark oil.  
Entry 1. The compound was synthesized according to the general procedure. After stirring in toluene at 60 
°C using Grubbs catalyst 2nd generation (0.2 equiv) as the catalyst, the product was obtained in 38% yield 
(60% BRSM).  
Entry 2. The compound was synthesized according to the general procedure. After stirring in toluene at 60 
°C using Hoveyda-Grubbs catalyst 2nd generation (0.2 equiv) as the catalyst, the product was obtained in 
26% yield (47% BRSM). 
104 
Entry 3 The compound was synthesized according to the general procedure. After stirring in DCE at 90 °C 
using Hoveyda-Grubbs catalyst 2nd generation (0.1 equiv) as the catalyst, the product was obtained in 15% 
yield (33% BRSM) 
Entry 4. The compound was synthesized according to the general procedure. After stirring in toluene at 60 
°C using Zhan catalyst 1B (0.2 equiv) as the catalyst, the product was obtained in 42% yield. 
Entry 5. The compound was synthesized according to the general procedure. After stirring in toluene at 60 
°C using 2.11 (0.2 equiv) as the catalyst, the product was obtained in 43% yield (66% BRSM). 
Entry 6. The compound was synthesized according to the general procedure. After stirring in DCE at 90 °C 
using 2.11 (0.1 equiv + 0.05 equiv) as the catalyst, the product was obtained in 12% yield  
1H NMR (300 MHz, CDCl3) δ 5.59 (dt, J = 15.5, 6.0 Hz, 1H), 5.49 (dd, J = 15.5, 5.4 Hz, 1H), 5.14 (brs, 1H), 4.41 
(brs, 1H), 2.88 (t, J = 7.3 Hz, 2H), 2.63 – 2.49 (m, 2H), 2.47 (d, J = 5.3 Hz, 2H), 2.28 (dd, J = 13.7, 7.1 Hz, 2H), 
1.72 – 1.55 (m, 2H), 1.44 (s, 18H), 1.37 – 1.12 (m, 8H), 0.87 (t, J = 6.7 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 
199.7, 170.6, 155.1, 131.4, 129, 81.2, 79.5, 49.1, 44.3, 40.9, 32.4, 31.8, 29.9, 29.1, 28.5, 28.4, 28.2, 25.8, 22.7, 
14.2. HRMS calc’d for C24H43NO5SH+ [M+H+] = 458.2935, found 458.2940. 
(S,E)-3-((tert-butoxycarbonyl)amino)-7-(octanoylthio)hept-4-enoic acid (3.6) 
 To the mixture of 3.5 and 2.7 in CH2Cl2 (25 mL) was added TFA (15 mL). The reaction was 
stirred for 2h, then evaporated and used without further purification. HRMS calc’d for 
C15H27NO3SH+ [M+H+] = 302.1784, found 302.1809. 
To the crude amino acid in anhydrous CH2Cl2 (20 mL) was added DIPEA (0.37 mL, 2.1 
mmol), followed by Boc2O (235 mg, 1.1 mmol). After stirring at rt for 24h, the organic phase was washed with 
1M HCl (2 x 30 mL), brine (30 mL), dried and evaporated. The crude compound (3.6) was used without further 
purification. 1H NMR (300 MHz, CDCl3) δ 5.77 (ddt, J = 16.9, 10.2, 6.6 Hz, 1H), 5.11 – 4.99 (m, 2H), 2.92 (t, J = 
7.3 Hz, 2H), 2.58 – 2.46 (m, 2H), 2.38 – 2.23 (m, 2H), 1.64 (p, J = 7.4 Hz, 2H), 1.39 – 1.11 (m, 8H), 0.96 – 0.81 
(m, 3H). 13C NMR (75 MHz, CDCl3) δ 199.6, 136.3, 116.5, 44.3, 33.8, 31.7, 29.03, 29.01, 28.1, 25.8, 22.7, 14.2. 
HRMS calc’d for C20H35NO5SH+ [M+H+] = 402.2309, found 402.2312. 
((S,E)-3-amino-7-(octanoylthio)hept-4-enoyl)-D-valyl-D-alanyl-D-tyrosine (3.7). 
3.6 (81.5 mg (∼1:1 mixture with the vinyl compound, equal to  ∼0.13 
mmol)) was preactivated with HATU (90 mg, 0.24 mmol) and 2,6-lutidine 
(55.6 μL, 0.48 mmol) in DMF (5 mL) and added to a tripeptide (H-D-Val-D-
Ala-D-Tyr(tBu)) bound to a polystyrene 2-chlorotrityl resin in a fritted 
syringe. The reaction was put on a tilting table for 15h, then washed with 
DMF (x3), MeOH (x3), CH2Cl2 (x3). The peptide was cleaved with 50% TFA in CH2Cl2, then triturated with Et2O. 
Purification by preparative HPLC, provided the compound (8.7 mg, 10% yield) as a white solid. 1H NMR (300 
MHz, DMSO-d6) δ 9.20 (s, 1H), 8.18 (d, J = 9.0 Hz, 1H), 8.08 (d, J = 7.5 Hz, 1H), 7.92 (d, J = 7.5 Hz, 1H), 6.98 (d, 
J = 8.4 Hz, 2H), 6.62 (d, J = 8.4 Hz, 2H), 5.74 (dt, J = 15.0, 6.6 Hz, 1H), 5.46 (dd, J = 15.6, 7.4 Hz, 1H), 4.42 – 4.11 
(m, 3H), 3.94 (q, J = 6.8 Hz, 1H), 2.99 – 2.69 (m, 4H), 2.68 – 2.51 (m, 4H), 2.33 – 2.12 (m, 2H), 2.04 – 1.84 (m, 
1H), 1.66 – 1.44 (m, 2H), 1.32 – 1.13 (m, 11H), 0.88 – 0.75 (m, 9H). HRMS calc’d for C32H50N4O7SH+ [M+H+] = 
635.3473, found 635.3475. 
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(S)-but-3-en-1-yl 3-((tert-butoxycarbonyl)amino)pent-4-enoate (3.11) 
4-bromo-1-butene (0.32 ml, 3.19 mmol) was added to a solution of 2.8 (341.4 mg, 1.59 
mmol) and K2CO3 (264.2 mg, 1.9 mmol) in anhydrous DMF (4 mL). The reaction was stirred 
for 3h and another portion of 4-bromo-1-butene was added (80 μL, 0.8 mmol). The 
reaction was stirred for 3h and diluted with H2O (5 mL). The aqueous phase was extracted 
with AcOEt (2 x 10 mL) and the combined organic phases washed with 1M HCl (2 x 15 mL), NaHCO3 (2 x 15 
mL), brine (2 x 15 mL), dried (Na2SO4) and evaporated. The product (87%, 373.2 mg) was obtained as a clear 
oil. 1H NMR (300 MHz, cdcl3) δ 5.90 – 5.68 (m, 2H), 5.26 – 5.02 (m, 4H), 4.49 (s, 1H), 4.13 (t, J = 6.6 Hz, 2H), 
2.60 (d, J = 5.7 Hz, 2H), 2.46 – 2.25 (m, 2H), 1.43 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 171.2, 155.2, 137.3, 134, 
117.5, 115.5, 79.7, 63.8, 49.4, 39.3, 33.1, 28.5; [α]25D = +23°. 
tert-butyl (S,E)-(2-oxo-3,4,7,8-tetrahydro-2H-oxocin-4-yl)carbamate (3.12) 
To 3.11 (156 mg, 0.58 mmol) in degassed anhydrous CH2Cl2 (3 mL) was added Grubbs 2nd 
generation catalyst and the reaction was heated to reflux for 18h. Purification by VLC (0–30% 
EtOAc in heptane), afforded an unclean product (59 mg, ∼42%). 1H NMR (300 MHz, CDCl3) δ 
5.84 – 5.32 (m, 2H), 4.48 (brs, 1H), 4.35 – 3.86 (m, 3H), 2.77 – 2.49 (m, 2H), 2.43 – 2.26 (m, 2H), 1.44 (s, 9H). 
5-((3-((tert-butyldimethylsilyl)oxy)propyl)thio)-1-phenyl-1H-tetrazole (3.14a)[212] 
 To a solution of PPh3 (357 mg, 1.58 mmol) in anhydrous THF (8 mL) at 0 °C was added 
DIAD (282 μL, 1.43 mmol). The reaction was stirred for 5 min and 3.13a (253 mg, 1.3 
mmol) in anhydrous THF (2 mL) was added. The reaction mixture was stirred for 10 
min and 1-phenyl-1H-tetrazole-5-thiol (281 mg, 1.58 mmol) was added. The reaction was allowed to warm 
to rt and stirred for 4h where after additional DIAD (26 mg, 0.13 mmol) was added at 0 °C. The reaction was 
allowed to warm to rt, stirred for 1h and evaporated. Purification by VLC (0 – 20% AcOEt/heptane) gave the 
product (81%, 369 mg) as a clear oil. 1H NMR (300 MHz, CDCl3) δ 7.74 – 7.40 (m, 5H), 3.73 (q, J = 5.8 Hz, 2H), 
3.48 (q, J = 7.0 Hz, 2H), 2.04 (tt, J = 6.9, 5.8 Hz, 2H), 0.87 (s, 9H), 0.04 (s, 6H). 13C NMR (75 MHz, CDCl3) δ 154.6, 
133.8, 130.2, 129.9, 124, 61.2, 32, 30.3, 26, 18.4, -5.3. 
1-phenyl-5-((3-((triisopropylsilyl)oxy)propyl)thio)-1H-tetrazole (3.14b) 
 To a solution of PPh3 (1.11 g, 4.9 mmol) in anhydrous THF (25 mL) at 0 °C was added 
DIAD (965 μL, 4.9 mmol). The reaction was stirred for 5 min and 3.13b (956 mg, 4.1 
mmol) in anhydrous THF (5 mL) was added. The reaction mixture was stirred for 20 min 
and 1-phenyl-1H-tetrazole-5-thiol (801 mg, 4.5 mmol) was added. The reaction was allowed to warm to rt, 
stirred for 2.5h and evaporated. Purification by VLC (0 – 20% AcOEt/heptane) gave the desired product as a 
clear oil (82%, 1.33 g). 1H NMR (300 MHz, CDCl3) δ 7.65 – 7.47 (m, 5H), 3.82 (t, J = 5.7 Hz, 2H), 3.52 (t, J = 7.0 
Hz, 2H), 2.25 – 1.89 (m, 2H), 1.14 – 0.99 (m, 21H). 13C NMR (75 MHz, CDCl3) δ 154.7, 133.9, 130.2, 129.9, 124, 
61.5, 32.2, 30.3, 18.1, 12. 
5-((3-((tert-butyldimethylsilyl)oxy)propyl)sulfonyl)-1-phenyl-1H-tetrazole (3.15a) 
 To a solution of 3.14a (296 mg, 0.85 mmol) and NaHCO3 (714 mg, 8.5 mmol) in CH2Cl2 
(20 mL) was added <77% m-CPBA (1.42 g, 6.35 mmol).  The reaction was stirred for 
3h, then quenched with 1% aqueous NaOH (20 mL). The aqueous phase was extracted 
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with AcOEt (2 x 30 mL) and the combined organic phases were washed with 1% aqueous NaOH (50 mL), brine 
(2 x 50 mL), dried (Na2SO4) and evaporated. Purification by VLC (0 – 4% AcOEt/heptane) gave the product 
(85%, 275 mg) as white crystals. 1H NMR (300 MHz, CDCl3) δ 7.75 – 7.55 (m, 5H), 4.07 – 3.59 (m, 4H), 2.33 – 
2.00 (m, 2H), 0.89 (s, 9H), 0.06 (s, 6H). 13C NMR (75 MHz, CDCl3) δ 131.6, 129.9, 125.2, 60.5, 53.5, 26, 25.7, 
18.4, -5.3; Mp = 57 °C – 59 °C. 
1-phenyl-5-((3-((triisopropylsilyl)oxy)propyl)sulfonyl)-1H-tetrazole (3.15b) 
 To a solution of 3.14b (914 mg, 2.77 mmol) and NaHCO3 (2.33 g, 27.7 mmol) in CH2Cl2 
(50 mL) was added <77% m-CPBA (3.59 g, 20.8 mmol).  The reaction was stirred for 3h, 
then quenched with 1% aqueous NaOH (25 mL). The aqueous phase was extracted with 
AcOEt (3 x 50 mL) and the combined organic phases were washed brine (2 x 50 mL), dried (MgSO4) and 
evaporated. Purification by VLC (0 – 3% AcOEt/heptane) gave the product (66%, 656 mg) as a clear oil. 1H 
NMR (300 MHz, CDCl3) δ 7.79 – 7.49 (m, 5H), 4.00 – 3.68 (m, 4H), 2.26 – 2.09 (m, 2H), 1.21 – 0.89 (m, 21H). 
13C NMR (75 MHz, CDCl3) δ 131.5, 129.8, 125.2, 60.8, 53.5, 25.8, 18.1, 12.  
tert-butyl 3-((tert-butoxycarbonyl)amino)-7-((tert-butyldimethylsilyl)oxy)hept-4-enoate (3.18) 
To 3.15b (80 mg, 0.22 mmol) in anhydrous THF (2 mL) at –78 °C, was added KHMDS 
(0.5 M in toluene, 0.42 mL) dropwise. 3.16 (96 mg, 0.35 mmol) in anhydrous THF (0.5 
mL) was added dropwise to the reaction. After 3h, an extra equivalent of KHMDS was 
added. After 10 min, the reaction was quenched with H2O and purified by VLC (1–20% 
EtOAc in heptane). The product was obtained in 29% yield with impurities present. 1H NMR (300 MHz, CDCl3) 
δ 5.75 – 5.32 (m, 2H), 5.08 (s, 1H), 4.68 (s, 1H), 4.42 (s, 1H), 3.67 (t, J = 6.9 Hz, 2H), 2.60 – 2.33 (m, 2H), 2.26 
(q, J = 6.8 Hz, 2H), 1.43 (s, 18H), 1.18 – 0.90 (m, 21H). 
(S)-1-benzyl 4-tert-butyl 2-(tert-butoxycarbonylamino)succinate (3.19) 
 To Boc-L-Asp(tBu)-OH (397 mg, 1.37 mmol) in DMF (3 mL) was added K2CO3 (379 mg, 2.74 
mmol) followed by benzylbromide (179 µL, 1.5 mmol). The reaction was stirred at rt for 2 h, 
then diluted with EtOAc (3 mL) and H2O (5 mL).The aqueous phase was extracted with EtOAc 
(3 x 6 mL) and the combined organic phases were washed with 1M HCl (2x 20 mL), NaHCO3 
(2 x20 mL), brine (2 x 20 mL), dried (MgSO4) and evaporated. The product was obtained as white crystals 
(97%, 505 mg). 1H NMR (300 MHz, CDCl3) δ 7.39 – 7.29 (m, 5H), 5.50 (d, J = 8.5 Hz, 1H), 5.17 (q, J = 12.3 Hz, 
2H), 4.57 (dt, J = 8.8, 4.6 Hz, 1H), 2.92 (dd, J = 16.9, 4.8 Hz, 1H), 2.72 (dd, J = 16.8, 4.6 Hz, 1H), 1.41 (d, J = 11.7 
Hz, 18H). 13C NMR (75 MHz, CDCl3) δ 171.3, 170.2, 155.6, 135.5, 128.7, 128.3, 81.8, 80.1, 67.4, 50.3, 38, 28.4, 
28.1; [α]25D = +5.1°, Mp: 50.1 °C – 52.5 °C. 
(S)-1-benzyl 4-tert-butyl 2-di(tert-butoxycarbonylamino)succinate (3.20). 
 Boc2O (235.7 mg, 0.11 mmol) in MeCN (0.5 mL) was added to 3.19 and DMAP (13.2 mg, 0.11 
mmol) in MeCN (1 mL). The reaction was stirred at rt for 20h, then diluted with AcOEt (3 mL), 
washed with 1M NaHSO4 (2 x 5 mL), NaHCO3 (2 x 5 mL), brine (2 x 5 mL), dried (MgSO4) and 
evaporated. Purification by VLC (0 – 10 % AcOEt/heptane) gave the desired product as white 
crystals (88%, 153.5 mg). 1H NMR (300 MHz, CDCl3) δ 7.49 – 7.21 (m, 5H), 5.46 (t, J = 6.9 Hz, 1H), 5.15 (s, 2H), 
3.15 (dd, J = 16.0, 7.1 Hz, 1H), 2.65 (dd, J = 16.0, 6.8 Hz, 1H), 1.49 – 1.44 (m, 18H), 1.42 (s, 9H). 13C NMR (75 
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MHz, CDCl3) δ 170, 169.8, 151.9, 135.6, 128.6, 128.3, 128.2, 83.5, 81.2, 67.2, 55.3, 37.1, 28.1, 28.07. Mp: 
61.4–62.4 °C; [α]25D = -40°. 
(S)-4-(tert-butoxy)-2-(di(tert-butoxycarbonyl)amino)-4-oxobutanoic acid (3.21) 
3.20 (244.8 mg, 0.51 mmol) in MeOH (2 mL) was purged with argon. 10 % Pd/C (25 mg) was 
added and the reaction purged with H2 for 5 min. The reaction was stirred under H2 
atmosphere for 24h, filtered on celite and evaporated to obtain the product as white crystals 
(97%, 192.8 mg.) 1H NMR (300 MHz, CDCl3) δ 5.81 (dd, J = 7.1, 6.7 Hz, 1H), 3.43 (dd, J = 16.0, 
7.3 Hz, 1H), 2.97 (dd, J = 16.0, 6.6 Hz, 1H), 1.83 (s, 18H), 1.77 (s, 9H). 13C NMR (75 MHz, CDCl3) δ 176.3, 169.7, 
151.6, 83.8, 81.3, 55, 37, 28.1. Mp: 115.6–118.9°C; [α]25D = -51.8°. 
(S)-tert-butyl 3-(di(tert-butoxycarbonyl)amino)-4-hydroxybutanoate (3.22) 
 To a solution of 3.21 (150 mg, 0.385 mmol) in THF (2 mL) at –25°C was added NMM (43.3 μL, 
0.393 mmol) followed by dropwise addition of iBuOCOCl (51 μL, 0.393 mmol). After 15 min., 
the reaction was heated to –10°C and stirred for 30 min before NaBH4 (43.7 mg, 1.15 mmol) 
was added in one portion, followed by dropwise addition of MeOH (0.4 mL). After 30 min at 
–10°C, the reaction was warmed to rt and stirred for another 90 min. The reaction was quenched with NH4Cl 
(8 mL), washed with 1M HCl (2 x 10 mL), brine (2 x 10 mL), dried (MgSO4) and evaporated. Purification by VLC 
(0 – 10% AcOEt/heptane) gave the desired product (29%, 41.4 mg) as a white solid. 1H NMR (300 MHz, CDCl3) 
δ 5.12 (d, J = 7.0 Hz, 1H), 4.26 – 3.99 (m, 3H), 2.49 (d, J = 5.9 Hz, 2H), 1.51 – 1.37 (m, 27H). 13C NMR (75 MHz, 
CDCl3) δ 170.3, 155.1, 153.4, 82.5, 81.4, 79.7, 67.6, 46.8, 37.2, 28.5, 28.2, 27.8; [α]25D = -5.3°. 
(3-bromopropoxy)triisopropylsilane (3.25) 
 Imidazole (1.7 g, 25.18 mmol) was added to 3-bromopropanol (1.4 g, 10.07 mmol) in CH2Cl2 
(20 mL). TIPSCl (2.14 mL, 10.07 mmol) was then added and the reaction was stirred for 17h at room 
temperature. The solution was diluted with H2O (15 mL) and the aqueous phase was extracted with CH2Cl2 
(3 x 15 mL). The combined organic phases were washed with NaHCO3 (2 x 30 mL), brine (2 x 30 mL), dried 
(MgSO4), and evaporated. Purification by VLC (heptane) gave the desired product (86%, 2.46 g) as a clear oil. 
1H NMR (300 MHz, CDCl3) δ 3.82 (t, J = 5.7 Hz, 2H), 3.55 (t, J = 6.5 Hz, 2H), 2.06 (tt, J = 11.5, 5.7 Hz, 2H), 1.21 
– 0.93 (m, 21H). 13C NMR (75 MHz, CDCl3) δ 60.9, 36.0, 31, 18.2, 12.1. 
 
3-Triisopropylsilanyloxypropyltriphenylphosphonium bromide (3.26).[213] 
 3.25 (1.16 g, 3.95 mmol) and PPh3 in anhydrous toluene was heated to reflux for 4 days. 
The reaction was cooled to rt and diluted with heptane (25 mL). The product was 
filtered, washed with heptane (2 x 25 mL) and dried on high vacuum. The product was obtained as a white 
solid (69%, 1.52 g). 1H NMR (300 MHz, CDCl3) δ 7.81 – 7.53 (m, 15H), 3.90 – 3.47 (m, 4H), 1.99 – 1.60 (m, 
2H), 0.92 (m, 21H). 13C NMR (75 MHz, CDCl3) δ 135.05 (t, J = 2.7 Hz), 133.41 (dd, J = 9.8, 8.5 Hz), 130.48 (dd, 
J = 12.5, 2.0 Hz), 118.11 (dd, J = 86.3, 8.8 Hz), 61.01 (dd, J = 125.5, 16.8 Hz), 25.93 (dd, J = 22.1, 3.9 Hz), 
19.53 (dd, J = 86.7, 52.8 Hz), 17.78 (d, J = 20.7 Hz), 11.95 (d, J = 35.3 Hz). 
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(S,Z)-tert-butyl 3-((tert-butoxycarbonyl)amino)-7-((triisopropylsilyl)oxy)hept-4-enoate (3.27) 
To oxalylchloride (0.21 mL, 2.39 mmol) in anhydrous CH2Cl2 (10 mL) at -78°C was added 
DMSO (0.34 mL, 4.78 mmol) dropwise. The reaction was stirred for 30 min and 3.16 (398.7 
mg, 1.44 mmol) in anhydrous CH2Cl2 (2 mL) was added dropwise. After stirring for 20 min, 
Et3N (1 mL, 7.24 mmol) was added dropwise and the reaction heated to -40°C. After stirring 
for 1h, the reaction was poured onto a 1:1 mixture of NaHSO4/Et2O (50 mL). The combined organic phases 
were washed with NaHSO4, dried (Na2SO4), evaporated and put on high vacuum for 15 min while the Wittig 
reagent was prepared. 
 0.5 M KHMDS in toluene (4 mL, 2 mmol) was added dropwise to a solution of 3.26 in anhydrous THF (20 
mL). After stirring for 30 min at rt, the reaction was cooled to -78°C and the above prepared aldehyde in THF 
(5 mL) was added dropwise. After stirring for 40 min, the reaction was allowed to warm to rt and stirred for 
15h. The reaction mixture was diluted with Et2O (25 mL), washed with 1M HCl (2 x 50 mL), NaHCO3 (2x 50 
mL), brine (50 mL), dried (Na2SO4) and evaporated. Purification by VLC (0 – 2% AcOEt/heptane) gave the 
desired product (41%, 281 mg 2 steps) as a clear oil. 1H NMR (300 MHz, CDCl3) δ 5.56 (dt, J = 11.0, 7.3 Hz, 
1H), 5.42 (dd, J = 10.6, 9.0 Hz, 1H), 5.09 (s, 1H), 4.79 – 4.56 (m, 1H), 3.88 – 3.51 (m, 2H), 2.46 (d, J = 5.8 Hz, 
2H), 2.43 – 2.30 (m, 2H), 1.42 (s, 9H), 1.41 (s, 9H), 1.12 – 0.98 (m, 21H). 13C NMR (75 MHz, CDCl3) δ 170.7, 
155, 130.3, 129.4, 128.2, 81, 63, 41.4, 31.6, 28.5, 28.2, 18.1, 17.8, 12.5, 12.4, 12.1, HRMS calc’d for 
C25H49NO5SiH+ [M+H+] = 472.3453, found 472.3460. [α]25D = +5.16°. 
(R)-tert-butyl 3-((tert-butoxycarbonyl)amino)-7-hydroxyheptanoate (3.28) 
3.27 (404 mg, 0.856 mmol) was dissolved in anhydrous MeOH (10 mL) and purged with 
argon. 10% Pt/C (40 mg) was added and the reaction was purged with H2. After stirring for 
20h under H2 atmosphere, the product was filtered on celite and evaporated to obtain the 
desired compound (98%, 396 mg) as a yellow oil, then used without further purification. 1H 
NMR (300 MHz, CDCl3) δ 4.91 (s, 1H), 3.95 – 3.80 (m, 1H), 3.66 (t, J = 6.2 Hz, 2H), 2.43 (dd, J = 15.1, 5.2 Hz, 
1H), 2.36 (dd, J = 5.9, 15.1 Hz, 1H), 1.79 – 1.19 (m, 22H), 1.05 (s, 21H). 13C NMR (75 MHz, cdcl3) δ 171.2, 155.5, 
80.9, 79.1, 63.3, 47.9, 40.7, 34.8, 32.9, 28.5, 28.2, 22.6, 18.2, 12.1. HRMS calc’d for C25H51NO5SiH+ [M+H+] = 
474.3609, found 474.3615. [α]25D = +3.8°. 
The crude compound (351.3 mg, 0.74 mmol) in THF (2 mL) at 0°C were added AcOH (42 μL, 0.74 mmol) 
and TBAF (3 mL, 2.96 mmol). The reaction was allowed to warm to rt and stirred for 17h. The reaction was 
diluted with AcOEt (10 mL) and washed with 1M HCl (2 x  20 mL), NaHCO3 (2 x 20 mL), brine (2 x 20 mL), dried 
(Na2SO4) and evaporated. Purification by flash chromatography (0–5% MeOH/CH2Cl2) gave the desired 
product (88%, 206 mg) as a clear oil. 1H NMR (300 MHz, CDCl3) δ 4.91 (d, J = 7.1 Hz, 1H), 4.02 – 3.72 (m, 1H), 
2.42 (dd, J = 5.14, 14.8 Hz, 1H), 2.36 (dd, J = 5.85, 14.8 Hz, 2H), 1.68 (brs, 1H), 1.55 – 1.21 (m, 26H), 0.88 (t, J 
= 6.8 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ 171.4, 155.5, 81, 48, 40.7, 34.6, 28.5, 28.4, 28.2, 22.6, 14.1; [α]25D = 
+3.6°. 
(R)-tert-butyl 3-((tert-butoxycarbonyl)amino)-7-(tosyloxy)heptanoate (3.30) 
 To 3.28 (213.7 mg, 0.67 mmol) in anhydrous CH2Cl2 was added TsCl (192.5 mg, 1 mmol) 
followed by Et3N (281.5 μL, 2 mmol) and DMAP (8.2 mg, 0.07 mmol).The reaction was stirred 
for 5h at rt, then quenched with 1M HCl (12 mL). The aqueous phase was extracted with 
CH2Cl2 (2 x 20 mL) and the combined organic phases were washed with brine (20 mL), dried 
(Na2SO4) and evaporated. Purification by flash chromatography (5 – 15% AcOEt/hexane) gave the desired 
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product (83%, 263.5 mg) as a clear oil. 1H NMR (300 MHz, CDCl3) δ 7.77 (d, J = 8.4 Hz, 2H), 7.50 – 7.29 (m, 2H), 
4.90 (d, J = 9.1 Hz, 1H), 4.00 (td, J = 6.3, 1.8 Hz, 2H), 3.91 – 3.67 (m, 1H), 2.44 (s, 3H), 2.39 (dd, J = 5.4, 15.3 
Hz, 1H), 2.31 (dd, J = 15.3, 6.0 Hz, 1H), 1.77 – 1.58 (m, 2H), 1.43 (s, 9H), 1.41 (s, 9H). 13C NMR (75 MHz, CDCl3) 
δ 171, 155.4, 144.8, 133.2, 130.1, 130, 128, 81.1, 79.3, 70.5, 54.6, 47.5, 40.6, 34.2, 28.6, 28.5, 28.2, 22.2, 21.8. 
HRMS calc’d for C23H37NO7SH+ [M+H+] = 472.2363, found 472.2379, [α]25D = +2.8°. 
(R)-tert-butyl 3-((tert-butoxycarbonyl)amino)-7-(tritylthio)heptanoate (3.31) 
 Ph3CSH (313.6 mg, 1.125 mmol) and KOtBu (180 mg, 1.58 mmol) was dissolved in anhydrous 
degassed THF (2 mL). The reaction was stirred for 5 min at rt, then cooled to 0°C where 3.30 
(211 mg, 0.45 mmol) in anhydrous degassed THF (3 mL) was added dropwise to the solution. 
The reaction was slowly warmed to rt and stirred for 4h, then quenched with NH4Cl (10 mL). 
The aqueous phase was extracted with Et2O (3 x 10 mL) and the combined organic phases washed with brine 
(2 x 20 mL), dried (Na2SO4) and evaporated. 1H NMR (300 MHz, cdcl3) δ 7.44 – 7.34 (m, 5H), 7.30 – 7.14 (m, 
10H), 4.86 (d, J = 7.9 Hz, 1H), 3.78 (brs, 1H), 2.37 (dd, J = 15.2, 5.4 Hz, 1H), 2.29 (dd, J = 15.2, 6.1 Hz, 1H), 2.12 
(t, J = 7.1 Hz, 2H), 1.51 – 1.18 (m, 24H). 13C NMR (75 MHz, CDCl3) δ 171.1, 155.4, 145.1, 129.7, 127.9, 126.6, 
81, 79.2, 66.5, 47.8, 40.6, 34.5, 31.9, 28.5, 28.2, 25.6. HRMS calc’d for C35H45NO4SNa+ [M+Na+] = 598.2962, 
found 598.2962. 
(R)-3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-7-(tritylthio)heptanoic acid (3.32).  
To 3.31 (48 mg, 0.08 mmol) in anhydrous CH2Cl2 (3 mL) at 0 °C was added TFA (0.87 mL) and 
the reaction was stirred for 4h. The solvent was evaporated and used without further 
purification. The crude compound was dissolved in a mixture of K2CO3 (19 mg, 0.14 mmol), 
H2O (1 mL), and DMF (1.5 mL). FmocOSu (31 mg, 0.09 mmol) in DMF (0.5 mL) was added and 
the reaction was allowed to warm to room temperature. After 3h. the reaction was quenched with 1 M HCl 
(2 mL) and extracted with Et2O (3x 5 mL). The combined organic phases were washed with brine (15 mL), 
dried and evaporated. Purification by VLC (5–15% EtOAc in heptane + 0.2% AcOH) afforded the product as a 
clear oil (56%, 30 mg, 2 steps). 1H NMR (300 MHz, DMSO-d6) δ 7.87 (d, J = 7.5 Hz, 2H), 7.65 (d, J = 7.8 Hz, 1H), 
7.50 – 7.04 (m, 19H), 4.26 (d, J = 36.7 Hz, 3H), 3.90 – 3.54 (m, 1H), 2.39 – 2.20 (m, 1H), 2.04 (t, J = 6.9 Hz, 1H), 
1.52 – 0.93 (m, 6H). 
(R)-3-((R)-2-((R)-2-((R)-2-amino-3-methylbutanamido)propanamido)-3-(4-(tert-butoxy)phenyl)propanamido)-7-
(tritylthio)heptanoic acid (3.33) 
The linier peptide was synthesized using the standard conditions for SPPS. 
The peptide was cleaved with a mixture of CF3CH2OH:AcOH:CH2Cl2 (2:2:6) 
for 45 min. then cleavage was then repeated for 15 min. The solvent was 
evaporated and dried on high vacuum to afford the crude compound with 
some impurities present (64%, 68 mg, 9 steps). 1H NMR (300 MHz, DMSO-
d6) δ 8.14 – 7.94 (m, 2H), 7.90 – 7.73 (m, 1H), 7.39 – 7.18 (m, 15H), 7.07 
(d, J = 8.1 Hz, 2H), 6.81 (d, J = 8.3 Hz, 2H), 4.34 (s, 1H), 4.23 (s, 2H), 3.89 (s, 1H), 3.06 – 2.66 (m, 4H), 2.15 (t, J 
= 12.2 Hz, 2H), 2.02 (t, J = 7.0 Hz, 2H), 1.36 – 1.04 (m, 20H), 0.80 (dd, J = 29.6, 6.8 Hz, 6H). 
FmocHN
O
OH
TrtS
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(3R,6R,9R,13R)-3-(4-(tert-butoxy)benzyl)-9-isopropyl-6-methyl-13-(4-(tritylthio)butyl)-1,4,7,10-
tetraazacyclotridecane-2,5,8,11-tetraone (3.34) 
To 3.33 (63 mg, 0.072 mmol) and iPrEt2N (0.1 mL, 0.58 mmol) in DMF (144 mL) 
was added  HATU (56 mg, 0,144 mmol). The reaction was stirred at room 
temperature for 19h, then evaporated. The crude mixture was dissolved in 
EtOAc (100 mL), washed with 1M HCl (2x 10 mL) and purified by VLC (0–10% 
MeOH in CH2Cl2) to obtain the product (∼18%, 10 mg) as a white solid with some 
impurities present. 
(3R,6R,9R,13R)-3-(4-hydroxybenzyl)-9-isopropyl-13-(4-mercaptobutyl)-6-methyl-
1,4,7,10-tetraazacyclotridecane-2,5,8,11-tetraone (3.35) 
To 3.34 (10 mg, 0.013) in CH2Cl2 (2 mL) at 0 °C was added TFA (40 μL, 0.52 mmol) 
and iPr3SiH (3.2 μL, 0.026 mmol) and the reaction was then allowed to warm slowly 
to room temperature. After 2h the solvent was evaporated. 1H NMR (400 MHz, 
DMSO-d6) δ 9.12 (s, 1H), 7.91 (d, J = 8.0 Hz, 1H), 7.74 (d, J = 8.3 Hz, 1H), 7.56 (d, J 
= 8.1 Hz, 1H), 6.93 (d, J = 8.4 Hz, 2H), 6.86 (d, J = 9.1 Hz, 1H), 6.61 (d, J = 8.4 Hz, 
2H), 4.25 (q, J = 8.0 Hz, 1H), 4.14 – 4.01 (m, 1H), 3.92 (brs, 1H), 3.79 (s, 1H), 3.06 
(dd, J = 13.7, 6.7 Hz, 1H), 2.70 – 2.65 (m, 1H), 2.36 – 2.29 (m, 2H), 2.22 (d, J = 7.6 
Hz, 2H), 2.01 – 1.87 (m, 1H), 1.50 (d, J = 3.8 Hz, 6H), 1.14 (d, J = 7.3 Hz, 3H), 0.88 (d, J = 6.4 Hz, 6H). 
(S)-4-(tert-butoxy)-4-oxo-2-(((2-(trimethylsilyl)ethoxy)carbonyl)amino)butanoic acid (3.40) 
To L-Asp-OH (1 g, 5.3 mmol) and Et3N (1.84 mL, 13.2 mmol) in H2O (5 mL) and dioxane (5 mL) 
was added 4-Nitrophenyl 2-(trimethylsilyl)ethyl carbonate (1.5 g, 5.3 mmol). The reaction 
was stirred at room temperature for 24h, then diluted with H2O (5mL) and acidified with 1M 
KHSO4 (10 mL). The mixture was extracted with Et2O (4x 40 mL) and washed with brine (2x 
60 mL). Purification by VLC (10–30% EtOAc in hexane + 2% AcOH) afforded the product (1.63 g, 93%) as white 
crystals. 1H NMR (400 MHz, CDCl3) δ 5.63 (d, J = 8.4 Hz, 1H), 4.65 – 4.56 (m, 1H), 4.18 (t, J = 8.5 Hz, 2H), 2.97 
(dd, J = 17.1, 4.1 Hz, 1H), 2.75 (dd, J = 17.1, 5.1 Hz, 1H), 1.44 (s, 9H), 1.00 (t, J = 8.4 Hz, 2H), 0.04 (s, 9H). 13C 
NMR (101 MHz, CDCl3) δ 175.6, 170.5, 156.6, 82.4, 63.9, 50.4, 37.8, 28.2, 17.8, -1.36. Mp: 39.8–42.3 °C. 
tert-butyl (S)-4-hydroxy-3-(((2-(trimethylsilyl)ethoxy)carbonyl)amino)butanoate (3.39) 
To 3.40 (275 mg, 0.82 mmol) and NMM (91 μL, 0.82 mmol) in 1,2-Dimethoxyethane (1 mL) 
at –15 °C was added iBuOCOCl (106 μL, 0.82 mmol). The reaction was stirred 20 min, then 
filtered and cooled to –20 °C followed by addition of NaBH4 (47 mg, 1.23 mmol) in H2O (0.5 
mL). Additional H2O (6 mL) was added, then stirred for 10 min, warmed to room temperature 
and stirred for 20 min. The mixture was extracted with EtOAc (3x 10 mL), washed with brine (2x 10 mL), dried 
(MgSO4) and evaporated. Purification by VLC (30% EtOAC in hexane) afforded the product (204 mg, 77%) as 
a clear oil. 1H NMR (400 MHz, CDCl3) δ 5.33 (brs, 1H), 4.15 (d, J = 8.3 Hz, 2H), 4.05 – 3.92 (m, 1H), 3.71 (t, J = 
5.1 Hz, 2H), 2.63 – 2.45 (m, 3H), 1.45 (d, J = 1.6 Hz, 9H), 0.98 (t, J = 8.4 Hz, 2H), 0.03 (s, 9H). 13C NMR (101 
MHz, CDCl3) δ 171.2, 156.9, 81.6, 64.8, 63.4, 50, 37.5, 28.2, 17.8, -1.4. 
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4-(benzyloxy)butan-1-ol (3.41a).[214] 
To 1,4-butanediol (2.42 mL, 27.3 mmol) and NaH (60% in mineral oil, 1.09 g, 27.3 mmol) in 
anhydrous THF (125 mL) was added BnBr (2.5 mL, 21 mmol) in anhydrous THF (7.5 mL) dropwise.  The 
reaction was heated to reflux for 18h, then quenched with H2O (50 mL). The aqueous phase was extracted 
with Et2O (3x 50 mL) and the combined organic phases were washed with brine (2x75 mL, dried (MgSO4) and 
evaporated. Purification by VLC (0–40% EtOAc in hexane) afforded the product as a yellow oil (85%, 3.22 g). 
1H NMR (400 MHz, CDCl3) δ 7.40 – 7.24 (m, 5H), 4.53 (s, 2H), 3.66 (q, J = 5.9 Hz, 2H), 3.53 (t, J = 5.8 Hz, 2H), 
2.12 (t, J = 5.7 Hz, 1H), 1.79 – 1.62 (m, 4H); 13C NMR (101 MHz, CDCl3) δ 138.1, 128.4, 127.8, 127.7, 73.1, 70.4, 
62.8, 30.2, 26.7 
5-(benzyloxy)pentan-1-ol (3.41b).  
To 1,5-pentanediol (2.86 mL, 27.3 mmol) and NaH (60% in mineral oil, 1.09 g, 27.3 mmol) 
in anhydrous THF (125 mL) was added BnBr (2.5 mL, 21 mmol) in anhydrous THF (7.5 mL) dropwise.  The 
reaction was heated to reflux for 18h, then quenched with H2O (50 mL). The aqueous phase was extracted 
with Et2O (3x 50 mL) and the combined organic phases were washed with brine (2x75 mL, dried (MgSO4) and 
evaporated. Purification by VLC (0–40% EtOAc in hexane) afforded the product as a yellow oil (68%, 2.76 g). 
1H NMR (400 MHz, CDCl3) δ 7.32 – 7.16 (m, 5H), 4.43 (s, 2H), 3.62 – 3.52 (m, 2H), 3.41 (t, J = 6.5 Hz, 2H), 1.64 
– 1.46 (m, 4H), 1.44 – 1.31 (m, 2H), 1.27 (s, 1H). 
((4-bromobutoxy)methyl)benzene (3.42a).[214] 
To PPh3 (3.4 g, 13 mmol) in Et2O (20 mL) at 0 °C was added CBr4 (4.3 g, 13 mmol) in one 
portion and the reaction was stirred for 20 min. 3.41a (1.02g, 5.65 mmol) in Et2O (11 mL) was then added 
dropwise. The reaction was heated to reflux for 2h, then diluted with hexane and evaporated. The mixture 
was filtered on celite, diluted with hexane and evaporated again. This procedure was repeated four times. 
Purification by VLC (0–3% EtOAc in hexane) afforded the product as a clear oil (87%, 1.2 g). 1H NMR (400 
MHz, CDCl3) δ 7.33 – 7.16 (m, 5H), 4.43 (s, 2H), 3.44 (t, J = 6.2 Hz, 2H), 3.37 (t, J = 6.7 Hz, 2H), 1.97 – 1.85 (m, 
2H), 1.75 – 1.64 (m, 2H). 
(((5-bromopentyl)oxy)methyl)benzene (3.42b). 
 To PPh3 (3.4 g, 13 mmol) in Et2O (20 mL) at 0 °C was added CBr4 (4.3 g, 13 mmol) in one 
portion and the reaction was stirred for 20 min. 3.41a (1.02g, 5.65 mmol) in Et2O (11 mL) was then added 
dropwise. The reaction was heated to reflux for 2h, then diluted with hexane and evaporated. The mixture 
was filtered on celite, diluted with hexane and evaporated again. This procedure was repeated three times. 
Purification by VLC (0–3% EtOAc in hexane) afforded the product as a clear oil (89%, 1.3 g). 1H NMR (400 
MHz, CDCl3) δ 7.32 – 7.16 (m, 5H), 4.43 (s, 2H), 3.41 (t, J = 6.3 Hz, 2H), 3.33 (t, J = 6.8 Hz, 2H), 1.81 (p, J = 7.1 
Hz, 2H), 1.62 – 1.53 (m, 2H), 1.50 – 1.41 (m, 2H). 
(4-(benzyloxy)butyl)triphenylphosphonium bromide (3.43a) 
To PPh3 (3.25 g, 12.4 mmol) in anhydrous toluene (40mL) was added 3.42a (2.9 g, 11.8 
mmol) and the reaction was heated to reflux for 24h. The crude product was dissolved in 
CH2Cl2 (4 mL) and triturated with Et2O. The product was obtained as a white precipitate (45%, 2.7 g).  1H NMR 
(400 MHz, CDCl3) δ 7.89 – 7.59 (m, 15H), 7.38 – 7.08 (m, 5H), 4.46 (s, 2H), 3.88 – 3.73 (m, 2H), 3.66 – 3.56 (m, 
2H), 2.09 – 1.96 (m, 2H), 1.85 – 1.73 (m, 2H). 
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benzyl 2-(1H-indol-3-yl)ethylcarbamate (4.19).[215] 
To a solution of tryptamine (13.67 mmol, 2.19 g) in 80 mL CH2Cl2 was added NaHCO3 (68.3 mmol, 
5.74 g) in 80 mL H2O. Cbz-Cl (15.03 mmol, 2.2 mL) was then added slowly and stirred vigorously 
at rt for 40 min. The aqueous phase was extracted with CH2Cl2 (2 x 50 mL) and the combined 
organic phases were washed with brine (2 x 80 mL), dried (Na2SO4), and concentrated. 
Purification by silica gel chromatography (0–2% MeOH/DCM) afforded the product (3.57 g, 89%) as a white 
solid. 1H NMR (500 MHz, CDCl3) δ 8.07 (s, 1H), 7.61 (d, J = 7.8 Hz, 1H), 7.41 – 7.29 (m, 6H), 7.21 (t, J = 7.1 Hz, 
1H), 7.13 (t, J = 7.4 Hz, 1H), 6.99 (s, 1H), 5.11 (s, 2H), 4.85 (s, 1H), 3.55 (dd, J = 12.8, 6.4 Hz, 2H), 2.99 (t, J = 6.7 
Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 156.5, 136.7, 136.5, 128.5, 128.2, 127.3, 122.23, 122.16, 119.5, 118.8, 
112.7, 111.4, 66.7, 41.4, 25.8. 
N-Cbz-N,1-dimethyltryptamine (4.20). 
 To a solution of 4.19 (3.16 mmol, 931 mg) in 20 mL anhydrous THF at 0 ⁰C was added NaH (60% 
in mineral oil; 12.6 mmol, 504 mg). The reaction was stirred for 10 min where after MeI (14.2 
mol, 0.9 mL) was added. After 10 min, the reaction was allowed to warm to rt. After stirring for 
11 h, additional NaH (60% in mineral oil; 6.3 mmol, 202 mg) and MeI (8.2 mmol, 0.6 mL) was 
added and the reaction was stirred for 1.5 h. The reaction was quenched with NH4Cl (10 mL) and the aqueous 
phase was extracted with EtOAc (2 x 10 mL). The combined organic phases were washed with NaHCO3 (2 x 
40 mL), brine (2 x 40 mL), dried (Na2SO4), and concentrated. Purified by silica gel chromatography (10–20% 
EtOAc in hexanes) afforded the product (954 mg, 93%) as a clear yellow oil. 1H NMR (500 MHz, CDCl3, 
compound exists as a 1.4:1 mixture of rotamers, the major rotamer is designated by *, minor rotamer 
designated by §) δ 7.65 (d, J = 7.9 Hz, 1H§), 7.45 (d, J = 7.9 Hz, 1H*), 7.42–7.26 (m, 6H*, 6H§), 7.25–7.18 (m, 
1H*, 1H§), 7.11 (dd, J = 7.4, 7.4 Hz, 1H§), 7.02 (dd, J = 7.4, 7.4 Hz, 1H*), 6.89 (s, 1H§), 6.79 (s, 1H*), 5.17 (s, 
2H§), 5.10 (s, 2H*), 3.73 (s, 3H§), 3.71  (s, 3H*), 3.59 (t, J = 7.9 Hz, 2H§), 3.54 (t, J = 7.7 Hz, 2H*), 3.01 (t, J = 7.9 
Hz, 2H§), 2.96 (t, J = 7.8 Hz, 2H*), 2.95 (s, 3H*), 2.92 (s, 3H§).; 13C NMR (125 MHz, CDCl3; compound exists as 
a 1.4:1 mixture of rotamers) δ 156.3, 156.2, 136.9, 136.8, 128.4, 128.0, 127.9, 127.86, 127.8, 127.7, 126.7, 
121.5, 118.83, 118.78, 118.7, 111.5, 111.4, 109.2, 67.1, 66.9, 50.2, 49.8, 35.0, 34.5, 24.1, 23.4.; FTIR 
(NaCl/thin film): 3056, 3030, 1703, 1699, 1484, 1475, 1403, 1211, 1192, 1134 cm-1; HRMS (MM) calc’d for 
C20H23N2O2 [M+H]+323.1754, found 323.1758. 
 
benzyl methyl(2-(1-methyl-2-phenyl-1H-indol-3-yl)ethyl)carbamate (4.21).[195] 
Four oven-dried microwave vials were each charged with 4.20 (231 mg, 0.72 mmol), 2-NO2Bz 
(288 mg, 1.1 mmol), Pd(OAc)2 (6.25 mg, 37.4 µmol), AgBF4 (228 mg, 1.2 mmol, weighed into 
small vials in a glovebox then removed from the glovebox and transferred quickly to the 
microwave vials), PhI (0.33 mL, 3.0 mmol), and 4.5 mL DMF. The microwave vials were sealed 
under argon and the orange reaction mixtures were stirred at room temperature for 30 minutes, then heated 
in the microwave for 4 min at 150 ⁰C. The four reaction mixtures were then combined and filtered through 
celite with 60 mL EtOAc, washed (3 x 40 mL saturated aqueous NH4Cl, 3 x 40 mL saturated aqueous NaHCO3, 
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3 x 40 mL brine), dried (Na2SO4), filtered, and concentrated. Purification by silica gel column chromatography 
(8% EtOAc in hexanes) afforded the product (921 mg, 81%) as a yellow solid. 1H NMR (500 MHz, CDCl3, 
compound exists as a 1.7:1 mixture of rotamers, the major rotamer is designated by *, minor rotamer 
designated by §) δ 7.74 (d, J = 7.9 Hz, 1H§), 7.53-7.22 (m, 13H*, 12H§), 7.17 (dd, J = 7.5, 7.5 Hz, 1H§), 7.06 (dd, 
J = 7.6, 7.6 Hz, 1H*), 5.09 (s, 2H§), 4.98 (s, 2H*), 3.59 (s, 3H§), 3.57 (s, 3H*), 3.50 (t, J = 8.2 Hz, 2H§), 3.45 (t, J 
= 7.8 Hz, 2H*), 2.97 (t, J = 7.5 Hz, 2H§), 2.91 (t, J = 7.8 Hz, 2H*), 2.78 (s, 3H*), 2.76 (s, 3H§).; 13C NMR (125 MHz, 
CDCl3; compound exists as a 1.7:1 mixture of rotamers) δ 156.1, 156.0, 138.6, 138.4, 137.1, 136.8, 131.8, 
131.7, 130.4, 128.4, 128.14, 128.10, 128.0, 127.84, 127.81, 127.7, 127.5, 121.8, 119.42, 119.37, 119.0, 118.6, 
109.7, 109.6, 109.4, 109.3, 67.0, 66.8, 50.5, 49.7, 34.8, 34.6, 30.81, 30.76, 23.5, 23.0; FTIR (NaCl/thin film): 
3055, 3030, 2939, 1703, 1699, 1695, 1471, 1403, 1362, 1197, 1138 cm-1; HRMS (MM) calc’d for C26H27N2O2 
[M+H]+ 399.2067, found 399.2087. 
N,1-dimethyl-2-phenyltryptamine (4.22).[216] 
A solution of 4.21 (574 mg, 1.44 mmol) in CH2Cl2 (15 mL) was prepared in a flame-dried flask 
under argon. Et3SiH (9.2 mL, 57.7 mmol) and Et3N (0.4 mL, 2.87 mmol) were then added, 
followed by Pd2(dba)3•CHCl3 (298 mg, 0.288 mmol). The dark red reaction solution was stirred 
for 16 hours and the resultant dark brown mixture was filtered through celite with 50 mL EtOAc, 
washed (2 x 40 mL saturated aqueous NaHCO3, 2 x 40 mL brine), dried (Na2SO4), filtered, and concentrated. 
The crude residue was purified by silica gel column chromatography (0–8% MeOH in DCM) to afford the 
product (332 mg, 87%) as a yellow oil. 1H NMR (500 MHz, CDCl3) δ 7.68 (d, J = 7.8 Hz, 1H), 7.53–7.38 (m, 5H), 
7.35 (ddd, J = 8.2, 0.8, 0.8 Hz, 1H), 7.26 (ddd, J = 8.1, 6.9, 1.0 Hz, 1H), 7.16 (ddd, J = 8.1, 7.0, 1.0 Hz, 1H), 3.59 
(s, 3H), 2.92 (t, J = 7.2 Hz, 2H), 2.82 (t, J = 7.1 Hz, 2H), 2.34 (s, 3H), 1.37 (s, 1H).; 13C NMR (125 MHz, CDCl3) δ 
138.7, 137.0, 131.1, 130.3, 128.8, 128.5, 127.0, 122.0, 119.8, 118.7, 109.46, 107.0, 49.3, 32.4, 30.8, 21.3.; 
FTIR (NaCl/thin film): 3051, 2934, 2840, 2789, 1468, 1442, 1430, 1364, 1333, 1236, 1131, 1013 cm-1; HRMS 
(MM) calc’d for C18H21N2 [M+H]+ 265.1699, found 265.1707. 
3a-hydroxy-1,1a-dimethyl-2a-phenylpyrroloindoline (4.16) 
 A 15 mL flame-dried flask containing 4.22 (59.5 mg, 0.23 mmol) was charged with flame-
dried 4Å molecular sieves and MeCN (1.3 mL). NCS (recrystallized from toluene, 30.2 mg, 
0.225 mmol) was then added as a solution in 2 mL MeCN dropwise and the reaction was 
stirred in the dark at room temperature for 4 hours, followed by addition of more NCS (15.4 mg, 0.115 mmol) 
as a solution in 1 mL MeCN. After 1.5 hours, the dark green reaction solution was quenched with 5 mL 
aqueous Na2S2O3 (10 wt %) and extracted with EtOAc (3 x 5 mL). The combined organic layers were washed 
with 30 mL brine, dried (Na2SO4), filtered, and concentrated. The crude oil was combined with MeCN (5 mL), 
H2O (5 mL) and SiO2 (5 mL), then vigorously stirred open to air at room temperature for 30 minutes, filtered 
and washed with EtOAc, dried (Na2SO4), filtered and concentrated. The crude was subjected to silica gel 
column chromatography (0–1% MeOH/DCM) and then to reverse phase preparative HPLC (0.01:18:82 to 
0.01:80:20 TFA:MeCN:H2O) using an Agilent 1200 Series HPLC with an Agilent XDB-C18 5 µM column (9.4 x 
250 mm). The combined product-containing eluent was diluted with 20 mL saturated aqueous NaHCO3 and 
extracted with EtOAc (3 x 30 mL).  The combined organic layers were dried (Na2SO4), filtered, and 
concentrated to afford the product (21.0 mg, 33%) as a yellow solid. 1H NMR (500 MHz, CDCl3) δ 7.75 – 6.90 
(m, 6H), 7.32 (ddd, J = 8.6, 7.3, 1.4 Hz, 1H), 6.71 (ddd, J = 7.4, 7.4, 1.0 Hz, 1H), 6.44 (d, J = 7.8 Hz, 1H), 3.07 – 
3.01 (m, 1H), 2.77 (s, 3H), 2.62 – 2.55 (m, 1H), 2.49 (s, 3H), 2.29 – 2.23 (m, 2H), 1.44 (br s, 1H).; 13C NMR (125 
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MHz, CDCl3) δ 152.5, 137.1, 130.7, 129.9, 128.7, 128.0, 123.9, 116.9, 104.0, 98.3, 90.6, 51.4, 40.5, 36.6, 34.4.; 
FTIR (NaCl/thin film): 3540, 3435, 3051, 2931, 2791, 1608, 1492, 1473, 1445, 1370, 1308, 1106, 1028 cm-1; 
HRMS (MM) calc’d for C18H21N2O [M+H]+ 281.1648, found 281.1655. 
3a-amino-1,1a-dimethyl-2a-phenylpyrroloindoline (4.24) 
 A 15 mL oven-dried flask containing 4.22 (39.6 mg, 0.15 mmol) was charged with flame-dried 
4Å molecular sieves and MeCN (0.9 mL). NCS (recrystallized from toluene, 20.1 mg, 0.15 
mmol) was then added as a solution in MeCN (1.75 mL) dropwise. After stirring in the dark at 
room temperature for 3 hours, the off-white reaction solution was quenched with 2.8 mL aqueous ammonia 
and stirred vigorously open to air for 20 minutes. The mixture was then diluted with H2O (10 mL) and 
extracted with EtOAc (3 x 5 mL). The combined organic layers were washed with brine (15 mL), dried (Na2SO4), 
filtered, and concentrated. The crude oil was purified by silica gel column chromatography (0–1% MeOH in 
DCM) to afford the product (24.0 mg, 57% yield) as a yellow oil. 1H NMR (500 MHz, CDCl3) δ 7.73 (br s, 1H), 
7.54 – 7.27 (m, 3H), 7.24 (dd, J = 7.2, 1.3 Hz, 1H), 7.19 (ddd, J = 7.7, 7.7, 1.4 Hz, 1H), 6.83 (br s, 1H), 6.68 (ddd, 
J = 7.4, 7.4, 1.0 Hz, 1H), 6.40 (d, J = 7.8 Hz, 1H), 2.96 (dd, J = 9.1, 7.0 Hz, 1H), 2.79 (s, 3H), 2.58 (ddd, J = 12.0, 
9.1, 5.1 Hz, 1H), 2.47 (s, 3H), 2.20 (dd, J = 12.2, 5.1 Hz, 1H), 1.95 (ddd, J = 12.1, 12.1, 7.1 Hz, 1H), 1.12 (br s, 
2H).; 13C NMR (125 MHz, CDCl3) δ 152.5, 138.6, 132.0, 129.1, 128.9, 128.5, 127.8, 127.7, 123.9, 116.6, 103.6, 
99.0, 74.8, 51.2, 42.0, 36.8, 34.6.; FTIR (NaCl/thin film): 3051, 2930, 2861, 2791, 2254, 1606, 1495, 1473, 
1445, 1372, 1308, 1035 cm-1; HRMS (MM) calc’d for C18H22N3 [M+H]+ 280.1808, found 280.1818.  
N-Cbz-1-methyltryptamine (4.25).[217] 
 To 4.19 (212 mg, 0.721 mmol) in acetone (3 mL) was added KOH (202 mg, 3.60 mmol). After 10 
min, MeI (49 µL, 0.787 mmol) was added and the orange reaction solution was stirred 1 hour at 
room temperature, followed by addition of more KOH (202 mg, 3.60 mmol) and MeI (49 µL, 
0.787 mmol). After stirring for 3.5 hours at room temperature, the reaction was diluted with 
toluene, filtered, and concentrated. Purification by silica gel column chromatography (5–20% EtOAc in 
hexanes) afforded the product (151 mg, 68%). 1H NMR (500 MHz, CDCl3) δ 7.59 (d, J = 7.9 Hz, 1H), 7.43 – 7.29 
(m, 6H), 7.24 (ddd, J = 8.2, 7.0, 1.1 Hz, 1H), 7.11 (t, J = 7.4 Hz, 1H), 6.86 (s, 1H), 5.11 (s, 2H), 4.83 (brs, 1H), 
3.74 (s, 3H), 3.54 (dd, J = 12.8, 6.5 Hz, 2H), 2.97 (t, J = 6.7 Hz, 2H). 
N-Cbz-1-methyl-2-phenyltryptamine (4.26).[195] 
An oven-dried microwave vial was charged with 4.25 (134 mg, 0.435 mmol), 2-NO2Bz (147 mg, 
0.653 mmol), Pd(OAc)2 (3.3 mg, 20 µmol), AgBF4 (131 mg, 0.672 mmol), weighed into a small 
vial in a glovebox then removed from the glovebox and transferred quickly to the microwave 
vial), PhI (0.19 mL, 1.70 mmol), and 4.3 mL DMF. The microwave vial was sealed under argon 
and the orange solution was stirred at room temperature for 30 minutes, then heated in the microwave for 
4 min at 150 ⁰C. The resultant brown reaction mixture was filtered through celite with EtOAc, washed (2 x 10 
mL saturated aqueous NH4Cl, 2 x 10 mL saturated aqueous NaHCO3, 2 x 10 mL brine), dried (Na2SO4), filtered, 
and concentrated. Purification by silica gel column chromatography (6–12% EtOAc in hexanes) afforded the 
product (142 mg, 85%) as an orange oil. 1H NMR (500 MHz, CDCl3, compound exists as a 5.6:1 mixture of 
rotamers, the major rotamer is designated by *, minor rotamer designated by §) δ 7.67 (d, J = 7.9 Hz, 1H*), 
7.54 (br s, 1H§), 7.50 – 7.41 (m, 3H*, 3H§), 7.40 – 7.26 (m, 9H*, 9H§), 7.17 (dd, J = 7.4 Hz, 1H*), 7.12 (br s, 1H§), 
5.04 (s, 2H*, 2H§), 4.73 (t, J = 6.8 Hz, 1H*), 4.51 (br s, 1H§), 3.58 (s, 3H*, 3H§), 3.44 (td, J = 6.7, 6.7 Hz, 2H*), 
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3.38 (br s, 1H§), 2.94 (t, J = 6.9 Hz, 2H*), 2.90 (br s, 1H§).; 13C NMR (125 MHz, CDCl3; compound exists as a 
5.6:1 mixture of rotamers, only the major rotamer is reported) δ 156.2, 138.8, 137.1, 131.7, 130.6, 128.5, 
128.4, 128.2, 128.0, 121.9, 119.5, 118.9, 109.6, 109.4, 66.4, 41.7, 30.8, 25.1.; FTIR (NaCl/thin film): 3413, 
3339, 3055, 3030, 2940, 1718, 1701, 1511, 1368, 1361, 1334, 1233, 1132 cm-1; HRMS (MM) calc’d for 
C25H25N2O2 [M+H]+ 385.1911, found 385.1924. 
3a-hydroxy-1a-methyl-2a-phenylpyrroloindoline (4.27). 
 A 5 mL oven-dried flask containing 4.26 (24.0 mg, 62.5 µmol) was charged with flame-dried 
4Å molecular sieves and MeCN (0.5 mL). NCS (recrystallized from toluene, 8.4 mg, 0.225 
mmol) was then added as a solution in MeCN (1.25 mL) dropwise. After stirring in the dark at 
room temperature for 6 hours, the light yellow reaction solution was quenched with aqueous Na2S2O3 (10 wt 
%, 5 mL) and extracted with EtOAc (4 x 5 mL). The combined organic layers were washed with brine (15 mL), 
dried (Na2SO4), filtered, and concentrated. The crude residue was combined with MeCN (1.5 mL), H2O (1.5 
mL) and SiO2 (1.5 mL), then vigorously stirred open to air at room temperature for 30 minutes, filtered 
through a 1.5 mL silica plug with EtOAc, and concentrated. Purification by reverse phase preparative HPLC 
(60:40 to 90:10 MeCN:H2O) using an Agilent 1200 Series HPLC with an Agilent XDB-C18 5 µM column (9.4 x 
250 mm) afforded the product (13.7 mg, 55%) as a light yellow-green oil. 1H NMR (500 MHz, CDCl3, compound 
exists as a 1.1:1 mixture of rotamers, the major rotamer is designated by *, minor rotamer designated by §; 
due to overlap in the NMR, the rotamer shifts were confirmed by HSQC 2D NMR) δ 7.48 – 7.09 (m, 11H*, 
11H§), 6.83 – 6.75 (m, 2H*), 6.75 – 6.68 (m, 2H§), 6.58 (d, J = 7.8 Hz, 1H*), 6.50 (d, J = 7.9 Hz, 1H§), 5.12 (d, J = 
12.4 Hz, 1H*), 5.07 – 5.01 (m, 1H*, 1H§), 4.85 (d, J = 12.3 Hz, 1H§), 4.05 (dd, J = 9.7 Hz, 1H§), 3.98 (dd, J = 9.5 
Hz, 1H*), 3.30 (ddd, J = 11.1, 11.1, 6.2 Hz, 1H*), 3.21 (ddd, J = 11.5, 11.5, 5.9 Hz, 1H§), 3.04 (s, 3H*), 2.75 (s, 
3H§), 2.50 – 2.39 (m, 1H*, 1H§), 2.31 – 2.19 (m, 1H*, 1H§), 1.50 (br s, 1H*, 1H§).; 13C NMR (125 MHz, CDCl3, 
compound exists as a 1.1:1 mixture of rotamers) δ 155.0, 154.5, 151.1, 151.0, 136.7, 135.6, 130.8, 128.6, 
128.4, 128.2, 128.1, 128.0, 127.8, 127.7, 127.6, 127.4, 127.3, 123.62, 123.59, 118.1, 117.8, 106.53, 106.45, 
89.6, 88.6, 67.0, 66.7, 46.3, 46.2, 34.1, 33.6, 31.9, 31.3.; FTIR (NaCl/thin film): 3049, 3056, 3032, 2945, 2891, 
1695, 1684, 1675, 1609, 1491, 1401, 1348, 1186, 1117, 1004 cm-1; HRMS (MM) calc’d for C25H25N2O3 
[M+H]+401.1860, found 401.1877. 
3a-hydroxy-1a-methyl-2a-phenylpyrroloindoline (4.17) 
 A solution of 4.27 (10.1 mg, 25.2 µmol) in THF (1.0 mL) was prepared in a flame-dried flask. 
Et3SiH (0.16 mL, 1.0 mmol) and Et3N (7.0 µL, 50 µmol) were then added, followed by 
Pd2(dba)3•CHCl3 (5.0 mg, 4.8 µmol). The dark red reaction solution was stirred for 19 hours at 
room temperature, then filtered through celite with THF, combined with an equal volume of saturated 
aqueous NaHCO3, and stirred at room temperature for 5 hours. The aqueous layer was then extracted with 
EtOAc (3 x 15 mL) and the combined organic layers were dried (Na2SO4), filtered and concentrated. The crude 
residue was purified by silica gel column chromatography (0–2% MeOH in DCM) to afford the product (6.1 
mg, 91% yield) as a yellow solid. 1H NMR (300 MHz, CDCl3) δ 7.50 – 7.27 (m, 5H), 7.25 (ddd, J = 7.2, 1.4, 0.5 
Hz, 1H), 7.20 (ddd, J = 7.7, 7.7, 1.3 Hz, 1H), 6.68 (ddd, J = 7.4, 7.4, 1.0 Hz, 1H), 6.42 (d, J = 7.9 Hz, 1H), 3.25 
(ddd, J = 9.4, 5.1, 3.8 Hz, 1H), 2.94 – 2.83 (m, 1H), 2.63 (s, 3H), 2.32 – 2.25 (m, 2H), 1.03 – 0.89 (br m, 1H), 
0.65 – 0.51 (br m, 1H).;13C NMR (125 MHz, CDCl3) δ 151.2, 138.2, 130.7, 130.1, 128.6, 128.2, 127.4, 123.9, 
117.1, 104.3, 95.2, 89.6, 43.3, 41.9, 28.5.; FTIR (NaCl/thin film): 3340, 3051, 2931, 2874, 1609, 1495, 1446, 
1375, 1307, 1121, 1062 cm-1; HRMS (MM) calc’d for C17H19N2O [M+H]+ 267.1492, found 267.1502. 
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(L)-Nα-Cbz-tryptophan (4.29).[218] 
A solution of L-tryptophan (896 mg, 4.39 mmol) and K2CO3 (1.52 g, 10.97 mmol) in H2O (25 mL) 
was cooled to 0 °C in an ice bath. N-(Benzyloxycarbonyloxy)succinimide (988 mg, 3.97 mmol) 
was then added as a solution in wet DMF (25 mL) and the reaction was allowed to warm to 
room temperature. After stirring 40 minutes, the mixture was diluted with 300 mL H2O and 
washed with EtOAc (2 x 10 mL). The aqueous layer was then cooled to 0 °C, acifidied with 6 mL concentrated 
HCl, and extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with brine (2 x 150 
mL), dried (Na2SO4), filtered, and concentrated (coevaporated with DCM and MeOH) to afford the product 
(1.07 g, 80%) as a white foam. 1H NMR spectral data were in agreement with the literature.[219] 
(L)-Nα-Cbz-Nα,1-dimethyltryptophan (4.30). 
 A solution of 4.29 (875 mg, 2.59 mmol) in THF (5 mL) was cooled to 0 °C in an ice bath. NaH (60% 
dispersion in oil, 516 mg, 12.9 mmol) was then added, followed by MeI (0.96 mL, 15.4 mmol).  
The yellow reaction mixture was allowed to warm to room temperature and stirred for 29 hours, 
then diluted with H2O (10 mL) and acidified with 1 mL concentrated HCl. The aqueous layer was 
extracted with EtOAc (3 x 10 mL) and the combined organic layers were washed with brine (3 x 
30 mL), dried (Na2SO4), filtered, and concentrated. Purified by silica gel column chromatography (5–50% 
EtOAc in hexanes with 2–4% AcOH) afforded the product (600 mg, 63%) as a yellow-brown foam. 1H NMR 
(500 MHz, CDCl3, compound exists as a 1.3:1 mixture of rotamers, the major rotamer is designated by *, 
minor rotamer designated by §) δ 10.54 (br s, 1H*, 1H§), 7.60 (d, J = 7.9 Hz, 1H*), 7.55 (d, J = 7.9 Hz, 1H§), 7.38 
– 7.21 (m, 6H*, 6H§), 7.16 – 7.07 (m, 2H*, 2H§), 6.85 (s, 1H*), 6.76 (s, 1H§), 5.17 (s, 2H*), 5.09 – 4.99 (m, 1H*, 
3H§), 3.684 (s, 3H*), 3.677 (s, 3H§), 3.50 (d, J = 5.0 Hz, 1H§), 3.47 (d, J = 4.9 Hz, 1H*), 3.32 (dd, J = 15.5, 10.6 
Hz, 1H*), 3.18 (dd, J = 15.3, 10.5 Hz, 1H§), 2.92 (s, 3H§), 2.83 (s, 3H*).; 13C NMR (125 MHz, CDCl3; compound 
exists as a 1.3:1 mixture of rotamers, the major rotamer is designated by *, minor rotamer designated by §)) 
δ 176.5§, 176.4*, 157.0*, 156.3§, 136.93§, 136.88*, 136.6*, 136.2§, 128.5*, 128.4§, 128.01*, 127.96§, 127.9§, 
127.7*, 127.3§, 127.1*, 121.8§, 121.7*, 119.1§, 119.0*, 118.5*, 118.4§, 109.5§, 109.4*, 109.32§, 109.27*, 
67.6§, 67.5*, 59.9*, 59.4§, 32.67*, 32.66§, 32.0*, 31.7§, 25.0§, 24.4*.; FTIR (NaCl/thin film): 3034, 2939, 1741, 
1701, 1664, 1475, 1455, 1403, 1326, 1214, 1141 cm-1; [α]D25 = –40.6º (c = 0.68, CHCl3). HRMS (MM) calc’d for 
C21H23N2O4 [M+H]+ 367.1652, found 367.1667. 
(L)-Nα-Cbz-Nα,1-dimethyl-2-phenyltryptophan (4.31).[195] 
Two oven-dried microwave vials were each charged with 2-NO2Bz (255 mg, 1.13 mmol), 
Pd(OAc)2 (6.25 mg, 37.4 µmol), AgBF4 (240 mg, 1.23 mmol, weighed into small vials in a 
glovebox then removed from the glovebox and transferred quickly to the microwave vials), and 
PhI (0.34 mL, 3.04 mmol). A solution of 4.30 (276 mg, 0.754 mmol) in DMF (4 mL) was then 
added to each vial. The microwave vials were sealed under argon and the reaction mixtures 
were stirred at room temperature for 30 minutes, then heated in the microwave for 4 min at 150 °C. The two 
reaction mixtures were then combined and filtered through celite with 15 mL EtOAc, washed with saturated 
aqueous NH4Cl (2 x 20 mL), brine (2 x 20 mL), dried (Na2SO4), filtered, and concentrated. Purification by silica 
gel column chromatography (5–20% EtOAc in hexanes, with 4% AcOH) followed by washing with saturated 
aqueous NaHCO3 afforded the product (366 mg, 55%) as a light yellow foam. The enantiomeric excess was 
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determined to be 94% by chiral SFC analysis (AD-H, 2.5 mL/min, 25% IPA in CO2, λ = 254 nm): tR(major) = 4.6 
min tR(minor) = 7.2 min. 1H NMR (300 MHz, CDCl3, compound exists as a 2.6:1 mixture of rotamers, the major 
rotamer is designated by *, minor rotamer designated by §) δ 7.55 (d, J = 7.9 Hz, 1H*), 7.46 (d, J = 7.9 Hz, 1H§), 
7.32 – 6.85 (m, 13H*, 12H§), 6.57 (d, J = 7.4 Hz, 1H§), 4.87 (br d, J = 11.6 Hz, 1H§), 4.78 (d, J = 12.6 Hz, 1H*), 
4.64 (d, J = 12.6 Hz, 1H*), 4.51 (d, J = 12.6 Hz, 1H§), 4.35 (d, J = 12.5 Hz, 1H§), 4.04 (br d, J = 10.3 Hz, 1H*), 3.53 
– 3.25 (m, 5H*, 4H§), 3.03 – 2.88 (m, 1H§), 2.28 (s, 3H*), 2.11 (s, 3H§).; 13C NMR (125 MHz, CDCl3; compound 
exists as a 2.6:1 mixture of rotamers) δ 176.5, 176.3, 156.3, 155.6, 139.4, 139.0, 137.1, 136.5, 136.1, 131.6, 
131.4, 130.6, 130.5, 128.5, 128.4, 128.3, 128.2, 127.8, 127.6, 127.4, 127.1, 121.9, 121.8, 119.6, 118.6, 118.4, 
109.6, 109.4, 108.2, 107.8, 67.18, 67.15, 61.1, 59.7, 33.0, 32.2, 30.8, 30.7, 24.4, 23.9.; FTIR (NaCl/thin film): 
3056, 3031, 2936, 1699, 1695, 1683, 1605, 1469, 1401, 1363, 1328, 1137 cm-1; [α]D25 = –133.3° (c = 0.84, 
CHCl3). HRMS (MM) calc’d for C27H27N2O4 [M+H]+ 443.1965, found 443.1984. 
(S)-2-(((benzyloxy)carbonyl)(methyl)amino)-3-(1-methyl-2-phenyl-1H-indol-3-yl)propanoic acid (4.32) 
 To a solution of 4.31 (90 mg, 0.2 mmol) in anhydrous CH2Cl2 (2.0 mL) was added Et3SiH (1.2 
mL, 8 mmol) and Et3N (56 µL, 0.4 mmol) followed by Pd2(dba)3•CHCl3 (30 mg, 0.04 mol). The 
dark red reaction solution was stirred for 24 hours at room temperature, then filtered through 
celite with CH2Cl2 and MeOH. Purification by silica gel column chromatography (2–5% MeOH 
in CH2Cl2) afforded an impure product (38 mg) and attempts to purify the product further lead 
to loss of the product. Purification was achieved after several fractions from different reaction was combined. 
1H NMR (500 MHz, CD3OD) δ 7.78 (d, J = 7.6 Hz, 1H), 7.56 (t, J = 7.1 Hz, 2H), 7.50 (t, J = 6.7 Hz, 3H), 7.41 (d, J 
= 8.1 Hz, 1H), 7.24 (t, J = 7.5 Hz, 1H), 7.14 (t, J = 7.2 Hz, 1H), 3.72 (brs, 1H), 3.59 (s, 3H), 3.54 – 3.40 (m, 1H), 
3.23 – 2.99 (m, 1H), 2.38 (s, 3H). 
(S)-Nα-Cbz-Nα,1-dimethyl-2-phenyltryptophan methyl ester (4.33). 
 A solution of 4.31 (104 mg, 0.235 mmol) in wet MeOH (3 mL) was charged with SOCl2 (34 µL, 
0.47 mmol), then heated to 40 °C. After stirring for 5 hours, the reaction was diluted with 10 
mL H2O and extracted with EtOAc (3 x 10 mL). The combined organic layers were dried 
(Na2SO4) and concentrated. Purification by silica gel column chromatography (15% EtOAc in 
hexanes) afforded the product (92.6 mg, 86%) as a yellow oil. 1H NMR (500 MHz, CDCl3, 
compound exists as a 1.5:1 mixture of rotamers, the major rotamer is designated by *, minor rotamer 
designated by §) δ 7.67 (d, J = 7.9 Hz, 1H§), 7.59 (d, J = 7.9 Hz, 1H*), 7.49 – 7.19 (m, 11H§, 11H*), 7.17 – 7.10 
(m, 1H§, 1H*), 6.97 – 6.90 (m, 1H§, 1H*), 5.02 (d, J = 12.5 Hz, 1H§), 4.89 (d, J = 12.6 Hz, 1H§), 4.82 – 4.71 (m, 
2H*, 1H§), 4.62 (d, J = 12.3 Hz, 1H*), 3.65 (s, 3H§), 3.55 (s, 3H*), 3.531 (s, 3H§), 3.527 (s, 3H*), 3.51 – 3.45 (m, 
1H*, 1H§), 3.27 (dd, J = 14.9, 10.3 Hz, 1H§), 3.21 (dd, J = 14.9, 10.8 Hz, 1H*), 2.49 (s, 3H§), 2.40 (s, 3H*).; 13C 
NMR (125 MHz, CDCl3; compound exists as a 1.5:1 mixture of rotamers) δ 171.6, 171.4, 156.0, 155.5, 139.4, 
139.0, 137.0, 136.7, 136.2, 131.6, 131.5, 130.6, 130.5, 128.5, 128.4, 128.3, 128.17, 128.15, 128.1, 127.71, 
127.68, 127.6, 127.54, 127.46, 127.2, 121.8, 121.7, 119.49, 119.47, 118.6, 118.4, 109.5, 109.3, 108.3, 108.0, 
66.92, 66.86, 60.5, 59.9, 52.03, 51.98, 32.4, 32.3, 30.70, 30.67, 24.5, 24.1.; FTIR (NaCl/thin film): 3033, 2946, 
1743, 1740, 1734, 1704, 1700, 1696, 1468, 1399, 1363, 1314, 1270, 1214, 1139 cm-1; [α]D25 = –82.8º (c = 0.22, 
CHCl3). HRMS (MM) calc’d for C28H29N2O4 [M+H]+ 457.2122, found 457.2128. 
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(L)-Nα,1-dimethyl-2-phenyltryptophan methyl ester (4.34). 
 A solution of 4.33 (91.0 mg, 0.199 mmol) in DCM (2 mL) was prepared in a flame-dried flask 
under nitrogen. Et3SiH (1.3 mL, 8.1 mmol) and Et3N (55 µL, 0.40 mmol) were then added, 
followed by Pd2(dba)3 (41.0 mg, 44.8 µmol). The dark red reaction solution was stirred for 20 
hours and the resultant dark brown mixture was filtered through celite with EtOAc (15 mL), 
washed with saturated aqueous NaHCO3 (2 x 15 mL), brine (2 x 15 mL), dried (Na2SO4), filtered, and 
concentrated. Purification by silica gel column chromatography (5–15% EtOAc in hexanes, then 15% EtOAc 
in hexanes with 4% NH4OH, then 5% MeOH in DCM with NH4OH) afforded the product (26.4 mg, 41%) as a 
colorless oil. 1H NMR (500 MHz, CDCl3) δ 7.69 (d, J = 7.9 Hz, 1H), 7.59 – 7.38 (m, 5H), 7.34 (d, J = 8.2 Hz, 1H), 
7.26 (ddd, J = 8.2, 7.1, 1.2 Hz, 1H), 7.17 (ddd, J = 8.0, 7.0, 1.0 Hz, 1H), 3.57 (s, 3H), 3.51 (s, 3H), 3.48 (dd, J = 
7.7, 6.4 Hz, 1H), 3.15 (dd, J = 14.3, 6.4 Hz, 1H), 3.05 (dd, J = 14.3, 7.7 Hz, 1H), 2.24 (s, 3H). [α]D25 = +16.1° (c = 
0.19, CHCl3). 13C NMR (126 MHz, CDCl3) δ 175.2, 139.4, 137.2, 131.8, 130.86, 130.85, 128.63, 128.62, 128.4, 
127.8, 121.9, 119.6, 119.2, 109.5, 108.3, 64.3, 51.7, 35, 31, 28.8. 
3a-hydroxypyrroloindoline methyl ester (4.35, 4.36). 
 A flame-dried flask containing 4.34 (24.1 mg, 0.748 mmol) was charged 
with flame-dried 4Å molecular sieves and MeCN (1 mL). NCS 
(recrystallized from toluene, 10.0 mg, 0.746 mmol) was then added as a 
solution in MeCN (1 mL) dropwise. After stirring in the dark at room temperature for 5.5 hours, more NCS 
(5.0 mg, 0.37 mmol, 0.50 equiv) was added as a solution in MeCN (0.5 mL). After stirring an additional 40 
minutes, the reaction was quenched with aqueous Na2S2O3 (10 wt %,1 mL) and the organic layer was washed 
with brine (2 x 3 mL), dried (Na2SO4), filtered, and concentrated. The residue was combined with MeCN (2 
mL), H2O (2 mL) and SiO2 (2 mL), then stirred open to air at room temperature for 30 minutes. The mixture 
was then filtered with EtOAc (20 mL) and the aqueous layer was extracted with EtOAc (2 x 2 mL). The 
combined organic layers were concentrated and purification by silica gel column chromatography (10–15% 
EtOAc in hexanes) afforded the product (10.3 mg, 41%) as a yellow oil (note: by then exchanging the column 
solvent to 2% MeOH in DCM, 6.0 mg (25%) of the starting material, 4.34 could be recovered).  4.35, 436 was 
isolated as a 1.3:1 mixture favoring the exo diastereomer as determined by 1H NMR. Optical rotation, HRMS, 
and spectral data are reported for the mixture of diastereomers. The relative stereochemistry and respective 
1H and 13C NMR data for each diastereomer was determined by 2D NMR analysis and by comparison to the 
1H NMR spectrum of re-isolated endo diastereomer (4.35) in the subsequent saponification step generating 
exo-3a-hydroxypyrroloindoline carboxylic acid (4.13). 1H NMR (500 MHz, CDCl3) δ  7.47 – 7.28 (m, 4Hexo, 
4Hendo), 7.26 – 7.08 (m, 3Hexo, 3Hendo), 6.73 (ddd, J = 7.4, 7.4, 1.0 Hz, 1Hexo), 6.64 (ddd, J = 7.4, 7.4, 1.0 Hz, 
1Hendo), 6.46 (dd, J = 8.3, 0.8 Hz, 1Hexo), 6.43 (d, J = 7.9 Hz, 1Hendo), 3.97 (d, J = 8.3 Hz, 1Hendo), 3.76 (s, 3Hexo), 
3.42 (dd, J = 11.2, 5.4 Hz, 1Hexo), 3.24 (s, 3Hendo), 2.91 (s, 3Hendo), 2.80 (s, 3Hexo), 2.79 (s, 3Hendo), 2.73 (dd, J = 
12.4, 1.0 Hz, 1Hendo), 2.59 (dd, J = 11.9, 5.4 Hz, 1Hexo), 2.53 (dd, J = 12.3, 8.5 Hz, 1Hendo), 2.41 (s, 3Hexo), 2.31 
(dd, J = 11.6, 11.6 Hz, 1Hexo), 1.43 (s, 1Hexo), 1.31 (s, 1Hendo).; 13C NMR (125 MHz, CDCl3) δ 173.9endo, 173.3exo, 
151.7exo, 151.5endo, 137.6endo, 136.9exo, 130.6endo, 130.3exo, 129.5exo, 128.8endo,exo, 128.5endo, 128.4exo, 128.2endo, 
124.3endo, 124.0exo, 117.2exo, 116.6endo, 104.9endo, 104.6exo, 98.2exo, 95.9endo, 88.9endo, 88.0exo, 64.2endo, 63.4exo, 
52.0exo, 51.2endo, 43.7exo, 41.3endo, 34.9exo, 34.8endo, 33.9exo, 31.6endo.; FTIR (NaCl/thin film): 3467, 2920, 2850, 
1750, 1734, 1609, 1494, 1447, 1375, 1311, 1202, 1101 cm-1; [α]D25 = +33.2º (c = 0.55, CHCl3). HRMS (MM) 
calc’d for C20H23N2O3 [M+H]+ 339.1703, found 339.1715. 
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exo-hydroxypyrroloindoline carboxylic acid (4.13). 
 A solution of the 1.3:1 mixture of hydroxypyrroloindoline methyl esters 4.35, 4.36  (5.5 mg, 
16 µmol, 1.0 equiv) in THF (0.5 mL) was cooled to 0 °C in an ice bath. LiOH (3.9 mg, 0.16 
mmol, 10 equiv) was then added as a solution in H2O (0.5 mL). After stirring 2.5 hours at 0 
°C, the reaction was quenched with 3 drops 3 M HCl, diluted with H2O (3 mL), and extracted 
with EtOAc (3 x 4 mL). The combined organic layers were washed with brine (10 mL), dried (Na2SO4), filtered, 
and concentrated. Purified by silica gel column chromatography (10% EtOAc:hexanes then 2–10% MeOH in 
CH2Cl2) afforded the product (1.4 mg, 47% based on 4.36) as a yellow oil and 1.2 mg (50% recovery) of 4.35. 
The enantiomeric excess of 4.13 was determined to be 82% by chiral SFC analysis (OJ-H, 2.5 mL/min, 20% IPA 
in CO2, λ = 254 nm): tR(major) = 2.4 min tR(minor) = 3.3 min. [α]D25 = -99.0° (c = 0.14, MeCN). 1H NMR (500 
MHz, CDCl3) δ 7.66 – 7.26 (m, 7H), 6.77 (ddd, J = 7.4, 7.4, 0.9 Hz, 1H), 6.50 (ddd, J = 7.6, 0.8, 0.8 Hz, 1H), 3.44 
(dd, J = 10.9, 6.0 Hz, 1H), 2.80 (s, 3H), 2.70 (dd, J =12.4, 6.0 Hz, 1H), 2.48 (s, 3H), 2.34 (dd, J = 12.4, 10.9 Hz, 
1H), 1.51 (br s, 1H). 
N-Cbz-N-methyltryptophol (4.37). 
A solution of 4.31 (305 mg, 0.69 mmol) in THF (11 mL) was prepared in a flame-dried flask and 
cooled to –30 °C using a Neslab CC 100 cryocool.  The flask was then charged with 4-
methylmorpholine (111 µL, 1.01 mmol), followed by methyl chloroformate (59 µL, 0.69 mmol). 
The reaction solution was then warmed to –10 °C and stirred for 30 minutes, then cooled to -
30 °C. NaBH4 (78 mg, 2.07 mmol) was then added, followed by dropwise addition of wet MeOH 
(0.7 mL) over 10 minutes and subsequent warming to –20 °C. After stirring for 1 hour at –20 °C, the reaction 
mixture was allowed to warm to room temperature and quenched with saturated aqueous NH4Cl (5 mL). The 
aqueous layer was extracted with EtOAc (2 x 5 mL) and the combined organic layers were washed with 
saturated aqueous NaHCO3 (2 x 4 mL), brine (2 x 5 mL), dried (Na2SO4), filtered and concentrated. Purified by 
silica gel column chromatography (0–1% MeOH in DCM) afforded the product (222 mg, 75%) as a light yellow 
oil. 1H NMR (500 MHz, CDCl3, compound exists as a 1:1 mixture of rotamers) δ 7.73 (d, J = 7.9 Hz, 0.5H), 7.54 
(d, J = 8.0 Hz, 0.5H), 7.51 – 7.26 (m, 11H), 7.22 – 7.15 (m, 0.5H), 7.14 – 7.02 (m, 1.5H), 5.08 (d, J = 12.5 Hz, 
0.5H), 5.00 (d, J = 12.5 Hz, 0.5H), 4.90 (d, J = 12.2 Hz, 0.5H), 4.85 (d, J = 12.3 Hz, 0.5H), 4.54 – 4.43 (m, 0.5H), 
4.29 – 4.18 (m, 0.5H), 3.66 (dd, J = 11.8, 3.5 Hz, 0.5H), 3.60 – 3.44 (m, 5.5H), 3.08 (dd, J = 14.4, 7.1 Hz, 0.5H), 
2.97 (dd, J = 14.4, 7.5 Hz, 0.5H), 2.88 (d, J = 7.2 Hz, 1H), 2.61 (s, 1.5H), 2.58 (s, 1.5H).; 13C NMR (125 MHz, 
CDCl3; compound exists as a 1:1 mixture of rotamers) δ 157.0, 156.7, 138.7, 138.6, 137.0, 136.7, 136.5, 131.7, 
131.6, 130.6, 130.5, 128.8, 128.6, 128.5, 128.44, 128.38, 128.36, 128.29, 128.25, 128.2, 127.9, 127.81, 
127.80, 127.7, 127.5, 127.3, 121.8, 119.53, 119.45, 118.9, 118.7, 109.40, 109.36, 109.3, 109.2, 108.7, 67.1, 
66.9, 63.2, 62.52, 60.50, 58.3, 31.5, 30.8, 30.7, 28.8, 24.3, 23.9.; FTIR (NaCl/thin film): 3436, 3056, 2936, 1699, 
1694, 1683, 1470, 1455, 1443, 1404, 1366, 1339, 1237, 1216, 1143 cm-1; [α]D25 = –39.6° (c = 2.02, CHCl3). 
HRMS (ESI) calc’d for C27H29N2O3 [M+H]+ 429.2173, found 429.2175.  
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(S)-3-(1-methyl-2-phenyl-1H-indol-3-yl)-2-(methylamino)propan-1-ol (4.38). 
A solution of 4.37 (174 mg, 0.4 mmol) in DCM (8 mL) was prepared in a flame-dried flask. 
Et3SiH (2.6 mL, 16.3 mmol) and Et3N (0.11 mL, 0.8 mmol) were then added, followed by 
Pd2(dba)3•CHCl3 (84 mg, 81 µmol). The dark red reaction solution was stirred for 17.5 hours at 
room temperature, then filtered through celite with EtOAc (60 mL), washed with saturated 
aqueous NaHCO3 (2 x 20 mL), brine (2 x 15 mL), dried (Na2SO4), filtered and concentrated. 
Purification by silica gel column chromatography (0–1% MeOH in DCM) afforded the product (110 mg, 92%) 
as white crystals. 1H NMR (300 MHz, CDCl3) δ 7.65 (dddd, J = 7.9, 1.2, 0.8, 0.3 Hz, 1H), 7.54 – 7.36 (m, 5H), 
7.36 (ddd, J = 8.1, 0.9, 0.9 Hz, 1H), 7.27 (ddd, J = 8.2, 6.9, 1.2 Hz, 1H), 7.17 (ddd, J = 8.0, 6.9, 1.2 Hz, 1H), 3.58 
(s, 3H), 3.55 (dd, J = 10.7, 3.5 Hz, 1H), 3.21 (dd, J = 10.8, 4.9 Hz, 1H), 2.99 (dd, J = 16.4, 9.3 Hz, 1H), 2.84 – 2.74 
(m, 2H), 2.25 (s, 3H), 1.93 (br s, 2H).; 13C NMR (125 MHz, CDCl3) δ 139.0, 137.0, 131.8, 130.63, 130.61, 128.60, 
128.59, 128.3, 127.8, 121.8, 119.5, 118.9, 109.4, 109.2, 62.3, 61.3, 33.6, 30.8, 26.1.; FTIR (NaCl/thin film): 
3306, 3054, 2920, 2852, 2799, 1468, 1442, 1365, 1334, 1237, 1066, 1013 cm-1; [α]D25 = +13.3° (c = 1.10, CHCl3). 
HRMS (ESI) calc’d for C19H23N2O [M+H]+ 295.1805, found 295.1810. 
(S)-N-methyl-1-(1-methyl-2-phenyl-1H-indol-3-yl)-3-((triethylsilyl)oxy)propan-2-amine (4.39). 
 To a solution of 4.38 (52 mg, 0.177 mmol) in THF (2.5 mL) at 0 ⁰C was added was added 
Et3N (49 µL, 0.35 mmol), DMAP (4.3 mg, 35 µmol) followed  by dropwise addition of TESCl 
(59 µL, 0.35 mmol). The reaction was allowed to warm to room temperature over 1 hour, 
then stirred an additional 2 hours. The reaction was quenched with saturated aqueous 
NaHCO3 (3 mL). The aqueous layer was extracted with EtOAc (2 x 3 mL) and the combined 
organic phases were washed with brine (2 x 6 mL), dried (Na2SO4) and concentrated. Purification by silica gel 
column chromatography (0–4% MeOH in DCM) afforded the product (52 mg, 71%) as a yellow oil. 1H NMR 
(500 MHz, CDCl3) δ 7.68 (d, J = 7.9 Hz, 1H), 7.51 – 7.44 (m, 3H), 7.44 – 7.35 (m, 2H), 7.33 (d, J = 8.2 Hz, 1H), 
7.25 (ddd, J = 8.2, 7.0, 1.3 Hz, 1H), 7.15 (ddd, J = 7.9, 7.0, 1.0 Hz, 1H), 3.57 (s, 3H), 3.43 (dd, J = 10.0, 4.4 Hz, 
1H), 3.34 (dd, J = 10.0, 6.3 Hz, 1H), 2.93 (dd, J = 13.5, 5.1 Hz, 1H), 2.85 – 2.71 (m, 2H), 2.33 (s, 3H), 0.86 (t, J = 
8.0 Hz, 9H), 0.49 (q, J = 8.0 Hz, 5H); 13C NMR (126 MHz, CDCl3) δ 138.8, 137.0, 131.9, 130.6, 130.6, 128.4, 
128.1, 127.9, 121.7, 119.2, 119.1, 109.8, 109.2, 64.6, 62.4, 34.1, 30.8, 25.8, 6.7, 4.3; FTIR (NaCl/thin film): 
3057, 2952, 2908, 2873, 2799, 1602, 1466, 1362, 1332, 1238, 1095, 1014, 972, 819 cm-1; [α]D25 = +16.7° (c = 
2.59, CHCl3). 
(3S,4R)-4-(sec-butyl)-3-methyloxetan-2-one (4.51). [202] 
General procedure for 2+2 cycloaddition 
 A flame dried 25 mL flask was charged with LiClO4 (492 mg, 4.62 mmol) (transferred in a 
glovebox), then dissolved in Et2O (1.4 mL) under vigorous stirring. TMS protected quinidine (55.5 mg, 0.14 
mmol) in 2.8 DCM was added and the reaction was cooled to – 40 ⁰C where after anhydrous DIPEA (0.61 mL, 
3.5 mmol) was added followed by 2-methylbutyraldehyde (0.15 mL, 1.4 mmol). Propionyl chloride (0.24 mL, 
2.8 mmol) in 0.7 mL DCM was then added over 6 hours and the reaction was stirred for another 6 hours. The 
reaction was then quenched with Et2O (10 mL) and the reaction allowed to warm to room temperature. The 
mixture was filtered on SiO2 (5mL) with Et2O (3 x 20 mL). The crude residue was purified by silica gel 
chromatography (gradient elution, 8 –15% EtOAc in hexanes) to give the product as a clear oil. 
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methyl (tert-butoxycarbonyl)-L-phenylalaninate (4.60).[220] 
To a solution of L-Phe-OMe (1.52 g, 7.03 mmol) in DCM (50 mL) at 0 ⁰C was added anhydrous 
DIPEA (1.59 mL, 9.14 mmol) followed by di-tert-butyl dicarbonate (2.1 mL, 9.14 mmol). The 
reaction was allowed to warm to room temperature overnight, then washed with 1M HCl (2 
x 50 mL), NaHCO3,(2 x 50 mL), brine (2 x 50 mL), dried (Na2SO4) and concentrated. Purification by silica gel 
chromatography (0–10% EtOAc in hexanes) afforded the product (1.96 g, >99% yield) as a clear oil. 1H NMR 
(300 MHz, CDCl3) δ 7.37 – 7.19 (m, 3H), 7.19 – 7.06 (m, 2H), 4.99 (d, J = 7.6 Hz, 1H), 4.59 (dd, J = 13.7, 6.7 Hz, 
1H), 3.72 (s, 3H), 3.09 (qd, J = 13.9, 6.0 Hz, 2H), 1.42 (s, 9H). 
(S)-tert-butyl (3-hydroxy-3-methyl-1-phenylbutan-2-yl)carbamate (4.61).[221] 
To a solution of 4.60 (477 mg, 1.7 mmol) in THF (2 mL) at 0 ⁰C was added MeMgBr (3 M in 
Et2O, 2.3 mL, 6.8 mmol) over 30 min then stirred overnight. The reaction was diluted with 7 
mL THF, then quenched by dropwise addition of MeOH (1 mL) followed by H2O (1 mL). The 
reaction mixture was diluted with EtOAc (10 mL) and the organic phase was filtered on Celite with EtOAc (2 
x 10 mL). The combined filtrates were evaporated and redissolved in Et2O (10 mL), filtered on Celite and 
concentrated again to give the product (448 mg, 94%) of as white crystals. 1H NMR (300 MHz, CDCl3) δ 7.34 
– 7.12 (m, 5H), 4.58 (d, J = 9.4 Hz, 1H), 3.76 – 3.62 (m, 1H), 3.09 (dd, J = 14.2, 3.6 Hz, 1H), 2.60 (dd, J = 14.2, 
11.1 Hz, 1H), 2.34 (brs, 1H), 1.31 (s, 6H), 1.30 (s, 9H). 
 (S)-4-benzyl-5,5-dimethyloxazolidin-2-one (4.62).[221] 
To a solution of 4.61 (905 mg, 3.24 mmol) in THF (20 mL) at 0 ⁰C was added potassium t-butoxide 
(440 mg, 3.92 mmol) in one portion. The yellow reaction was stirred for 30 min, then quenched with 
saturated aqueous NH4Cl (15 mL). The aqueous phases were extracted with EtOAc (3 x 15 mL) and 
the combined organic phases were washed with brine (2 x 15 mL), dried (Na2SO4) and concentrated. 
Purification by silica gel chromatography (0–1% MeOH/DCM with 2% NH4OH) afforded the product (539 mg, 
81%) as white needle crystals. 1H NMR (300 MHz, CDCl3) δ 7.40 – 7.13 (m, 5H), 4.73 (brs, 1H), 3.68 (ddd, J = 
10.9, 3.7, 0.7 Hz, 1H), 2.84 (dd, J = 13.3, 3.7 Hz, 1H), 2.66 (dd, J = 13.3, 10.9 Hz, 1H), 1.49 (s, 3H), 1.46 (s, 3H). 
(S)-4-benzyl-5,5-dimethyl-3-propionyloxazolidin-2-one (4.55). [222] 
To 4.62 (102 mg, 0.496 mmol) in THF (5 mL) at –78 ⁰C was added n-BuLi (2.5 M, 208 µL, 0.52 
mmol) dropwise. The reaction was stirred for 30 min where after propionyl chloride (46 µl, 0.52 
mmol) was added dropwise. After stirring for 10 min at -78 ⁰C, the reaction was allowed to warm 
to room temperature and stirred for another 3 hours. The reaction was quenched with saturated 
aqueous NH4Cl (2 mL) and extracted with EtOAc (3x 2 mL). The combined organic phases were washed with 
NaHCO3 (2 x 6 mL), brine (2x6 mL), dried (Na2SO4) and concentrated. Purification by silica gel chromatography 
(6% EtOAc in hexanes) afforded the product (105 mg, 81% yield) as white needle crystals. 1H NMR (300 MHz, 
CDCl3) δ 7.39 – 7.16 (m, 5H), 4.51 (dd, J = 9.5, 3.9 Hz, 1H), 3.15 (dd, J = 14.3, 3.9 Hz, 1H), 3.01 – 2.79 (m, 3H), 
1.37 (s, 3H), 1.36 (s, 3H), 1.14 (t, J = 7.4 Hz, 3H). 
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(S)-4-benzyl-3-((2S,3S)-3-hydroxy-2-methyl-4-methylenehexanoyl)-5,5-dimethyloxazolidin-2-one (4.54).[223] 
To a solution of 4.55 (49 mg, 0.19 mmol) in CH2Cl2 (4 mL) at 0 ⁰C was added n-Bu2BOTf (1M 
in CH2Cl2, 210 µL, 0.21 mmol) dropwise. After 30 min, freshly distilled DIPEA (58 µL, 0.33 
mmol) was added dropwise and the reaction was stirred for another 30 min. The reaction 
was then cooled to –78 ⁰C, stirred for 30 min where after 2-ethyl acrolein was added 
dropwise. The reaction was allowed to warm to room temperature overnight. The reaction was quenched 
with a pH=7 buffer (2 mL) and a mixture of H2O2/MeOH (1:2, 2 mL). After stirring for 1 hour, the mixture was 
concentrated, then dissolved in CH2Cl2 (8 mL). The aqueous phase was extracted with CH2Cl2 (2x2 mL) and 
the combined organic phases were washed with NaHCO3 (2x10 mL), brine (2x10mL), dried (Na2SO4) and 
concentrated. Purification by silica gel chromatography (0–1% MeOH in CH2Cl2) afforded the product (43 mg, 
67%) as a clear oil. 1H NMR (500 MHz, CDCl3) δ 7.38 – 7.17 (m, 5H), 5.17 – 5.14 (m, 1H), 4.99 – 4.97 (m, 1H), 
4.54 (dd, J = 9.1, 4.4 Hz, 1H), 4.40 (brs, 1H), 3.96 (dtd, J = 10.6, 7.0, 3.5 Hz, 1H), 3.08 (dd, J = 14.3, 4.4 Hz, 1H), 
2.91 (dd, J = 14.3, 9.1 Hz, 1H), 2.77 (brs, 1H), 2.14 – 1.92 (m, 2H), 1.40 (s, 3H), 1.38 (s, 3H), 1.11 (d, J = 7.0 Hz, 
3H), 1.07 (t, J = 7.4 Hz, 3H). dr (94:6) determined by NMR. 
(S)-4-benzyl-3-((2S,3R,4R)-3-hydroxy-2,4-dimethylhexanoyl)-5,5-dimethyloxazolidin-2-one (4.53).[203] 
To a solution of 4.54 (94 mg, 0.27 mmol) in degassed CH2Cl2 (4.5 mL) (in a glass inlet in the 
glovebox) was added [Rh(NBD)(DIPHOS-4)BF4]. The reaction was then sealed in a pressure 
chamber and removed from the glovebox. The reaction was pressurized to 100 psi H2 then 
flushed to replace any O2 leftovers. The reaction was then pressurized to 460 psi and stirred 
for 1 hour. The crude mixture was filtered on a short SiO2 column with a 50:50 mixture of EtOAc/hexanes to 
give the product (76 mg, 80%) as a clear oil. 1H NMR (500 MHz, CDCl3) δ 7.41 – 7.14 (m, 5H), 4.54 (dd, J = 9.0, 
4.6 Hz, 1H), 3.92 (qd, J = 7.0, 2.5 Hz, 1H), 3.58 (dd, J = 8.9, 2.5 Hz, 1H), 3.06 (dd, J = 14.3, 4.6 Hz, 1H), 2.91 (dd, 
J = 14.3, 9.0 Hz, 1H), 1.86 – 1.70 (m, 1H), 1.54 – 1.45 (m, 2H), 1.40 (s, 3H), 1.38 (s, 3H), 1.15 (d, J = 7.1 Hz, 3H), 
0.90 (t, J = 7.4 Hz, 3H), 0.86 (d, J = 6.8 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 178.4, 152.2, 136.7, 129.2, 128.8, 
127, 82.4, 75, 63.4, 39.8, 37, 35.6, 28.6, 25.2, 22.4, 14.9, 11, 10.2. dr (83:11:6). 
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ABSTRACT: Cyclic tetrapeptide and depsipeptide natural
products have proven useful as biological probes and drug
candidates due to their potent activities as histone deacetylase
(HDAC) inhibitors. Here, we present the syntheses of a class
of cyclic tetrapeptide HDAC inhibitors, the azumamides, by a
concise route in which the key step in preparation of the
noncanonical disubstituted β-amino acid building block was an
Ellman-type Mannich reaction. By tweaking the reaction
conditions during this transformation, we gained access to the
natural products as well as two epimeric homologues. Thus,
the ﬁrst total syntheses of azumamides B−D corroborated the
originally assigned structures, and the synthetic eﬀorts enabled the ﬁrst full proﬁling of HDAC inhibitory properties of the entire
selection of azumamides A−E. This revealed unexpected diﬀerences in the relative potencies within the class and showed that
azumamides C and E are both potent inhibitors of HDAC10 and HDAC11.
■ INTRODUCTION
Macrocyclic peptides have played important roles in the ﬁeld of
epigenetics due to their potent activities as inhibitors of histone
deacetylase (HDAC) enzymes. One of the two HDAC target-
ing drugs (11 and 3) that are approved by the U.S. Food and
Drug Administration (FDA) for clinical treatment of cutaneous
T-cell lymphoma is the macrocyclic natural product romidepsin
(3).2 Furthermore, a cyclic tetrapeptide, trapoxin,3 played an
instrumental role in the ﬁrst isolation of a mammalian HDAC
enzyme.4,5 Thus, this class of inhibitors holds promise as tool
compounds as well as potential drug candidates targeting
HDACs.6−9
Though clearly bearing an overall resemblence to the classical
cyclic tetrapeptide HDAC inhibitors [including, for example,
apicidin (4)],10 the azumamides (5−9) are structurally unique
in that their extended Zn2+-coordinating amino acid (shown in
yellow in Figure 1) is a disubstituted β-amino acid.11 Further-
more, we found the azumamides interesting due to the relatively
strong potencies reported for azumamide E against class I
HDACs12 in spite of its weak Zn2+-coordinating carboxylic acid
functionality.13 Previously, azumamide A14,15 and azumamide
E12,14−16 have been prepared by multistep chemical syntheses,
but only azumamide E was tested against recombinant HDAC
isoforms 1−9.12 Furthermore, in vitro proﬁling with recombi-
nant HDACs has witnessed important new developments since
the publication of those results.17,18 We therefore found it
relevant to explore the properties of these macrocycles in more
detail by preparing the complete selection of natural products
(5−9), and proﬁling their activities against the full panel of
recombinant human Zn2+-dependent HDAC enzymes, HDAC1−11.
As total syntheses of azumamides B−D had not been reported
previously, this work would also allow unequivocal validation of
the proposed structures.11
For syntheses of the azumamides, we envisaged two
signiﬁcant challenges: ﬁrst, eﬃcient stereoselective synthesis
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Figure 1. Structures of archetypical HDAC inhibitors (1−4) and
target azumamides 5−9.
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of the disubstituted β-amino acid, and second, the macro-
cyclization step, which is known to be diﬃcult for small cyclic
peptides in general19 and furthermore proved challenging in
previously reported syntheses of azumamide analogues.12
■ RESULTS AND DISCUSSION
Building Block Synthesis. For our synthesis of the β-amino
acid building block, we chose a diastereoselective Ellman-type
Mannich reaction to set the stereochemistry, as also previously
reported by Ganesan and co-workers.15 However, to avoid having
this important transformation at a late stage in our synthetic route,
we decided to optimize this reaction between a propionate ester
and a simple imine as shown in eq 1.
This should give an intermediate with the correct stereo-
chemistry (2S,3R), which could be readily elaborated to give
the desired β-amino acid by robust organic synthetic trans-
formations (vide infra). Mannich reactions between ester
enolates and chiral sulﬁnylimines have been studied exten-
sively,20,21 and using previously reported conditions as our
starting point we conducted an optimization study as outlined
in Table 1. The tert-butyl ester showed superior selectivity
(entry 5) compared to the less bulky methyl, ethyl, allyl, and
PMB esters (entries 1−4), and furthermore, the methyl ester
did not proceed to completion in our hands. Somewhat
surprisingly, however, the major diastereoisomer in entry 5
proved to have (2S,3S) conﬁguration as determined by X-ray
crystallography upon desilylation (Figure 2).
This indicates that the pathway leading to our major isomer
did not proceed through the six-membered Zimmerman−
Traxler-type transition state,22 which has been proposed to be
responsible for the diastereoselectivity with similar sub-
strates.20,23 By using HMPA as an additive instead of a Lewis
acid, this reaction has previously been shown to proceed
through a diﬀerent transition state,20 and indeed we saw the
same product distribution when using HMPA and TiCl(OiPr)3
as additives with our substrates (entries 5 and 6). This indicates
that the six-membered transition state, where coordination of
titanium is crucial, is highly unlikely to play a signiﬁcant role in
the formation of our major isomer. This is not in agreement
with the diastereoselectivities observed with the substrates reported
by Ganesan and co-workers.15 Thus, to address whether the steric
bulk of the triisopropylsilyl ether was responsible for interrupting
the six-membered transition state, we performed the reaction with
diﬀerent means of protecting the alcohol (entries 7−9). No
signiﬁcant eﬀect was observed, however, indicating instead that the
steric bulk of the tert-butyl ester caused the predominance of a
diﬀerent transition state when using our substrates. This is also in
agreement with the original study by Tang and Ellman20 where the
level of selectivity decreased for 2,3-disubstituted β-amino acids
when the bulk of the ester increased from methyl to tert-butyl.
Because we were interested in taking advantage of solid-
phase synthesis methods to prepare the linear tetrapeptide
azumamide precursors with a minimum of chromatographic
puriﬁcation steps, we were keen on keeping the acid-labile tert-
butyl ester protecting group, which would allow easy protecting
group manipulation to give an Fmoc-protected β-amino acid
building block. Hence, instead of substituting this protecting
group, we decided to optimize the Mannich reaction conditions
to deliver the desired stereochemistry. First, we changed the
stereochemistry of the sulﬁnylimine to the R-enantiomer, which
expectedly furnished the enantiomer of entries 5−9 (2R,3R) as
the major isomer (entry 10). We then hypothesized that the
conﬁguration of the 2-position would be sensitive to the E/Z
conﬁguration of the enolate. Using Ireland’s conditions for
forming the enolate in the presence of HMPA,24,25 we achieved
>80% Z-isomer, which gratifyingly aﬀorded the (2S,3R)
product as major isomer (entry 11). Under the developed
conditions, we prepared compound 12, which was further
elaborated to give Fmoc-protected β-amino acid 16 in 15%
overall yield with just four column chromatographic puriﬁcation
steps from compound 10 (Scheme 1).
Table 1. Optimization of Stereochemical Outcome of the Mannich Reaction Shown in Equation 1
entry auxiliary* R1 R2 additive enolatea drb major isomer
1 R Me OSi(iPr)3 TiCl(O
iPr)3 E 47:39:10:4 ND
c
2 R Et OSi(iPr)3 TiCl(O
iPr)3 E 49:29:11:11 ND
3 R allyl OSi(iPr)3 TiCl(O
iPr)3 E 46:34:10:10 ND
4 R PMB OSi(iPr)3 TiCl(O
iPr)3 E 46:33:11:10 ND
5 R tBu OSi(iPr)3 TiCl(O
iPr)3 E 60:26:8:6 (2S,3S)
d
6 R tBu OSi(iPr)3 HMPA E 71:15:14:0 (2S,3S)
7 R tBu OBn TiCl(OiPr)3 E 70:18:12:0 ND
8 R tBu OPMB TiCl(OiPr)3 E 77:13:10:0 (2S,3S)
9 R tBu OSi(Et)3 TiCl(O
iPr)3 E 75:21:4:0 (2S,3S)
d
10 S tBu OSi(iPr)3 HMPA E 77:18:5:0 (2R,3R)
e
11 S tBu OSi(iPr)3 HMPA
f Z 64:25:8:2 (2S,3R)g
aMajor conﬁguration of the enolate as determined by NMR and by trapping with tBuMe2SiCl.
bDiastereomeric ratio determined by 1H NMR.
cND = not determined. dDetermined by X-ray crystallography on its desilylated homologue. eDetermined spectroscopically by comparison with its
enantiomer from entries 5 and 9. fHMPA (5.4 equiv) was added prior to the substrate to obtain the (Z)-enolate (>80%). gDetermined by
comparison of spectroscopic data of the fully elaborated Boc-protected β-amino acid with previously reported data.12
Figure 2. X-ray crystal structure of the (2S,3S) precursor obtained by
desilylation of the major product in entry 5 of Table 1.
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The Boc-protected homologue of 16 was also prepared to
conﬁrm the (2S,3R) stereochemistry by comparison of
spectroscopic data (optical rotation and NMR) with those
previously reported (Figure S1 in Supporting Information).12
Furthermore, the β2- and β3-epimeric building blocks were
prepared by elaboration of the major isomers from entries 10
and 5, respectively (see Supporting Information for details).
Although the achieved diastereomeric ratios were not par-
ticularly impressive, this strategy very nicely provided the
correct stereochemistry along with two novel β-amino acids,
enabling investigation of the biochemical eﬀect of stereo-
chemical conﬁguration at these two chiral centers.
Cyclic Peptide Synthesis. Because three diﬀerent points of
cyclization had been reported for azumamide E and since these
were all performed with diﬀerent coupling reagents,12,14,15 we
performed cyclization experiments using a simpliﬁed model
peptide to address the issue. Not too surprisingly, this showed
that macrolactamizations with the most sterically hindered
amino acids at the C-terminal were particularly poor, resulting
in signiﬁcant amounts of N-terminal guanidinylation, incom-
plete cyclization, epimerization, and/or dimerization (Table S1
in Supporting Information). Thus, we prepared the linear
tetrapeptides 17, 19, and 21 on solid support by standard Fmoc
solid-phase synthesis using β-amino acid 16 and commercially
available Fmoc-D-amino acids.
In Scheme 2A, the cyclization was then performed at the
β-amino acid position and in Scheme 2B at the alanine residue,
whereas the preparation of azumamide D (8) was achieved by
cyclization between the two least sterically challenging alanine
residues (Scheme 2C). After cleavage from the 2-chlorotrityl
polystyrene resin with dilute TFA, the linear tetramers were
ring-closed by use of HATU under dilute conditions (0.4−
0.5 mM),26−29 and furthermore slow addition of the linear
peptide by syringe pump to a solution of Hünig’s base and
HATU, as described by Ganesan and co-workers,15 was tested.
Judging from LC−MS analyses of the reaction mixtures, we
could not observe any signiﬁcant diﬀerences between the cycliza-
tion yields obtained with the diﬀerent methods. Although all
the couplings proceeded satisfactorily, with full conversion of
linear peptides and minor amounts of the corresponding dimers
as the only observed byproducts, the resulting overall isolated
yields were relatively low (∼10%). We ascribe this to diﬃculties
during puriﬁcation of the macrocyclic products by preparative
reversed-phase HPLC caused by poor water solubility, as we
were able to recover more material by purifying the macrocycles
by column chromatography. Unfortunately, however, this did
not provide the ﬁnal compounds in satisfyingly high purity for
the bioassays, and thus the ﬁnal compounds were all subjected
to preparative reversed-phase HPLC puriﬁcation although this
resulted in a loss of material. Carbodiimide-mediated amidation
of the side chain was attempted for conversion of 7 to 6 and 23
to 8, but the reaction was slow and gave varying yields (6 vs 8,
Scheme 2). Instead, HATU-mediated coupling was attempted
for conversion of 9 to 5, and this proved faster and gave an
acceptable yield (5). Spectral data of all the natural products
5−9 were in excellent agreement with those originally reported
for the azumamides isolated from natural sources,5 thus
corroborating the original structural assignment (Figures S2−S6
in Supporting Information). Finally, the two epimeric β-amino
acid building blocks were applied in analogous syntheses of
β3-epi-azumamide E (26) and β2-epi-azumamide E (29) as
shown in Scheme 3.
HDAC Screening. As an initial test of the HDAC inhibitory
potency of all seven compounds, we ﬁrst screened against the
full panel of recombinant human HDACs at two compound
concentrations (50 μM and 5 μM). Protocols for HDAC1−9
were adapted from Bradner et al.,18 using the ﬂuorogenic
Ac-LeuGlyLys(Ac)-AMC substrate for HDAC1−3 and 6 while
using the Ac-LeuGlyLys(tfa)-AMC substrate for HDAC4, 5,
and 7−9. For HDAC10 we used the tetrapeptide Ac-ArgThr-
Lys(Ac)Lys(Ac)-AMC,30 which was recently reported to
perform well with this enzyme.31 Finally, for HDAC11, we
also used Ac-LeuGlyLys(Ac)-AMC as substrate.32
The site-speciﬁcally epimerized compounds exhibited no
activity as previously reported for an analogue having both
stereocenters inverted.7 It was not surprising that 26 was
inactive, but it is noteworthy that the subtle change of inverting
the stereochemistry of a single methyl group in 29 had such a
detrimental eﬀect across the entire selection of enzymes
(Figure 3). Furthermore, none of the compounds 5−9 were
able to inhibit class IIa HDAC activity against a triﬂuoroacety-
lated substrate (Figure 3).
Inhibitor Ki Values. Next, we performed dose−response
experiments for all compound−HDAC combinations that gave
above 50% inhibition in the initial assay (Figure S7 and Table
S2 in Supporting Information). The obtained IC50 values were
converted to Ki values by use of the Cheng−Prusoﬀ equation
[Ki = IC50/(1 + [S]/Km)] with the assumption of a standard
fast-on−fast-oﬀ mechanism of inhibition. Reported Km values
were applied for the calculations except HDAC10, where we
determined the Km for the used substrate to be 1.5 ± 0.2 μM
(Figure 4).
Low potencies were recorded against HDACs 6 and 8, which
is in accordance with previous data for azumamide E (Table 2);6
however, compounds 7 and 9 were both potent inhibitors
of HDACs 10 and 11. Although they are classiﬁed together
Scheme 1. Synthesis of β-Amino Acid Building Block 16.a
aReagents and conditions: (a) HMPA (6.4 equiv), LDA (2.6 equiv),
11 (2.5 equiv), THF, −78 °C, 30 min; then 10, −78 °C, 30 min. (b)
AcOH (1.0 equiv), Bu4NF (2.0 equiv), THF, 0 °C → rt, 1.5 h. (c)
NaHCO3 (1.5 equiv), Dess−Martin periodinane (1.4 equiv), dry
CH2Cl2, 0 °C → rt, 1.5 h. (d) KHMDS (1.9 equiv), Ph3PBr-
(CH2)3COOEt (2.0 equiv), THF, −78 °C → rt, 18 h. (e) TFA−
CH2Cl2 (1:1, 10 mL, 80 equiv), 0 °C → rt, 3 h. (f) HCl (4.0 M in
dioxane, 3.0 equiv), dioxane, 3 h. (g) Na2CO3 (4.0 equiv), Fmoc-OSuc
(1.2 equiv), dioxane−H2O, 0 °C → rt, 2 h.
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(class IIb), HDACs 6 and 10 clearly interact very diﬀerently
with these inhibitors.
Generally, we found the compounds with a carboxylic acid
Zn2+-binding group (7 and 9) to be more potent than the
Scheme 3. Synthesis of the Two Epimers 26 and 29 of Azumamide E by Solid-Phase Synthesis Followed by Head-to-Tail
Macrolactamization in Solutiona
aReagents and conditions: (a) TFA−CH2Cl2 (1:1), 2 × 30 min. (b) HATU, iPr2NEt (8.0 equiv), DMF (0.3−0.7 mM peptide concn), 17−21 h. (c)
LiOH, THF−H2O (1:1).
Scheme 2. Synthesis of Azumamides A−E by Solid-Phase Synthesis Followed by Head-to-Tail Macrolactamization in Solutiona
aReagents and conditions: (a) TFA−CH2Cl2 (1:1), 2 × 30 min. (b) HATU, iPr2NEt (8.0 equiv), DMF (0.4−0.5 mM peptide concn), 17−21 h;
then HATU (0.5 equiv), 1−3 h [A, 11% 18 after preparative HPLC; B, 25% 20 after column chromatography; C, 19% 22 after column
chromatography]. (c) LiOH, THF−H2O (1:1). (d) DIC (11 equiv), HOBt (3.0 equiv), iPr2NEt (4.0 equiv), NH3−dioxane (25 equiv), DMF−
CH2Cl2 (2:1), 5 days, 67%. (e) HATU (2.0 equiv),
iPr2NEt (5.5 equiv), NH3−dioxane (25 equiv), DMF, 5.5 h, 40% (for steps c and e). (f) DIC
(6.0 equiv), HOBt (3.0 equiv), iPr2NEt (4.0 equiv), NH3−dioxane and NH3−MeOH (30 equiv), CH2Cl2−DMF (2:1), 13 days, 11% (for steps c and f).
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carboxamides (5, 6, and 8), which is in contrast to the originally
reported HDAC inhibition data obtained for the natural
products against an HDAC-containing cell extract.5 However,
the data presented herein agree with subsequent work from
Ganesan and co-workers15 on azumamide A (5) and azumamide
E (9). We thus show that this applies to all the azumamides,
which also conﬁrms that a carboxylate Zn2+-binding group
renders HDAC inhibitors signiﬁcantly more potent than a
corresponding carboxamide, as would be expected from
literature precendents.19,26,27 Furthermore, compound 7 was
more potent than 9 against HDACs 1−3, 6, 10, and 11, which
is also in contrast to the original evaluation that found azuE (9)
more potent than azuC (7) against crude enzymes from K562
cell extract.5 The tyrosine-containing compound (7) exhibited
∼2-fold higher potency against HDACs 1, 3, 6, 10, and 11,
whereas the phenylalanine-containing azumamide E (9) was only
more potent against HDAC8, albeit at micromolar Ki values.
Finally, the inhibition of HDAC11 by azumamides C (7) and
E (9) is, to the best of our knowledge, the ﬁrst demonstration
of potent cyclic peptide inhibitors of this isozyme.33 Notably,
these binding aﬃnities were achieved without the presence of a
strong Zn2+ chelator, such as hydroxamic acid.
■ CONCLUSIONS
In summary, we report total syntheses of all ﬁve azumamides,
including for the ﬁrst time azumamides B−D, which corro-
borate the originally proposed structures. Our synthetic route
furthermore enabled preparation of site-speciﬁcally edited
analogues for exploration of structure−activity relationships
(SAR).34−36 The HDAC proﬁling results show that the β-amino
acid residue, present in all the azumamides, is sensitive to even
slight modiﬁcations. In addition, the original HDAC testing
using cell extract indicated that azumamide E was the most
Figure 3. Single-dose HDAC inhibitory screening. Assays were per-
formed at 50 μM (shown) and 5 μM (not shown) peptide
concentrations. We chose <50% inhibition at 50 μM as our cutoﬀ to
sort away inactive compounds before performing full dose−response
experiments. All compound−enzyme combinations that were
discarded at this stage were tested in at least two individual assays
performed in duplicate. Error bars represent the standard deviation.
(*) Fusion protein of GST-tagged HDAC3 with the deacetylase
activation domain (DAD) of nuclear receptor corepressor (NCoR1).
Figure 4. Michaelis−Menten plot for HDAC10.
Table 2. Potencies of Azumamides against Zn2+-Dependent Histone Deacetylasesa
Ki values (nM)
class I class IIa class IIb class IV
compd HDAC1 HDAC2 HDAC3b HDAC8 HDAC4 HDAC5 HDAC7 HDAC9 HDAC6 HDAC10 HDAC11
5 (azuA) >5000 >5000 3200 >5000 52%c IAd IA IA IA IA >5000
6 (azuB) 5000 3000 3000 IA IA IA IA IA IA IA >5000
7 (azuC) 32 ± 1 40 ± 20 14 ± 1 >5000 IA IA IA IA 2000 10 ± 4 35 ± 3
8 (azuD) >5000 >5000 3700 IA IA IA IA IA IA IA >5000
9 (azuE) 67 ± 7 50 ± 30 25 ± 5 4400 IA IA IA IA >5000 20 ± 12 60 ± 16
26 (β3-epi-azuE) IA IA IA IA IA IA IA IA IA IA IA
29 (β2-epi-azuE) IA IA IA IA IA IA IA IA IA IA IA
1 (SAHA) 8 ± 1.5 7 ± 1.5 12 ± 4 700 ± 20 IA IA IA IA 22 ± 9 NTe 13 ± 2
3 (FK-228)f 0.002 0.038 0.15 0.15 20.5 550 1250 1100 10 NT NT
aIC50 values were determined from at least two individual dose−response experiments performed in duplicate (Figure S7 in Supporting
Information), and Ki values were calculated from the Cheng−Prusoﬀ equation.
bFusion protein of GST-tagged HDAC3 with deacetylase activation
domain NCoR1. cPercent inhibition at 50 μM inhibitor concentration. dIA = inactive (<50% inhibition at 50 μM [inhibitor], Figure 3). eNT = not
tested. fData from Bradner et al.18
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potent of the series, but the comprehensive proﬁling presented
herein shows that azumamide C is in fact ∼2-fold more potent
than azumamide E against the majority of the isozymes.
By taking advantage of the modular methodologies described
in this article and building on the gained SAR information, we
are currently investigating collections of azumamide analogues
in search of more potent and selective ligands based on this
promising scaﬀold.
■ EXPERIMENTAL SECTION
General. All chemicals and solvents were analytical-grade and were
used without further puriﬁcation. Vacuum liquid chromatography
(VLC) was performed on silica gel 60 (particle size 0.015−0.040 μm).
UPLC−MS analyses were performed on a Phenomenex Kinetex
column (1.7 μm, 50 × 2.10 mm) by use of a Waters Acquity ultra-
high-performance liquid chromatography system. A gradient with
eluent I (0.1% HCOOH in water) and eluent II (0.1% HCOOH in
acetonitrile) rising linearly from 0% to 95% II during t = 0.00−2.50
min was applied at a ﬂow rate of 1 mL/min (gradient A) or during
t = 0.00−5.20 min (gradient B). Analytical HPLC was performed on a
Phenomenex Luna column [150 mm × 4.6 mm, C18 (3 μm)] by use of
an Agilent 1100 LC system equipped with a UV detector. Gradient C,
with eluent III (0.1% TFA in water) and eluent IV (0.1% TFA in
acetonitrile) rising linearly from 0% to 95% IV during t = 2−20 min,
was applied at a ﬂow rate of 1 mL/min. Preparative reversed-phase
HPLC was performed on a Phenomenex Luna column [250 mm ×
20 mm, C18 (5 μm, 100 Å)] by use of an Agilent 1260 LC system
equipped with a diode-array UV detector and an evaporative light
scattering detector (ELSD). A gradient, with eluent V (95:5:0.1, water−
MeCN−TFA) and eluent VI (0.1% TFA in acetonitrile) rising linearly
from 0% to 95% IV during t = 5−45 min, was applied at a ﬂow rate of
20 mL/min. All tested compounds were puriﬁed to homogeneity and
shown by both analytical HPLC (gradient C) and LC−MS (gradient A)
to be of more than 95% purity. One- and two-dimensional NMR spectra
were recorded on a Varian Mercury 300 instrument or a Varian INOVA
500 MHz instrument. All spectra were recorded at 298 K. Correlation
spectroscopy (COSY) spectra were recorded with a relaxation delay of
1.5 s before each scan, a spectral width of 6k × 6k, and eight FIDs and
1k × 512 data points collected. Heteronuclear single quantum coherence
(HSQC) spectra were recorded with a relaxation delay of 1.5 s before
each scan, a spectral width of 6k × 25k, and 16 FIDs and 1k × 128 data
points collected. Heteronuclear two-bond correlation (H2BC) spectra
were recorded with a relaxation delay of 1.5 s before each scan, a spectral
width of 4k × 35k, and 16 FIDs at 295 K and 1k × 256 data points
collected. Heteronuclear multiple-bond correlation (HMBC) spectra
were recorded with a relaxation delay of 1.5 s before each scan, a spectral
width of 6k × 35k, and 32 FIDs and 1k × 256 data points collected.
Chemical shifts are reported in parts per million (ppm) relative to
deuterated solvent peaks as internal standards (δH, DMSO-d6 2.50 ppm;
δC, DMSO-d6 39.52 ppm, δH, CD3OH 3.30 ppm; δH, CDCl3 7.26 ppm;
δC, CDCl3 77.16 ppm). Coupling constants (J) are given in hertz (Hz).
Multiplicities of 1H NMR signals are reported as follows: s, singlet; d,
doublet; t, triplet; q, quartet; m, multiplet.
General Procedure for Mannich Reactions. A solution of LDA
(2.1 equiv) was added dropwise to a solution of the ester (2.0 equiv)
in dry THF at −78 °C. After the mixture was stirred for 30 min,
Ti(O-iPr)3Cl (4.2 equiv) in dry THF was added dropwise. The orange
solution was stirred for 30 min and the imine (1.0 equiv) in dry THF
was added dropwise. The mixture was stirred for 3 h or until thin-layer
chromatography (TLC) showed full conversion of the imine. The
mixture was quenched with saturated aqueous NH4Cl and allowed to
reach room temperature. Water was added and the mixture was
decanted into a separatory funnel. EtOAc−water (1:1) was added to
the remaining Ti precipitate, and the mixture was stirred vigorously for
5 min before being added to the separatory funnel. The aqueous phase
was extracted with EtOAc and the combined organic phases were
washed again with water, dried (MgSO4), ﬁltered, and concentrated in
vacuo.
Azumamide A, (Z)-6-[(2R,5R,8R,11R,12S)-8-Benzyl-2-iso-
propyl-5,12-dimethyl-3,6,9,13-tetraoxo-1,4,7,10-tetraazacy-
clotridecan-11-yl]hex-4-enamide (5). LiOH (89 mg, 3.72 mmol,
85 equiv) in water (4.0 mL) was added to a stirred solution of the
impure cyclic peptide 20 (24.2 mg, approximately 0.045 mmol) in
THF (4 mL). After 2.5 h of stirring, the organic solvent was removed
in vacuo. The aqueous phase was acidiﬁed with 1 M HCl to pH 2 and
extracted with EtOAc (4 × 30 mL) and CH2Cl2 (40 mL). The organic
phases were dried (Na2SO4), ﬁltered, and concentrated to aﬀord crude
azumamide E, which was used without further puriﬁcation. Analytical
UPLC−MS gradient A, tR = 1.47 min. To a solution of the above
crude azumamide E (≈0.045 mmol) in DMF (3.0 mL) were added
HATU (34 mg, 0.09 mmol, 2 equiv), iPr2NEt (43 μL, 0.25 mmol,
5.5 equiv), and, after 5 min, NH3−dioxane (0.9 mL, 0.45 mmol,
10 equiv). After 1 h, NH3−dioxane (0.45 mL, 0.23 mmol, 5 equiv)
was added. UPLC−MS analysis showed 50% conversion after 3 h, and
HATU (34 mg, 0.09 mmol, 2 equiv) and NH3−dioxane (0.45 mL,
0.23 mmol, 5 equiv) were added. After an additional 1 h, DMF
(1.0 mL) followed by HATU (17 mg, 0.045 mmol, 1 equiv) and
NH3−dioxane (0.45 mL, 0.23 mmol, 5 equiv) were added, and stirring
was continued for 1 h before concentration in vacuo. The residue was
dissolved in MeCN−H2O and puriﬁed by preperative HPLC to give
azumamide A (5) (4.8 mg, 12% overall). [α]D +56° (c = 0.2, MeOH);
previously reported11 [α]D +33° (c = 0.1, MeOH).
1H NMR (500 MHz,
CD3OH) δ 8.18 (d, J = 8.6 Hz, 1H), 8.16 (d, J = 9.0 Hz, 1H), 7.72
(d, J = 8.2 Hz, 1H), 7.59 (m, 2H), 7.20 (m, 5H), 6.74 (br s, 1H), 5.48
(m, 1H), 5.37 (m, 1H), 4.33 (dt, J = 9.0, 7.0 Hz, 1H), 4.24 (m, 2H),
3.81 (dd, J = 10.4 Hz and 8.4 Hz, 1H), 3.10 (m, 2H), 2.72 (m, 1H),
2.57 (dt, J = 14.1, 6.9 Hz, 1H), 2.41 (m, 2H), 2.27 (m, 4H), 1.30 (d,
J = 7.5 Hz, 3H), 1.23 (d, J = 7.3 Hz, 3H), 0.96 (d, J = 6.5 Hz, 3H), 0.94
(d, J = 6.7 Hz, 3H). HRMS (ESI-TOF) m/z calcd for C27H38N4O7H
+
514.3029; found 514.3032 [M + H]+. HPLC gradient C, tR = 11.62
min (>95%).
Azumamide B, (Z)-6-[(2R,5R,8R,11R,12S)-8-(4-Hydroxyben-
zyl)-2-isopropyl-5,12-dimethyl-3,6,9,13-tetraoxo-1,4,7,10-tet-
raazacyclotridecan-11-yl]hex-4-enamide (6). An aqueous sol-
ution of LiOH (0.5 M, 55 μL, 2.0 mmol, 2.5 equiv) was added to the
cyclic peptide 18 (6.1 mg) in THF−H2O (1:1, 2 mL) at 0 °C. After
30 min the ice bath was removed. Additional portions of LiOH
solution (55 μL, 2.0 mmol, 2.5 equiv) were added after 2, 4, and 6 h,
and stirring was continued for an additional 19 h to ensure full
conversion. Then water (0.5 mL) was added and the organic solvent
was removed in vacuo. The aqueous phase was acidiﬁed with 1 M HCl
and extracted with EtOAc (5 × 20 mL). The organic phase was
dried (Na2SO4), ﬁltered, and concentrated in vacuo to aﬀord the
crude azumamide C, which was used without further puriﬁcation.
To a solution of crude azumamide C (5.8 mg, 10.9 μmol) in DMF
(2 mL) were added HOBt (4.4 mg, 33 μmol, 3 equiv), DIC
(5.1 μL, 34 μmol, 3 equiv), and iPr2NEt (7.6 μL, 44 μmol, 4 equiv).
After 10 min, NH3−dioxane (0.5 M, 0.11 mL, 55 μmol, 5 equiv) was
added. After 1.5 h, DIC (5 μL, 34 μmol, 3 equiv) was added, followed
by NH3−dioxane (0.5 M, 0.11 mL, 55 μmol, 5 equiv). After the
mixture was stirred for 16 h, additional DIC (2 equiv) and NH3−
dioxane (5 equiv) were added, and this procedure was repeated once
more after 18 h. Finally, CH2Cl2 (1 mL) was added, followed by DIC
(3 equiv) and NH3−dioxane (10 equiv), and after 2 days of stirring at
room temperature, the reaction mixture was concentrated, dissolved
in MeCN−H2O (2:1), and puriﬁed by preparative HPLC to give
azumamide B (6) (3.6 mg, 62%, two steps) as a white solid. [α]D +65°
(c = 0.15, MeOH); previously reported11 [α]D +45° (c = 0.1, MeOH).
1H NMR (500 MHz, CD3OH) δ 8.13 (d, J = 7.9 Hz, 1H), 8.00 (d, J =
8.9 Hz, 1H), 7.85 (d, J = 7.2 Hz, 1H), 7.61 (d, J = 8.2 Hz, 1H), 7.01
(d, J = 8.4 Hz, 3H), 6.67 (d, J = 8.4 Hz, 3H), 5.49 (m, 1H), 5.37 (dd,
J = 18.0 and 7.3 Hz, 2H), 4.29 (pentet, J = 7.2 Hz, 1H), 4.15 (m, 1H),
4.05 (m, 1H), 3.60 (m, 1H), 3.13 (dd, J = 13.7, 10.1 Hz, 1H), 3.00
(dd, J = 13.8, 6.3 Hz, 1H), 2.70 (m, 2H), 2.36 (ddd, J = 22.3, 21.5, 7.1
Hz, 11H), 1.29 (d, J = 7.2 Hz, 3H), 1.27 (d, J = 7.4 Hz, 3H), 0.95 (d,
J = 5.7 Hz, 3H), 0.93 (d, J = 6.0 Hz, 3H). HRMS (ESI-TOF) m/z
calcd for C27H39N5O6H
+ 530.2978; found 530.2973 [M + H]+. HPLC
gradient C, tR = 10.31 min (>95%).
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Azumamide C, (Z)-6-[(2R,5R,8R,11R,12S)-8-(4-Hydroxyben-
zyl)-2-isopropyl-5,12-dimethyl-3,6,9,13-tetraoxo-1,4,7,10-tet-
raazacyclotridecan-11-yl]hex-4-enoic Acid (7). LiOH (49 mg,
2.0 mmol, 35 equiv) in water (5.0 mL) was added to the crude cyclic
peptide 18 (61 mg) in THF (5.0 mL). The solution was stirred for
16 h and concentrated in vacuo. The resulting residue was dissolved in
THF−H2O (1:1, 10 mL) by adding a few drops of TFA, and then
puriﬁcation by preparative HPLC aﬀorded azumamide C (7) (2.2 mg,
9% overall) as a white solid. [α]D +49° (c = 0.14, MeOH); previously
reported11 [α]D +21° (c = 0.1, MeOH).
1H NMR (500 MHz,
CD3OH) δ 8.08 (d, J = 7.7 Hz, 1H), 7.99 (d, J = 8.4 Hz, 1H), 7.84
(s, 1H), 7.62 (d, J = 8.1 Hz, 1H), 7.01 (d, J = 8.4 Hz, 2H), 6.67 (d,
J = 8.4 Hz, 2H), 5.48 (t, J = 8.8 Hz, 1H), 5.38 (dt, J = 10.7, 7.0 Hz,
1H), 4.29 (pentet, J = 7.3 Hz 1H), 4.16 (m, 1H), 4.01 (m, 1H),
3.58 (m, 1H), 3.15 (dd, J = 13.7, 10.2 Hz 1H), 3.00 (dd, J = 13.7,
6.0 Hz, 1H), 2.72 (m, 1H), 2.67 (m, 1H) 2.39 (m, 5H), 1.29 (d, J =
7.2 Hz, 3H), 1.27 (d, J = 7.3 Hz, 3H), 0.95 (d, J = 6.0 Hz, 3H), 0.93
(d, J = 6.0 Hz, 3H). HRMS (ESI-TOF) m/z calcd for C27H38N4O7H
+
531.2819; found 531.2815 [M + H]+. HPLC gradient C, tR =
11.04 min (>95%).
Azumamide D, (Z)-6-[(2R,5R,8R,11R,12S)-8-Benzyl-2,5,12-tri-
methyl-3,6,9,13-tetraoxo-1,4,7,10-tetraazacyclotridecan-11-
yl]hex-4-enamide (8). LiOH (53 mg, 2.21 mmol) in water (5.0 mL)
was added to a stirred solution of the impure cyclic peptide 22
(22.7 mg, approximately 0.044 mmol) in THF (3 mL). After 4 h the
organic solvent was removed in vacuo and the water (0.5 mL) was
added to the aqueous phase, which was then acidiﬁed with 1 M HCl
(2 mL) and extracted with EtOAc (4 × 20 mL). The organic phases
were dried (MgSO4), ﬁltered, and concentrated to give the crude acid
23, which was used without further puriﬁcation. To a solution of the
crude acid 23 (≈23 μmol) in CH2Cl2−DMF (8:1, 2.3 mL) were added
HOBt (10 mg, 66 μmol, 3.0 equiv), DIC (10 μL, 66 μmol, 3 equiv),
and iPr2NEt (15 μL, 88 μmol, 4 equiv). After 5 min, NH3−dioxane
(0.5 M, 0.22 mL, 110 μmol, 5 equiv) was added. After 1 h, NH3−
dioxane (0.5 M, 0.22 mL, 110 μmol, 5 equiv) was added. After the
mixture was stirred for 18 h, additional DMF (0.5 mL) was added,
followed by NH3−MeOH (2.0 M, 0.11 mL, 230 μmol, 10 equiv). After
an additional 5 h, DIC (7 μL, 46 μmol, 2 equiv) was added. The next
day NH3−MeOH (2.0 M, 0.06 mL, 111 μmol, 5 equiv) was added and
the mixture was stirred for 10 days. Finally, DIC (3.4 μL, 23 μmol,
1 equiv) was added, followed by NH3−MeOH (2.0 M, 0.055 mL,
210 μmol, 5 equiv), and after 2 days the mixture was concentrated,
dissolved in MeCN−H2O (2:1), and puriﬁed by preparative HPLC to
aﬀord azumamide D (8) (1.2 mg, 4% overall) as a white solid. [α]D
+32° (c = 0.08, MeOH); previously reported11 [α]D +25° (c = 0.1,
MeOH). 1H NMR (500 MHz, CD3OH) δ 8.03 (d, J = 7.8 Hz, 1H),
8.01 (d, J = 8.8 Hz, 1H) 7.94 (d, J = 6.8 Hz, 1H), 7.58 (s, 1H), 7.32 (d,
J = 7.5 Hz, 1H), 7.25−7.14 (m, 5H), 6.75 (s, 1H), 5.47 (m, 1H),
5.39 (m, 1H), 4.35 (m, 1H), 4.19 (m, 1H) 4.17− 4.11 (m, 2H),
3.09 (m, 2H), 2.69 (m, 1H), 2.62 (m, 1H), 2.41 (m, 2H), 2.28
(m, 1H), 1.47 (d, J = 7.4 Hz, 3H), 1.28 (d, J = 7.4 Hz, 3H), 1.22 (d,
J = 7.3 Hz, 3H). HRMS (ESI-TOF) m/z calcd for C25H35N5O5H
+
486.2716; found 486.2710 [M + H]+. HPLC gradient C, tR =
10.55 min (>95%).
Azumamide E, (Z)-6-[(2R,5R,8R,11R,12S)-8-Benzyl-2-isoprop-
yl-5,12-dimethyl-3,6,9,13-tetraoxo-1,4,7,10-tetraazacyclotride-
can-11-yl]hex-4-enoic Acid (9). LiOH (18.5 mg, 0.77 mmol,
40 equiv) in water (4 mL) was added to a stirred solution of the impure
cyclic peptide 20 (10.5 mg, approximately 0.02 mmol) in THF (4 mL).
After 1 h, LiOH (10 mg, 0.42 mmol, 20 equiv) in water (1 mL) was
added, and after 2 h, LiOH (5.0 mg, 0.21 mmol, 1 equiv) in water
(0.5 mL) was added. The solution was stirred for 16 h and another
portion of LiOH (6.0 mg, 0.25 mmol, 1.3 equiv) in water (0.5 mL)
was added. After an additional 2.5 h of stirring, the organic solvent was
removed in vacuo. The aqueous phase was acidiﬁed with 1 M HCl and
extracted with EtOAc (4 × 25 mL). The combined organic phases
were dried (Na2SO4), ﬁltered, and concentrated. The resulting residue
was dissolved in MeCN−water [(3:2), 2.5 mL] and puriﬁed by
preparative HPLC to aﬀord azumamide E (9) (4.3 mg, 15% overall)
as a white solid. [α]D +66° (c = 0.2, MeOH); previously reported
11
[α]D +53° (c = 0.1, MeOH).
1H NMR (500 MHz, CD3OH)
δ 8.10 (d, J = 7.7 Hz, 1H), 7.95 (d, J = 8.8 Hz, 1H), 7.84 (br s, 1H),
7.63 (d, J = 8.4 Hz, 1H), 7.28−7.16 (m, 5H), 5.48 (m, 1H), 5.37 (m,
1H), 4.28 (pentet, J = 7.5 Hz, 1H), 4.16 (m, 1H), 4.08 (m, 1H), 3.59
(m, 1H), 3.25 (dd, J = 13.6, 10.4 Hz, 1H), 3.11 (dd, J = 13.6, 6.1 Hz,
1H), 2.72 (m, 1H), 2.68 (m, 1H), 2.39 (d, J = 1.7 Hz, 6H), 2.39 (m,
6H), 1.28 (d, J = 7.1 Hz, 3H), 1.27 (d, J = 7.4 Hz, 3H), 0.94 (m, 6H).
HRMS (ESI-TOF) m/z calcd for C27H38N4O6H
+ 515.2869; found
515.2869 [M + H]+. HPLC gradient C, tR = 12.53 min (>95%).
Assay Materials. HDAC1 (purity >45% by SDS−PAGE according
to the supplier), HDAC4 (purity >90% by SDS−PAGE according to
the supplier), and HDAC7 (purity >90% by SDS−PAGE according to
the supplier) were purchased from Millipore (Temecula, CA).
HDAC2 used for dose−response experiments (full length, purity
≥94% by SDS−PAGE according to the supplier), HDAC5 (full length,
purity ≥4% by SDS−PAGE according to the supplier), and HDAC8
used for dose−response experiments (purity ≥90% by SDS−PAGE
according to the supplier) were purchased from BPS Bioscience (San
Diego, CA). HDAC2 used for initial screening experiments (full
length, purity 50% by SDS−PAGE according to the supplier),
HDAC3−“NCoR1” complex [(purity 90% by SDS−PAGE according
to supplier; fusion protein of GST-tagged HDAC3 with the
deacetylase activation domain (DAD) of NCoR1 (nuclear receptor
corepressor)], HDAC6 (purity >90% by SDS−PAGE according to the
supplier), HDAC8 for initial screening experiments (purity >50% by
SDS−PAGE according to the supplier), HDAC10 (purity >50% by
SDS−PAGE according to the supplier), and HDAC11 (purity >50%
by SDS−PAGE according to the supplier) were purchased from Enzo
Life Sciences (Postfach, Switzerland). HDAC9 (full length, purity 12%
by SDS−PAGE according to the supplier) was purchased from
Abnova (Taipei, Taiwan). The HDAC assay buﬀer consisted of
50 mM Tris-HCl, pH 8.0, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2,
and bovine serum albumin (0.5 mg/mL). Trypsin [10 000 units/mg;,
from bovine pancreas, treated with L-(tosylamido-2-phenyl)ethyl chloro-
methyl ketone (TPCK)] was from Sigma Aldrich (Steinheim, Germany).
All peptides were puriﬁed to homogeneity (>95% purity by
HPLC230nm via reversed-phase preparative HPLC), and the white
ﬂuﬀy materials obtained by lyophilization were kept at −20 °C. For
assaying, peptides were reconstituted in DMSO to give 5−10 mM
stock solutions, the accurate concentrations of which were determined
by coinjection on HPLC with a standard of known concentration.
In Vitro Histone Deacetylase Inhibition Assays. For inhibition
of recombinant human HDACs, dose−response experiments with
internal controls were performed in black low-binding Nunc 96-well
microtiter plates. Dilution series (3-fold dilution, 10 concentrations)
were prepared in HDAC assay buﬀer from 5−10 mM DMSO stock
solutions. The appropriate dilution of inhibitor (10 μL of 5× the
desired ﬁnal concentration) was added to each well followed by
HDAC assay buﬀer (25 μL) containing substrate [Ac-Leu-Gly-
Lys(Ac)-AMC, 40 μM for HDAC1−3 and 80 μM for HDAC6 and
11; Ac-Leu-Gly-Lys(Tfa)-AMC, 40 μM for HDAC4, 240 μM for
HDAC5, 80 μM for HDAC7, 400 μM for HDAC8, and 160 μM for
HDAC9; Ac-Arg-His-Lys(Ac)-Lys(Ac)-AMC, 100 μM for HDAC10].
Finally, a solution of the appropriate HDAC (15 μL) was added
and the plate was incubated at 37 °C for 30 min [HDAC1, 150 ng/well;
HDAC2, 100 ng/well; HDAC3, 10 ng/well; HDAC4, 2 ng/well;
HDAC5, 40 ng/well; HDAC6, 60 ng/well; HDAC7, 2 ng/well; HDAC8,
5 ng/well; HDAC9, 40 ng/well; HDAC10, 500 ng/well; HDAC11,
500 ng/well]. Then trypsin (50 μL, 0.4 mg/mL) was added and the
assay development was allowed to proceed for 15−30 min at room
temperature, before the plate was read on a Perkin-Elmer Enspire
plate reader with excitation at 360 nm and detecting emission at 460 nm.
Each assay was performed in duplicate. The data were analyzed by
nonlinear regression with GraphPad Prism to aﬀord IC50 values from the
dose−response experiments, and Ki values were determined from the
Cheng−Prusoﬀ equation [Ki = IC50/(1 + [S]/Km)] with the assumption
of a standard fast-on−fast-oﬀ mechanism of inhibition.
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In our pursuit for potent and selective HDAC inhibitors, we designed four series of cyclic tetra peptide compounds, based on the azumamide 
scaffold. We have probed different modifications  in  the  unique  β-amino  acid  moiety  and  synthesized  tryptophan-containing  analogs.  
The biochemical profiling of the azumamide analogs was combined with high-resolution NMR solution structures to correlate the biological 
activity to specific structural features. We hypothesize that the β2-methyl group, found in the azumamides, has an important side chain 
directing function, which guides the zinc-binding side chain towards the active site. 10 
Introduction 
Histone deacetylases (HDACs) are a group of epigenetic 
modulators, which catalyze the removal of ε-N-acetylated lysine 
residues, found in the N-terminal tails of histone proteins. An 
aberrant HDAC expression has been associated with various types 15 
of cancer, the enzymes have therefore been a target in the 
development of anticancer drugs.1 So far, two HDAC inhibitors 
have been approved by the FDA (12 and 43) for clinical treatment 
of cutaneous T-cell lymphoma and several compounds are in 
clinical trials.4 20 
 
A pharmacophore model has been used to describe most HDAC 
inhibitors. The model consists of a cap group that interacts with 
motifs on the surface of the protein, a linker region, and a zinc-
binding group (ZBG), which reaches into the active site. HDAC 25 
inhibitors bearing a hydroxamic acid ZBG (1, 2), have proven to 
be potent HDAC inhibitors.5 However, macrocyclic tetra peptides 
as apicidin (3), azumamide C (5a), and azumamide E (5b) also 
demonstrate high activity, in spite of their weak Zn2+-coordinating 
side chain functionality.6 The azumamides are structurally related 30 
to apicidin (3), but the macrocyclic scaffold has a disubstituted β-
amino acid. Furthermore the azumamides are unique in having a 
retro-enantio arrangement.  
Macrocycles have been proposed to possess a scaffold with a 
higher potential for selectivity.7 This suggestion has been based on 35 
less conserved amino acids in the rim of the active site, across the 
HDAC isozymes.8 The combination of a large cap group and a 
poor ZBG, could be an advantage for obtaining selective HDAC 
inhibitors, as a strong ZBG might be too dominant an interaction 
to confer high selectivity. 40 
The structural changes reported for the azumamides are primarily 
limited to modification of the Zn2+-binding group9 and 
manipulation of the stereochemistry.6b, 10  
 
 45 
 
Figure 1. Known HDAC inhibitors (top) and target compounds (bottom) 
Interactions between the cyclic peptide core and the surface of the 
protein seem to be important for isoform selectivity.10-11 Isoform 
selective HDAC inhibitors could provide a powerful new tool for 50 
understanding the function of HDAC enzymes and be the basis for 
developing new drug candidates.12 
  
 
 55 
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Results and discussion 
Design and synthesis 
In pursuit of isoform selective compounds we conducted a 
structure-activity relationship (SAR) study, where we synthesized 
a variety of structurally edited azumamides. Our previous work 5 
have shown that changes in the stereochemistry of the β-amino 
acid substituents in azumamide E had a detrimental impact on 
activity.6b We therefore set out to explore modifications at the β2-
position, without altering the stereochemistry. Instead we 
incorporated a dimethylated as well as a desmethylated β-amino 10 
acid in the cyclic peptide, 6a-c and 7a-c, respectively. 
Considering the saturated side chain of 3 and the trans olefin in 4, 
we speculated that the cis olefin in the azumamides would not be 
essential for activity. To explore this hypothesis, we prepared 8 and 
9, as it could easily be obtained from commercially available Boc-15 
L-Asp-OtBu. We recently found that the nature of the aromatic 
amino acid effects the biological activity.6b Hence, an indole motif, 
also present in 3, was incorporated in our target compounds in 
addition to Phe and Tyr, which are found in the azumamides.  
Building block synthesis 20 
The building block, employed for the synthesis of the dimethylated  
analogs 6a–c, was prepared by a method recently developed in our  
laboratory. The diastereoselective Ellman-type Mannich reaction 
between the enolate of  tert -butyl isobutyrate and the enantiomer 
of 30 sulfinyl imine 10 afforded the desired Mannich product in 25 
58% yield and with a diastereoselectivity of (77:23) in favour of 
the R-isomer. 
Table 1 Screening of acetates for the Ellman-type Mannich reaction 
 
entry R1 additive d.r. major isomer, 
total yield (%)d 
1 Et TiCl(OiPr)3 >99:1  3Ra (94)b 
2 tBu TiCl(OiPr)3 74:16 3Rc (68) 
3 tBu HMPA 18:72 3Sc (61) 
4 PMB TiCl(OiPr)3 82:18 ND 
a
 Determined by X-ray crystallography from the desilylated and re-30 
esterified tert-butyl ester 19. b Crude yield. c Determined spectroscopically 
by comparison with the crystallized compound from entry 1. 
(supplementary figure S1). d Total yield of all diastereoisomers. 
The absolute stereochemistry of the Mannich product was 
determined by X-ray crystallography upon desilylation with 35 
Bu4NF. The alcohol was elaborated to give the Boc-protected β-
amino acid 22 (scheme 3) in 16% overall yield from the sulfinyl 
imine (Supplementary scheme S1). The desmethylated β-amino 
acid building blocks 15 (Boc protected) and 16 (Fmoc-protected) 
were prepared by a similar route (scheme 1). The Boc-derivative 40 
only allows one cyclization site, whereas the introduction of the 
Fmoc group would allow macrolactamization at all four positions. 
Initially, an optimization study was conducted, where various 
acetate enolates were investigated to produce the best 
diastereomeric ratio and yield in the Mannich reaction (table 1). 45 
Scheme 1. Reagents and conditions: (a) LDA (2.1 equiv), EtOAc (2.0 
equiv), TiCl(O-iPr)3 (4.2 equiv), THF, –78 ºC, 30 min; then 16, –78 ºC, 20 
min. (b) LiOH (4.5 equiv), THF–water, 17h. (c) Boc2O (1.4 equiv), DMAP 
(0.3 equiv), tert-butanol, 16 h, then Boc2O (0.3 equiv), 15 h  (d) AcOH (1.0 
equiv), Bu4NF (2.0 equiv), THF, 0 ºC → rt, 75 min. (e) NaHCO3 (1.5 50 
equiv), Dess-Martin periodinane (1.5 equiv), dry CH2Cl2, 0 ºC → rt, 40 
min. (f) KHMDS (1.9 equiv), Ph3PBr(CH2)3COOEt, (2.0 equiv), THF, –78 
ºC → rt, 40 min. (g) TFA–CH2Cl2 (1:1, 10 mL, 117–192 equiv), 0 ºC → rt, 
2–3 h. (h) HCl (4.0 M in dioxane, 1.8–2.5 equiv), dioxane, 1–3 h. (i) iPr2Net 
(3.0 equiv), Boc2O (2.0 equiv), dry CH2Cl2, 6 h, then Boc2O (1.0 equiv), 55 
16 h. (j) Na2CO (4.0 equiv), FmocOSu (1.2 equiv) water–dioxane (5:1, 6 
mL), 0 ºC → rt, 45 min. 
It is interesting, that the desired (3R) configuration is obtained from 
the (R)-auxillary in the case of tert-butyl acetates, whereas the 
equivalent tert-butyl isobutyrate reaction yields the (3S) 60 
configuration as the major diastereomer. The high dr obtained with 
ethyl acetate and the switchover in diastereoselectivity induced by 
the addition of HMPA confirms the hypothesis that the acetate 
mediated reaction proceeds through a six-membered Zimmerman–
Traxler-type transition state, where coordination to titanium is 65 
essential for the high diastereoselectivity.  
To establish the stereochemistry of the product from entry 1, the 
compound was re-esterified to the tert -butyl ester, since the tert-
butyl ester alcohols in most cases were crystalline. Gratifyingly, 
the alcohol crystallized and the stereochemistry was determined by 70 
X-ray crystallography. Furthermore, an acid labile protection 
group for the carboxylic acid was required to obtain orthogonality. 
This strategy nicely provided the Fmoc- and Boc-protected β- 
amino acids 15 and 16 (Scheme 1).   
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Scheme 2.  (a) N-methylmorpholine (1.0 equiv), isobutyl chloroformate 
(1.0 equiv), NaBH4 (3.0 equiv), MeOH, THF, –30 ºC → rt, 160 min. (b) 
oxalyl chloride (1.7 equiv), DMSO (3.3 equiv), Et3N (5.0 equiv.), CH2Cl2, 
–78 ºC → –40 ºC → rt, 2h. (c) PPh3CH3Br (2.2 equiv), KHMDS (0.5 M 5 
in toluene) (2.1 equiv), THF, –78 ºC → rt, 4 h. (d) methyl 5-hexenoate (3 
equiv), Hoveyda Grubbs 2nd gen. catalyst (0.1 equiv), CH2Cl2, 40 ºC, 
24h. (e) TFA–CH2Cl2 (1:3), 2h. (f) Boc2O (1.3 equiv.), iPr2NEt (2.6 
equiv.), CH2Cl2. (g) H2, Pd/C (1% w/w), THF, 19h. 
The building blocks used to synthesize compound 8a-c and 9a-c 10 
were prepared from the readily available Boc-L-Asp-OtBu 22. 
Using a slightly modified procedure from Bradner et al13, acid 22 
was reduced to the corresponding alcohol and a subsequent Swern 
oxidation yielded the aldehyde, which was used immediately in a 
Wittig reaction to produce the terminal alkene 23.  15 
Table 2 Catalyst screening for cross-methatesis 
entry catalyst yield (%)a 
1 Grubbs cat. 1st gen., 0.1 equiv 11 
2 Grubbs cat. 2nd gen., 0.05 equiv 54 
3 Grubbs cat. 2nd gen., 0.1 equiv 62 
4 Hoveyda Grubbs cat. 1st gen., 0.1 
equiv 
12 
5 Hoveyda Grubbs cat. 2nd gen., 0.1 
equiv 
67 
6 cat. (A) 62 
7 cat. (B) 52 
a Isolated trans isomer. 
The optimal conditions for the succeeding cross methathesis was 
found using Hoveyda-Grubbs 2nd generation catalyst (see table 2), 
which afforded the trans olefin in a good yield. Acidic deprotection 20 
followed by reprotection of the amino functionality gave the final 
building block for 8 whereas hydrogenation of 25 gave the desired 
β-amino acid 26 for the synthesis of 9 (Scheme 2). 
All the synthesized building blocks were coupled to a tripeptide on 
solid support, which after deprotection and cleavage were cyclized 25 
using HATU under dilute conditions (0.3–0.8 mM). Saponification 
of the cyclic peptides gave the final compounds albeit in poor 
yield. The synthesis of the tryptophan analogues proved 
particularly challenging, revealed by an unsuccessful synthesis of 
9c by the original synthetic route. Changing the point of cyclization 30 
had previous shown to have an effect on a simplified linear 
tetrapeptide. The Boc protection group of 27 was therefore 
substituted for an Fmoc group allowing the building block to be 
loaded directly on to the resin. Even though we expected a better 
cyclization reaction, using the less hindered and more flexible β-35 
amino acid at the C-terminal, we were surprised to find the 
dramatic effect this alteration had, when we isolated 9c with a yield 
of 48% (12 steps) from the Fmoc building block. (supplementary 
scheme S2).  
 40 
Biochemical profiling 
An initial screen against HDAC4 and 7 at concentrations between 
10–100 µM, indicated that the analogs were poor inhibitors of class 
IIa. All desmethylated compounds were therefore characterized 
with dose–response experiments on recombinant human HDACs 45 
on class I, class IIb, and class IV.  
Preliminary testing of the dimethylated series (6a–c) indicated low 
activity. With this in mind, these compounds were only screened 
at two concentrations (10 µM and 20 µM, see SI, table S1). The 
Phe- and Tyr-containing analogs (6a and 6b) were poor inhibitors 50 
of HDAC1–3 and no inhibition was observed on HDAC6, 
HDAC8, HDAC10, and HDAC11 at 20 µM. However, 6c, 
containing a tryptophan as the aromatic residue, displayed activity 
against HDAC1–3 (∼50% inhibition at 10 µM). 6c also showed 
activity against HDAC6, HDAC8, HDAC10, and HDAC11, 55 
although none of  the  isoforms  were  inhibited  more  than  50%  
at  20  µM. The positive effect of tryptophan indicates that this 
aromatic amino acid is superior to Phe and Tyr in establishing 
favorable interactions with the surface of the HDAC enzymes. The 
low activity of 6a–6c emphasize the sensitivity of modifications to 60 
the β2-position.  
The IC50 values obtained from dose-response experiments on the 
six cyclic peptides (7a–7c, 8a–8c, and 9a–9c) were converted to Ki 
values, using Cheng-Prusoff’s equation [Ki = IC50/(1 + [S]/Km), 
assuming a fast-on−fast-off mechanism. The results are shown in 65 
table 3. 
The compounds showed the highest activity against HDAC10, 
followed by HDAC1-3. Activity was also found against HDAC11, 
while poor inhibition was observed against HDAC6 and 8. 
Compared to HDAC6 and 8, removal of the methyl group seem to 70 
have a minor effect compared to the azumamides. However, 
azumamide C and E are relatively weak inhibitors of these 
isozymes, so the small difference is also an expression of the 
general poor activity against the enzymes.  
When the other HDAC isoforms are compared, it is evident that 75 
the methyl group has an important function, as 7a and 7b show a 5 
to 36-fold decrease in potency. 
Compounds with a trans olefin in the side chain shows the weakest 
inhibitory activity, while analogs containing a cis olefin and a 
saturated side chain are equally potent. Regarding the aromatic 80 
residue, phenylalanine-containing compounds are the weakest 
inhibitors, while differences between compounds containing a 
tyrosine relative to a tryptophane is insignificant. These data are in 
agreement with the activity of azumamide C, which is the most 
potent inhibitor for all HDAC enzymes. The negative effect of 85 
incorporating a phenylalanine and a trans olefin is evident from 
compound 8a, which portray the weakest inhibition for HDAC1–
3, 10 and 11. 
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Scheme 4. Reagents and conditions: (a) Resin (1.5 equiv), x (1.0 equiv), HATU or COMU (1.5 equiv), iPr2Net (3.0 equiv), DMF, 16 h or x (1.1 equiv), 
resin (1.0 equiv), HATU (1.5 equiv), iPr2Net (3.0 equiv), DMF, 17 h (b) TFA–CH2Cl2 (1:1), 2 × 30 min. (c) HATU (1.5–2.2 equiv), iPr2NEt (5–10 equiv), 
DMF (0.4 mM peptide concentration), 16 h. 17–21 h (d) LiOH (36–50 equiv), THF–water (1:1), 16–17 h. (e) Resin (1.0 or 1.5 equiv), HATU (1.5 equiv), 5 
2,6-lutidine (3.0 equiv), x (1.1 or 1.0 equiv), DMF, 16 h. (f) TFA–CH2Cl2 (1:1), 2 × 30 min or piperidine–DMF (1:4, 2 × 30 min); DBU–piperidine–DMF 
(2:2:96, 30 min); AcOH–TFE–CH2Cl2 (6:2:2, 1.5 mL), 2 × 2 h. (g) TFA–CH2Cl2 (1:1), 1 h.    
NMR Studies 
All amide bonds in azumamide A-E exhibit trans conformations,10 
we therefore analyzed the NMR spectra of the azumamide analogs, 10 
to see if any cis amides were present. NOESY/ROESY interactions 
between Hα on adjacent amino acids would indicate a cis amide, 
but no correlations were found.  
We hoped to solve the 3D-solution structure in water, as this 
conformation would resemble the assay conditions best. 15 
Unfortunately, the azumamide analogs were insoluble in H2O. Up 
to 15% DMSO-d6 was added, but an insufficient amount of 
compound was dissolved to obtain a useful NMR spectrum. All 
samples were therefore analyzed in DMSO-d6. 
NOESY/ROESY data were used to set constraints to the cyclic 20 
structure when the simulations were performed in the program 
‘Maestro’. This was done by adding a penalty to the system if the 
distance between two protons changed more than 20%, compared 
to the data from the NMR spectra.  
An amide NH between the aromatic residue and alanine from the 25 
natural compound points to the middle of the structure. This 
conformation originates from the 
NOESY correlation between the NH 
and Hα-Ala. However, in this 
conformation, the distance between 30 
the NH and the methyl group in 
alanine does not correlate with the 
NMR data; so even though the 
cyclic peptide can be viewed as a 
rigid structure, the 3-D 35 
conformation is an ensample of closely related structures with a 
certain flexibility. Overall, the structural difference in the 
backbone between the azumamides and the des-methylated 
compounds were small. Similar NOESY/ROESY correlations 
were found and the J-couplings were comparable (SI). 40 
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 Ki (µM) 
 Class I  Class IIb  Class IV 
Compound HDAC1 HDAC2 HDAC3 HDAC8  HDAC6 HDAC10  HDAC11 
8a 1.41±0.37 1.86±0.04 1.62±0.31 8.57±3.61  IAa IA  3.60±0.61 
8b 0.83±0.26 0.66±0.28 0.55±0.26 IA  2.60±0.96 0.30±0.004  1.43±0.42 
8c 0.57±0.08 0.45±0.31 0.65±0.44 3.35±2.06  4.44±0.36 0.26±0.005  1.24±0.61 
9a 1.02±0.39 0.85±0.11 0.78±0.23 IA  IA 0.53±0.163  2.43±1.27 
9b 0.78±0.68 0.32±0.20 0.26±0.16 IA  3.96±2.24 0.15±0.074  0.98±0.82 
9cb 1.15±0.13 1.58±0.38 2.35±0.91 12.17±0.77  IA 0.38±0.068  3.20±1.80 
7a 0.65±0.26 0.98±0.14 0.91±0.16 IA  IA 0.27±0.034  1.72±0.26 
7b 0.34±0.23 0.21±0.07 0.37±0.29 IA  7.08±0.72 0.15±0.007  0.87±0.40 
7c 0.23±0.13 0.17±0.01 0.57±0.16 5.93±0.71  IA 0.13±0.036  0.95±0.71 
NMR Studies 
The docking simulations on 7a–7c, 8a–8c, and 9a–9c were 
performed in HDAC3 (PDB: 4A69).14 It should be noted that these 5 
preliminary docking results were performed on a rigid enzyme and 
thus neglects potential 
induced fit effects. 
Optimized structures will be 
obtained by allowing the 10 
enzyme to minimize after 
the docking. 
Each analog bind in a similar 
fashion to HDAC3, 
compound 7b, 8b, 9b is 15 
shown as representative 
examples in figure 1. 
Asp93 has a particularly important interaction by coordinating 
with all the amide nitrogens in the cyclic core. Besides from 
coordination with the zinc atom, the carboxylic acid ZBG forms 20 
favorable interactions with His 134, His135, and Tyr298 (Figure 
2.11). It is not clear from the docking results why the natural 
products possess a higher HDAC inhibitory activity relative to the 
analogs. However, favorable lipophilic interactions could occur 
between Phe200 and the methyl group in the azumamides.  25 
The phenylalanine containing compounds (including azumamide 
E), show a lower activity towards HDAC1–3. Since tyrosine and 
tryptophan can form hydrogen bonds, these interactions would be 
an obvious explanation for the higher activity. However, the 
phenylalanine containing compounds are only 2-fold less potent. 30 
The change in activity might therefore be a combination of the 
negative effect from removing a water molecule from the binding 
site and the positive effect from obtaining favorable hydrogen bond 
interactions. No hydrophilic interactions can be seen from the 
docking results, but since a rigid enzyme has been used for the 35 
simulations, amino acids near the cavity might move to interact 
with the ligand. His22 and Asp92 are located close to the aromatic 
substituent and might have a role in the binding. 
 
 40 
Cytotoxicity tests 
The work is ongoing. 
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